

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 310 571 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
15.02.2006 Bulletin 2006/07

(51) Int Cl.:  
**C12Q 1/70** <sup>(2006.01)</sup> **C07K 14/015** <sup>(2006.01)</sup>  
**C12N 15/86** <sup>(2006.01)</sup> **C12N 15/10** <sup>(2006.01)</sup>  
**C12Q 1/68** <sup>(2006.01)</sup> **C12N 5/10** <sup>(2006.01)</sup>

(21) Application number: **02257826.4**

(22) Date of filing: **12.11.2002**

(54) **A Method of identifying unknown adeno-associated virus (AVV) sequences and a kit for the method**

Verfahren zur Identifizierung von Adeno-assoziiertem Virus (AAV) Sequenzen sowie Kit zur Ausführung der Methode

Une méthode d'identification de séquences de virus adéno-associés et kit permettant d'appliquer la méthode

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
IE IT LI LU MC NL PT SE SK TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **13.11.2001 US 350607 P**  
**17.12.2001 US 341117 P**  
**01.05.2002 US 377066 P**  
**05.06.2002 US 386675 P**

(43) Date of publication of application:  
**14.05.2003 Bulletin 2003/20**

(73) Proprietor: **THE TRUSTEES OF THE UNIVERSITY  
OF PENNSYLVANIA**  
Philadelphia,  
Pennsylvania 19104-6283 (US)

(72) Inventors:  
• **Gao, Guangping**  
Rosemont, Pennsylvania 19010 (US)  
• **Wilson, James M.**  
Gladwyne, Pennsylvania 19035 (US)  
• **Alvira, Maricio**  
Philadelphia, Pennsylvania 19104 (US)

(74) Representative: **Hale, Stephen Geoffrey et al**  
**Bromhead Johnson,**  
**Kingsbourne House,**  
**229-231 High Holborn**  
**London WC1V 7DP (GB)**

(56) References cited:  
**WO-A-02/18659**

- **GAO GUANG-PING ET AL: "Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 18, 3 September 2002 (2002-09-03), pages 11854-11859, XP002229849 <http://www.pnas.org> September 3, 2002 ISSN: 0027-8424**
- **FORSLUND OLA ET AL: "A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin." JOURNAL OF GENERAL VIROLOGY, vol. 80, no. 9, 1999, pages 2437-2443, XP002229850 ISSN: 0022-1317**
- **XIAO WEIDONG ET AL: "Gene therapy vectors based on adeno-associated virus type 1." JOURNAL OF VIROLOGY, vol. 73, no. 5, May 1999 (1999-05), pages 3994-4003, XP002229851 ISSN: 0022-538X**
- **GENE THERAPY, vol. 10, 2003, pages 194-196,**
- **PROC. NATL. ACAD. SCI. USA, vol. 100, no. 10, 2003, pages 6081-6086,**
- **J. VIROL., vol. 78, no. 12, 2004, pages 6381-6388,**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention)

**P 1 310 571 B1**

## Description

## BACKGROUND OF THE INVENTION

5 **[0001]** Adeno-associated virus (AAV), a member of the Parvovirus family, is a small nonenveloped, icosahedral virus with single-stranded linear DNA genomes of 4.7 kilobases (kb) to 6 kb. AAV is assigned to the genus, Dependovirus, because the virus was discovered as a contaminant in purified adenovirus stocks. AAV's life cycle includes a latent phase at which AAV genomes, after infection, are site specifically integrated into host chromosomes and an infectious phase in which, following either adenovirus or herpes simplex virus infection, the integrated genomes are subsequently

10 rescued, replicated, and packaged into infectious viruses. The properties of non-pathogenicity, broad host range of infectivity, including non-dividing cells, and potential site-specific chromosomal integration make AAV an attractive tool for gene transfer.

**[0002]** Recent studies suggest that AAV vectors may be the preferred vehicle for gene therapy. To date, there have been 6 different serotypes of AAVs isolated from human or non-human primates (NHP) and well characterized. Among

15 them, human serotype 2 is the first AAV that was developed as a gene transfer vector; it has been widely used for efficient gene transfer experiments in different target tissues and animal models. Gene therapy vectors based on adeno-associated virus type 1 have also been disclosed (Xiao et al. J. Virology; May 1999; pages 3994-4008). Clinical trials of the experimental application of AAV2 based vectors to some human disease models are in progress, and include such diseases as cystic fibrosis and hemophilia B.

20 **[0003]** A general PCR method suitable for detecting human papillomavirus types in cutaneous tumours and normal skin is known (Forslund et al J. of General Virology: 1999 80: P2437-2443).

**[0004]** What are desirable are AAV-based constructs for gene delivery.

## SUMMARY OF THE INVENTION

25 **[0005]** In one aspect, the invention provides a novel method of identifying unknown AAV sequences from cellular DNAs of various human and non-human primate (NHP) tissues using bioinformatics analysis, PCR based gene amplification and cloning technology, based on the nature of latency and integration of AAVs in the absence of helper virus co-infection, the method being defined in claim 1 hereinafter.

30 **[0006]** In another aspect the invention provides a kit for use in the method of the invention, the kit being as defined in claim 23 hereinafter.

## DETAILED DESCRIPTION OF THE INVENTION

35 **[0007]** In the present invention, the inventors have found a method which takes advantage of the ability of adeno-associated virus (AAV) to penetrate the nucleus, and, in the absence of a helper virus co-infection, to integrate into cellular DNA and establish a latent infection. This method utilizes a polymerase chain reaction (PCR)-based strategy for detection, identification of sequences of AAVs from DNAs from tissues of human and non-human primate origin as well as from other sources.

40 **[0008]** Nucleic acid sequences can be identified according to the method of the invention. One such adeno-associated virus is of the serotype, termed herein serotype 7 (AAV7). Other novel adeno-associated virus serotypes identified by the method include AAV10, AAV11, and AAV12.

**[0009]** Among particularly desirable AAV fragments which can be identified are the cap proteins, including the vp1, vp2, vp3, the hypervariable regions, the rep proteins, including rep 78, rep 68, rep 52, and rep 40, and the sequences encoding these proteins. Each of these fragments may be readily utilized in a variety of vector systems and host cells.

45 Such fragments may be used alone, in combination with other AAV sequences or fragments, or in combination with elements from other AAV or non-AAV viral sequences. In one particularly desirable embodiment, a vector contains the AAV cap and/or rep sequences.

**[0010]** As described herein, alignments are performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs, such as "Clustal W", accessible through Web Servers on the internet. Alternatively, Vector NTI utilities are also used. There are also a number of algorithms known in the art which can be used to measure nucleotide sequence identity, including those contained in the programs described above. As another example, polynucleotide sequences can be compared using Fasta, a program in GCG Version 6.1. Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. For instance,

55 percent sequence identity between nucleic acid sequences can be determined using Fasta with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) as provided in GCG Version 6.1. Similar programs are available for amino acid sequences, e.g., the "Clustal X" program. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize

another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs.

**[0011]** The term "substantial homology" or "substantial similarity," when referring to a nucleic acid, or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 95 to 99% of the aligned sequences. Preferably, the homology is over full-length sequence, or an open reading frame thereof, or another suitable fragment which is at least 15 nucleotides in length. Examples of suitable fragments are described herein.

**[0012]** The term "substantial homology" or "substantial similarity," when referring to amino acids or fragments thereof, indicates that, when optimally aligned with appropriate amino acid insertions or deletions with another amino acid, there is amino acid sequence identity in at least about 95 to 99% of the aligned sequences. Preferably, the homology is over full-length sequence, or a protein thereof, e.g., a cap protein, a rep protein, or a fragment thereof which is at least 8 amino acids, or more desirably, at least 15 amino acids in length. Examples of suitable fragments are described herein.

**[0013]** By the term "highly conserved" is meant at least 80% identity, preferably at least 90% identity, and more preferably, over 97% identity. Identity is readily determined by one of skill in the art by resort to algorithms and computer programs known by those of skill in the art.

**[0014]** The term "percent sequence identity" or "identical" in the context of nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over the full-length of the genome, the full-length of a gene coding sequence, or a fragment of at least about 500 to 5000 nucleotides, is desired. However, identity among smaller fragments, e.g. of at least about nine nucleotides, usually at least about 20 to 24 nucleotides, at least about 28 to 32 nucleotides, at least about 36 or more nucleotides, may also be desired. Similarly, "percent sequence identity" may be readily determined for amino acid sequences, over the full-length of a protein, or a fragment thereof. Suitably, a fragment is at least about 8 amino acids in length, and may be up to about 700 amino acids. Examples of suitable fragments are described herein.

**[0015]** The AAV sequences and fragments thereof are useful in production of rAAV, and are also useful as antisense delivery vectors, gene therapy vectors, or vaccine vectors.

**[0016]** As described herein, the vectors containing the AAV capsid proteins are particularly well suited for use in applications in which the neutralizing antibodies diminish the effectiveness of other AAV serotype based vectors, as well as other viral vectors. The rAAV vectors are particularly advantageous in rAAV readministration and repeat gene therapy.

**[0017]** As used throughout this specification and the claims, the terms "comprising" and "including" and their variants are inclusive of other components, elements, integers, steps and the like. Conversely, the term "consisting" and its variants is exclusive of other components, elements, integers, steps and the like.

## I. Methods of the Invention

### A. Detection of Sequences Via Molecular Cloning

**[0018]** In one aspect, the invention provides a method of identifying target (unknown) nucleic acid sequences in a sample. This method is particularly well suited for detection of viral sequences which are integrated into the chromosome of a cell, e.g., adeno-associated viruses (AAV) and retroviruses, among others.

**[0019]** As used herein, a sample is any source containing nucleic acids, e.g., tissue, tissue culture, cells, cell culture, and biological fluids including, without limitation, urine and blood. These nucleic acid sequences may be DNA or RNA from plasmids, natural DNA or RNA from any source, including bacteria, yeast, viruses, and higher organisms such as plants or animals. DNA or RNA is extracted from the sample by a variety of techniques known to those of skill in the art, such as those described by Sambrook, *Molecular Cloning: A Laboratory Manual* (New York: Cold Spring Harbor Laboratory). The origin of the sample and the method by which the nucleic acids are obtained for application of the method of the invention is not a limitation of the present invention. Optionally, the method of the invention can be performed directly on the source of DNA, or on nucleic acids obtained (e.g., extracted) from a source.

**[0020]** The method of the invention involves subjecting a sample containing DNA to amplification via polymerase chain reaction (PCR) using a first set of primers specific for a first region of double-stranded nucleic acid sequences, thereby obtaining amplified sequences.

**[0021]** As used herein, each of the "regions" is predetermined based upon the alignment of the nucleic acid sequences of at least two serotypes (e.g., AAV) or strains (e.g., lentiviruses), and wherein each of said regions is composed of sequences having a 5' end which is highly conserved, a middle which is variable, and a 3' end which is highly conserved, each of these being conserved or variable relative to the sequences of at least AAV1-AAV6. The 5' and 3' ends are highly conserved over at least 18 base pairs (bp). However, one or both of the sequences at the 5' or 3' end may be conserved over more than 18 bp, more than 25 bp, more than 30 bp, or more than 50 bp at the 5' end. With respect to the variable region, there is no requirement for conserved sequences, these sequences may be relatively conserved, or may have less than 90, 80, or 70% identity among the aligned serotypes or strains.

[0022] Each of the regions may span about 100 bp to about 10 kilobase pairs in length, provided that the first region is at least 250 bp in length. However, it is particularly desirable that one of the regions is a "signature region", i.e., a region which is sufficiently unique to positively identify the amplified sequence as being from the target source. For example, in one embodiment, the first region is about 250 bp in length, and is sufficiently unique among known AAV sequences, that it positively identifies the amplified region as being of AAV origin. Further, the variable sequences within this region are sufficiently unique that can be used to identify the serotype from which the amplified sequences originate. Once amplified (and thereby detected), the sequences can be identified by performing conventional restriction digestion and comparison to restriction digestion patterns for this region in any of AAV1, AAV2, AAV3, AAV4, AAV5, or AAV6, or that of AAV7, AAV10, AAV11, AAV12, or any of the other novel serotypes identified by the invention, which is predetermined and provided by the present invention.

[0023] Given the guidance provided herein, one of skill in the art can readily identify such regions among other integrated viruses to permit ready detection and identification of these sequences. Thereafter, an optimal set of generic primers located within the highly conserved ends can be designed and tested for efficient amplification of the selected region from samples. This aspect of the invention is readily adapted to a diagnostic kit for detecting the presence of the target sequence (e.g., AAV) and for identifying the AAV serotype, using standards which include the restriction patterns for the AAV serotypes described herein or isolated using the techniques described herein. For example, quick identification or molecular serotyping of PCR products can be accomplished by digesting the PCR products and comparing restriction patterns.

[0024] Thus, in one embodiment, the "signature region" for AAV spans about bp 2800 to about 3200 of AAV 1 [SEQ ID NO:6], and corresponding base pairs in AAV 2, AAV3, AAV4, AAV5, and AAV6. More desirably, the region is about 250 bp, located within bp 2886 to about 3143 bp of AAV 1 [SEQ ID NO:6], and corresponding base pairs in AAV 2 [SEQ ID NO:7], AAV3 [SEQ ID NO:8], and other AAV serotypes. To permit rapid detection of AAV in the sample, primers which specifically amplify this signature region are utilized. However, the present invention is not limited to the exact sequences identified herein for the AAV signature region, as one of skill in the art may readily alter this region to encompass a shorter fragment, or a larger fragment of this signature region.

[0025] The PCR primers are generated using techniques known to those of skill in the art. Each of the PCR primer sets is composed of a 5' primer and a 3' primer. See, e.g., Sambrook et al, cited herein. The term "primer" refers to an oligonucleotide which acts as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced. The primer is preferably single stranded. However, if a double stranded primer is utilized, it is treated to separate its strands before being used to prepare extension products. The primers may be about 15 to 25 or more nucleotides, and preferably at least 18 nucleotides. However, for certain applications shorter nucleotides, e.g., 7 to 15 nucleotides are utilized.

[0026] The primers are selected to be sufficiently complementary to the different strands of each specific sequence to be amplified to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the region being amplified. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being completely complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to be amplified to hybridize therewith and form a template for synthesis of the extension product of the other primer.

[0027] The PCR primers for the signature region are based upon the highly conserved sequences of two or more aligned sequences (e.g., two or more AAV serotypes). The primers can accommodate less than exact identity among the two or more aligned AAV serotypes at the 5' end or in the middle. However, the sequences at the 3' end of the primers correspond to a region of two or more aligned AAV serotypes in which there is exact identity over at least five, preferably, over at least nine base pairs, and more preferably, over at least 18 base pairs at the 3' end of the primers. Thus, the 3' end of the primers is composed of sequences with 100% identity to the aligned sequences over at least five nucleotides. However, one can optionally utilize one, two, or more degenerate nucleotides at the 3' end of the primer.

[0028] For example, the primer set for the signature region of AAV was designed based upon a unique region within the AAV capsid, as follows. The 5' primer was based upon nt 2867-2891 of AAV2 [SEQ ID NO:7], 5'-GGTAATTCCTCCGGAATTGGCATT3'. The 3' primer was designed based upon nt 3096-3122 of AAV2 [SEQ ID NO:7], 5'-GACTCATCAACAACAACTGGGGATTTC-3'. However, one of skill in the art may have readily designed the primer set based upon the corresponding regions of AAV 1, AAV3, AAV4, AAV5, AAV6, or based upon the information provided herein, AAV7, AAV10, AAV11, AAV12, or another novel AAV. In addition, still other primer sets can be readily designed to amplify this signature region, using techniques known to those of skill in the art.

## B. Isolation of Target Sequences

[0029] As described herein, the present invention uses a first primer set which specifically amplifies the signature region of the target sequence, e.g., an AAV serotype, in order to permit detection of the target. In a situation in which



further sequences are desired, e.g., if a novel AA V serotype is identified, the signature region may be extended. Thus, the invention may further utilize one or more additional primer sets.

**[0030]** Suitably, these primer sets are designed to include either the 5' or 3' primer of the first primer set and a second primer unique to the primer set, such that the primer set amplifies a region 5' or 3' to the signature region which anneals to either the 5' end or the 3' end of the signature region. For example, a first primer set is composed of a 5' primer, P1 and a 3' primer P2 to amplify the signature region. In order to extend the signature region on its 3' end, a second primer set is composed of primer P1 and a 3' primer P4, which amplifies the signature region and contiguous sequences downstream of the signature region. In order to extend the signature region on its 5' end, a third primer set is composed of a 5' primer, P5, and primer P2, such that the signature region and contiguous sequences upstream of the signature region are amplified. These extension steps are repeated (or performed at the same time), as needed or desired. Thereafter, the products results from these amplification steps are fused using conventional steps to produce an isolated sequence of the desired length.

**[0031]** The second and third primer sets are designed, as with the primer set for the signature region, to amplify a region having highly conserved sequences among the aligned sequences. Reference herein to the term "second" or "third" primer set is for each of discussion only, and without regard to the order in which these primers are added to the reaction mixture, or used for amplification. The region amplified by the second primer set is selected so that upon amplification it anneals at its 5' end to the 3' end of the signature region. Similarly, the region amplified by the third primer set is selected so that upon amplification it anneals at its 3' end anneals to the 5' end of the signature region. Additional primer sets can be designed such that the regions which they amplify anneal to the either the 5' end or the 3' end of the extension products formed by the second or third primer sets, or by subsequent primer sets.

**[0032]** For example, where AAV is the target sequence, a first set of primers (P1 and P2) are used to amplify the signature region from the sample. In one desirable embodiment, this signature region is located within the AAV capsid. A second set of primers (P1 and P4) is used to extend the 3' end of the signature region to a location in the AAV sequence which is just before the AAV 3' ITR, i.e., providing an extension product containing the entire 3' end of the AAV capsid when using the signature region as an anchor. In one embodiment, the P4 primer corresponds to nt 4435 to 4462 of AAV2 [SEQ ID NO:7], and corresponding sequences in the other AAV serotypes. This results in amplification of a region of about 1.6 kb, which contains the 0.25 kb signature region. A third set of primers (P3 and P2) is used to extend the 5' end of signature region to a location in the AAV sequences which is in the 3' end of the rep genes, i.e., providing an extension product containing the entire 5' end of the AAV capsid when using the signature region as an anchor. In one embodiment, the P3 primer corresponds to nt 1384 to 1409 of AAV2 [SEQ ID NO:7], and corresponding sequences in the other AAV serotypes. This results in amplification of a region of about 1.7 kb, which contains the 0.25 kb signature region. Optionally, a fourth set of primers are used to further extend the extension product containing the entire 5' end of the AAV capsid to also include the rep sequences. In one embodiment, the primer designated P5 corresponds to nt 108 to 133 of AAV2 [SEQ ID NO:7], and corresponding sequences in the other AAV serotypes and is used in conjunction with the P2 primer.

**[0033]** Following completion of the desired number of extension steps, the various extension products are fused, making use of the signature region as an anchor or marker, to construct an intact sequence. In the example provided herein, AAV sequences containing, at a minimum, an intact AAV cap gene are obtained. Larger sequences may be obtained, depending upon the number of extension steps performed.

**[0034]** Suitably, the extension products are assembled into an intact AAV sequence using methods known to those of skill in the art. For example, the extension products may be digested with DralII, which cleaves at the DralII site located within the signature region, to provide restriction fragments which are re-ligated to provide products containing (at a minimum) an intact AAV cap gene. However, other suitable techniques for assembling the extension products into an intact sequence may be utilized. See, generally, Sambrook et al, cited herein.

**[0035]** As an alternative to the multiple extension steps described above, another embodiment of the invention provides for direct amplification of a 3.1 kb fragment which allows isolation of full-length cap sequences. To directly amplify a 3.1 kb full-length cap fragment from NHP tissue and blood DNAs, two other highly conserved regions were identified in AAV genomes for use in PCR amplification of large fragments. A primer within a conserved region located in the middle of the rep gene is utilized (AV1ns: 5' GCTGCGTCAACTGGACCAATGAGAAC 3', nt of SEQ ID NO:6) in combination with the 3' primer located in another conserved region downstream of the Cap gene (AV2cas: 5' CGCAGAGACCAAAGT-TCAACTGAAACGA 3', SEQ ID NO: 7) for amplification of AAV sequences including the full-length AAV cap. Typically, following amplification, the products are cloned and sequence analysis is performed with an accuracy of  $\geq 99.9\%$ . Using this method, the inventors have isolated at least 50 capsid clones which have subsequently been characterized. Among them, 37 clones were derived from Rhesus macaque tissues (rh.1 - rh.37), 6 clones from cynomolgous macaques (cy.1 - cy.6), 2 clones from Baboons (bb.1 and bb.2) and 5 clones from Chimps (ch.1 - ch.5). These clones are identified elsewhere in the specification, together with the species of animal from which they were identified and the tissues in that animal these novel sequences have been located.

## II. Diagnostic Kit

**[0036]** In another aspect, the invention provides a diagnostic kit as defined in claim 23 hereinafter for detecting the presence of an unknown adeno-associated virus (AAV) in a sample. Such a kit may contain a first set of 5' and 3' PCR primers specific for a signature region of the AAV nucleic acid sequence. Alternatively, or additionally, such a kit can contain a first set of 5' and 3' PCR primers specific for the 3.1 kb fragment which includes the full-length AAV capsid nucleic acid sequence identified herein (e.g., the AV1ns and AV2cas primers.) Optionally, a kit of the invention may further contain two or more additional sets of 5' and 3' primers, as described herein, and/or PCR probes. These primers and probes are used according to the present invention to amplify signature regions of each AAV serotype, e.g., using quantitative PCR.

**[0037]** Such a kit may further include one or more restriction enzymes, standards for AAV serotypes providing their "signature restriction enzyme digestions analyses", and/or other means for determining the serotype of the AAV detected.

**[0038]** In addition, kits of the invention may include, instructions, a negative and/or positive control, containers, diluents and buffers for the sample, indicator charts for signature comparisons, disposable gloves, decontamination instructions, applicator sticks or containers, and sample preparator cups, as well as any desired reagents, including media, wash reagents and concentration reagents. Such reagents may be readily selected from among the reagents described herein, and from among conventional concentration reagents. In one desirable embodiment, the wash reagent is an isotonic saline solution which has been buffered to physiologic pH, such as phosphate buffered saline (PBS); the elution reagent is PBS containing 0.4 M NaCl, and the concentration reagents and devices. For example, one of skill in the art will recognize that reagents such as polyethylene glycol (PEG), or  $\text{NH}_4\text{SO}_4$  may be useful, or that devices such as filter devices. For example, a filter device with a 100 K membrane would concentrate rAAV.

**[0039]** The kits provided by the present invention are useful for performing the methods described herein, and for study of biodistribution, epidemiology, mode of transmission of novel AAV serotypes in human and NHPs.

**[0040]** Thus, the methods and kits of the invention permit identification of target AAV sequences, particularly integrated AAV sequences.

**[0041]** In one notable example, the method of the invention facilitated analysis of cloned AAV sequences by the inventors, which revealed heterogeneity of proviral sequences between cloned fragments from different animals, all of which were distinct from the known six AAV serotypes, with the majority of the variation localized to hypervariable regions of the capsid protein. Surprising divergence of AAV sequences was noted in clones isolated from single tissue sources, such as lymph node, from an individual rhesus monkey. This heterogeneity is best explained by apparent evolution of AAV sequence within individual animals due, in part, to extensive homologous recombination between a limited number of co-infecting parenteral viruses. These studies suggest sequence evolution of widely disseminated virus during the course of a natural AAV infection that presumably leads to the formation of swarms of quasispecies which differ from one another in the array of capsid hypervariable regions. This is the first example of rapid molecular evolution of a DNA virus in a way that formerly was thought to be restricted to RNA viruses.

**[0042]** Sequences of several novel AAV serotypes identified by the method of the invention and characterization of these serotypes is provided.

## III. Novel AAV Serotypes

### A. Nucleic Acid Sequences

**[0043]** Nucleic acid sequences of novel AAV serotypes identified by the methods of the invention are provided. See, SEQ ID NO:1, 9 - 59, and 117 - 120. See also and the sequence listing.

**[0044]** For novel serotype AAV7, the full-length sequences, including the AAV 5' ITRs, capsid, rep, and AAV 3' ITRs are provided in SEQ ID NO:1.

**[0045]** For other novel AAV serotypes, the approximately 3.1 kb fragment isolated according to the method of the invention is provided. This fragment contains sequences encoding full-length capsid protein and all or part of the sequences encoding the rep protein. These sequences include the clones identified below.

**[0046]** For still other novel AAV serotypes, the signature region encoding the capsid protein is provided. For example, the AAV10 nucleic acid sequences include those illustrated in See, SEQ ID NO:117, which spans 255 bases. The AAV11 nucleic acid sequences include the DNA sequences illustrated in SEQ ID NO:118 which spans 258 bases. The AAV12 nucleic acid sequences include the DNA sequences illustrated in SEQ ID NO: 119, which consists of 255 bases. Using the methodology described above, further AAV10, AAV11 and AAV 12 sequences can be readily identified and used for a variety of purposes, including those described for AAV7 and the other novel serotypes herein.

**[0047]** Novel NHP sequences identified by the invention include those provided in the following Table I, which are identified by clone number:

Table 1

AAV Cap Sequence	Clone Number	Source		
		Species	Tissue	SEQ ID NO (DNA)
Rh.1	Clone 9 (AAV9)	Rhesus	Heart	5
Rh.2	Clone 43.1	Rhesus	MLN	39
Rh.3	Clone 43.5	Rhesus	MLN	40
Rh.4	Clone 43.12	Rhesus	MLN	41
Rh.5	Clone 43.20	Rhesus	MLN	42
Rh.6	Clone 43.21	Rhesus	MLN	43
Rh.7	Clone 43.23	Rhesus	MLN	44

Table 1 (cont'd)

5	Rh.8	Clone 43.25	Rhesus	MLN	45
	Rh.9	Clone 44.1	Rhesus	Liver	46
	Rh.10	Clone 44.2	Rhesus	Liver	59
10	Rh.11	Clone 44.5	Rhesus	Liver	47
	Rh.12	Clone 42.1B	Rhesus	MLN	30
	Rh.13	42.2	Rhesus	MLN	9
15	Rh.14	Clone 42.3A	Rhesus	MLN	32
	Rh.15	Clone 42.3B	Rhesus	MLN	36
	Rh.16	Clone 42.4	Rhesus	MLN	33
20	Rh.17	Clone 42.5A	Rhesus	MLN	34
	Rh.18	Clone 42.5B	Rhesus	MLN	29
25	Rh.19	Clone 42.6B	Rhesus	MLN	38
	Rh.20	Clone 42.8	Rhesus	MLN	27
	Rh.21	Clone 42.10	Rhesus	MLN	35
	Rh.22	Clone 42.11	Rhesus	MLN	37
30	Rh.23	Clone 42.12	Rhesus	MLN	58
	Rh.24	Clone 42.13	Rhesus	MLN	31
	Rh.25	Clone 42.15	Rhesus	MLN	28
	Rh.26	Clone 223.2	Rhesus	Liver	49
35	Rh.27	Clone 223.4	Rhesus	Liver	50
	Rh.28	Clone 223.5	Rhesus	Liver	51
	Rh.29	Clone 223.6	Rhesus	Liver	52
	Rh.30	Clone 223.7	Rhesus	Liver	53
40	Rh.31	Clone 223.10	Rhesus	Liver	48
	Rh.32	Clone C1	Rhesus	Spleen, Duo, Kid & Liver	19
	Rh.33	Clone C3	Rhesus		20
45	Rh.34	Clone C5	Rhesus		21
	Rh.35	Clone F1	Rhesus	Liver	22
	Rh.36	Clone F3	Rhesus		23
	Rh.37	Clone F5	Rhesus		24
50	Cy.1	Clone 1.3	Cyno	Blood	14
	Cy.2	Clone 13.3B	Cyno	Blood	15
	Cy.3	Clone 24.1	Cyno	Blood	16
	Cy.4	Clone 27.3	Cyno	Blood	17
55	Cy.5	Clone 7.2	Cyno	Blood	18
	Cy.6	Clone 16.3	Cyno	Blood	10

Table 1 (cont'd)

bb.1	Clone 29.3	Baboon	Blood	11
bb.2	Clone 29.5	Baboon	Blood	13
Ch.1	Clone A3.3	Chimp	Blood	57
Ch.2	Clone A3.4	Chimp	Blood	54
Ch.3	Clone A3.5	Chimp	Blood	55
Ch.4	Clone A3.7	Chimp	Blood	56

**[0048]** A novel NHP clone was made by splicing capsids fragments of two chimp adenoviruses into an AAV2 rep construct. This new clone, A3.1, is also termed Ch.5 [SEQ ID NO:20]. Additionally, the present invention includes two human AAV sequences, termed H6 [SEQ ID NO:25] and H2 [SEQ ID NO:26].

**[0049]** The AAV nucleic acid sequences further encompass the strand which is complementary to the strands provided in the sequences provided in the Sequence Listing [SEQ ID NO:1, 9 - 59, 117-120], nucleic acid sequences, as well as the RNA and cDNA sequences corresponding to the sequences provided in the Sequence Listing [SEQ ID NO:1, 9 - 59, 117-120], and their complementary strands. Also included in the nucleic acid sequences are natural variants and engineered modifications of the sequences of the Sequence Listing [SEQ ID NO:1, 9 - 59, 117-120], and their complementary strands. Such modifications include, for example, labels which are known in the art, methylation, and substitution of one or more of the naturally occurring nucleotides with a degenerate nucleotide.

**[0050]** Further included are nucleic acid sequences which are greater than 85%, preferably at least about 90%, more preferably at least about 95%, and most preferably at least about 98 to 99% identical or homologous to the sequences of the invention, including the Sequence Listing [SEQ ID NO:1, 9 - 59, 117-120]. These terms are as defined herein.

**[0051]** Also included are fragments of the novel AAV sequences identified by the method described herein. Suitable fragments are at least 15 nucleotides in length, and encompass functional fragments, i.e., fragments which are of biological interest. In one embodiment, these fragments are fragments of the novel sequences of the Sequence Listing [SEQ ID NO:1, 9 - 59, 117-120], their complementary strands, cDNA and RNA complementary thereto.

**[0052]** Examples of suitable fragments are provided with respect to the location of these fragments on AAV1, AAV2, or AAV7. However, using the alignment provided herein (obtained using the Clustal W program at default settings), or similar techniques for generating an alignment with other novel serotypes of the invention, one of skill in the art can readily identify the precise nucleotide start and stop codons for desired fragments.

**[0053]** Examples of suitable fragments include the sequences encoding the three variable proteins (vp) of the AAV capsid which are alternative splice variants: vp1 [e.g., nt 825 to 3049 of AA V7, SEQ ID NO: 1]; vp2 [e.g., nt 1234 - 3049 of AAV7, SEQ ID NO: 1]; and vp 3 [e.g., nt 1434 - 3049 of AAV7, SEQ ID NO:1]. It is notable that AAV7 has an unusual GTG start codon. With the exception of a few house-keeping genes, such a start codon has not previously been reported in DNA viruses. The start codons for vp1, vp2 and vp3 for other AAV serotypes have been believed to be such that they permit the cellular mechanism of the host cell in which they reside to produce vp1, vp2 and vp3 in a ratio of 10%:10%:80%, respectively, in order to permit efficient assembly of the virion. However, the AAV7 virion has been found to assemble efficiently even with this rare GTG start codon. Thus, the inventors anticipate this it is desirable to alter the start codon of the vp3 of other AAV serotypes to contain this rare GTG start codon, in order to improve packaging efficiency, to alter the virion structure and/or to alter location of epitopes (e.g., neutralizing antibody epitopes) of other AAV serotypes. The start codons may be altered using conventional techniques including, e.g., site directed mutagenesis. The altered AAV virions may be of any selected serotype, composed of a vp 3, and/or optionally, vp 1 and/or vp2 having start codons altered to GTG.

**[0054]** Other suitable fragments of AAV, include a fragment containing the start codon for the AAV capsid protein [e.g., nt 468 to 3090 of AAV7, SEQ ID NO:1, nt 725 to 3090 of AAV7, SEQ ID NO: 1, and corresponding regions of the other AAV serotypes]. Still other fragments of AAV7 and the other novel AAV semtypes identified using the methods described herein include those encoding the rep proteins, including *rep* 78 [e.g., initiation codon 334 for AAV7], *rep* 68 [initiation codon nt 334 for AAV7], *rep* 52 [initiation codon 1006 for AAV7], and *rep* 40 [initiation codon 1006 for AAV7]. Other fragments of interest may include the AAV 5' inverted terminal repeats ITRs, [nt 1 to 107 for AAV7]; the AA V 3' ITRs [nt 4704 to 4721 for AAV7], P19 sequences. AAV P40 sequences, the rep binding site, and the terminal resolute site (TRS). Still other suitable fragments will be readily apparent to those of skill in the art.

**[0055]** In addition to the nucleic acid sequences provided in the figures and Sequence Listing, there are nucleic acid molecules and sequences which are designed to express the amino acid sequences, proteins and peptides of the AAV serotypes of the invention. These include nucleic acid sequences which encode the following novel AAV amino acid sequences: C1 [SEQ ID NO:60], C2 [SEQ ID NO:61], C5 [SEQ ID NO:62], A3-3 [SEQ ID NO:66], A3-7 [SEQ ID NO:67],

A3-4 [SEQ ID NO:68], A3-5 [SEQ ID NO: 69], 3.3b [SEQ ID NO: 62], 223.4 [SEQ ID NO: 73], 223-5 [SEQ ID NO:74], 223-10 [SEQ ID NO:75], 223-2 [SEQ ID NO:76], 223-7 [SEQ ID NO: 77], 223-6 [SEQ ID NO: 78], 44-1 [SEQ ID NO: 79], 44-5 [SEQ ID NO:80], 44-2 [SEQ ID NO:81], 42-15 [SEQ ID NO: 84], 42-8 [SEQ ID NO: 85], 42-13 [SEQ ID NO:86], 42-3A [SEQ ID NO:87], 42-4 [SEQ ID NO:88], 42-5A [SEQ ID NO:89], 42-1B [SEQ ID NO:90], 42-5B [SEQ ID NO:91], 43-1 [SEQ ID NO: 92], 43-12 [SEQ ID NO: 93], 43-5 [SEQ ID NO:94], 43-21 [SEQ ID NO:96], 43-25 [SEQ ID NO: 97], 43-20 [SEQ ID NO:99], 24.1 [SEQ ID NO: 101], 42.2 [SEQ ID NO:102], 7.2 [SEQ ID NO: 103], 27.3 [SEQ ID NO: 104], 16.3 [SEQ ID NO: 105], 42.10 [SEQ ID NO: 106], 42-38 [SEQ ID NO: 107], 42-11 [SEQ ID NO: 108], F1 [SEQ ID NO: 109], F5 [SEQ ID NO: 110], F3 [SEQ ID NO:111], 42-6B [SEQ ID NO: 112], and/or 42-12 [SEQ ID NO: 113], and artificial AAV serotypes generated using these sequences and/or unique fragments thereof.

**[0056]** As used herein, artificial AAV serotypes include, without limitation, AAV with a non-naturally occurring capsid protein. Such an artificial capsid may be generated by any suitable technique, using a novel AAV sequence (e.g., a fragment of a vp1 capsid protein) in combination with heterologous sequences which may be obtained from another AAV serotype (known or novel), non-contiguous portions of the same AAV serotype, from a non-AAV viral source, or from a non-viral source. An artificial AAV serotype may be, without limitation, a chimeric AAV capsid, a recombinant AAV capsid, or a "humanized" AAV capsid.

#### B. AAV Amino Acid Sequences, Proteins and Peptides

**[0057]** The invention provides proteins and fragments thereof which are encoded by the nucleic acid sequences of the novel AAV serotypes identified herein, including, e.g., AA V7 [nt 825 to 3049 of AA V7, SEQ ID NO: 1] the other novel serotypes provided herein. Thus, the capsid proteins of the novel serotypes of the invention, including: H6 [SEQ ID NO: 25], H2 [SEQ ID NO: 26], 42-2 [SEQ ID NO:9], 42-8 [SEQ ID NO:27], 42-15 [SEQ ID NO:28], 42-5b [SEQ ID NO: 29], 42-1b [SEQ ID NO:30], 42-13 [SEQ ID NO: 31], 42-3a [SEQ ID NO: 32], 42-4 [SEQ ID NO:33], 42-5a [SEQ ID NO: 34], 42-10 [SEQ ID NO:35], 42-3b [SEQ ID NO: 36], 42-11 [SEQ ID NO: 37], 42-6b [SEQ ID NO:38], 43-1 [SEQ ID NO: 39], 43-5 [SEQ ID NO: 40], 43-12 [SEQ ID NO:41], 43-20 [SEQ ID NO:42], 43-21 [SEQ ID NO: 43], 43-23 [SEQ ID NO:44], 43-25 [SEQ ID NO: 45], 44.1 [SEQ ID NO:47], 44.5 [SEQ ID NO:47], 223.10 [SEQ ID NO:48], 223.2 [SEQ ID NO:49], 223.4 [SEQ ID NO:50], 223.5 [SEQ ID NO:51], 223.6 [SEQ ID NO: 52], 223.7 [SEQ ID NO: 53], A3.4 [SEQ ID NO: 54], A3.5 [SEQ ID NO:55], A3.7 [SEQ ID NO: 56], A3.3 [SEQ ID NO:57], 42.12 [SEQ ID NO: 58], and 44.2 [SEQ ID NO: 59], can be readily generated using conventional techniques from the open reading frames provided for the above-listed clones.

**[0058]** The sequences, proteins, and fragments may be produced by any suitable means, including recombinant production, chemical synthesis, or other synthetic means. Such production methods are within the knowledge of those of skill in the art.

#### IV. Production of rAAV with novel AAV capsids

**[0059]** Novel, wild-type AAV serotypes can be identified by the invention, the sequences of which wild-type AAV serotypes are free of DNA and/or cellular material with these viruses are associated in nature. In another aspect, the present invention provides molecules which utilize the novel AAV sequences of the invention, including fragments thereof, for production of molecules useful in delivery of a heterologous gene or other nucleic acid sequences to a target cell.

**[0060]** The following examples illustrate several aspects and embodiments of the invention.

#### EXAMPLES

**Example 1: PCR amplification, cloning and characterization of novel AAV sequences.**

**[0061]** Tissues from nonhuman primates were screened for AAV sequences using a PCR method based on oligonucleotides to highly conserved regions of known AAVs. A stretch of AAV sequence spanning 2886 to 3143 bp of AAV1 [SEQ ID NO:6] was selected as a PCR amplicon in which a hypervariable region of the capsid protein (Cap) that is unique to each known AAV serotype, which is termed herein a "signature region," is flanked by conserved sequences. In later analysis, this signature region was shown to be located between conserved residues spanning hypervariable region 3.

**[0062]** An initial survey of peripheral blood of a number of nonhuman primate species revealed detectable AAV in a subset of animals from species such as rhesus macaques, cynomolgous macaques, chimpanzees and baboons. However, there were no AAV sequences detected in some other species tested, including Japanese macaques, pig-tailed macaques and squirrel monkeys. A more extensive analysis of vector distribution was conducted in tissues of rhesus monkeys of the University of Pennsylvania and Tulane colonies recovered at necropsy. This revealed AAV sequence throughout a wide array of tissues.

**[0064]** In the line of study, a 257 bp region spanning 2886 bp to 3143 bp of AAV 1 [SEQ ID NO: 6], and the corresponding region in the genomes of AAV 2-6 genomes was identified by the inventors. This region is located with the AAV capsid gene and has highly conserved sequences among at both 5' and 3' ends and is relatively variable sequence in the middle. In addition, this region contains a DraIII restriction enzyme site (CACCACGTC, SEQ ID NO:15) . The inventors have found that this region serves as specific signature for each known type of AAV DNA. In other words, following PCR reactions, digestion with endonucleases that are specific to each known serotypes and gel electrophoresis analysis, this regions can be used to definitively identify amplified DNA as being from serotype 1, 2, 3, 4, 5, 6, or another serotype.

**[0066]** Cellular DNAs from different tissues including blood, brain, liver, lung, testis, etc. of different rhesus monkeys were studied utilizing the strategy described above. The results revealed that DNAs from different tissues of these monkeys gave rise to strong PCR amplifications. Further restriction analyses of PCR products indicated that they were amplified from AAV sequences different from any published AAV sequences.

**[0067]** PCR products (about 255 bp in size) from DNAs of a variety of monkey tissues have been cloned and sequenced. Bioinformatics study of these novel AAV sequences indicated that they are novel AAV sequences of capsid gene and distinct from each other. Multiple sequence alignment analysis was performed using the Clustal W (1.81) program. The percentage of sequence identity between the signature regions of AAV 1-7 and AAV 10-12 genomes is provided below.

Sequence #	AAV Serotype	Size (bp)
1	AAV1	258
2	AAV2	255
3	AAV3	255
4	AAV4	246
5	AAV5	258
6	AAV6	258
7	AAV7	258
10	AAV10	255
11	AAV11	258
12	AAV12	255

[illegible]

Table continued

	AAV2	AAV3	AAV4	AAV5	AAV6	AAV7	AAV10	AAV11	AAV12
AAV11									94

**[0068]** Over 300 clones containing novel AAV serotype sequences that span the selected 257 bp region were isolated and sequenced. Bioinformatics analysis of these 300+ clones suggests that this 257 bp region is critical in serving as a good land marker or signature sequence for quick isolation and identification of novel AAV serotype.

#### B. Use of the signature region for PCR amplification.

**[0069]** The 257 bp signature region was used as a PCR anchor to extend PCR amplifications to 5' of the genome to cover the junction region of rep and cap genes (1398 bp - 3143 bp, SEQ ID NO:6) and 3' of the genome to obtain the entire cap gene sequence (2866 bp - 4600 bp, SEQ ID NO:6). PCR amplifications were carried out using the standard conditions, including denaturing at 95°C for 0.5-1 min, annealing at 60-65°C for 0.5-1 min and extension at 72° C for 1 min per kb with a total number of amplification cycles ranging from 28 to 42.

**[0070]** Using the aligned sequences as described in "A", two other relative conserved regions were identified in the sequence located in 3' end of rep genes and 5' to the 257 bp region and in the sequence down stream of the 257 bp fragment but before the AAV' 3 ITR. Two sets of new primers were designed and PCR conditions optimized for recovery of entire capsid and a part of rep sequences of novel AAV serotypes. More specifically, for the 5' amplification, the 5' primer, AV1Ns, was GCTGCGTCAACTGGACCAATGAGAAC [nt 1398-1423 of AAV1, SEQ ID NO:6] and the 3' primer was 18as, identified above. For the 3' amplification, the 5' primer was 1s, identified above, and the 3' primer was AV2Las, TCGTTTCAGTTGAACTTTGGTCTCTGCG [nt 4435-4462 of AAV2, SEQ ID NO:7].

**[0071]** In these PCR amplifications, the 257 bp region was used as a PCR anchor and land marker to generate overlapping fragments to construct a complete capsid gene by fusion at the DraIII site in the signature region following amplification of the 5' and 3' extension fragments obtained as described herein. More particularly, to generate the intact AAV7 cap gene, the three amplification products (a) the sequences of the signature region; (b) the sequences of the 5' extension; and (c) the sequences of the 3' extension were cloned into a pCR4-Topo [Invitrogen] plasmid backbone according to manufacturer's instructions. Thereafter, the plasmids were digested with DraIII and recombined to form an intact cap gene.

**[0072]** In this line of work, about 80 % of capsid sequences of AAV7 and AAV 8 were isolated and analyzed. Another novel serotype, AAV9, was also discovered from Monkey #2.

**[0073]** Using the PCR conditions described above, the remaining portion of the rep gene sequence for AAV7 is isolated and cloned using the primers that amplify 108 bp to 1461 bp of AAV genome (calculated based on the numbering of AAV2, SEQ ID NO:7). This clone is sequenced for construction of a complete AAV7 genome without ITRs.

#### C. Direct Amplification of 3.1 kb Cap fragment

**[0074]** To directly amplify a 3.1 kb full-length Cap fragment from NHP tissue and blood DNAs, two other highly conserved regions were identified in AAV genomes for use in PCR amplification of large fragments. A primer within a conserved region located in the middle of the rep gene was selected (AV1ns: 5' GCTGCGTCAACTGGACCAATGAGAAC 3', nt 1398-1423 of SEQ ID NO:6) in combination with the 3' primer located in another conserved region downstream of the Cap gene (AV2cas: 5' CGCAGAGACCAAAGTTCAACTGAAACGA 3', SEQ ID NO:7) for amplification of full-length cap fragments. The PCR products were Topo-cloned according to manufacturer's directions (Invitrogen) and sequence analysis was performed by Qiagenomics (Qiagenomics, Seattle, WA) with an accuracy of ≥ 99.9%. A total of 50 capsid clones were isolated and characterized. Among them, 37 clones were derived from Rhesus macaque tissues (rh.1 - rh.37), 6 clones from cynomolgous macaques (cy.1 - cy.6), 2 clones from Baboons (bb.1 and bb.2) and 5 clones from Chimps (ch.1 - ch.5).

**[0075]** To rule out the possibility that sequence diversity within the novel AAV family was not an artifact of the PCR, such as PCR-mediated gene splicing by overlap extension between different partial DNA templates with homologous sequences, or the result of recombination process in bacteria, a series of experiments were performed under identical conditions for VP1 amplification using total cellular DNAs. First, intact AAV7 and AAV8 plasmids were mixed at an equal molar ratio followed by serial dilutions. The serially diluted mixtures were used as templates for PCR amplification of 3.1 kb VP1 fragments using universal primers and identical PCR conditions to that were used for DNA amplifications to see whether any hybrid PCR products were generated. The mixture was transformed into bacteria and isolated transformants to look for hybrid clones possibly derived from recombination process in bacterial cells. In a different experiment, we restricted AAV7 and AAV8 plasmids with Msp I, Ava I and HaeI, all of which cut both genomes multiple times at different



positions, mixed the digestions in different combinations and used them for PCR amplification of VP1 fragments under the same conditions to test whether any PCR products could be generated through overlap sequence extension of partial AAV sequences. In another experiment, a mixture of gel purified 5' 1.5 kb AAV7 VP1 fragment and 3' 1.7 kb AAV8 VP1 fragment with overlap in the signature region was serially diluted and used for PCR amplification in the presence and absence of 200 ng cellular DNA extracted from a monkey cell line that was free of AAV sequences by TaqMan analysis. None of these experiments demonstrated efficient PCR-mediated overlap sequence production under the conditions of the genomic DNA Cap amplification (data not shown). As a further confirmation, 3 pairs of primers were designed, which were located at different HVRs, and were sequence specific to the variants of clone 42s from Rhesus macaque F953, in different combinations to amplify shorter fragments from mesenteric lymph node (MLN) DNA from F953 from which clone 42s were isolated. All sequence variations identified in full-length Cap clones were found in these short fragments (data not shown).

#### Example 2: Adeno-Associated Viruses Undergo Substantial Evolution in Primates During Natural Infections

**[0076]** Sequence analysis of selected AAV isolates revealed divergence throughout the genome that is most concentrated in hypervariable regions of the capsid proteins. Epidemiologic data indicate that all known serotypes are endemic to primates, although isolation of clinical isolates has been restricted to AAV2 and AAV3 from anal and throat swabs of human infants and AAV5 from a human condylomatous wart. No known clinical sequelae have been associated with AAV infection.

**[0077]** In an attempt to better understand the biology of AAV, nonhuman primates were used as models to characterize the sequelae of natural infections. Tissues from nonhuman primates were screened for AAV sequences using the PCR method of the invention based on oligonucleotides to highly conserved regions of known AAVs (see Example 1). A stretch of AAV sequence spanning 2886 to 3143 bp of AAV1 [SEQ ID NO:6] was selected as a PCR amplicon in which conserved sequences are flanked by a hypervariable region that is unique to each known AAV serotype, termed herein a "signature region."

**[0078]** An initial survey of peripheral blood of a number of nonhuman primate species including rhesus monkeys, cynomolgous monkeys, chimpanzees, and baboons revealed detectable AAV in a subset of animals from all species. A more extensive analysis of vector distribution was conducted in tissues of rhesus monkeys of the University of Pennsylvania and Tulane colonies recovered at necropsy. This revealed AAV sequence throughout a wide array of tissues.

**[0079]** The amplified signature sequences were subcloned into plasmids and individual transformants were subjected to sequence analysis. This revealed substantial variation in nucleotide sequence of clones derived from different animals. Variation in the signature sequence was also noted in clones obtained within individual animals. Tissues harvested from two animals in which unique signature sequences were identified (i.e., colon from 98E044 and heart from 98E056) were further characterized by expanding the sequence amplified by PCR using oligonucleotides to highly conserved sequences. In this way, complete proviral structures were reconstructed for viral genomes from both tissues as described herein. These proviruses differ from the other known AAVs with the greatest sequence divergence noted in regions of the Cap gene.

**[0080]** Additional experiments were performed to confirm that AAV sequences resident to the nonhuman primate tissue represented proviral genomes of infectious virus that is capable of being rescued and form virions. Genomic DNA from liver tissue of animal 98E056, from which AAV8 signature sequence was detected, was digested with an endonuclease that does not have a site within the AAV sequence and transfected into 293 cells with a plasmid containing an E1 deleted genome of human adenovirus serotype 5 as a source of helper functions. The resulting lysate was passaged on 293 cells once and the lysate was recovered and analyzed for the presence of AAV Cap proteins using a broadly reacting polyclonal antibody to Cap proteins and for the presence and abundance of DNA sequences from the PCR amplified AAV provirus from which AAV8 was derived. Transfection of endonuclease restricted heart DNA and the adenovirus helper plasmid yielded high quantities of AAV8 virus as demonstrated by the detection of Cap proteins by Western blot analysis and the presence of  $10^4$  AAV8 vector genomes per 293 cell. Lysates were generated from a large-scale preparation and the AAV was purified by cesium sedimentation. The purified preparation demonstrated 26 nm icosahedral structures that look identical to those of AAV serotype 2. Transfection with the adenovirus helper alone did not yield AAV proteins or genomes, ruling out contamination as a source of the rescued AAV.

**[0081]** To further characterize the inter and intra animal variation of AAV signature sequence, selected tissues were subjected to extended PCR to amplify entire Cap open reading frames.

**[0082]** The resulting fragments were cloned into bacterial plasmids and individual transformants were isolated and fully sequenced. This analysis involved mesenteric lymph nodes from three rhesus monkeys (Tulane/V223 - 6 clones; Tulane/T612 - 7 clones; Tulane/F953 - 14 clones), liver from two rhesus monkeys (Tulane/V251 - 3 clones; Penn/00E033 - 3 clones), spleen from one rhesus monkey (Penn/97E043 - 3 clones), heart from one rhesus monkey (IHGT/98E046-1 clone) and peripheral blood from one chimpanzee (New Iberia/X133 - 5 clones), six cynomolgous macaques (Charles River/A1378, A3099, A3388, A3442, A2821, A3242 - 6 clones total) and one Baboon (SFRB/8644 - 2 clones). Of the

50 clones that were sequenced from 15 different animals, 30 were considered non-redundant based on the finding of at least 7 amino acid differences from one another. The non-redundant VP1 clones are numbered sequentially as they were isolated, with a prefix indicating the species of non-human primate from which they were derived. The structural relationships between these 30 non-redundant clones and the previously described 8 AAV serotypes were determined using the SplitsTree program [Huson, D. H. SplitsTree: analyzing and visualizing evolutionary data. *Bioinformatics* **14**, 68-73 (1998)] with implementation of the method of split decomposition. The analysis depicts homoplasy between a set of sequences in a tree-like network rather than a bifurcating tree. The advantage is to enable detection of groupings that are the result of convergence and to exhibit phylogenetic relationships even when they are distorted by parallel events. Extensive phylogenetic research will be required in order to elucidate the AAV evolution, whereas the intention here only is to group the different clones as to their sequence similarity.

**[0083]** To confirm that the novel VP1 sequences were derived from infectious viral genomes, cellular DNA from tissues with high abundance of viral DNA was restricted with an endonuclease that should not cleave within AAV and transfected into 293 cells, followed by infection with adenovirus. This resulted in rescue and amplification of AAV genomes from DNA of tissues from two different animals (data not shown).

**[0084]** VP1 sequences of the novel AAVs were further characterized with respect to the nature and location of amino acid sequence variation. All 30 VP1 clones that were shown to differ from one another by greater than 1% amino acid sequence were aligned and scored for variation at each residue. An algorithm developed to determine areas of sequence divergence yielded 12 hypervariable regions (HVR) of which 5 overlap or are part of the 4 previously described variable regions [Kotin, cited above; Rutledge, cited above]. The threefold-proximal peaks contain most of the variability (HVR5-10). Interestingly the loops located at the 2 and 5 fold axis show intense variation as well. The HVRs 1 and 2 occur in the N-terminal portion of the capsid protein that is not resolved in the X-ray structure suggesting that the N-terminus of the VP1 protein is exposed on the surface of the virion.

**[0085]** Real-time PCR was used to quantify AAV sequences from tissues of 21 rhesus monkeys using primers and probes to highly conserved regions of Rep (one set) and Cap (two sets) of known AAVs. Each data point represents analysis from tissue DNA from an individual animal. This confirmed the wide distribution of AAV sequences, although the quantitative distribution differed between individual animals. The source of animals and previous history or treatments did not appear to influence distribution of AAV sequences in rhesus macaques. The three different sets of primers and probes used to quantify AAV yielded consistent results. The highest levels of AAV were found consistently in mesenteric lymph nodes at an average of 0.01 copies per diploid genome for 13 animals that were positive. Liver and spleen also contained high abundance of virus DNA. There were examples of very high AAV, such as in heart of rhesus macaque 98E056, spleen of rhesus macaque 97E043 and liver of rhesus macaque RQ4407, which demonstrated 1.5, 3 and 20 copies of AAV sequence per diploid genome respectively. Relatively low levels of virus DNA were noted in peripheral blood mononuclear cells, suggesting the data in tissue are not due to resident blood components (data not shown). It should be noted that this method would not necessarily capture all AAVs resident to the nonhuman primates since detection requires high homology to both the oligonucleotides and the real time PCR probe. Tissues from animals with high abundance AAV DNA was further analyzed for the molecular state of the DNA, by DNA hybridization techniques, and its cellular distribution, by *in situ* hybridization.

**[0086]** The kind of sequence variation revealed in AAV proviral fragments isolated from different animals and within tissues of the same animals is reminiscent of the evolution that occurs for many RNA viruses during pandemics or even within the infection of an individual. In some situations the notion of a wild-type virus has been replaced by the existence of swarms of quasispecies that evolve as a result of rapid replication and mutations in the presence of selective pressure. One example is infection by HIV, which evolves in response to immunologic and pharmacologic pressure. Several mechanisms contribute to the high rate of mutations in RNA viruses, including low fidelity and lack of proof reading capacity of reverse transcriptase and non-homologous and homologous recombination.

**[0087]** Evidence for the formation of quasispecies of AAV was illustrated in this study by the systematic sequencing of multiple cloned proviral fragments. In fact, identical sequences could not be found within any extended clones isolated between or within animals. An important mechanism for this evolution of sequence appears to be a high rate of homologous recombination between a more limited number of parenteral viruses. The net result is extensive swapping of hypervariable regions of the Cap protein leading to an array of chimeras that could have different tropisms and serologic specificities (i.e., the ability to escape immunologic responses especially as it relates to neutralizing antibodies). Mechanisms by which homologous recombination could occur are unclear. One possibility is that + and - strands of different single stranded AAV genomes anneal during replication as has been described during high multiplicity of infections with AAV recombinants. It is unclear if other mechanisms contribute to sequence evolution in AAV infections. The overall rate of mutation that occurs during AAV replication appears to be relatively low and the data do not suggest high frequencies of replication errors. However, substantial rearrangements of the AAV genome have been described during lytic infection leading to the formation of defective interfering particles. Irrespective of the mechanisms that lead to sequence divergence, with few exceptions, vp1 structures of the quasispecies remained intact without frameshifts or nonsense mutations suggesting that competitive selection of viruses with the most favorable profile of fitness contribute to the population

dynamics.

[0088] These studies have implications in several areas of biology and medicine. The concept of rapid virus evolution, formerly thought to be a property restricted to RNA viruses, should be considered in DNA viruses, which classically have been characterized by serologic assays. It will be important in terms of parvoviruses to develop a new method for describing virus isolates that captures the complexity of its structure and biology, such as with HIV, which are categorized as general families of similar structure and function called Clades. An alternative strategy is to continue to categorize isolates with respect to serologic specificity and develop criteria for describing variants within serologic groups.

Example 3: Vectorology of recombinant AAV genomes equipped with AAV2 ITRs using chimeric plasmids containing AAV2 rep and novel AAV cap genes for serological and gene transfer studies in different animal models.

[0089] Chimeric packaging constructs are generated by fusing AAV2 rep with cap sequences of novel AAV serotypes. These chimeric packaging constructs are used, initially, for pseudotyping recombinant AAV genomes carrying AAV2 ITRs by triple transfection in 293 cell using Ad5 helper plasmid. These pseudotyped vectors are used to evaluate performance in transduction-based serological studies and evaluate gene transfer efficiency of novel AAV serotypes in different animal models including NHP and rodents, before intact and infectious viruses of these novel serotypes are isolated.

#### A. pAAV2GFP

[0090] The AAV2 plasmid which contains the AAV2 ITRs and green fluorescent protein expressed under the control of a constitutive promoter. This plasmid contains the following elements: the AAV2 ITRs, a CMV promoter, and the GFP coding sequences.

#### B. Cloning of trans plasmid

[0091] To construct the chimeric trans-plasmid for production of recombinant pseudotyped AAV7 vectors, p5E18 plasmid (Xiao *et al.*, 1999, *J. Virol* 73:3994-4003) was partially digested with Xho I to linearize the plasmid at the Xho I site at the position of 3169 bp only. The Xho I cut ends were then filled in and ligated back. This modified p5E18 plasmid was restricted with Xba I and Xho I in a complete digestion to remove the AAV2 cap gene sequence and replaced with a 2267 bp Spe I/Xho I fragment containing the AAV7 cap gene which was isolated from pCRAAV7 6-5+15-4 plasmid.

[0092] The resulting plasmid contains the AAV2 rep sequences for Rep78/68 under the control of the AAV2 P5 promoter, and the AAV2 rep sequences for Rep52/40 under the control of the AAV2 P19 promoter. The AAV7 capsid sequences are under the control of the AAV2 P40 promoter, which is located within the Rep sequences. This plasmid further contains a spacer 5' of the rep ORF.

#### C. Production of Pseudotyped rAAV

[0093] The rAAV particles (AAV2 vector in AAV7 capsid) are generated using an adenovirus-free method. Briefly, the cis plasmid (pAAV2.1 lacZ plasmid containing AAV2 ITRs), and the trans plasmid pCRAAV7 6-5+15-4 (containing the AAV2 rep and AAV7 cap) and a helper plasmid, respectively, were simultaneously co-transfected into 293 cells in a ratio of 1:1:2 by calcium phosphate precipitation.

[0094] For the construction of the pAd helper plasmids, pBG 10 plasmid was purchased from Microbix (Canada). A RsrII fragment containing L2 and L3 was deleted from pBHG10, resulting in the first helper plasmid, pAdΔF13. Plasmid AdΔ F1 was constructed by cloning Asp700/Sall fragment with a PmeI/SgfI deletion, isolating from pBHG10, into Bluescript. MLP, L2, L2 and L3 were deleted in the pAdΔF1. Further deletions of a 2.3 kb NruI fragment and, subsequently, a 0.5 kb RsrII/NruI fragment generated helper plasmids pAdΔF5 and pAdΔF6, respectively. The helper plasmid, termed pΔF6, provides the essential helper functions of E2a and E4 ORF6 not provided by the E1-expressing helper cell, but is deleted of adenoviral capsid proteins and functional E1 regions).

[0095] Typically, 50 μg of DNA (cis:trans:helper) was transfected onto a 150 mm tissue culture dish. The 293 cells were harvested 72 hours post-transfection, sonicated and treated with 0.5% sodium deoxycholate (37°C for 10 min.) Cell lysates were then subjected to two rounds of a CsCl gradient. Peak fractions containing rAAV vector are collected, pooled and dialyzed against PBS.

Example 4: Creation of infectious clones carrying intact novel AAV serotypes for study of basic virology in human and NHP derived cell lines and evaluation of pathogenesis of novel AAV serotypes in NHP and other animal models.

[0096] To achieve this goal, the genome walker system is employed to obtain 5' and 3' terminal sequences (ITRs)

and complete construction of clones containing intact novel AAV serotype genomes.

**[0097]** Briefly, utilizing a commercially available Universal Genome Walker Kit [Clontech], genomic DNAs from monkey tissues or cell lines that are identified as positive for the presence of AAV7 sequence are digested with Dra I, EcoR V, Pvu II and Stu I endonucleases and ligated to Genome Walker Adaptor to generate 4 individual Genome Walker Libraries (GWLs). Using DNAs from GWLs as templates, AAV7 and adjacent genomic sequences will be PCR-amplified by the adaptor primer 1 (API, provided in the kit) and an AAV7 specific primer 1, followed by a nested PCR using the adaptor primer 2 (AP2) and another AAV7 specific primer 2, both of which are internal to the first set of primers. The major PCR products from the nested PCR are cloned and characterized by sequencing analysis.

**[0098]** In this experiment, the primers covering the 257 bp or other signature fragment of a generic AAV genome are used for PCR amplification of cellular DNAs extracted from Human and NHP derived cell lines to identify and characterize latent AAV sequences. The identified latent AAV genomes are rescued from the positive cell lines using adenovirus helpers of different species and strains.

**[0099]** To isolate infectious AAV clones from NHP derived cell lines, a desired cell line is obtained from ATCC and screened by PCR to identify the 257 bp amplicon, i.e., signature region of the invention. The 257 bp PCR product is cloned and serotyped by sequencing analysis. For these cell lines containing the AAV7 sequence, the cells are infected with SV-15, a simian adenovirus purchased from ATCC, human Ad5 or transfected with plasmid construct housing the human Ad genes that are responsible for AAV helper functions. At 48 hour post infection or transfection, the cells are harvested and Hirt DNA is prepared for cloning of AAV7 genome following Xiao et al., 1999, J. Virol, 73:3994-4003.

#### Example 5 - Production of AAV Vectors

**[0100]** A pseudotyping strategy similar to that of Example 3 for AAV1/7 was employed to produce AAV2 vectors packaged with AAV1, AAV5 and AAV8 capsid proteins. Briefly, recombinant AAV genomes equipped with AAV2 ITRs were packaged by triple transfection of 293 cells with cis-plasmid, adenovirus helper plasmid and a chimeric packaging construct where the AAV2 rep gene is fused with cap genes of novel AAV serotypes. To create the chimeric packaging constructs, the Xho I site of p5E18 plasmid at 3169 bp was ablated and the modified plasmid was restricted with Xba I and Xho I in a complete digestion to remove the AAV2 cap gene and replace it with a 2267 bp Spe I/Xho I fragment containing the AAV8 cap gene [Xiao, W., et al., (1999) *J Virol* 73, 3994-4003]. A similar cloning strategy was used for creation of chimeric packaging plasmids of AAV2/1 and AAV2/5. All recombinant vectors were purified by the standard CsCl<sub>2</sub> sedimentation method except for AAV2/2, which was purified by single step heparin chromatography.

**[0101]** Genome copy (GC) titers of AAV vectors were determined by TaqMan analysis using probes and primers targeting SV40 poly A region as described previously [Gao, G., et al., (2000) *Hum Gene Ther* 11, 2079-91].

**[0102]** Vectors were constructed for each serotype for a number of *in vitro* and *in vivo* studies. Eight different transgene cassettes were incorporated into the vectors and recombinant virions were produced for each serotype. The recovery of virus, based on genome copies, is summarized in Table 4 below. The yields of vector were high for each serotype with no consistent differences between serotypes. Data presented in the table are average genome copy yields with standard deviation x 10<sup>13</sup> of multiple production lots of 50 plate (150 mm) transfections.

**Table 4. Production of Recombinant Vectors**

	AAV2/1	AAV2/2	AAV2/5	AAV2/7	AAV2/8
<b>CMV LacZ</b>	7.30 ± 4.33 (n=9)	4.49 ± 2.89 (n=6)	5.19 ± 5.19 (n=8)	3.42 (n=1)	0.87 (n=1)
<b>CMV EGFP</b>	6.43 ± 2.42 (n=2)	3.39 ± 2.42 (n=2)	5.55 ± 6.49 (n=4)	2.98 ± 2.66 (n=2)	3.74 ± 3.88 (n=2)
<b>TBG LacZ</b>	4.18 (n=1)	0.23 (n=1)	0.704 ± 0.43 (n=2)	2.16 (n=1)	0.532 (n=1)
<b>Alb A1AT</b>	4.67 ± 0.75 (n=2)	4.77 (n=1)	4.09 (n=1)	5.04 (n=1)	2.02 (n=1)
<b>CB A1AT</b>	0.567 (n=1)	0.438 (n=1)	2.82 (n=1)	2.78 (n=1)	0.816 ± 0.679 (n=2)
<b>TBG rhCG</b>	8.51 ± 6.65 (n=6)	3.47 ± 2.09 (n=5)	5.26 ± 3.85 (n=4)	6.52 ± 3.08 (n=4)	1.83 ± 0.98 (n=5)
<b>TBG cFIX</b>	1.24 ± 1.29 (n=3)	0.63 ± 0.394 (n=6)	3.74 ± 2.48 (n=7)	4.05 (n=1)	15.8 ± 15.0 (n=5)

#### Example 6 - Serologic Analysis of Pseudotyped Vectors

**[0103]** C57BL/6 mice were injected with vectors of different serotypes of AAVCBA1AT vectors intramuscularly (5 x

10<sup>11</sup> GC) and serum samples were collected 34 days later. To test neutralizing and cross-neutralizing activity of sera to each serotype of AAV, sera was analyzed in a transduction based neutralizing antibody assay [Gao, G. P., et al., (1996) *J Virol* **70**, 8934-43]. More specifically, the presence of neutralizing antibodies was determined by assessing the ability of serum to inhibit transduction of 84-31 cells by reporter viruses (AAVCMVEGFP) of different serotypes. Specifically, the reporter virus AAVCMVEGFP of each serotype [at multiplicity of infection (MOI) that led to a transduction of 90% of indicator cells] was pre-incubated with heat-inactivated serum from animals that received different serotypes of AAV or from naïve mice. After 1-hour incubation at 37° C, viruses were added to 84-31 cells in 96 well plates for 48 or 72- hour, depending on the virus serotype. Expression of GFP was measured by Fluorolmagin (Molecular Dynamics) and quantified by Image Quant Software. Neutralizing antibody titers were reported as the highest serum dilution that inhibited transduction to less than 50%.

[0104] The availability of GFP expressing vectors simplified the development of an assay for neutralizing antibodies that was based on inhibition of transduction in a permissive cell line (i.e., 293 cells stably expressing E4 from Ad5). Sera to selected AAV serotypes were generated by intramuscular injection of the recombinant viruses. Neutralization of AAV transduction by 1:20 and 1:80 dilutions of the antisera was evaluated (See Table 5 below). Antisera to AAV1, AAV2, AAV5 and AAV8 neutralized transduction of the serotype to which the antiserum was generated (AAV5 and AAV8 to a lesser extent than AAV1 and AAV2) but not to the other serotype (i.e., there was no evidence of cross neutralization suggesting that AAV 8 is a truly unique serotype).

Table 5. Serological Analysis of New AAV Serotypes.

		% Infection on 84-31 cells with AAVCMVEGFP virus:									
		AAV2/1		AAV2/2		AAV2/5		AAV2/7		AAV2/8	
		Serum dilution:		Serum dilution:		Serum dilution:		Serum dilution:		Serum dilution:	
Sera:	Immunization Vector	1/20	1/80	1/20	1/80	1/20	1/80	1/20	1/80	1/20	1/80
Group 1	AAV2/1	0	0	100	100	100	100	100	100	100	100
Group 2	AAV2/2	100	100	0	0	100	100	100	100	100	100
Group 3	AAV2/5	100	100	100	100	16.5	16.5	100	100	100	100
Group 4	AAV2/7	100	100	100	100	100	100	61.5	100	100	100
Group 5	AAV2/8	100	100	100	100	100	100	100	100	26.3	60

[0105] Human sera from 52 normal subjects were screened for neutralization against selected serotypes. No serum sample was found to neutralize AAV2/7 and AAV2/8 while AAV2/2 and AAV2/1 vectors were neutralized in 20% and 10% of sera, respectively. A fraction of human pooled IgG representing a collection of 60,000 individual samples did not neutralize AAV2/7 and AAV2/8, whereas AAV2/2 and AAV2/1 vectors were neutralized at titers of serum equal to 1/1280 and 1/640, respectively.

#### Example 7 - *In vivo* Evaluation of Different Serotypes of AAV Vectors

[0106] In this study, 7 recombinant AAV genomes, AAV2CBhA1AT, AAV2AlbA1AT, AAV2CMVrhCG, AAV2TBGrhCG, AAV2TBGcFIX, AAV2CMVLacZ and AAV2TBGLacZ were packaged with capsid proteins of different serotypes. In all 7 constructs, minigene cassettes were flanked with AAV2 ITRs. cDNAs of human  $\alpha$ -antitrypsin (A1AT) [Xiao, W., et al., (1999) *J Virol* **73**, 3994-4003]  $\beta$ -subunit of rhesus monkey choriogonadotropic hormone (CG) [Zoltick, P. W. & Wilson, J. M. (2000) *Mol Ther* **2**, 657-9] canine factor IX [Wang, L., et al., (1997) *Proc Natl Acad Sci USA* **94**, 11563-6] and bacterial  $\beta$ -galactosidase (i.e., Lac Z) genes were used as reporter genes. For liver-directed gene transfer, either mouse albumin gene promoter (Alb) [Xiao, W. (1999), cited above] or human thyroid hormone binding globulin gene promoter (TBG) [Wang (1997), cited above] was used to drive liver specific expression of reporter genes. In muscle-directed gene transfer experiments, either cytomegalovirus early promoter (CMV) or chicken  $\beta$ -actin promoter with CMV enhancer (CB) was employed to direct expression of reporters.

[0107] For muscle-directed gene transfer, vectors were injected into the right tibialis anterior of 4-6 week old NCR nude or C57BL/6 mice (Taconic, Germantown, NY). In liver-directed gene transfer studies, vectors were infused intraportally into 7-9 week old NCR nude or C57BL/6 mice (Taconic, Germantown, NY). Serum samples were collected intraorbitally at different time points after vector administration. Muscle and liver tissues were harvested at different time points for cryosectioning and Xgal histochemical staining from animals that received the lacZ vectors. For the re-administration experiment, C56BL/6 mice initially received AAV2/1, 2/2, 2/5, 2/7 and 2/8CBA1AT vectors intramuscularly and followed for A1AT gene expression for 7 weeks. Animals were then treated with AAV2/8TBGcFIX intraportally and studied for cFIX gene expression.

[0108] ELISA based assays were performed to quantify serum levels of hA1AT, rhCG and cFIX proteins as described previously [Gao, G. P., et al., (1996) *J Virol* **70**, 8934-43; Zoltick, P. W. & Wilson, J. M. (2000) *Mol Ther* **2**, 657-9; Wang, L., et al., *Proc Natl Acad Sci U S A* **94**, 11563-6]. The experiments were completed when animals were sacrificed for harvest of muscle and liver tissues for DNA extraction and quantitative analysis of genome copies of vectors present in target tissues by TaqMan using the same set of primers and probe as in titration of vector preparations [Zhang, Y., et al., (2001) *Mol Ther* **3**, 697-707].

[0109] The performance of vectors base on the new serotypes were evaluated in murine models of muscle and liver-directed gene transfer and compared to vectors based on the known serotypes AAV1, AAV2 and AAV5. Vectors expressing secreted proteins (alpha-antitrypsin (A1AT) and chorionic gonadotropin (CG)) were used to quantitate relative transduction efficiencies between different serotypes through ELISA analysis of sera. The cellular distribution of transduction within the target organ was evaluated using lacZ expressing vectors and X-gal histochemistry.

[0110] The performance of AAV vectors in skeletal muscle was analyzed following direct injection into the tibialis anterior muscles. Vectors contained the same AAV2 based genome with the immediate early gene of CMV or a CMV enhanced  $\beta$ -actin promoter driving expression of the transgene. Previous studies indicated that immune competent C57BL/6 mice elicit limited humoral responses to the human A1AT protein when expressed from AAV vectors [Xiao, W., et al., (1999) *J Virol* **73**, 3994-4003].

[0111] In each strain, AAV2/1 vector produced the highest levels of A1AT and AAV2/2 vector the lowest, with AAV2/7 and AAV2/8 vectors showing intermediate levels of expression. Peak levels of CG at 28 days following injection of nu/nu NCR mice showed the highest levels from AAV2/7 and the lowest from AAV2/2 with AAV2/8 and AAV2/1 in between. Injection of AAV2/1 and AAV2/7 lacZ vectors yielded gene expression at the injection sites in all muscle fibers with substantially fewer lacZ positive fibers observed with AAV2/2 and AAV 2/8 vectors. These data indicate that the efficiency of transduction with AA V2/7 vectors in skeletal muscle is similar to that obtained with AAV2/1, which is the most efficient in skeletal muscle of the previously described serotypes [Xiao, W. (1999), cited above; Chao, H., et al., (2001) *Mol Ther* **4**, 217-22; Chao, H., et al., (2000) *Mol Ther* **2**, 619-23].

[0112] Similar murine models were used to evaluate liver-directed gene transfer. Identical doses of vector based on genome copies were infused into the portal veins of mice that were analyzed subsequently for expression of the transgene. Each vector contained an AAV2 based genome using previously described liver-specific promoters (i.e., albumin or thyroid hormone binding globulin) to drive expression of the transgene. More particularly, CMVCG and TBGCG minigene cassettes were used for muscle and liver-directed gene transfer, respectively. Levels of rhCG were defined as relative units (RUs  $\times 10^3$ ). The data were from assaying serum samples collected at day 28, post vector administration (4 animals per group). As shown in Table 3, the impact of capsid proteins on the efficiency of transduction of A1AT vectors in nu/nu and C57BL/6 mice and CG vectors in C57BL/6 mice was consistent (See Table 6).

Table 6. Expression of  $\beta$ -unit of Rhesus Monkey Chorionic Gonadotropin (rhCG)

Vector	Muscle	Liver
AAV2/1	4.5 $\pm$ 2.1	1.6 $\pm$ 1.0
AAV2	0.5 $\pm$ 0.1	0.7 $\pm$ 0.3
AAV2/5	ND*	4.8 $\pm$ 0.8
AAV2/7	14.2 $\pm$ 2.4	8.2 $\pm$ 4.3
AAV2/8	4.0 $\pm$ 0.7	76.0 $\pm$ 22.8

\* Not determined in this experiment.

[0113] In all cases, AAV2/8 vectors yielded the highest levels of transgene expression that ranged from 16 to 110 greater than what was obtained with AAV2/2 vectors; expression from AAV2/5 and AAV2/7 vectors was intermediate with AAV2/7 higher than AAV2/5. Analysis of X-Gal stained liver sections of animals that received the corresponding lacZ vectors showed a correlation between the number of transduced cells and overall levels of transgene expression. DNAs extracted from livers of C57BL/6 mice who received the A1AT vectors were analyzed for abundance of vector DNA using real time PCR technology.

[0114] The amount of vector DNA found in liver 56 days after injection correlated with the levels of transgene expression (See Table 7). For this experiment, a set of probe and primers targeting the SV40 polyA region of the vector genome was used for TaqMan PCR. Values shown are means of three individual animals with standard deviations. The animals were sacrificed at day 56 to harvest liver tissues for DNA extraction. These studies indicate that AAV8 is the most efficient vector for liver-directed gene transfer due to increased numbers of transduced hepatocytes.

**Table 7 - Real Time PCR Analysis for Abundance of AAV Vectors in nu/nu Mouse Liver Following Injection of  $1 \times 10^{11}$  Genome Copies of Vector.**

AAV vectors/Dose	Genome Copies per Cell
AAV2/1A1bA1AT	$0.6 \pm 0.36$
AAV2A1bA1AT	$0.003 \pm 0.001$
AAV2/5A1bA1AT	$0.83 \pm 0.64$
AAV2/7A1bA1AT	$2.2 \pm 1.7$
AAV2/8A1bA1AT	$18 \pm 11$

[0115] The serologic data described above suggest that AAV2/8 vector should not be neutralized *in vivo* following immunization with the other serotypes. C57BL/6 mice received intraportal injections of AAV2/8 vector expressing canine factor IX ( $10^{11}$  genome copies) 56 days after they received intramuscular injections of A1AT vectors of different serotypes. High levels of factor IX expression were obtained 14 days following infusion of AAV2/8 into naïve animals ( $17 \pm 2$   $\mu\text{g/ml}$ ,  $n=4$ ) which were not significantly different than what was observed in animals immunized with AAV2/1 ( $31 \pm 23$   $\mu\text{g/ml}$ ,  $n=4$ ), AAV2/2 ( $16$   $\mu\text{g/ml}$ ,  $n=2$ ), and AAV2/7 ( $12$   $\mu\text{g/ml}$ ,  $n=2$ ). This contrasts to what was observed in AAV2/8 immunized animals that were infused with the AAV2/8 factor IX vector in which no detectable factor IX was observed ( $<0.1$   $\mu\text{g/ml}$ ,  $n=4$ ).

[0116] Oligonucleotides to conserved regions of the cap gene did amplify sequences from rhesus monkeys that represented unique AAVs. Identical cap signature sequences were found in multiple tissues from rhesus monkeys derived from at least two different colonies. Full-length rep and cap open reading frames were isolated and sequenced from single sources. Only the cap open reading frames of the novel AAVs were necessary to evaluate their potential as vectors because vectors with the AAV7 or AAV8 capsids were generated using the ITRs and rep from AAV2. This also simplified the comparison of different vectors since the actual vector genome is identical between different vector serotypes. In fact, the yields of recombinant vectors generated using this approach did not differ between serotypes.

[0117] Vectors based on AAV7 and AAV8 appear to be immunologically distinct (i.e., they are not neutralized by antibodies generated against other serotypes). Furthermore, sera from humans do not neutralize transduction by AAV7 and AAV8 vectors, which is a substantial advantage over the human derived AAVs currently under development for which a significant proportion of the human population has pre-existing immunity that is neutralizing [Chirmule, N., et al., (1999) *Gene Ther* 6, 1574-83].

[0118] The tropism of each new vector is favorable for *in vivo* applications. AAV2/7 vectors appear to transduce skeletal muscle as efficiently as AAV2/1, which is the serotype that confers the highest level of transduction in skeletal muscle of the primate AAVs tested to date [Xiao, W., cited above; Chou (2001), cited above, and Chou (2000), cited above]. Importantly, AAV2/8 provides a substantial advantage over the other serotypes in terms of efficiency of gene transfer to liver that until now has been relatively disappointing in terms of the numbers of hepatocytes stably transduced. AAV2/8 consistently achieved a 10 to 100-fold improvement in gene transfer efficiency as compared to the other vectors. The basis for the improved efficiency of AAV2/8 is unclear, although it presumably is due to uptake via a different receptor that is more active on the basolateral surface of hepatocytes. This improved efficiency will be quite useful in the development of liver-directed gene transfer where the number of transduced cells is critical, such as in urea cycle disorders and familial hypercholesterolemia.

[0119] Thus, the present invention provides a novel approach for isolating new AAVs based on PCR retrieval of genomic sequences. The amplified sequences were easily incorporated into vectors and tested in animals. The lack of pre-existing immunity to AAV7 and the favorable tropism of the vectors for muscle indicates that AAV7 is suitable for use as a vector in human gene therapy and other *in vivo* applications. Similarly, the lack of pre-existing immunity to the AAV serotypes of the invention, and their tropisms, renders them useful in delivery of therapeutic molecules and other useful molecules.

#### Example 9 - Tissue Tropism Studies

[0120] In the design of a high throughput functional screening scheme for novel AAV constructs, a non-tissue specific and highly active promoter, CB promoter (CMV enhanced chicken  $\beta$  actin promoter) was selected to drive an easily detectable and quantifiable reporter gene, human  $\alpha$  anti-trypsin gene. Thus only one vector for each new AAV clone needs to be made for gene transfer studies targeting 3 different tissues, liver, lung and muscle to screen for tissue tropism of a particular AAV construct. The following table summarizes data generated from 4 novel AAV vectors in the tissue tropism studies (AAVCBA1AT), from which a novel AAV capsid clone, 44.2, was found to be a very potent gene transfer vehicle in all 3 tissues with a big lead in the lung tissue particularly. Table 8 reports data obtained (in  $\mu\text{g}$  A1AT/mL serum) at day 14 of the study.

Table 8

Vector	Target Tissue		
	Lung	Liver	Muscle
AAV2/1	ND	ND	45±11
AAV2/5	0.6±0.2	ND	ND
AAV2/8	ND	84±30	ND
AAV2/rh.2 (43.1)	14±7	25±7.4	35±14
AAV2/rh.10 (44.2)	23±6	53±19	46±11
AAV2/rh.13 (42.2)	3.5±2	2±0.8	3.5±1.7
AAV2/rh.21 (42.10)	3.1±2	2±1.4	4.3±2

A couple of other experiments were then performed to confirm the superior tropism of AAV 44.2 in lung tissue. First, AAV vector carried CC10hA1AT minigene for lung specific expression were pseudotyped with capsids of novel AAVs were given to Immune deficient animals (NCR nude) in equal volume (50  $\mu$ l each of the original preps without dilution) via intratracheal injections as provided in the following table. In Table 9, 50  $\mu$ l of each original prep per mouse, NCR Nude, detection limit  $\geq 0.033$   $\mu$ g/ml, Day 28

Table 9

Vector	Total GC in 50 $\mu$ l vector	$\mu$ g of A1AT/ml with 50 $\mu$ l vector	$\mu$ g of A1AT/ml with $1 \times 10^{11}$ vector	Relative Gene transfer as compared to rh.10 (clone 44.2)
2/1	$3 \times 10^{12}$	$2.6 \pm 0.5$	$0.09 \pm 0.02$	2.2
2/2	$5.5 \times 10^{11}$	<0.03	<0.005	<0.1
2/5	$3.6 \times 10^{12}$	$0.65 \pm 0.16$	$0.02 \pm 0.004$	0.5
2/7	$4.2 \times 10^{12}$	$1 \pm 0.53$	$0.02 \pm 0.01$	0.5
2/8	$7.5 \times 10^{11}$	$0.9 \pm 0.7$	$0.12 \pm 0.09$	2.9
2/ch.5 (A.3.1)	$9 \times 10^{12}$	$1 \pm 0.7$	$0.01 \pm 0.008$	0.24
2/rh.8 (43.25)	$4.6 \times 10^{12}$	$26 \pm 21$	$0.56 \pm 0.46$	13.7
2/rh.10 (44.2)	$2.8 \times 10^{12}$	$115 \pm 38$	$4.1 \pm 1.4$	100
2/rh.13 (42.2)	$6 \times 10^{12}$	$7.3 \pm 0.8$	$0.12 \pm 0.01$	2.9
2/rh.21 (42.10)	$2.4 \times 10^{12}$	$9 \pm 0.9$	$0.38 \pm 0.04$	9.3
2/rh.22 (42.11)	$2.6 \times 10^{12}$	$6 \pm 0.4$	$0.23 \pm 0.02$	5.6
2/rh.24 (42.13)	$1.1 \times 10^{11}$	$0.4 \pm 0.3$	$0.4 \pm 0.3$	1

The vectors were also administered to immune competent animals (C57BL/6) in equal genome copies ( $1 \times 10^{11}$  GC) as shown in the Table 10. ( $1 \times 10^{11}$  GC per animal, C57BL/6, day 14, detection limit  $\geq 0.033$   $\mu$ g/ml)

Table 10

AAV Vector	$\mu$ g of A1AT/ml with $1 \times 10^{11}$ vector	Relative Gene transfer as compared to rh.10 (clone 44.2)
2/1	$0.076 \pm 0.031$	2.6
2/2	$0.1 \pm 0.09$	3.4
2/5	$0.084 \pm 0.033$	2.9



Table continued

AAV Vector	$\mu\text{g}$ of A1AT/ml with $1 \times 10^{11}$ vector	Relative Gene transfer as compared to rh.10 (clone 44.2)
2/7	$0.33 \pm 0.01$	11
2/8	$1.92 \pm 1.3$	2.9
2/ch.5 (A.3.1)	$0.048 \pm 0.004$	1.6
2/rh.8 (43.25)	$1.7 \pm 0.7$	58
2/rh.10 (44.2)	$2.93 \pm 1.7$	100
2/rh.13 (42.2)	$0.45 \pm 0.15$	15
2/rh.21 (42.10)	$0.86 \pm 0.32$	29
2/rh.22 (42.11)	$0.38 \pm 0.18$	13
2/rh.24 (42.13)	$0.3 \pm 0.19$	10

[0121] The data from both experiments confirmed the superb tropism of clone 44.2 in lung-directed gene transfer.

[0122] Interestingly, performance of clone 44.2 in liver and muscle directed gene transfer was also outstanding, close to that of the best liver transducer, AAV8 and the best muscle transducer AAV1, suggesting that this novel AAV has some intriguing biological significance.

[0123] To study serological properties of those novel AAVs, pseudotyped AAVGFP vectors were created for immunization of rabbits and in vitro transduction of 84-31 cells in the presence and absence of antisera against different capsids. The data are summarized below:

Table 11a. Cross-NAB assay in 8431 cells and adenovirus (Adv) coinfection Infection in 8431 cells (coinfecting with Adv) with:

Serum from rabbit immunized with:	$10^9$ GC	$10^9$ GC	$10^9$ GC	$10^{10}$ GC
	rh.13	rh.21	rh.22	rh.24
	AAV2/42.2	AAV2/42.10	AAV2/42.1	AAV2/42.13
AAV2/1	1/20	1/20	1/20	No NAB
AAV2/2	1/640	1/1280	1/5120	No NAB
AAV2/5	No NAB	1/40	1/160	No NAB
AAV2/7	1/81920	1/81920	1/40960	1/640
AAV2/8	1/640	1/640	1/320	1/5120
Ch.5 AAV2/A3	1/20	1/160	1/640	1/640
rh.8 AAV2/43.25	1/20	1/20	1/20	1/320
rh.10 AAV2/44.2	No NAB	No NAB	No NAB	1/5120
rh.13 AAV2/42.2	1/5120	1/5120	1/5120	No NAB
rh.21 AAV2/42.10	1/5120	1/10240	1/5120	1/20
rh.22 AAV2/42.11	1/20480	1/20480	1/40960	No NAB
rh.24 AAV2/42.13	No NAB	1/20	1/20	1/5120

Table 11b. Cross-NAB assay in 8431 cells and Adv coinfection Infection in 8431 cells (coinfected with Adv) with:

Serum from rabbit immunized with:	10 <sup>9</sup> GC	10 <sup>10</sup> GC	10 <sup>10</sup> GC	10 <sup>9</sup> GC	10 <sup>9</sup> GC
	<i>rh.12</i>	<i>ch.5</i>	<i>rh. 8</i>	<i>rh.10</i>	<i>rh.20</i>
	AAV2/42.1B	AAV2/A3	AAV2/43.25	AAV2/44.2	AAV2/42.8.2
AAV2/1	No NAB	1/20480	No NAB	1/80	ND
AAV2/2	1/20	No NAB	No NAB	No NAB	ND
AAV2/5	No NAB	1/320	No NAB	No NAB	ND
AAV2/7	1/2560	1/640	1/160	1/81920	ND
AAV2/8	1/10240	1/2560	1/2560	1/81920	ND
<i>ch.5</i> AAV2/A3	1/1280	1/10240	ND	1/5120	1/320
<i>rh.8</i> AAV2/43.25	1/1280	ND	1/20400	1/5120	1/2560
<i>rh.10</i> AAV2/44.2	1/5120	ND	ND	1/5120	1/5120
<i>rh.13</i> AAV2/42.2	1/20	ND	ND	No NAB	1/320
<i>rh.21</i> AAV2/42.10	1/20	ND	ND	1/40	1/80
<i>rh.22</i> AAV2/42.1 1	No NAB	ND	ND	ND	No NAB
<i>rh.24</i> AAV2/42.13	1/5120	ND	ND	ND	1/2560

Table 12

Titer of rabbit sera			Titer after Boosting
Vector		Titer d21	
<i>ch.5</i> AAV2/A3		1/10,240	1/40,960
<i>rh.8</i> AAV2/43.25		1/20,400	1/163,840
<i>rh.10</i> AAV2/44.2		1/10,240	1/527,680
<i>rh.13</i> AAV2/42.2		1/5,120	1/20,960
<i>rh.21</i> AAV2/42.10		1/20,400	1/81,920
<i>rh.22</i> AAV2/42.11		1/40,960	N D
<i>rh.24</i> AAV2/42.13		1/5,120	ND

Table 13 a. Infection in 8431 cells (coinfected with Adv) with GFP

	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well
						<i>ch.5</i>
	AAV2/1	AAV2/2	AAV2/5	AAV2/7	AAV2/8	AAV2/A3
# GFU/field	128	>200	95	56	13	1
	83	>200	65	54	11	1

Table 13b. Infection in 8431 cells (coinfecting with Adv) with GFP

	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well	10 <sup>9</sup> GC/well
	<i>rh.8</i>	<i>rh.10</i>	<i>rh.13</i>	<i>rh.21</i>	<i>rh.22</i>	<i>rh.24</i>	<i>rh.12</i>
	AAV2/43.25	AAV2/44.2	AAV2/42.2	AAV2/42.10	AAV2/42.11	AAV2/42.13	AAV2/42.1B
	3	13	54	62	10	3	18
# GFU/field	2	12	71	60	14	2	20
			48	47	16	3	12

## Example 10 - Mouse Model of Familial Hypercholesterolemia

**[0124]** The following experiment demonstrates that the AAV2/7 construct of the invention delivers the LDL receptor and express LDL receptor in an amount sufficient to reduce the levels of plasma cholesterol and triglycerides in animal models of familial hypercholesterolemia.

## A. Vector Construction

**[0125]** AAV vectors packaged with AAV7 or AAV8 capsid proteins were constructed using a pseudotyping strategy [Hildinger M, *et al.*, *J. Virol* 2001; 75:6199-6203]. Recombinant AAV genomes with AAV2 inverted terminal repeats (ITR) were packaged by triple transfection of 293 cells with the *cis*-plasmid, the adenovirus helper plasmid and a chimeric packaging construct, a fusion of the capsids of the novel AAV serotypes with the rep gene of AAV2. The chimeric packaging plasmid was constructed as previously described [Hildinger et al, cited above]. The recombinant vectors were purified by the standard CsCl<sub>2</sub> sedimentation method. To determine the yield TaqMan (Applied Biosystems) analysis was performed using probes and primers targeting the SV40 poly(A) region of the vectors [Gao GP, *et al.*, *Hum Gene Ther.* 2000 Oct 10;11(15):2079-91]. The resulting vectors express the transgene under the control of the human thyroid hormone binding globulin gene promoter (TBG).

## B. Animals

**[0126]** LDL receptor deficient mice on the C57Bl/6 background were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained as a breeding colony. Mice were given unrestricted access to water and obtained a high fat Western Diet (high % cholesterol) starting three weeks prior vector injection. At day -7 as well at day 0, blood was obtained via retroorbital bleeds and the lipid profile evaluated. The mice were randomly divided into seven groups. The vector was injected via an intraportal injection as previously described ([Chen SJ *et al.*, *Mol Therapy* 2000; 2(3), 256-261]. Briefly, the mice were anaesthetized with ketamine and xylazine. A laparotomy was performed and the portal vein exposed. Using a 30g needle the appropriate dose of vector diluted in 100ul PBS was directly injected into the portal vein. Pressure was applied to the injection site to ensure a stop of the bleeding. The skin wound was closed and draped and the mice carefully monitored for the following day. Weekly bleeds were performed starting at day 14 after liver directed gene transfer to measure blood lipids. Two animals of each group were sacrificed at the time points week 6 and week 12 after vector injection to examine atherosclerotic plaque size as well as receptor expression. The remaining mice were sacrificed at week 20 for plaque measurement and determination of transgene expression.

Table 14

	Vector	dose	n
Group 1	AAV2/7-TBG-hLDLr	1x 10 <sup>12</sup> gc	12
Group 2	AAV2/7-TBG-hLDLr	3x 10 <sup>11</sup> gc	12
Group 3	AAV2/7-TBG-hLDLr	1x 10 <sup>11</sup> gc	12
Group 4	AAV2/8-TBG-hLDLr	1x 10 <sup>12</sup> gc	12
Group 5	AAV2/8-TBG-hLDLr	3x 10 <sup>11</sup> gc	12
Group 6	AAV2/8-TBG-hLDLr	1x 10 <sup>11</sup> gc	12
Group 7	AAV2/7-TBG-LacZ	1x 10 <sup>11</sup> gc	16

## C. Serum lipoprotein and liver function analysis

**[0127]** Blood samples were obtained from the retroorbital plexus after a 6 hour fasting period. The serum was separated from the plasma by centrifugation. The amount of plasma lipoproteins and liver transaminases in the serum were detected using an automatized clinical chemistry analyzer (ACE, Schiapparelli Biosystems, Alpha Wassermann)

## D. Detection of transgene expression

**[0128]** LDL receptor expression was evaluated by immuno-fluorescence staining and Western blotting. For Western Blot frozen liver tissue was homogenized with lysis buffer (20 mM Tris, pH7.4, 130mM NaCl, 1% Triton X 100, proteinase inhibitor (complete, EDTA-free, Roche, Mannheim, Germany). Protein concentration was determined using the Micro

BCA Protein Assay Reagent Kit (Pierce, Rockford, IL). 40 µg of protein was resolved on 4- 15% Tris-HCl Ready Gels (Biorad, Hercules, CA) and transferred to a nitrocellulose membrane (Invitrogen,). To generate Anti-hLDL receptor antibodies a rabbit was injected intravenously with an AdhLDLr prep ( $1 \times 10^{13}$  GC). Four weeks later the rabbit serum was obtained and used for Western Blot. A 1:100 dilution of the serum was used as a primary antibody followed by a HRP-conjugated anti-rabbit IgG and ECL chemiluminescent detection (ECL Western Blot Detection Kit, Amersham, Arlington Heights, IL).

#### E. Immunocytochemistry

**[0129]** For determination of LDL receptor expression in frozen liver sections immunohistochemistry analyses were performed. 10µm cryostat sections were either fixed in acetone for 5 minutes, or unfixed. Blocking was obtained *via* a 1 hour incubation period with 10% of goat serum. Sections were then incubated for one hour with the primary antibody at room temperature. A rabbit polyclonal antibody anti-human LDL (Biomedical Technologies Inc., Stoughton, MA) was used diluted accordingly to the instructions of the manufacturer. The sections were washed with PBS, and incubated with 1:100 diluted fluorescein goat anti-rabbit IgG (Sigma, St Louis, MO). Specimens were finally examined under fluorescence microscope Nikon Microphot-FXA. In all cases, each incubation was followed by extensive washing with PBS. Negative controls consisted of preincubation with PBS, omission of the primary antibody, and substitution of the primary antibody by an isotype-matched non-immune control antibody. The three types of controls mentioned above were performed for each experiment on the same day.

#### F. Gene transfer efficiency

**[0130]** Liver tissue was obtained after sacrificing the mice at the designated time points. The tissue was shock frozen in liquid nitrogen and stored at -80°C until further processing. DNA was extracted from the liver tissue using a QIAamp DNA Mini Kit (QIAGEN GmbH, Germany) according to the manufacturers protocol. Genome copies of AAV vectors in the liver tissue were evaluated using Taqman analysis using probes and primers against the SV40 poly(A) tail as described above.

#### G. Atherosclerotic plaque measurement

**[0131]** For the quantification of the atherosclerotic plaques in the mouse aorta the mice were anaesthetized (10% ketamine and xylazine, ip), the chest opened and the arterial system perfused with ice-cold phosphate buffered saline through the left ventricle. The aorta was then carefully harvested, slit down along the ventral midline from the aortic arch down to the femoral arteries and fixed in formalin. The lipid-rich atherosclerotic plaques were stained with Sudan IV (Sigma, Germany) and the aorta pinned out flat on a black wax surface. The image was captured with a Sony DXC-960 MD color video camera. The area of the plaque as well as of the complete aortic surface was determined using Phase 3 Imaging Systems (Media Cybernetics).

#### H. Clearance of $^{125}$ I LDL

**[0132]** Two animals per experimental group were tested. A bolus of  $^{125}$ I-labeled LDL (generously provided by Dan Rader, U Penn) was infused slowly through the tail vein over a period of 30 sec (1,000,000 counts of [ $^{125}$ I]-LDL diluted in 100µl sterile PBS/ animal). At time points 3min, 30 min, 1.5hr, 3hr, 6hr after injection a blood sample was obtained *via* the retro-orbital plexus. The plasma was separated off from the whole blood and 10µl plasma counted in the gamma counter. Finally the fractional catabolic rate was calculated from the lipoprotein clearance data.

#### I. Evaluation of Liver Lipid accumulation

**[0133]** Oil Red Staining of frozen liver sections was performed to determine lipid accumulation. The frozen liver sections were briefly rinsed in distilled water followed by a 2 minute incubation in absolute propylene glycol. The sections were then stained in oil red solution (0.5% in propylene glycol) for 16 hours followed by counterstaining with Mayer's hematoxylin solution for 30 seconds and mounting in warmed glycerin jelly solution.

**[0134]** For quantification of the liver cholesterol and triglyceride content liver sections were homogenized and incubated in chloroform/methanol (2:1) overnight. After adding of 0.05%  $H_2SO_4$  and centrifugation for 10 minutes, the lower layer of each sample was collected, divided in two aliquots and dried under nitrogen. For the cholesterol measurement the dried lipids of the first aliquot were dissolved in 1% Triton X-100 in chloroform. Once dissolved, the solution was dried under nitrogen. After dissolving the lipids in  $ddH_2O$  and incubation for 30 minutes at 37°C the total cholesterol concentration was measured using a Total Cholesterol Kit (Wako Diagnostics). For the second aliquot the dried lipids were dissolved

in alcoholic KOH and incubated at 60°C for 30 minutes. Then 1 M MgCl<sub>2</sub> was added, followed by incubation on ice for 10 minutes and centrifugation at 14,000 rpm for 30 minutes. The supernatant was finally evaluated for triglycerides (Wako Diagnostics).

[0135] All of the vectors pseudotyped in an AAV2/8 or AAV2/7 capsid lowered total cholesterol, LDL and triglycerides as compared to the control. These test vectors also corrected phenotype of hypercholesterolemia in a dose-dependent manner. A reduction in plaque area for the AAV2/8 and AAV2/7 mice was observed in treated mice at the first test (2 months), and the effect was observed to persist over the length of the experiment (6 months).

#### Example 10 - Functional Factor IX Expression and Correction of Hemophilia

##### A. Knock-Out Mice

[0136] Functional canine factor IX (FIX) expression was assessed in hemophilia B mice. Vectors with capsids of AAV1, AAV2, AAV5, AAV7 or AAV8 were constructed to deliver AAV2 5' ITR - liver-specific promoter [LSP] - canine FIX - woodchuck hepatitis post-regulatory element (WPRE) - AAV2 3' ITR. The vectors were constructed as described in Wang et al, 2000, *Molecular Therapy* 2: 154-158, using the appropriate capsids.

[0137] Knock-out mice were generated as described in Wang et al, 1997, *Proc. Natl. Acad. Sci. USA* 94: 11563-11566. This model closely mimics the phenotypes of hemophilia B in human.

[0138] Vectors of different serotypes (AAV1, AAV2, AAV5, AAV7 and AAV8) were delivered as a single intraportal injection into the liver of adult hemophiliac C57Bl/6 mice in a dose of  $1 \times 10^{11}$  GC/mouse for the five different serotypes and one group received an AAV8 vector at a lower dose,  $1 \times 10^{10}$  GC/mouse. Control group was injected with  $1 \times 10^{11}$  GC of AAV2/8 TBG LacZ3. Each group contains 5-10 male and female mice. Mice were bled bi-weekly after vector administration.

##### 1. ELISA

[0139] The canine FIX concentration in the mouse plasma was determined by an ELISA assay specific for canine factor IX, performed essentially as described by Axelrod et al, 1990, *Proc. Natl. Acad. Sci. USA*, 87:5173-5177 with modifications. Sheep anti-canine factor IX (Enzyme Research Laboratories) was used as primary antibody and rabbit anti-canine factor IX (Enzyme Research Laboratories) was used as secondary antibody. Beginning at two weeks following injection, increased plasma levels of cFIX were detected for all test vectors. The increased levels were sustained at therapeutic levels throughout the length of the experiment, i.e., to 12 weeks. Therapeutic levels are considered to be 5% of normal levels, i.e., at about 250 ng/mL.

[0140] The highest levels of expression were observed for the AAV2/8 (at  $10^{11}$ ) and AAV2/7 constructs, with sustained superphysiology levels cFIX levels (ten-fold higher than the normal level). Expression levels for AAV2/8 ( $10^{11}$ ) were approximately 10 fold higher than those observed for AAV2/2 and AAV2/8 ( $10^{10}$ ). The lowest expression levels, although still above the therapeutic range, were observed for AAV2/5.

##### 2. In Vitro Activated Partial Thromboplastin time (aPTT) Assay

[0141] Functional factor IX activity in plasma of the FIX knock-out mice was determined by an *in vitro* activated partial thromboplastin time (aPTT) assay-Mouse blood samples were collected from the retro-orbital plexus into 1/10 volume of citrate buffer. The aPTT assay was performed as described by Wang et al, 1997, *Proc. Natl. Acad. Sci. USA* 94: 11563-11566.

[0142] Clotting times by aPTT on plasma samples of all vector injected mice were within the normal range (approximately 60 sec) when measured at two weeks post-injection, and sustained clotting times in the normal or shorter than normal range throughout the study period (12 weeks).

[0143] Lowest sustained clotting times were observed in the animals receiving AAV2/8 ( $10^{11}$ ) and AAV2/7. By week 12, AAV2/2 also induced clotting times similar to those for AAV2/8 and AAV2/7. However, this lowered clotting time was not observed for AAV2/2 until week 12, whereas lowered clotting times (in the 25 - 40 sec range) were observed for AAV2/8 and AAV2/7 beginning at week two.

[0144] Immuno-histochemistry staining on the liver tissues harvested from some of the treated mice is currently being performed. About 70-80% of hepatocytes are stained positive for canine FIX in the mouse injected with AAV2/8.cFIX vector.

##### B. Hemophilia B Dogs

[0145] Dogs that have a point mutation in the catalytic domain of the F.IX gene, which, based on modeling studies,

appears to render the protein unstable, suffer from hemophilia B [Evans et al, 1989, Proc. Natl. Acad. Sci. USA, 86:10095-10099]. A colony of such dogs has been maintained for more than two decades at the University of North Carolina, Chapel Hill. The homeostatic parameters of these dogs are well described and include the absence of plasma F.IX antigen, whole blood clotting times in excess of 60 minutes, whereas normal dogs are 6-8 minutes, and prolonged activated partial thromboplastin time of 50-80 seconds, whereas normal dogs are 13-28 seconds. These dogs experience recurrent spontaneous hemorrhages. Typically, significant bleeding episodes are successfully managed by the single intravenous infusion of 10 ml/kg of normal canine plasma; occasionally, repeat infusions are required to control bleeding.

[0146] Four dogs are injected intraportally with AAV.cFIX according to the schedule below. A first dog receives a single injection with AAV2/2.cFIX at a dose of  $3.7 \times 10^{11}$  genome copies (GC)/kg. A second dog receives a first injection of AAV2/2.cFIX ( $2.8 \times 10^{11}$  GC/kg), followed by a second injection with AAV2/7.cFIX ( $2.3 \times 10^{13}$  GC/kg) at day 1180. A third dog receives a single injection with AAV2/2.cFIX at a dose of  $4.6 \times 10^{12}$  GC/kg. The fourth dog receives an injection with AAV2/2.cFIX ( $2.8 \times 10^{12}$  GC/kg) and an injection at day 99.5 with AAV2/7.cFIX ( $5 \times 10^{12}$  GC/kg).

[0147] The abdomen of hemophilia dogs are aseptically and surgically opened under general anesthesia and a single infusion of vector is administered into the portal vein. The animals are protected from hemorrhage in the peri-operative period by intravenous administration of normal canine plasma. The dog is sedated, intubated to induce general anesthesia, and the abdomen shaved and prepped. After the abdomen is opened, the spleen is moved into the operative field. The splenic vein is located and a suture is loosely placed proximal to a small distal incision in the vein. A needle is rapidly inserted into the vein, then the suture loosened and a 5 F cannula is threaded to an intravenous location near the portal vein threaded to an intravenous location near the portal vein bifurcation. After hemostasis is secured and the catheter balloon inflated, approximately 5.0 ml of vector diluted in PBS is infused into the portal vein over a 5 minute interval. The vector infusion is followed by a 5.0 ml infusion of saline. The balloon is then deflated, the cannula removed and venous hemostasis is secured. The spleen is then replaced, bleeding vessels are cauterized and the operative wound is closed. The animal is extubated having tolerated the surgical procedure well. Blood samples are analyzed as described. [Wang et al, 2000, *Molecular Therapy* 2: 154-158]

[0148] Results showing correction or partial correction are anticipated for AAV2/7.

#### SEQUENCE LISTING

##### [0149]

<110> The Trustees of The University of Pennsylvania

<120> A Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby

<130> UPN-02735ff

<150> US 60/350,607

<151> 2001-11-13

<150> US 60/341,117

<151> 2001-12-17

<150> US 60/377,066

<151> 2002-05-01

<150> US 60/386,675

<151> 2002-06-05

<160> 120

<170> PatentIn version 3.1

<210> 1

<211> 4721

<212> DNA

<213> adeno-associated virus serotype 7

## EP 1 310 571 B1

&lt;400&gt; 1

5           ttggccactc cctctatgcg cgctcgctcg ctcggtgggg cctgcggacc aaaggtccgc       60  
          agacggcaga gctctgctct gccggcccca ccgagcgagc gagcgcgcat agagggagtg       120  
          gccaaactcca tcactagggg taccgcgaag cgcctccac gctgccgctg cagcgctgac       180  
          gtaaatcacg tcatagggga gtggtcctgt attagctgtc acgtgagtgc ttttgcgaca       240  
10          ttttgcgaca ccacgtggcc atttgaggta tatatggccg agtgagcgag caggatctcc       300  
          at ttgtgaccg cgaaatttga acgagcagca gccatgccgg gtttctacga gatcgtgatc       360  
          aaggtgccga gcgacctgga cgagcacctg ccgggcattt ctgactcgtt tgtgaactgg       420  
15          gtggccgaga aggaatggga gctgcccccg gattctgaca tggatctgaa tctgatcgag       480  
          caggcacccc tgaccgtggc cgagaagctg cagcgcgact tcctggcca atggcgccgc       540  
          gtgagtaagg ccccgagggc cctgttcttt gttcagttcg agaagggcga gagctacttc       600  
20          caccttcacg ttctggtgga gaccacgggg gtcaagtcca tggtgctagg ccgcttcctg       660  
          agtcagattc gggagaagct ggtccagacc atctaccgcg gggtcgagcc cacgctgccc       720  
          aactggttcg cggtgaccaa gacgcgtaat ggcgccggcg gggggaacaa ggtggtggac       780  
25          gagtgtctaca tccccaaacta cctcctgccc aagaccagc ccgagctgca gtgggcgtgg       840  
          actaacatgg aggagtatat aagcgctgtg ttgaacctgg ccgaacgcaa acggctcgtg       900  
30  
35  
40  
45  
50  
55



EP 1 310 571 B1

	gcgcagcacc	tgacccacgt	cagccagacg	caggagcaga	acaaggagaa	tctgaacccc	960
	aattctgacg	cgcccgatgat	caggtcaaaa	acctccgcgc	gctacatgga	gctggctcggg	1020
5	tggtctggtgg	accggggcat	cacctccgag	aagcagtgga	tccaggagga	ccaggcctcg	1080
	tacatctcct	tcaacgccgc	ctccaactcg	cggtcccaga	tcaaggccgc	gctggacaat	1140
	gccggcaaga	tcatggcgct	gaccaaatec	gcgcccgaact	acctgggtggg	gccctcgctg	1200
10	cccgcggaca	ttaaaaccaa	ccgcactctac	cgcatcctgg	agctgaacgg	gtacgatcct	1260
	gcctacgccg	gctccgtctt	tctcggtctg	gcccagaaaa	agttcgggaa	gcgcaacacc	1320
	atctggctgt	ttggggcccgc	caccaccggc	aagaccaaca	ttgcggaagc	catcgccccac	1380
15	gccgtgccct	tctacggctg	cgteaactgg	accaatgaga	actttccctt	caacgattgc	1440
	gtcgacaaga	tggtgatctg	gtgggaggag	ggcaagatga	cggccaaggt	cgtaggagtcc	1500
	gccaaaggcca	ttctcggcgg	cagcaagggtg	cgcgtaggacc	aaaagtgcga	gtcgtccgcc	1560
20	cagatcgacc	ccacccccgt	gatcgtcacc	tccaacacca	acatgtgcgc	cgtgattgac	1620
	gggaacagca	ccaccttcga	gcaccagcag	ccgttgccagg	accggatggt	caaatttgaa	1680
	ctcaccgcc	gtctggagca	cgactttggc	aaggtagcga	agcaggaagt	caaagagtgc	1740
25	ttccgctggg	ccagtgatca	cgtgaccgag	gtggcgcatg	agttctacgt	cagaaagggc	1800
	ggagccagca	aaagacccgc	ccccgatgac	gcggatataa	gcgagcccaa	gcgggcctgc	1860
	ccctcagtcg	cggatccatc	gacgtcagac	gcggaaggag	ctccggtgga	ctttgccgac	1920
30	aggtaccaa	acaaatgttc	tcgtcacgcg	ggcatgattc	agatgctggt	tccctgcaaa	1980
	acgtgcgaga	gaatgaatca	gaatttcaac	atttgcttca	cacacggggt	cagagactgt	2040
	ttagagtgtt	tccccggcgt	gtcagaatct	caaccggctg	tcagaaaaaa	gacgtatcgg	2100
35	aaactctgcg	cgattcatca	tctgctgggg	cgggcgcccc	agattgcttg	ctcggcctgc	2160
	gacctggtca	acgtggacct	ggacgactgc	gtttctgagc	aataaatgac	ttaaaccagg	2220
	tatggctgcc	gatggttatc	ttccagattg	gctcgaggac	aacctctctg	agggcattcg	2280
40	cgagtgggtg	gacctgaaac	ctggagcccc	gaaacccaaa	gccaaccagc	aaaagcagga	2340
	caacggccgg	ggtctggtgc	ttcctggcta	caagtacctc	ggacccttca	acggactcga	2400
	caagggggag	cccgtcaacg	cggcggacgc	agcggccctc	gagcacgaca	aggcctacga	2460
45	ccagcagetc	aaagcgggtg	acaatccgta	cctgcggtat	aaccacgccg	acgccgagtt	2520
	tcaggagcgt	ctgcaagaag	atacgtcatt	tgggggcaac	ctcgggagag	cagtcttcca	2580
	ggccaagaag	cgggttctcg	aacctctcgg	tctggttgag	gaaggcgcta	agacggctcc	2640
50	tgcaaagaag	agaccggtag	agccgtcacc	tcagcgttcc	cccgaactct	ccacgggcat	2700
	cggcaagaaa	ggccagcagc	ccgccagaaa	gagactcaat	ttcggtcaga	ctggcgactc	2760
55	agagtcagtc	cccgaccctc	aacctctcgg	agaacctcca	gcagcgccct	ctagtgtggg	2820

## EP 1 310 571 B1

atctggtaca gtggctgcag gcgggtggcgc accaatggca gacaataacg aaggtgccga 2880  
 cggagtggtt aatgcctcag gaaattggca ttgcgattcc acatggctgg gcgacagagt 2940  
 5 cattaccacc agcaccgaa cctggggccct gcccacctac aacaaccacc tctacaagca 3000  
 aatctccagt gaaactgcag gtagtaccaa cgacaacacc tacttcgggt acagcacccc 3060  
 ctgggggtat tttgacttta acagattcca ctgccacttc tcaccacgtg actggcagcg 3120  
 10 actcatcaac aacaactggg gattccggcc caagaagctg cggttcaagc tcttcaacat 3180  
 ccaggtaag gaggtcacga cgaatgacgg cgttacgacc atcgctaata accttaccag 3240  
 cacgattcag gtattctcgg actcgggaata ccagctgccg tacgtcctcg gctctgcga 3300  
 15 ccagggtgc ctgcctcgt tcccggcgga cgtcttcattg attcctcagt acggctacct 3360  
 gactctcaac aatggcagtc agtctgtggg acgttcctcc ttctactgcc tggagtactt 3420  
 cccctctcag atgctgagaa cgggcaacaa ctttgagttc agctacagct tcgaggacgt 3480  
 20 gcctttccac agcagctacg cacacagcca gagcctggac cggctgatga atccctcat 3540  
 cgaccagtac ttgtactacc tggccagaac acagagtaac ccaggaggca cagctggcaa 3600  
 tcgggaactg cagttttacc agggcgggccc ttcaactatg gccgaacaag ccaagaattg 3660  
 25 gttacctgga ccttgcttcc ggcaacaaag agtctccaaa acgctggatc aaaacaacaa 3720  
 cagcaacttt gcttggactg gtgccaccaa atatcacctg aacggcagaa actcgttgggt 3780  
 taatcccggc gtcgccatgg caactcaca ggacgacgag gaccgctttt tcccatccag 3840  
 30 cggagtccctg atttttggaa aaactggagc aactaacaaa actacattgg aaaatgtgtt 3900  
 aatgacaaat gaagaagaaa ttcgtcctac taatcctgta gccacggaag aatacgggat 3960  
 agtcagcagc aacttacaag cggctaatac tgcagcccag acacaagttg tcaacaacca 4020  
 35 gggagcctta cctggcatgg tctggcagaa ccgggacgtg tacctgcagg gtcccactctg 4080  
 ggccaagatt cctcacacgg atggcaactt tcaccctgtt cctttgatgg gcggctttgg 4140  
 acttaaacat ccgcctctc agatcctgat caagaacact cccgttcccg ctaatcctcc 4200  
 40 ggaggtgttt actcctgcca agtttgcttc gttcatcaca cagtacagca ccggacaagt 4260  
 cagcgtggaa atcgagtggg agctgcagaa ggaaaacagc aagcgtgga acccgagat 4320  
 tcagtacacc tccaactttg aaaagcagac tgggtgtggac tttgccgttg acagccaggg 4380  
 45 tgtttactct gagcctcgcc ctattggcac tcgttacctc acccgtaatc tgtaattgca 4440  
 tgtaaatcaa taaaccggtt gattcgtttc agttgaactt tggctctcctg tgcttcttat 4500  
 cttatcggtt tccatagcaa ctggttacac attaactgct tgggtgcgct tcacgataag 4560  
 50 aacactgacg tcaccgcggt acccctagtg atggagttgg ccactccctc tatgcgcgct 4620  
 cgctcgctcg gtggggcctg cggaccaaag gtccgcagac ggacagctc tgctctgccg 4680  
 gccccaccga gcgagcgagc gcgcatagag ggagtggcca a 4721  
 55

&lt;210&gt; 2

&lt;211&gt; 737

EP 1 310 571 B1

<212> PRT

<213> capsid protein of adeno-associated virus serotype 7

<400> 2

5

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

10

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

15

Lys Ala Asn Gln Gln Lys Gln Asp Asn Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

20

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

25

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

30

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

35

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Ala Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

40

Gly Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln  
165 170 175

45

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro  
180 185 190

Pro Ala Ala Pro Ser Ser Val Gly Ser Gly Thr Val Ala Ala Gly Gly  
195 200 205

50

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn  
210 215 220

55

Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

EP 1 310 571 B1

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
 245 250 255  
 5  
 Leu Tyr Lys Gln Ile Ser Ser Glu Thr Ala Gly Ser Thr Asn Asp Asn  
 260 265 270  
 10  
 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
 275 280 285  
 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
 290 295 300  
 15  
 Asn Trp Gly Phe Arg Pro Lys Lys Leu Arg Phe Lys Leu Phe Asn Ile  
 305 310 315 320  
 20  
 Gln Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn  
 325 330 335  
 Asn Leu Thr Ser Thr Ile Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu  
 340 345 350  
 25  
 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
 355 360 365  
 30  
 Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
 370 375 380  
 Gly Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
 385 390 395 400  
 35  
 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser  
 405 410 415  
 40  
 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
 420 425 430  
 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala  
 435 440 445  
 45  
 Arg Thr Gln Ser Asn Pro Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln  
 450 455 460  
 50  
 Phe Tyr Gln Gly Gly Pro Ser Thr Met Ala Glu Gln Ala Lys Asn Trp  
 465 470 475 480  
 Leu Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp  
 485 490 495  
 55

EP 1 310 571 B1

5 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

Leu Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

10 His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile  
530 535 540

Phe Gly Lys Thr Gly Ala Thr Asn Lys Thr Thr Leu Glu Asn Val Leu  
545 550 555 560

15 Met Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu  
565 570 575

20 Glu Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Asn Thr Ala Ala  
580 585 590

Gln Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp  
595 600 605

25 Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro  
610 615 620

30 His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly  
625 630 635 640

Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro  
645 650 655

35 Ala Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile  
660 665 670

40 Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu  
675 680 685

Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser  
690 695 700

45 Asn Phe Glu Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly  
705 710 715 720

50 Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn  
725 730 735

55 Leu

## EP 1 310 571 B1

&lt;211&gt; 623

&lt;212&gt; PRT

&lt;213&gt; rep protein of adeno-associated virus serotype 7

5 &lt;400&gt; 3

```

Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
1           5           10           15

10 Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Asn Trp Val Ala Glu
    20           25           30

15 Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
    35           40           45

20 Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
    50           55           60

25 Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
    65           70           75           80

30 Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Val Leu Val Glu
    85           90           95

Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
    100          105          110

35 Arg Glu Lys Leu Val Gln Thr Ile Tyr Arg Gly Val Glu Pro Thr Leu
    115          120          125

Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
    130          135          140

40 Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys
    145          150          155          160

Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile
    165          170          175

45 Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His
    180          185          190

Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn
    195          200          205

50 Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr
    210          215          220

55 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
    225          230          235          240

```

EP 1 310 571 B1

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 245 250 255  
 5  
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 260 265 270  
 10  
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ser  
 275 280 285  
 Leu Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu  
 290 295 300  
 15  
 Asn Gly Tyr Asp Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala  
 305 310 315 320  
 20  
 Gln Lys Lys Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala  
 325 330 335  
 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro  
 340 345 350  
 25  
 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp  
 355 360 365  
 30  
 Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala  
 370 375 380  
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg  
 385 390 395 400  
 35  
 Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val  
 405 410 415  
 40  
 Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser  
 420 425 430  
 Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe  
 435 440 445  
 45  
 Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln  
 450 455 460  
 50  
 Glu Val Lys Glu Phe Phe Arg Trp Ala Ser Asp His Val Thr Glu Val  
 465 470 475 480  
 Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Ser Lys Arg Pro Ala  
 485 490 495

**EP 1 310 571 B1**

Pro Asp Asp Ala Asp Ile Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
500 505 510

5

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
515 . 520 525

10

Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Ile Gln Met  
530 535 540

Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile  
545 550 555 560

15

Cys Phe Thr His Gly Val Arg Asp Cys Leu Glu Cys Phe Pro Gly Val  
565 570 575

20

Ser Glu Ser Gln Pro Val Val Arg Lys Lys Thr Tyr Arg Lys Leu Cys  
580 585 590

Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala  
595 600 605

**25**

Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln  
610 615 620

30

<210> 4  
<211> 4393  
<212> DNA  
<213> adeno-associated virus serotype 8

35

<400> 4

40

45

50

55



EP 1 310 571 B1

	cagagagggg	gtggccaact	ccatcactag	gggtagcgcg	aagcgccctcc	cacgctgccg	60
	cgtcagcgct	gacgtaaatt	acgtcatagg	ggagtgggtcc	tgtattagct	gtcacgtgag	120
5	tgcttttgcg	gcatttttgcg	acaccacgtg	gccatttgag	gtatatatgg	ccgagtgagc	180
	gagcaggatc	tccattttga	ccgcgaaatt	tgaacgagca	gcagccatgc	cgggcttcta	240
	cgagatcgtg	atcaagggtgc	cgagcgacct	ggacgagcac	ctgccgggca	tttctgactc	300
10	gtttgtgaac	tgggtggccg	agaaggaatg	ggagctgccc	ccggattctg	acatggatcg	360
	gaatctgata	gagcaggcac	ccctgaccgt	ggccgagaag	ctgcagcgcg	acttcctggg	420
	ccaatggcgc	cgcgtgagta	aggccccgga	ggccctcttc	tttgttcagt	tcgagaaggg	480
15	cgagagctac	tttcacctgc	acgttctggg	cgagaccacg	ggggccaagt	ccatggtgct	540
	aggccgcttc	ctgagtcaga	ttcgggaaaa	gcttgggtcca	gaccatctac	ccgcgggggc	600
	gagccccacc	ttgcccact	ggttcgcggt	gaccaaagac	gcggtaatgg	cgccggcggg	660
20	ggggaacaag	gtggtggacg	agtgctacat	ccccactac	ctcctgcca	agactcagcc	720
	cgagctgcag	tgggcgtgga	ctaactgga	ggagtatata	agcgctgct	tgaacctggc	780

25

30

35

40

45

50

55

# EP 1 310 571 B1

	cgagcgcaaa cggctcgtgg cgcagcacct gacccacgtc agccagacgc aggagcagaa	840
	caaggagaat ctgaacccca attctgacgc gcccgatgac aggtcaaaaa cctccgcgcg	900
5	ctatatggag ctggtcgggt ggctgggtgga cgggggcac acctccgaga agcagtggat	960
	ccaggaggac caggcctcgt acatctcctt caacgccgcc tccaactcgc ggtcccagat	1020
	caaggccgcg ctggacaatg ccggcaagat catggcgctg accaaatccg cggccgacta	1080
10	cctggtgggg ccctcgtcgc ccgaggacat taccagaac cgcattctacc gcattctcgc	1140
	tctcaacggc tacgacctg cctacgccg ctccgtcttt ctgggtggg ctcagaaaaa	1200
	gttcgggaaa cgcaacacca tctggctggt tggaccgcc accaccggca agaccaacat	1260
15	tgcggaagcc atcgccacg ccgtgccctt ctacggctgc gtcaactgga ccaatgagaa	1320
	ctttcccttc aatgattgcg tgcacaagat ggtgatctgg tgggaggagg gcaagatgac	1380
	ggccaaggct gtggagtccg ccaaggccat tctcggcggc agcaaggctg gcgtggacca	1440
20	aaagtgcag tcgtccgcc agatcgacc caccgccgtg atcgtcacct ccaacaccaa	1500
	catgtgcgcc gtgattgacg ggaacagcac caccttcgag caccagcagc ctctccagga	1560
	ccggatgttt aagttcgaac tcaccgccg tctggagcac gactttggca aggtgacaaa	1620
25	gcaggaagtc aaagagttct tccgctgggc cagtgatcac gtgaccgagg tggcgcatga	1680
	gttttacgtc agaaagggcg gagccagcaa aagaccgcc cccgatgacg cggataaaaag	1740
	cgagcccaag cgggcctgcc cctcagtcgc ggatccatcg acgtcagacg cggaaggagc	1800
30	tccggtggac ttgcccga ggtacaaaa caaatgttct cgtcacgcgg gcatgcttca	1860
	gatgctgttt ccctgcaaaa cgtgagagag aatgaatcag aatttcaaca ttgcttcac	1920
	acacggggct agagactgct cagagtgttt ccccgccgtg tcagaatctc aaccggctcgt	1980
35	cagaaagagg acgtatcgga aactctgtgc gattcatcat ctgctggggc gggctcccg	2040
	gattgcttgc tcggcctgcg atctggtcaa cgtggacctg gatgactgtg tttctgagca	2100
	ataaatgact taaaccaggt atggctgccg atggttatct tccagattgg ctgaggaca	2160
40	acctctctga gggcattcgc gagtgggtgg cgctgaaacc tggagccccg aagcccaag	2220
	ccaaccagca aaagcaggac gacggccggg gtctggtgct tcctggctac aagtacctcg	2280
	gacccttcaa cggactcgac aagggggagc ccgtcaacgc ggcggacgca gcggccctcg	2340
45	agcacgacaa ggcctacgac cagcagctgc aggcgggtga caatccgtac ctgcggtata	2400
	accacgccga cggcgagttt caggagcgtc tgcaagaaga tacgtctttt gggggcaacc	2460
	tcgggagagc agtcttccag gccaaagaag gggttctcga acctctcggg ctggttgagg	2520
50	aaggcgctaa gacggctcct ggaagaaga gaccggtaga gccatcacc cagcgttctc	2580
	cagactcctc tacgggcacg ggcaagaaag gccaacagcc cgccagaaaa agactcaatt	2640
55	ttggtcagac tggcgactca gagtcagttc cagaccctca acctctcgga gaacctccag	2700

EP 1 310 571 B1

	cagcgccctc	tggtgtggga	cctaatacaa	tggtgcagg	cggtggcgca	ccaatggcag	2760
	acaataacga	aggcgccgac	ggagtgggta	gttcctcggg	aaattggcat	tgcgattcca	2820
5	catggctggg	cgacagagtc	atcaccacca	gcacccgaac	ctgggccttg	cccacctaca	2880
	acaaccacct	ctacaagcaa	atctccaacg	ggacatcggt	aggagccacc	aacgacaaca	2940
	cctacttcgg	ctacagcacc	ccctgggggt	attttgactt	taacagattc	cactgccact	3000
10	tttcaccacg	tgactggcag	cgactcatca	acaacaactg	gggattccgg	cccaagagac	3060
	tcagcttcaa	gctcttcaac	atccagggtc	aggagggtcac	gcagaatgaa	ggcaccaaga	3120
	ccatcgccaa	taacctcacc	agcaccatcc	aggtgtttac	ggactcggag	taccagctgc	3180
15	cgtacgttct	cggtcttgcc	caccaggggt	gcctgcctcc	gttccggcg	gacgtgttca	3240
	tgattcccca	gtacggctac	ctaacactca	acaacggtag	tcaggccgtg	ggacgctcct	3300
	ccttctactg	cctggaatac	tttccttcgc	agatgctgag	aaccggcaac	aacttccagt	3360
20	ttacttacac	cttcgaggac	gtgcctttcc	acagcagcta	cgccacagc	cagagcttgg	3420
	accggctgat	gaatcctctg	attgaccagt	acctgtacta	cttgtctcgg	actcaaacaa	3480
	caggaggcac	ggcaaatacg	cagactcttg	gcttcagcca	aggtgggcct	aatacaatgg	3540
25	ccaatcaggc	aaagaactgg	ctgccaggac	cctgttaccg	ccaacaacgc	gtctcaacga	3600
	caaccgggca	aaacaacaat	agcaactttg	cctggactgc	tgggaccaa	taccatctga	3660
	atggaagaaa	ttcattggct	aatcctggca	tcgctatggc	aacacacaaa	gacgacgagg	3720
30	agcgtttttt	tcccagtaac	gggatcctga	tttttggcaa	acaaaatgct	gccagagaca	3780
	atgcggatta	cagcgatgtc	atgctcacca	gcgaggaaga	aatcaaaacc	actaaccttg	3840
	tggctacaga	ggaatacggg	atcgtggcag	ataacttgca	gcagcaaaac	acggctcctc	3900
35	aaattggaac	tgtcaacagc	cagggggcct	taccgggtat	ggtctggcag	aaccgggacg	3960
	tgtacctgca	gggtcccatc	tgggccaaga	ttcctcacac	ggacggcaac	ttccaccctg	4020
	ctccgtgat	gggcggcttt	ggcctgaaac	atcctccgcc	tcagatcctg	atcaagaaca	4080
40	cgcctgtacc	tgcggtacct	ccgaccacct	tcaaccagtc	aaagctgaac	tctttcatca	4140
	cgcaatacag	caccggacag	gtcagcgtgg	aaattgaatg	ggagctgcag	aaggaaaaca	4200
	gcaagcgctg	gaacccccgag	atccagtaca	cctccaacta	ctacaaatct	acaagtgtgg	4260
45	actttgctgt	taatacagaa	ggcgtgtact	ctgaaccccg	ccccattggc	accggttacc	4320
	tcacccgtaa	tctgtaattg	cctgttaatc	aataaaccgg	ttgattcgtt	tcagttgaac	4380
50	tttggctctct	gcg					4393

<210> 5

<211> 4385

<212> DNA

55 <213> adeno-associated virus serotype 9

<400> 5

## EP 1 310 571 B1

	cagagagggga	gtggccaact	ccatcactag	gggtaatcgc	gaagcgctc	ccacgctgcc	60
	gcgtcagcgc	tgacgtagat	tacgtcatag	gggagtggc	ctgtattagc	tgtcacgtga	120
5	gtgcttttgc	gacattttgc	gacaccacat	ggccatttga	ggtatatatg	gccgagttag	180
	cgagcaggat	ctccattttg	accgcgaaat	ttgaacgagc	agcagccatg	ccgggcttct	240
	acgagattgt	gatcaagggtg	ccgagcgacc	tggacgagca	cctgccgggc	atttctgact	300
10	cttttgtgaa	ctgggtggcc	gagaaggaat	gggagctgcc	cccggattct	gacatggatc	360
	ggaatctgat	cgagcaggca	cccctgaccg	tggccgagaa	gctgcagcgc	gacttcctgg	420
	tccaatggcg	ccgcgtgagt	aaggccccgg	aggccctctt	ctttgttcag	ttcgagaagg	480
15	gcgagagcta	ctttcacctg	cacgttctgg	tcgagaccac	gggggtcaag	tccatggtgc	540
	taggccgctt	cctgagtcag	attcgggaga	agctgggtcca	gaccatctac	cgcgggatcg	600
	agccgacctt	gcccactgg	ttcgcggtga	ccaagacgcg	taatggcgcc	ggcgggggga	660
20	acaagggtgg	ggacgagtgc	tacatcccca	actacctctt	gcccagact	cagcccgagc	720
	tgcagtgggc	gtggactaac	atggaggagt	atataagcgc	gtgcttgaac	ctggccgagc	780
	gcaaacggct	cgtggcgag	cacctgacct	acgtcagcca	gacgcaggag	cagaacaagg	840
25	agaatctgaa	ccccattctt	gacgcgccc	tgatcaggtc	aaaaacctcc	gcgcgctaca	900
	tggagctgg	cgggtggctg	gtggaccggg	gcacacctc	cgagaagcag	tggatccagg	960
	aggaccaggc	ctcgtacatc	tccttcaacg	ccgcctccaa	ctcgcggtcc	cagatcaagg	1020
30	ccgcgctgga	caatgccggc	aagatcatgg	cgctgaccaa	atccgcgccc	gactacctgg	1080
	taggcccttc	acttccggtg	gacattacgc	agaaccgcat	ctaccgcatc	ctgcagctca	1140
	acggctacga	ccctgcctac	gccggctccg	tctttctcgg	ctgggcacaa	aagaagttcg	1200
35	ggaaacgcaa	caccatctgg	ctgtttgggc	cggccaccac	gggaaagacc	aacatcgag	1260
	aagccattgc	ccacgccgtg	cccttctacg	gctgcgtcaa	ctggaccaat	gagaactttc	1320
	ccttcaacga	ttgcgtcgac	aagatggtga	tctggtggga	ggagggcaag	atgacggcca	1380
40	aggtcgtgga	gtccgccaa	gccattctcg	gcggcagcaa	ggtgcgcgtg	gacaaaaagt	1440
	gcaagtgcgc	cgcccgatc	gacccactc	ccgtgatcgt	cacctccaac	accaacatgt	1500
	gcgccgtgat	tgacgggaac	agcaccacct	tcgagcacca	gcagcctctc	caggaccgga	1560
45	tgtttaagtt	cgaactcacc	cgccgtctgg	agcacgactt	tggcaagggtg	acaaagcagg	1620
	aagtcaaaga	gttcttccgc	tgggccagtg	atcacgtgac	cgaggtggcg	catgagtttt	1680
	acgtcagaaa	gggaggagcc	agcaaaagac	ccgccccga	tgacgcggat	aaaagcgagc	1740
50	ccaagcgggc	ctgcccctca	gtcgcggatc	catcgacgtc	agacgcggaa	ggagctccgg	1800
	tggactttgc	cgacagggtac	caaaacaaat	gttctcgtca	cgcgggcatg	cttcagatgc	1860
55	tgcttccctg	caaaacgtgc	gagagaatga	atcagaattt	caacatttgc	ttcacacacg	1920

EP 1 310 571 B1

	gggtcagaga	ctgctcagag	tgtttccccc	gcgtgtcaga	atctcaaccg	gtcgtcagaa	1980
	agaggacgta	tcggaaactc	tgtgcgattc	atcatctgct	ggggcgggct	cccagattg	2040
5	cttgctcggc	ctgcgatctg	gtcaacgtgg	acctggatga	ctgtgtttct	gagcaataaa	2100
	tgacttaaac	caggatatgg	tgccgatggt	tatcttccag	attggctcga	ggacaacctc	2160
	tctgagggca	ttcgcgagtg	gtgggcgctg	aaacctggag	ccccgaagcc	caaagccaac	2220
10	cagcaaaagc	aggacgacgg	ccggggctctg	gtgcttccctg	gctacaagta	cctcggaccc	2280
	ttcaacggac	tcgacaaggg	ggagcccgtc	aacgcggcgg	acgcagcggc	cctcggagcac	2340
	ggcaaggcct	acgaccagca	gctgcaggcg	ggtgacaatc	cgtacctgcg	gtataaccac	2400
15	gccgacgccg	agtttcagga	gcgtctgcaa	gaagatacgt	cttttggggg	caacctcggg	2460
	cgagcagtct	tccaggccaa	gaagcggggt	ctcgaacctc	tcgggtctggt	tgaggaaggc	2520
	gctaagacgg	ctcctggaaa	gaagagaccg	gtagagccat	caccccagcg	ttctccagac	2580
20	tcctctacgg	gcatcggcaa	gaaaggccaa	cagcccggca	gaaaaagact	caattttggt	2640
	cagactggcg	actcagagtc	agttccagac	cctcaacctc	tcggagaacc	tccagcagcg	2700
	ccctctggty	tgggacctaa	tacaatggct	gcaggcggty	gcgcaccaat	ggcagacaat	2760
25	aacgaaggcg	ccgacggagt	gggtaattcc	tcgggaaatt	ggcattgcga	ttccacatgg	2820
	ctgggggaca	gagtcatcac	caccagcacc	cgaacctggg	cattgcccac	ctacaacaac	2880
	cacctctaca	agcaaacttc	caatggaaca	tcgggaggaa	gcaccaacga	caacacctac	2940
30	tttggtctaca	gcacccctg	ggggtatttt	gacttcaaca	gattccactg	ccacttctca	3000
	ccacgtgact	ggcagcgact	catcaacaac	aactggggat	tccggccaaa	gagactcaac	3060
	ttcaagctgt	tcaacatcca	ggtcaaggag	gttacgacga	acgaaggcac	caagaccatc	3120
35	gccaaataacc	ttaccagcac	cgtccaggtc	tttacggact	cggagtacca	gctaccgtac	3180
	gtcctagget	ctgcccacca	aggatgcctg	ccaccgtttc	ctgcagacgt	cttcatggtt	3240
	cctcagtacg	gctacctgac	gctcaacaat	ggaagtcaag	cgttaggacg	ttcttctttc	3300
40	tactgtctgg	aatacttccc	ttctcagatg	ctgagaaccg	gcaacaactt	tcagttcagc	3360
	tacactttcg	aggacgtgcc	tttccacagc	agctacgcac	acagccagag	tctagatcga	3420
	ctgatgaacc	ccctcatcga	ccagtaccta	tactacctgg	tcagaacaca	gacaactgga	3480
45	actgggggaa	ctcaaacttt	ggcattcagc	caagcaggcc	ctagctcaat	ggccaatcag	3540
	gctagaaaact	gggtacccgg	gccttgctac	cgtcagcagc	gcgtctccac	aaccaccaac	3600
	caaaataaca	acagcaactt	tgcgtggacg	ggagctgcta	aattcaagct	gaacgggaga	3660
50	gactcgctaa	tgaatcctgg	cgtggctatg	gcatcgcaca	aagacgacga	ggaccgcttc	3720
	tttccatcaa	gtggcgttct	catatttggc	aagcaaggag	ccgggaacga	tgaggtcgac	3780
55	tacagccagg	tgctgattac	agatgaggaa	gaaattaaag	ccaccaaccc	tgtagccaca	3840

EP 1 310 571 B1

gaggaatacg gagcagtggc catcaacaac caggccgcta acacgcaggc gcaaactgga 3900  
 cttgtgcata accagggagt tattcctggt atggtctggc agaaccggga cgtgtacctg 3960  
 5 cagggcccta tttgggctaa aatacctcac acagatggca actttcaccg gtctcctctg 4020  
 atgggtggat ttggactgaa acaccacact ccacagattc taattaaaaa tacaccagtg 4080  
 ccggcagatc ctcctcttac cttcaatcaa gccaaagtga actctttcat cagcagtagc 4140  
 10 agcacgggac aagtcagcgt ggaaatcgag tgggagctgc agaaagaaaa cagcaagcgc 4200  
 tggaatccag agatccagta tacttcaaac tactacaaat ctacaaatgt ggactttgct 4260  
 gtcaatacca aagggtgttta ctctgagcct cgccccattg gtactcgtta cctcaccggt 4320  
 15 aatttgtaat tgccctgttaa tcaataaacc ggttaattcg tttcagttga actttggtct 4380  
 ctgcg 4385  
 20  
 <210> 6  
 <211> 4718  
 <212> DNA  
 <213> adeno-associated virus serotype 1  
 25  
 <400> 6  
 30 ttgccactc cctctctgcg cgctcgctcg ctccggtgggg cctgcggacc aaagggtccgc 60  
 agacggcaga gctctgctct gccggcccca ccgagcgagc gagcgcgagc agagggagtg 120  
 ggcaactcca tctactagggg taatcgcgaa gcgcctccca cgctgccgcg tcagcgctga 180  
 cgtaaattac gtcataagggg agtggtcctg tattagctgt cacgtgagtg cttttgcgac 240  
 35 attttgcgac accacgtggc catttagggg atatatggcc gagtgagcga gcaggatctc 300  
 cattttgacc gcgaaatttg aacgagcagc agccatgccg ggcttctacg agatcgtgat 360  
 caagggtgccg agcgacctgg acgagcacct gccgggcatt tctgactcgt ttgtgagctg 420  
 40 ggtggccgag aaggaatggg agctgcccc ggattctgac atggatctga atctgattga 480  
 gcaggcacc ctagccgtgg ccgagaagct gcagcgcgac ttcttggtcc aatggcgccg 540  
 cgtgagtaag gccccggagg ccctcttctt tgttcagttc gagaagggcg agtcctactt 600  
 45 ccacctccat attctgggtg agaccacggg ggtcaaatac atggtgctgg gccgcttctc 660  
 gagtcagatt agggacaagc tgggtgcagac catctaccgc gggatcgagc cgacctgcc 720  
 caactggttc gcggtgacca agacgcgtaa tggcgccgga ggggggaaca aggtgggtgga 780  
 50 cgagtgtctac atccccaaact acctcctgcc caagactcag cccgagctgc agtgggctg 840  
 gactaacatg gaggagtata taagcgcctg tttgaacctg gccgagcgca aacggctcgt 900  
 ggcgcagcac ctgaccacg tcagccagac ccaggagcag aacaaggaga atctgaacct 960  
 55 caattctgac gcgcctgtca tccggtcaaa aacctccgcg cgctacatgg agctggctcg 1020  
 gtggctggtg gaccggggca tcacctccga gaagcagtgg atccaggagg accaggctc 1080

EP 1 310 571 B1

	gtacatctcc ttcaacgccg cttccaactc gcggtcccag atcaaggccg ctctggacaa	1140
	tgccggcaag atcatggcgc tgaccaaatc cgcgcccgac tacctggtag gccccgctcc	1200
5	gcccgcggac attaaaacca accgcatcta ccgcatcctg gagctgaacg gctacgaacc	1260
	tgccctacgcc ggctccgtct ttctcggctg ggcccagaaa aggttcggga agcgcaaacac	1320
	catctggctg tttggggccgg ccaccacggg caagaccaac atcgcggaag ccatcgccca	1380
10	cgccgtgccc ttctacggct gcgtcaactg gaccaatgag aactttccct tcaatgattg	1440
	cgtcgacaag atggtgatct ggtgggagga gggcaagatg acggccaagg tcgtggagtc	1500
	cgccaaggcc attctcggcg gcagcaaggc gcgctgggac caaaagtgc agtcgtccgc	1560
15	ccagatcgac cccacccccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga	1620
	cgggaacagc accaccttcg agcaccagca gccgttgacg gaccggatgt tcaaatattga	1680
	actcaccgc cgtctggagc atgactttgg caaggtgaca aagcaggaag tcaaagagtt	1740
20	cttccgctgg gcgcaggatc acgtgaccga ggtggcgcat gagttctacg tcagaaaggg	1800
	tggagccaac aaaagaccgc ccccgatga cgcgataaaa agcgagccca agcgggcctg	1860
	cccctcagtc gcggatccat cgacgtcaga cgcggaagga gctccggtgg actttgccga	1920
25	caggtaccaa aacaaatgtt ctcgtcacgc gggcatgctt cagatgctgt ttccctgcaa	1980
	gacatgcgag agaatgaatc agaatttcaa catttgcttc acgcacggga cgagagactg	2040
	ttcagagtgc ttccccggcg tgtcagaatc tcaaccggtc gtcagaaaga ggacgtatcg	2100
30	gaaactctgt gccattcatc atctgctggg gcgggctccc gagattgctt gctcggcctg	2160
	cgatctggtc aacgtggacc tggatgactg tgtttctgag caataaatga cttaaaccag	2220
	gtatggctgc cgatggttat cttccagatt ggctcgagga caacctctct gagggcattc	2280
35	gcgagtggcg ggacttgaaa cctggagccc cgaagcccaa agccaaccag caaaagcagg	2340
	acgacggccg gggctctggtg cttcctggct acaagtacct cggacccttc aacggactcg	2400
	acaaggggga gcccgtaaac gcggcggacg cagcggccct cgagcacgac aaggcctacg	2460
40	accagcagct caaagcgggt gacaatccgt acctgcggta taaccacgcc gacgccgagt	2520
	ttcaggagcg tctgcaagaa gatacgtctt ttgggggcaa cctcgggcga gcagtcttcc	2580
	aggccaagaa gcgggttctc gaacctctcg gtctggttga ggaaggcgct aagacggctc	2640
45	ctggaaagaa acgtccggtg gagcagtcgc cacaagagcc agactcctcc tcgggcatcg	2700
	gcaagacagg ccagcagccc gctaaaaaga gactcaattt tggtcagact ggcgactcag	2760
	agtcagtccc cgatccacaa cctctcggag aacctccagc aacccccgct gctgtgggac	2820
50	ctactacaat ggcttcaggc ggtggcgcac caatggcaga caataacgaa ggcgccgacg	2880
	gagtgggtaa tgcctcagga aattggcatt gcgattccac atggctgggc gacagagtca	2940
55	tcaccaccag caccgcacc tgggccttgc ccacctacaa taaccacctc tacaagcaaa	3000

EP 1 310 571 B1

	tctccagtgc ttcaacgggg gccagcaacg acaaccacta cttcgggtac agcaccacct	3060
	gggggtatatt tgatttcaac agattccact gccacttttc accacgtgac tggcagcgac	3120
5	tcatcaacaa caattgggga ttccggccca agagactcaa cttcaaaactc ttcaacatcc	3180
	aagtcaagga ggtcacgacg aatgatggcg tcacaaccat cgctaataac cttaccagca	3240
	cggttcaagt cttctcggac tcggagtacc agcttccgta cgtcctcggc tctgcgcacc	3300
10	agggctgcct ccctccgttc ccggcggacg tgttcattgat tccgcaatac ggctacctga	3360
	cgctcaacaa tggcagccaa gccgtgggac gttcatcctt ttactgcctg gaatatttcc	3420
	cttctcagat gctgagaacg ggcaacaact ttaccttcag ctacaccttt gaggaagtgc	3480
15	ctttccacag cagctacgag cacagccaga gcctggaccg gctgatgaat cctctcatcg	3540
	accaatacct gtattacctg aacagaactc aaaatcagtc cggaagtgcc caaaacaagg	3600
	acttgctgtt tagccgtggg tctccagctg gcatgtctgt tcagcccaaa aactggctac	3660
20	ctggaccctg ttatcggcag cagcgcgttt ctaaaacaaa aacagacaac aacaacagca	3720
	attttacctg gactggtgct tcaaaatata acctcaatgg gcgtgaatcc atcatcaacc	3780
	ctggcactgc tatggcctca cacaaagacg acgaagacaa gttctttccc atgagcgggtg	3840
25	tcatgatattt tggaaaagag agcgccggag cttcaaacac tgcattggac aatgtcatga	3900
	ttacagacga agaggaaatt aaagccacta accctgtggc caccgaaaga tttgggaccg	3960
	tggcagtcaa tttccagagc agcagcacag accctgcgac cggagatgtg catgctatgg	4020
30	gagcattacc tggcatggtg tggcaagata gagacgtgta cctgcagggc cccatttggg	4080
	ccaaaattcc tcacacagat ggacactttc acccgtctcc tcttatgggc ggctttggac	4140
	tcaagaacct gcctcctcag atcctcatca aaaacacgcc tgttcctgcg aatcctccgg	4200
35	cggagttttc agctacaaag tttgcttcat tcatcaccca atactccaca ggacaagtga	4260
	gtgtggaaat tgaatgggag ctgcagaaag aaaacagcaa gcgttggaat cccgaagtgc	4320
	agtacacatc caattatgca aaatctgcc aacgttgattt tactgtggac aacaatggac	4380
40	tttatactga gcctcgcccc attggcacc gttaccttac ccgtccccctg taattacgtg	4440
	ttaatcaata aaccggttga ttcgtttcag ttgaactttg gtctcctgtc cttcttatct	4500
	tatcgggttac catggttata gcttacacat taactgcttg gttgcgcttc gcgataaaag	4560
45	acttacgtca tcgggttacc cctagtgatg gagttgcccc ctccctctct gcgcgctcgc	4620
	tcgctcgggtg gggcctgcgg accaaaggtc cgcagacggc agagctctgc tctgccggcc	4680
50	ccaccgagcg agcagcgcg cagagaggga gtgggcaa	4718

<210> 7

<211> 4675

55 <212> DNA

<213> adeno-associated virus serotype 2

<400> 7



## EP 1 310 571 B1

	ttggccactc cctctctgcg cgctcgctcg ctactgagg ccgggcgacc aaaggctcgcc	60
	cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgag agagggagtg	120
5	gccaactcca tcaactagggg ttcctggagg ggtggagtcg tgacgtgaat tacgtcatag	180
	ggttagggag gtcctgtatt agaggtcacg tgagtgtttt gcgacatttt gcgacaccat	240
	gtggtcacgc tgggtattta agcccagtg agcacgcagg gtctccattt tgaagcggga	300
10	ggtttgaacg cgcagccgcc atgccggggg tttacgagat tgtgattaag gtccccagcg	360
	accttgacgg gcatctgccc ggcattttctg acagctttgt gaactgggtg gccgagaagg	420
	aatgggagtt gccgccagat tctgacatgg atctgaatct gattgagcag gcaccctga	480
15	ccgtggccga gaagctgcag cgcgactttc tgacggaatg gcgccgtgtg agtaaggccc	540
	cggaggccct tttctttgtg caatttgaga agggagagag ctacttcac atgcacgtgc	600
	tcgtggaac caccggggtg aaatccatgg ttttgggacg tttcctgagt cagattcgcg	660
20	aaaaactgat tcagagaatt taccgcgga tcgagccgac tttgccaaac tgggtcgcg	720
	tcacaaagac cagaaatggc gccggaggcg ggaacaagg ggtggatgag tgctacatcc	780
	ccaattactt gctcccaaa acccagcctg agctccagtg ggcgtggact aatatggaac	840
25	agtatttaag cgcctgtttg aatctcacgg agcgtaaacg gttggtggcg cagcatctga	900
	cgcacgtgtc gcagacgcag gagcagaaca aagagaatca gaatcccaat tctgatgcgc	960
	cggatgatcag atcaaaaact tcagccaggt acatggagct ggtcggtgg ctcgtggaca	1020
30	aggggattac ctcgagaag cagtggatcc agggaggacca ggcctcatac atctccttca	1080
	atgcccctc caactcgcg tcccaaatca aggctgcctt ggacaatgcg ggaaagatta	1140
	tgagcctgac taaaaccgcc ccgactacc tgggtggcca gcagcccgtg gaggacattt	1200
35	ccagcaatcg gatattataaa attttgaac taaacgggta cgatcccaa tatgcggctt	1260
	ccgtctttct gggatgggccc acgaaaaagt tcggcaagag gaacaccatc tggctgtttg	1320
	ggcctgcaac taccgggaag accaacatcg cggaggccat agcccacact gtgcccttct	1380
40	acgggtgcgt aaactggacc aatgagaact ttcccttcaa cgactgtgtc gacaagatgg	1440
	tgatctggtg ggaggagggg aagatgaccg ccaaggtcgt ggagtcggcc aaagccattc	1500
	tcggaggaag caaggtgcgc gtggaccaga aatgcaagtc ctcggccag atagaccga	1560
45	ctcccgtgat cgtcacctcc aacaccaaca tgtgcgccgt gattgacggg aactcaacga	1620
	ccttcgaaca ccagcagccg ttgcaagacc ggatgttcaa atttgaactc acccgccgtc	1680
	tggatcatga ctttgggaag gtcaccaagc aggaagtcaa agactttttc cgggtggcaa	1740
50	aggatcacgt ggttgagggt gagcatgaat tctacgtcaa aaagggtgga gccaagaaaa	1800
	gacccgcccc cagtgcgca gatataagt agcccaaacg ggtgcgcgag tcagttgcgc	1860
55	agccatcgac gtcagacgcg gaagcttcga tcaactacgc agacaggtac caaaacaaat	1920

## EP 1 310 571 B1

	gttctcgtca	cgtgggcatg	aatctgatgc	tgtttccctg	cagacaatgc	gagagaatga	1980
	atcagaattc	aaatatctgc	ttcactcacg	gacagaaaga	ctgttttagag	tgctttcccg	2040
5	tgtcagaatc	tcaacccggt	tctgtcgtca	aaaaggcgta	tcagaaactg	tgctacattc	2100
	atcatatcat	gggaaagggtg	ccagacgctt	gcactgcctg	cgatctgggtc	aatgtggatt	2160
	tggtatgactg	catctttgaa	caataaatga	tttaaatacag	gtatggctgc	cgatggttat	2220
10	cttccagatt	ggctcgagga	cactctctct	gaaggaataa	gacagtgggtg	gaagctcaaa	2280
	cctggcccac	caccaccaa	gcccgcagag	cggcataagg	acgacagcag	gggtcttggtg	2340
	cttcctgggt	acaagtacct	cggacccttc	aacggactcg	acaagggaga	gccggtcaac	2400
15	gaggcagacg	ccgcggccct	cgagcacgta	caaagcctac	gaccggcagc	tcgacagcgg	2460
	agacaacccg	tacctcaagt	acaaccacgc	cgacgcggag	tttcaggagc	gccttaaaga	2520
	agatacgtct	tttgggggca	acctcggacg	agcagtcttc	caggcgaaaa	agagggttct	2580
20	tgaacctctg	ggcctgggtg	aggaacctgt	taagacggct	ccgggaaaaa	agaggccggt	2640
	agagcactct	cctgtggagc	cagactcctc	ctcgggaacc	ggaaaggcgg	gccagcagcc	2700
	tgcaagaaaa	agattgaatt	ttggtcagac	tgagagcgca	gactcagtac	ctgacccccca	2760
25	gcctctcgga	cagccaccag	cagccccctc	tggtctggga	actaatcga	tggtctacagg	2820
	cagtggcgca	ccaatggcag	acaataacga	gggcgcgcag	ggagtgggta	attcctccgg	2880
	aaattggcat	tgcgattcca	catggatggg	cgacagagtc	atcaccacca	gcaccggaac	2940
30	ctggggccctg	cccacctaca	acaaccacct	ctacaaacaa	atttccagcc	aatcaggagc	3000
	ctcgaacgac	aatcactact	ttggctacag	cacccttggg	gggtattttg	acttcaacag	3060
	attccactgc	cacttttcac	cacgtgactg	gcaaagactc	atcaacaaca	actggggatt	3120
35	ccgacccaag	agactcaact	tcaagctctt	taacattcaa	gtcaaagagg	tcacgcagaa	3180
	tgacgggtacg	acgacgattg	ccaataacct	taccagcacg	gttcagggtg	ttactgactc	3240
	ggagtaccag	ctcccgtacg	tcctcggctc	ggcgcatcaa	ggatgcctcc	cgccgttccc	3300
40	agcagacgtc	ttcatgggtc	cacagtatgg	atacctcacc	ctgaacaacg	ggagtccaggc	3360
	agtaggacgc	tcttcatttt	actgcctgga	gtactttcct	tctcagatgc	tgcgtagccgg	3420
	aaacaacttt	accttcagct	acacttttga	ggacgttctt	ttccacagca	gctacgctca	3480
45	cagccagagt	ctggaccgtc	tcatgaatcc	tctcatcgac	cagtacctgt	attacttgag	3540
	cagaacaaac	actccaagtg	gaaccaccac	gcagtcaagg	cttcagtttt	ctcaggccgg	3600
	agcgagtgc	attcgggacc	agtctaggaa	ctggcttctt	ggaccctgtt	accgccagca	3660
50	gcgagtatca	aagacatctg	cggataacaa	caacagtcaa	tactcgtgga	ctggagctac	3720
	caagtaccac	ctcaatggca	gagactctct	ggtgaatccg	gccatggcaa	gccacaagga	3780
55	cgatgaagaa	aagttttttc	ctcagagcgg	ggttctcatc	tttgggaagc	aaggctcaga	3840

EP 1 310 571 B1

	gaaaacaaat gtgaacattg aaaagggtcat gattacagac gaagaggaaa tcggaacaac	3900
	caatcccgtg gctacggagc agtatggttc tgtatctacc aacctccaga gaggcaacag	3960
5	acaagcagct accgcagatg tcaacacaca aggcggttctt ccaggcatgg tctggcagga	4020
	cagagatgtg taccttcagg ggcccatctg ggcaaagatt ccacacacgg acggacattt	4080
	tcacccctct cccctcatgg gtggattcgg acttaaacac cctcctccac agattctcat	4140
10	caagaacacc ccggtacctg cgaatccttc gaccaccttc agtgcgggcaa agtttgcttc	4200
	cttcatacaca cagtactcca cgggacacgg tcagcgtgga gatcgagtgg gagctgcaga	4260
	aggaaaacag caaacgctgg aatcccgaat ttcagtacac ttccaactac aacaagtctg	4320
15	ttaatcgtgg acttaccgtg gataactaat gcgtgtattc agagcctcgc cccattggca	4380
	ccagatacct gactcgtaat ctgtaattgc ttgttaatac ataaaccgtt taattcgttt	4440
	cagttgaact ttggtctctg cgtatttctt tcttatctag tttccatggc tacgtagata	4500
20	agtagcatgg cgggttaatc attaaactaca aggaacccct agtgatggag ttggccactc	4560
	cctctctgcg cgctcgctcg ctactgagg ccgggcgacc aaaggctcgcc cgacgcccg	4620
	gctttgcccg ggcggcctca gtgagcgagc gagcgcgagc agagggagtg gccaa	4675
25		
	<210> 8	
	<211> 4726	
	<212> DNA	
30	<213> adeno-associated virus serotype 3	
	<400> 8	
35	ttggccactc cctctatgcg cactcgctcg ctcggtgggg cctggcgacc aaaggctcgcc	60
	agacggacgt gctttgcacg tccggcccca ccgagcgagc gagtgcgcat agagggagt	120
	gccaaactcca tctactagagg tatggcagtg acgtaacgcg aagcgcgcgga agcgagacca	180
40	cgccatccag ctgcgtcagc agtcagggtga cccttttgcg acagtttgcg acaccacgtg	240
	gccgctgagg gtatatattc tcgagtgagc gaaccaggag ctccattttg accgcgaaat	300
	ttgaacgagc agcagccatg ccgggggttct acgagattgt cctgaaggtc ccgagtgacc	360
45	tggacgagcg cctgccgggc atttctaact cgtttggttaa ctgggtggcc gagaaggaat	420
	gggacgtgcc gccggattct gacatggatc cgaatctgat tgagcaggca cccctgaccg	480
	tggccgaaaa gcttcagcgc gagttcctgg tggagtggcg ccgctgagt aaggccccgg	540
50	aggccctctt ttttgctccag ttcgaaaagg gggagacctt cttccacctg cagtgctga	600
	ttgagaccat cgggggtcaaa tccatggtgg tcggccgcta cgtgagccag attaaagaga	660
	agctggtgac ccgcattctac cgcggggtcg agccgcagct tccgaactgg ttgcggtga	720
55	ccaaaacgcg aaatggcgcc gggggcgagg acaagggtgg ggacgactgc tacatcccca	780
	actacctgct ccccaagacc cagcccagac tccagtgggc gtggactaac atggaccagt	840

EP 1 310 571 B1

	atttaagcgc	ctgtttgaat	ctcgcggagc	gtaaacggct	ggtggcgag	catctgacgc	900
	acgtgtcgc	gacgcaggag	cagaacaaag	agaatcagaa	ccccaattct	gacgcgccgg	960
5	tcatcaggtc	aaaaacctca	gccaggtaCa	tggagctggt	cgggtggctg	gtggaccgcg	1020
	ggatcacgtc	agaaaagcaa	tggattcagg	aggaccaggc	ctcgtacatc	tccttcaacg	1080
	ccgcctccaa	ctcgcgggtc	cagatcaagg	ccgcgctgga	caatgcctcc	aagatcatga	1140
10	gcctgacaaa	gacggctccg	gactacctgg	tgggcagcaa	cccgccggag	gacattacca	1200
	aaaatcggat	ctaccaaatc	ctggagctga	acgggtacga	tccgcagtac	gcggcctccg	1260
	tcttcctggg	ctgggcgcaa	aagaagtctg	ggaagaggaa	caccatctgg	ctctttgggc	1320
15	cggccacgac	gggtaaaacc	aacatcgcg	aagccatcgc	ccacgccgtg	cccttctacg	1380
	gctgcgtaaa	ctggaccaat	gagaactttc	ccttcaacga	ttgcgtcgac	aagatggtga	1440
	tctggtggga	ggagggcaag	atgacggcca	aggtcgtgga	gagcgccaag	gccattctgg	1500
20	gcggaagcaa	ggtgcgcgtg	gacaaaaagt	gcaagtcatc	ggcccagatc	gaaccactc	1560
	ccgtgatcgt	cacctccaac	accaacatgt	gcgccgtgat	tgacgggaac	agcaccacct	1620
	tcgagcatca	gcagccgctg	caggaccgga	tgtttgaatt	tgaacttacc	cgccgtttgg	1680
25	accatgactt	tggaaggtc	accaaacagg	aagtaaagga	ctttttccgg	tgggcttccg	1740
	atcacgtgac	tgacgtggct	catgagttct	acgtcagaaa	gggtggagct	aagaaacgcc	1800
	ccgcctccaa	tgacgcggat	gtaagcgagc	caaaacggga	gtgcacgtca	cttgccgagc	1860
30	cgacaacgtc	agacgcggaa	gcaccggcgg	actacgcgga	caggtaacca	aacaaatggt	1920
	ctcgtcacgt	gggcatgaat	ctgatgcttt	ttccctgtaa	aacatgcgag	agaatgaatc	1980
	aaattttccaa	tgtctgtttt	acgcatggtc	aaagagactg	tggggaatgc	ttccctggaa	2040
35	tgtcagaatc	tcaaccggtt	tctgtcgtca	aaaagaagac	ttatcagaaa	ctgtgtccaa	2100
	ttcatcatat	cctgggaagg	gcacccgaga	ttgcctgttc	ggcctgcgat	ttggccaatg	2160
	tggacttgga	tgactgtgtt	tctgagcaat	aaatgactta	aaccaggtat	ggctgctgac	2220
40	ggttatcttc	cagattggct	cgaggacaac	ctttctgaag	gcattcgtga	gtggtgggct	2280
	ctgaaacctg	gagtccctca	accaaagcg	aaccaacaac	accaggacaa	ccgtcgggggt	2340
	cttgtgtctc	cgggttacaa	atacctcgga	ccgggtaacg	gactcgacaa	aggagagccg	2400
45	gtcaacgagg	cggacgcggc	agccctcgaa	cacgacaaag	cttacgacca	gcagctcaag	2460
	gccggtgaca	acccgtacct	caagtacaac	cacgccgacg	ccgagtttca	ggagcgtctt	2520
	caagaagata	cgtctttttg	gggcaacctt	ggcagagcag	tcttccaggc	caaaaagagg	2580
50	atccttgagc	ctcttgggtc	ggttgaggaa	gcagctaaaa	cggctcctgg	aaagaagggg	2640
	gctgtagatc	agtctcctca	ggaaccggac	tcatcatctg	gtgttgga	atcgggcaaa	2700
55	cagcctgcc	gaaaaagact	aaatttcggt	cagactggag	actcagagtc	agtcccagac	2760

## EP 1 310 571 B1

	cctcaacctc tcggagaacc accagcagcc cccacaagtt tgggatctaa tacaatggct	2820
5	tcaggcgggtg gcgcaccaat ggcagacaat aacgaggggtg ccgatggagt gggtaattcc	2880
	tcaggaaatt ggcattgcga ttcccaatgg ctgggcgaca gagtcatcac caccagcacc	2940
	agaacctggg ccctgcccac ttacaacaac catctctaca agcaaattctc cagccaatca	3000
10	ggagcttcaa acgacaacca ctactttggc tacagcacc cttgggggta ttttgacttt	3060
	aacagattcc actgccactt ctcaccacgt gactggcagc gactcattaa caacaactgg	3120
	ggattccggc ccaagaaact cagcttcaag ctcttcaaca tccaagttag aggggtcacg	3180
15	cagaacgatg gcacgacgac tattgccaat aaccttacca gcacgggtca agtggtttacg	3240
	gactcggagt atcagctccc gtacgtgctc gggtcggcgc accaaggctg tctcccgccg	3300
	tttccagcgg acgtcttcat ggtccctcag tatggatacc tcaccctgaa caacggaagt	3360
20	caagcgggtg gacgctcatc cttttactgc ctggagtact tcccttcgca gatgctaagg	3420
	actggaaata acttccaatt cagctatacc ttcgaggatg taccttttca cagcagctac	3480
	gctcacagcc agagtttgga tcgcttgatg aatcctctta ttgatcagta tctgtactac	3540
25	ctgaacagaa cgcaaggaac aacctctgga acaaccaacc aatcacggct gcttttttagc	3600
	caggctgggc ctcagtctat gtctttgcag gccagaaatt ggctacctgg gccctgctac	3660
	cggcaacaga gactttcaaa gactgctaac gacaacaaca acagtaactt tccttggaca	3720
30	gcggccagca aatatcatct caatggccgc gactcgtctg tgaatccagg accagctatg	3780
	gccagtcaca aggacgatga agaaaaatct ttcctatgc acggcaatct aatatttggc	3840
	aaagaagga caacggcaag taacgcagaa ttagataatg taatgattac ggatgaagaa	3900
35	gagattcgta ccaccaatcc tgtggcaaca gagcagtatg gaactgtggc aaataacttg	3960
	cagagctcaa atacagctcc cagcactgga actgtcaatc atcagggggc cttacctggc	4020
	atggtgtggc aagatcgtga cgtgtacctt caaggacctt tctgggcaaa gattcctcac	4080
40	acggatggac actttcatcc ttctcctctg atgggaggct ttggactgaa acatccgctt	4140
	cctcaaatca tgatcaaaaa tactccggta ccggcaaatc ctccgacgac tttcagcccg	4200
	gccaaagttt cttcatttat cactcagtac tccactggac aggtcagcgt ggaaattgag	4260
45	tgggagctac agaaagaaaa cagcaaactg tggaatccag agattcagta cacttccaac	4320
	tacaacaagt ctgttaatgt ggactttact gtagacacta atggtgttta tagtgaacct	4380
	cgcctatttg gaaccggta tctcacacga aacttgtgaa tcctgggttaa tcaataaacc	4440
50	gtttaattcg tttcagttga actttggctc ttgtgcactt ctttatcttt atcttgtttc	4500
	catggctact gcgtagataa gcagcggcct gcggcgcttg cgcttcgcgg tttacaactg	4560
	ctggttaata ttttaactct gccatactc tagtgatgga gttggccact ccctctatgc	4620
55	gcactcgctc gctcgggtgg gcctggcgac caaaggctgc cagacggacg tgctttgcac	4680

## EP 1 310 571 B1

gtccggcccc accgagcgag cgagtgcgca tagagggagt ggccaa

4726

5 <210> 9  
 <211> 3098  
 <212> DNA  
 <213> new AAV serotype, clone 42.2

10 <400> 9

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
	gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
15	ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcttccg	180
	cccagatcga tcccaccccc gtgatcgtca cttccaacac caacatgtgc gctgtgattg	240
	acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatg ttcaaatttg	300
20	aactcaccgc ccgtctggag cacgactttg gcaaggtgac aaagcaggaa gtcaaagagt	360
	tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctac gtcagaaagg	420
	gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggcct	480
25	gccccctcagt cgcggatcca tgcagctcag acgcggaagg agctccggtg gactttgccg	540
	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
	agacatgcga gagaatgaat cagaatttca acatttgctt cagcacggg accagagact	660
30	gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc	720
	ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct	780
	gcgatctggt caacgtggac ctggatgacc gtgtttctga gcaataaatg acttaaacca	840
35	ggtatggctg ccgatggta tcttccagat tggctcgagg acaacctctc tgagggcatt	900
	cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag	960
	gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc	1020
40	gacaagggag agccggtcaa cgaggcagac gccgcggccc tcgagcacga caaggcctac	1080
	gacaagcagc tcgagcaggg ggacaacccg tacctcaagt acaaccacgc cgacgccgag	1140
	tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg agcagtcttc	1200
45	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
	cctggaaaaga agagacccat agaatcccc gactcctcca cgggcatcgg caagaaaggc	1320
	cagcagcccg ctaaaaagaa gctcaacttt gggcagactg gcgactcaga gtcagtgcc	1380
50	gacccccaac ctctcgga gaacctccgcc gcgccctcag gtctgggatc tggtaaatg	1440
	gctgcaggcg gtggcgacac aatggcagac aataacgaag gcgccgacgg agtgggtaat	1500
	gcctccggaa attggcattg cgattccaca tggctgggcg acagagtcac caccaccagc	1560
55	acccgcacct gggccctgcc cacctacaac aaccacctct acaagcagat atcaagtcag	1620
	agcggggcta ccaacgacaa ccacttcttc ggctacagca cccctgggg ctattttgac	1680

EP 1 310 571 B1

	ttcaacagat tccactgccca cttctcacca cgtgactggc agcgactcat caacaacaac	1740
5	tggggattcc ggcccagaaa gctgcggttc aagttgttca acatccaggt caaggaggtc	1800
	acgacgaacg acggcgttac gaccatcgct aataacctta ccagcacgat tcaggctcttc	1860
	tcggactcgg agtaccact gccgtacgtc ctcggtcttg cgcaccaggg ctgcctccct	1920
10	ccgttccttg cggacgtgtt catgattcct cagtacggat atctgactct aaacaacggc	1980
	agtcagtctg tgggacgttc ctcttcttac tgcctggagt actttccttc tcagatgctg	2040
	agaacgggca ataactttga attcagctac acctttgagg aagtgccttt ccacagcagc	2100
15	tatgcgacaca gccagagcct ggaccggctg atgaatcccc tcatcgacca gtacctgtac	2160
	tacctggccc ggaccagag cactacgggg tccacaaggg agctgcagtt ccatcaggct	2220
	gggccaaca ccatggccga gcaatcaaag aactggctgc ccggaccctg ttatcggcag	2280
20	cagagactgt caaaaaacat agacagcaac aacaacagta actttgcctg gaccggggcc	2340
	actaaatacc atctgaatgg tagaaattca ttaaccaacc cgggcgtagc catggccacc	2400
	aacaaggacg acgaggacca gttctttccc atcaacggag tgctggtttt tggcgaaacg	2460
25	ggggctgcc acaagacaac gctggaaaac gtgctaataa ccagcgagga ggagatcaaa	2520
	accaccaatc ccgtgggtac agaagaatac ggtgtggtct ccagcaacct gcaatcgtct	2580
	acggccggac ccagacaca gactgtcaac agccaggggg ctctgcccgg catggtctgg	2640
30	cagaaccggg acgtgtacct gcagggtccc atctgggcca aaattcctca cacggacggc	2700
	aactttcacc cgtctcccct gatgggaggga tttggactca aacaccgccc tcctcaaatt	2760
	ctcatcaaaa acaccccggt acctgctaata cctccagagg tgtttactcc tgccaagttt	2820
35	gcctcattta tcacgcagta cagcaccggc caggtcagcg tggagatcga gtgggaactg	2880
	cagaaagaaa acagcaaacg ctggaatcca gagattcagt acacctcaaa ttatgccaaag	2940
	tctaataatg tggaatttgc tgtcaacaac gaaggggttt atactgagcc tcgccccatt	3000
40	ggcaccggtt acctcacccg taacctgtaa ttgcctgtta atcaataaac cggttaattc	3060
	gtttcagttg aactttggtc tctgcgaagg gcgaattc	3098

<210> 10

<211> 3098

<212> DNA

<213> new AAV serotype, clone 16.3

<400> 10

	gaattcgccc ttcgcagaga ccaaagttca actgaaacga atcaaccggt ttattgatta	60
	acaagtaatt acaggttacg ggtgaggtaa cgggtgccaa tggggcgagg ctcagtataa	120
55	accccttcgt tgttgacagc aaattccaca ttattagact tggcataatt tgagggttac	180
	tgaatctctg gattccagcg tttgctgttt tctttctgca gttccactc gatctccacg	240

EP 1 310 571 B1

	ctgacctggc cgggtgctgta ctgcgtgata aatgaggcaa actaggcagg agtaaacacc	300
	cctggaggat tagcaggtag cgggggtgttt ttgatgagaa tttgaggagg cgggtgtttg	360
5	agtccaaatc cgcccatcag gggagacggg tgaaagttag cgtccgtgtg aggaattttg	420
	gcccagatgg gaccctgcag gtacacgtcc cggttctgcc agaccatgcc gggcagagcc	480
	ccctggctgt tgacagtctg tgtctggggg ccggccgtag acgattgcag gttgctggag	540
10	accacaccgt attcttctgt agccacggga ttgggtgggtt tgatctctct ctcgctgggc	600
	attagcacgt tttccagcgt tgtcttgttg gcagcccccg ttttgccaaa aaccagcact	660
	ccgttgatgg gaaagaactg gccctcgtcg tccttggttg tggccatggc tacgccggg	720
15	ttgggttaatg aatttctacc attcagatgg tatttagtgg ccccggtcca ggcaaagtta	780
	ctgttggtgt tgctgtctat gttttttgac agtctctgct gccgataaca gggtcggggc	840
	agccagttct ttgattgctc ggccatgggtg ttgggcccag cctgatggaa ctgcagctcc	900
20	cttgtggacc ccgtagtgtc ctgggtccgg gccaggtagt acaggtagct gtcgatgagg	960
	ggattcatca gccgggtccag gctctggctg tgcgcatagc tgctgtggaa aggcacttcc	1020
	tcaaagggtg agctgaattc aaagtattg cccgttctca gcatctgaga aggaaagtac	1080
25	tccaggcagt agaaggagga acgtcccata gactgactgc cgttggttag agtcagatat	1140
	ccgtactgag gaatcatgaa cacgtccgca gggaacggag ggaggcagcc ctggtgcgca	1200
	gagccgagga cgtacggcag ttggtactcc gagtccgaga agacctgaat cgtgctggta	1260
30	aggttattag cgatgggtcgt aacgccgtcg ttcgtcgtga cctccttgac ctggatgttg	1320
	aacaacttga accgcagctt tctgggccgg aatccccagt tgttggtgat gagtcgtgc	1380
	cagtcacgtg gtgagaagtg gcagtggaa ctgttgaaat caaaatagcc ccaggggggtg	1440
35	ctgtagccga agaagtgggt gtcgttggtg gccccgctct gacttgatat ctgctttag	1500
	agggtggtgt tgtagggtgg cagggcccag gtgcgggtgc tgggtggtgat gactctgtcg	1560
	cccagccatg tggaatcgca atgccaat tccggaggcat taccactcc gtcggcgcc	1620
40	tcgttattgt ctgccattgg tgcgccaccg cctgcagcca ttgtaccaga tcccagacct	1680
	gagggcgcg ggggaggttc tccgagaggt tgggggtcgg gcactgactc tgagtcgcca	1740
	gtctgcccga agttgagctt ctttttagcg ggctgctggc ctttcttgcc gatgcccggtg	1800
45	gaggagtcgg gggattctat gggctctctt tttccaggag cctctttagc gccttctca	1860
	accagaccga gaggttcgag aaccgccttc ttggcctgga agactgctcg cccgaggttg	1920
	ccccaaaag acgtatcttc ttgaagacgc tcctgaaact cagcgtcggc gtggttgtag	1980
50	ttgaggtacg ggttggtccc ctgctcgagc tgctgtcgt aggccttgct gtgctcgagg	2040
	gccgcggcgt ctgcctcgtt gaccggctct ccctgtcga gtccgttgaa gggtcggagg	2100
55	tactttagtc caggaagcac cagaccccg cgtcgtcct gcttttgctg gttggctttg	2160



# EP 1 310 571 B1

ggtttcgggg ctccagggtt caagtcccac cactcgcgaa tgccctcaga gaggttggtcc 2220  
 tcgagccaat ctggaagata accatcggca gccatacctg gtttaagtca tttattgctc 2280  
 5 agaaacacag tcatccagggt ccacgttgac cagatcgcag gccgagcaag caatctcggg 2340  
 agcccgcccc agcagatgat gaatggcaca gagtttccga tacgtcctct ttctgacgac 2400  
 cggttgagat tctgacacgc cggggaaaca ttctgaacag tctctggtcc cgtgcgtgaa 2460  
 10 gcaaagtgtg aaattctgat tcattctctc gcatgtcttg cagggaaaca gcatctgaag 2520  
 catgcccgcg tgacgagAAC atttgTTTTg gtacctgtcg gcaaagtcca ccggagctcc 2580  
 ttccgctgtc gacgtcgatg gatccgcgac tgaggggcag gcccgcttgg gctcgttttt 2640  
 15 atccgcgtca tcggggggcg gcctcttgtt ggctccaccc tttctgacgt agaactcatg 2700  
 cgccacctcg gtcacgtgat cctgcgcca gcggaagaac tctttgactt cctgctttgt 2760  
 caccttgcca aagtctgtc ccagacggcg ggtgagttca aatttgaaca tccgggtcttg 2820  
 20 taacggctgc tgggtgctga aggtggtgct gttcccgta atcacggcgc acatgttggt 2880  
 gttggaagtg acgatcacgg ggggtgggac gatctgggcg gacgacttgc acttttggtc 2940  
 cagcgcacc ttgctgccgc cgagaatggc cttggcggac tccacgacct tggccgcat 3000  
 25 cttgccctcc tcccaccaga tcaccatctt gtcgacgcaa tcgttgaagg gaaagtctc 3060  
 attggtccag ttgacgcagc cgtagaaagg gcgaattc 3098

30

<210> 11

<211> 3121

<212> DNA

<213> new AAV serotype, clone 29.3

35

<400> 11

40

45

50

55

EP 1 310 571 B1

	gaattcgccc ttcgcagaga ccaaagttca actgaaacga atcaaccggt ttattgatta	60
	acaagcaatt acagattacg ggtgaggtaa cgggtgccga tggggcgagg ctcaagaataa	120
5	gtgccatctg tgttaacagc aaagtccaca tttgtagatt tgtagtagtt ggaagtgtat	180
	tgaatctctg gggtccagcg tttgctgttt tctttctgca gctcccatte aatttcacg	240
	ctgacctgtc cggtgctgta ctgctgatg aacgacgcca gcttagcttg actgaaggta	300
10	gttggaggat ccgcgggaac aggtgtattc ttaatcagga tctgaggagg cgggtgtttc	360
	agtccaaagc ccccatcag cggcgaggga tgaaagtctc cgtccgtgtg aggaatcttg	420
	gcccagatag gacctgcag gtacacgtcc cggttctgcc agaccatgcc aggtaaggct	480
15	ccttgactgt tgacggcccc tacaatagga gcggcgtttt gctgttgca gttatcggcc	540
	accacgccgt actgttctgt ggccactggg ttggtggttt taatttcttc ctactgggt	600
	agcataacgc tgctatagtc cacgttgctt tttccagctc cctgtttccc aaacattaag	660
20	actccgctgg acggaaaaaa tcgtctcttc tcgtccttgt gggttgccat agcgacaccg	720
	ggatttacca gagagtctct gccattcaga tgatacttgg tggcaccggt ccaggcaaag	780

25

30

35

40

45

50

55

EP 1 310 571 B1

	ttgctgttgt tattttgcga cagtgtcgtg gagacgcgtt gctgccggta gcagggccccg	840
5	ggtagccagt ttttggcctg agccgacatg ttattaggcc cggcctgaga aaatagcaac	900
	tgctgagttc ctgcggtacc tcccgtaggac tgagtccgag acaggtagta cagggtactgg	960
	tcgatgaggg gggtcatcag ccgggtccagg ctttggctgt gcgcgtagct gctgtgaaaa	1020
10	ggcacgtcct caaactggta gctgaactca aagttgttgc ccgttctcag catttgagaa	1080
	ggaaagtact ccaggcagta gaaggaggaa cggcccacgg cctgactgcc attgttcaga	1140
	gtcagggtacc cgtactgagg aatcatgaag acgtccgccg ggaacggagg caggcagccc	1200
15	tggcgcgcag agccgaggac gtacgggagc tggattccg agtccgtaaa gacctgaatc	1260
	gtgctggtaa gggtattggc gatggtcttg gtgccctcat tctgcgtgac ctccttgacc	1320
	tggatgttga agagcttgaa gttgagtctc ttgggccgga atccccagtt gttgttgatg	1380
20	agtcgctgcc agtcacgtgg tgagaagtgg cagtggaatc tgttaaagtc aaaatacccc	1440
	caggggggtgc tgtagccgaa gtaggtgttg tcgttggtgc ttcctcccga agtcccgttg	1500
	gagatttgct tgtagaggty gttgtttag gtggggaggg cccaggttcg ggtgctggtg	1560
25	gtgatgactc tgtcggccag ccatgtggaa tcgcaatgcc aatttcctga ggaactacct	1620
	actccgtcgg cgccttcgtt attgtctgcc attggagcgc caccgcctgc agccattgta	1680
	ccagatccca gaccagaggg gcctgcgggg ggttctccga ttggttgagg gtcgggcact	1740
30	gactctgagt cgccagtctg cccaaagtgg agtctctttt tcgcgggctg ctggcctttc	1800
	ttgccgatgc ccgtagtgga gtctggagaa cgctgggggtg atggctctac cggctctctc	1860
	tttccaggag ccgtcttagc gccttcctca accagaccga gaggttcgag aaccgccttc	1920
35	ttggcctgga agactgctcg tccgagggtg ccccaaaaag acgtatcttc ttgcagacgc	1980
	tcctgaaact cggcgtcggc gtggttatac cgcaggtagc gattgtcacc cgctttgagc	2040
	tgctggctgt aggccttgte gtgctcgagg gccgctgcgt ccgccgcgtt gacgggctcc	2100
40	cccttgctga gtccgttgaa ggggtccgagg tacttgtagc caggaagcac cagaccccg	2160
	ccgtcgtcct gcttttgctg gttggctttg ggcttcgggg ctccagggtt cagcgccac	2220
	cactcgcgaa tgccttcaga gaggttgctc tcgagccaat ctggaagata accatcggca	2280
45	gccatacctg atctaaatca tttattgttc aaagatgcag tcatccaaat ccacattgac	2340
	cagatcgcag gcagtgaag cgtctggcac ctttcccatg atatgatgaa tgtagcacag	2400
	tttctgatac gcctttttga cgacagaaac ggggtgagat tctgacacgg gaaagcactc	2460
50	taaacagtct ttctgtccgt gagtgaagca gatatttgaa ttctgattca ttctctcgca	2520
	ttgtctgcag ggaaacagca tcagattcat gccacgtga cgagaacatt tgttttggtg	2580
	cctgtccgcg tagttgatcg aagcttccgc gtctgacgtc gatggctgcg caactgactc	2640
55	gcgcacccgt ttgggctcac ttatatctgc gtcactgggg gcgggtcttt tcttggtctc	2700

# EP 1 310 571 B1

	accctttttg acgtagaatt catgctccac ctcaaccacg tgatcctttg cccaccggaa	2760
5	aaagtctttg acttcctgct tggtagacctt cccaaagtca tgatccagac ggcgggtgag	2820
	ttcaaatttg aacatccggt cttgcaacgg ctgctggtgt tcgaagggtcg ttgagttccc	2880
	gtcaatcacg gcgcacatgt tgggtgttggg ggtgacgatc acgggagtcg ggtctatctg	2940
10	ggccgaggac ttgcatttct ggtccacgag caccttgctt cctccgagaa tggctttggc	3000
	cgactccacg accttggcgg tcatcttccc ctctccacac cagatcacca tcttgtcgac	3060
	acagtcgttg aagggaaaagt tctcattggt ccagttgacg cagccgtaga agggcgaatt	3120
15	c	3121

	<210> 12
	<211> 3121
20	<212> DNA
	<213> new AAV serotype, clone 29.4
	<400> 12

25

30

35

40

45

50

55

# EP 1 310 571 B1

	gaattcgccc ttctacggct gcgtcaactg gaccaatgag aactttccct tcaacgactg	60
	tgtcgacaag atggtgatct ggtgggagga ggggaagatg accgccaagg tcgtggagtc	120
5	ggccaaagcc attctcggag gaagcaaggt gcgcgtggac cagaaatgca agtcctcggc	180
	ccagatagac ccgactcccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga	240
	cgggaactca acgaccttcg aacaccagca gccgttgcaa gaccggatgt tcaaatttga	300
10	actcaccgcg cgtctggatc atgactttgg gaagggtcacc aagcaggaag tcaaagactt	360
	tttccggtgg gcaaaggatc acgtggttga ggtggagcac gaattctacg tcaaaaaggg	420
	tggagccaag aaaagacccg cccccagtga cgagatata agtgagcca aacgggtgcg	480
15	cgagtcagtt gcgcagccat cgacgtcaga cgcggaagct tcgatcaact acgcagacag	540
	gtacccaaac aaatgttctc gtcacgcggg catgaatctg atgctgtttc cctgcagaca	600
	atgcgagaga atgaatcaga attcaaatat ctgcttcaact cacggacaga aagactgttt	660
20	agagtgtttt cccgtgtcag aatctcaacc cgtttctgtc gtcaaaaagg cgtatcagaa	720
	actgtgttac attcatcata tcatgggaaa ggtgccagac gcttgcaact cctgcgatct	780
	ggtcgatgtg gatttggatg actgcatctt tgaacaataa atgatttaaa tcagggtatgg	840
25	ctgccgatgg ttatcttcca gattggctcg aggacaacct ctctgagggc attcgcgagt	900
	ggtgggcgct gaaacctgga gccccgaagc ccaaagccaa ccagcaaaag caggacggcg	960
	gccggggctt ggtgcttcct ggctacaagt acctcggacc cttcaacgga ctcgacaagg	1020
30	gggagcccggt caacgcggcg gacgcagcgg ccctcgagca cgacaaggcc tacgaccagc	1080
	agctcaaagc gggtgacaat ccgtacctgc ggtataacca cgccgacgcc gagtttcagg	1140
	agcgtctgca agaagatacg tcttttgggg gcaacctcgg gcgagcagtc ttccaggcca	1200

35

40

45

50

55

EP 1 310 571 B1

	agaagcgggt tctcgaaacct ctcggtctgg ttgaggaagg cgctaagacg gtccttgga	1260
	agaagagacc ggtagagcca tcaccccagc gttctccaga ctccctctacg ggcacgga	1320
5	agaaaggcca gcagcccgcg aaaaagagac tcaactttgg gcagactggc gactcagagt	1380
	cagtgccga ccctcaacca atcggagaac ccccgagcgg cccctctggt ctgggatctg	1440
	gtacaatggc tgcaggcggg ggcgctcaa tggcagacaa taacgaaggc gccgacggag	1500
10	tgggtagttc ctcaggaaat tggcattgag attccacatg gctgggagac tgagtcac	1560
	ccaccagcac ccgaacctgg gccctcccca cctacaacaa ccacctctac aagcaaatct	1620
	ccaacgggac ttcgggagga agcaccaacg acaacaccta cttcggctac agcacccct	1680
15	gggggtatct tgactttaac agattccact gccacttctc accacgtgac tggcagcgac	1740
	tcatcaacaa caactgggga ttccggccca agagactcaa cttcaagctc ttcaacatcc	1800
	aggtaagga ggtcacgcag aatgaaggca ccaagaccat cgccaataac cttaccagca	1860
20	cgattcaggt ctttacggac tcggaatacc agctcccgta cgtcctcggc tctgcgcacc	1920
	agggtgcct gcctccgttc ccggcgagc tcttcacgat tcctcagtac gggtagctga	1980
	ctctgaacaa tggcagtcag gccgtgggac gttcctcctt ctactgcctg gactactttc	2040
25	cttctcaaat gctgagaacg ggcaacaact ttgagttcag ctaccagttt gaggacgtgc	2100
	cttttcacag cagctacgcg cacagccaaa gcctggaccg gctgatgaac cccctcatcg	2160
	accagtacct gtactacctg tctcggactc agtccacggg aggtaccgca ggaactcagc	2220
30	agttgctatt ttctcaggcc gggcctaata acatgtcggc tcaggccaaa aactggctac	2280
	ccgggcccctg ctaccggcag taacgcgtct ccacgacact gtcgcaaaat aacaacagca	2340
	actttgtctg gaccgggtgcc accaagtatc atctgaatgg cagagactct ctggtagatc	2400
35	ccgggtgtcg tatggcaacc cacaaggacg acgaagagcg attttttccg tccagcggag	2460
	tcataatggt tgggaaacag ggagctggaa aagacaacgt ggactatagc agcgtcatgc	2520
	taaccagtga ggaagaaatt aaaaccacca acccagtggc cacagaacag tacggcgtgg	2580
40	tggccgataa cctgcaacag caaaacgcg ctcctattgt aggggcccgtc aacagtcaag	2640
	gagccttacc tggcatggc tggcagaacc gggacgtgta cctgcagggt cctacctggg	2700
	ccaagattcc tcacacggac ggaaactttc atccctcgcc gctgatggga ggctttggac	2760
45	tgaacacccc gcctcctcag atcctgatta agaatacacc tggtcccgcg gatcctccaa	2820
	ctaccttcag tcaagctaag ctggcgctgt tcatcacgca gtacagcacc ggacagggtca	2880
	gcgtggaaat tgaatgggag ctgcaggaag aaaacagcaa acgctggaa cagagattc	2940
50	aatacacttc caactactac aaatctacaa atgtggactt tgctgttaac acagatggca	3000
	cttattctga gcctcgcccc atcggcaccg gttacctcac ccgtaatctg taattgcttg	3060
55	ttaatcaata aaccgggtga ttcgtttcag ttgaactttg gtctctgcga agggcgaa	3120

c

3121

5

<210> 13

<211> 3121

<212> DNA

<213> new AAV serotype, clone 29.5

10

<400> 13

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

	gaattcgccc ttcgcgagac caaagttcaa ctgaaacgaa tcaaccggtt tattgattaa	60
	caagcaatta cagattacgg gtgaggtaac gggtgccgat ggggcgaggc tcagaataag	120
5	tgccatctgt gttaacagca aagtccacat ttgtagattt gtagtagttg gaagtgtatt	180
	gaatctcttg gttccagcgt ttgctgtttt ctttctgcag ctcccattca atttccacgc	240
	tgacctgtcc ggtgctgtac tgcgtgatga acgacgccag cttagcttga ctgaaggtag	300
10	ttggaggatc cgcgggaaca ggtgtattct taatcaggat ctgaggaggc ggggtgtttca	360
	gtccaaagcc tcccatcagc ggcgagggat gaaagtttcc gtccgtgtga ggaatcttgg	420
	cccagatagg accctgcagg tacacgtccc ggttctgcc aacctgcca ggtaaggctc	480
15	cttgactgtt gacggccctt acaataggag cggcgttttg ctgttgccagg ttatcggcca	540
	ccacgccgta ctgttctgtg gccactgggt tgggtggttt aatttcttcc tcaactggtta	600
	gcataacgct gctatagtcc acgttgtctt ttccagctcc ctgtttccca aacattaaga	660
20	ctccgctgga cggaaaaaat cgctcttcgt cgtccttggt ggttgccata gcgacaccgg	720
	gatttaccag agagtctctg ccattcagat gataacttgtt ggcaccgggtc caggcaaat	780
	tgctgttgtc attttgcgac agtgtcgtgg agacgcgttg ctgccggtag cagggcccg	840
25	gtagccagtt tttggcctga gccgacatgt tattaggccc ggcctgagaa aatagcaact	900
	gctgagttcc tgcggtacct cccgtggact gagtccgaga caggtagtac aggtactggt	960
	cgatgagggg gttcatcagc cgggtccaggc tttggctgtg cgcgtagctg ctgtgaaaag	1020
30	gcacgtcctc aaactggtag ctgaactcaa agttgttgcc cgttctcagc atttgagaag	1080
	gaaagtactc caggcagtag aaggaggaac ggcccacggc ctgactgcca ttgttcagag	1140
	tcaggtagcc gtagtgagga atcatgaaga cgtccgccgg gaacggaggc aggcagccct	1200
35	ggtgcgcaga gccgaggacg tacgggagct ggtattccga gtccgtaaag acctgaatcg	1260
	tgctggtaag gttattggcg atggtcttgg tgccttcatt ctgctgacc tccttgacct	1320
	ggatgttgaa gagcttgaag ttgaggctct tgggccggaa tcccagttg ttgttgatga	1380
40	gtcgtgccca gtcacgtggg gagaagtggc agtgaatct gttaaagtca aaatacccc	1440
	agggggtgct gtagccgaag taggtgttgt cgttggtgct tcctcccgaa gtcccgttgg	1500
	agatttgctt gtagaggtag ttgttgtagg tggggagggc ccagggttcgg gtgctggtgg	1560
45	tgatgactcc gtcgccagc catgtggaat cgcaatgcca atttctgag gaactacca	1620
	ctccgtcggc gccttcgtta ttgtctgcc ttggagcgcc accgcctgca gccattgtac	1680

50

55



EP 1 310 571 B1

	cagatcccag accagagggg cctgcggggg gttctccgat tggttgaggg tcgggcaactg	1740
	actctgagtc gccagtctgc ccaaagttga gtctcttttt cgcgggctgc tggcctttct	1800
5	tgccgatgcc cgtagaggag tctggagaac gctgggggtga tggctctacc ggtctcttct	1860
	ttccaggagc cgtcttagcg ccttcctcaa ccagaccgag aggttcgaga acccgcttct	1920
	tggcctggaa gactgctcgc ccgaggttgc ccccaaaaga cgtatcttct tgcagacgct	1980
10	cctgaaactc ggcgtcggcg tggttatacc gcaggtacgg attgtcacc gctttgagct	2040
	gctggtcgta ggccttgctg tgctcgaggg ccgctgcgtc cgccgcgttg acgggctccc	2100
	ccttgctcag tccgttgaag ggtccgaggt acttgtagcc aggaagcacc agaccccggc	2160
15	cgctcgtcctg cttttgctgg ttggctttgg gcttcggggc tccaggtttc agcgcccacc	2220
	actcgcgaat gccctcagag aggttgtcct cgagccaatc tggaaagataa ccatcggcag	2280
	ccatacctga tttaaactcat ttattgttca aagatgcagt catccaaatc cacattgacc	2340
20	agatcgcagg cagtgcgaagc gtctggcacc ttcccatga tatgatgaat gtagcacagt	2400
	ttctgatacg cttttttgac gacagaaacg ggttgagatt ctgacacggg aaagcactct	2460
	aaacagtctt tctgtccgtg agtgaagcag atatttgaat tctgattcat tctctcgc	2520
25	tgtctgcagg gaaacagcat cagattcatg cccacgtgac gagaacattt gttttggtac	2580
	ctgtctgcgt agttgatcga agcttccgcg tctgacgtcg atggctgcgc aactgactcg	2640
	cgcacccggt tgggctcact tatactcgcg tcaactgggg cgggctcttt cttggctcca	2700
30	ccctttttga cgtagaattc atgctccacc tcaaccacgt gatcctttgc ccaccggaaa	2760
	aagtctttga cttcctgctt ggtgaccttc ccaaagtc atgatccagacg gcgggtgagt	2820
	tcaaatttga acatccggtc ttgcaacggc tgctggtggt cgaaggctcg tgagttcccg	2880
35	tcaatcacgg cgcacatggt ggtgttgag gtgacgatca cgggagtcgg gtctatctgg	2940
	gccgaggact tgcatttctg gtccacgcgc accttgcttc ctccgagaat ggctttggcc	3000
	gactccacga ccttggcggt catcttcccc tctccacc agatcaccat cttgtcgaca	3060
40	cagtcgttga agggaaagtt ctcatgggtc cagttgacgc agccgtagaa agggcgaatt	3120
	c	3121
45	<210> 14 <211> 3131 <212> DNA <213> new AAV serotype, clone 1-3	
50	<400> 14	
	gcggccgcga attcgccctt ggctgcgtca actggaccaa tgagaacttt cccttcaatg	60
55	attgcgtcga caagatggtg atctgggtgg aggaggcaca gatgacggcc aaggtcgtgg	120
	agtccgcca ggccattctc ggcggcagca aggtgcgcgt ggacccaaag tgcaagtcgt	180

## EP 1 310 571 B1

	ccgcccagat	cgaccccacc	cccgtgatcg	tcacctccaa	caccaacatg	tgcgccgtga	240
	ttgacgggaa	cagcaccacc	ttcgagcacc	agcagcctct	ccaggaccgg	atgtttaagt	300
5	tcgaactcac	ccgccgtctg	gagcacgact	ttggcaaggt	gacaaagcag	gaagtcaaag	360
	agttcttccg	ctgggccagt	gatacacgtga	ccgaggtggc	gcatgagttt	tacgtcagaa	420
	agggcggagc	cagcaaaaga	cccgcctccg	atgacgcgga	taaaagcgag	cccaagcggg	480
10	cctgccccctc	agtcgcggat	ccatcgacgt	cagacgcgga	aggagctccg	gtggactttg	540
	ccgacaggta	ccaaaacaaa	tgttctcgtc	acgcgggcat	gcttcagatg	ctgtttccct	600
	gcaaaacgtg	cgagagaatg	aatcggaatt	tcaacatttg	cttcacacac	ggggtcagag	660
15	actgctcaga	gtgtttcccc	ggcgtgtcag	aatctcaacc	ggtcgtcaga	aagaggacgt	720
	atcggaact	ccgtgcgatt	catcatctgc	tggggcgggc	tcccagagatt	gcttgctcgg	780
	cctgcgatct	ggtcaacgtg	gacctggatg	actgtgtttc	tgagcaataa	atgacttaaa	840
20	ccaggatatgg	ctgccgatgg	ttatcttcca	gattggctcg	aggacaacct	ctctgagggc	900
	attcgcgagt	ggtgggcgct	gaaacctgga	gccccgaagc	ccaaagccaa	ccagcaaaag	960
	caggacgacg	gccgggggtct	ggtgcttcct	ggctacaagt	acctcggacc	cttcaacgga	1020
25	ctcgacaagg	gggagcccgt	caacgcggcg	gacgcagcgg	ccctcgagca	cgacaaggct	1080
	tacgaccagc	agctgcaggc	gggtgacaat	ccgtacctgc	ggtataacca	cgccgacgcc	1140
	gagtttcagg	agcgtctgca	agaagatacg	tcttttgggg	gcaacctcgg	gcgagcagtc	1200
30	ttccaggcca	agaagcgggt	tctcgaacct	ctcgggtctg	ttgaggaagg	cgctaagacg	1260
	gctcctggaa	agaagagacc	ggtagagcca	tcaccccagc	gttctccaga	ctcctctacg	1320
	ggcatcggca	agaaaggcca	acagcccggc	agaaaaagac	tcaatttttg	tcagactggc	1380
35	gactcagagt	cagttccaga	ccctcaacct	ctcggagaa	ctccagcagc	gccctctggt	1440
	gtgggacct	atacaatggc	tgaggcggt	ggcgaccaa	tgagagacaa	taacgaaggc	1500
	gccgacggag	tgggtagttc	ctcgggaaat	tggcattgcg	attccacatg	gctgggcgac	1560
40	agagtcatca	ccaccagcac	ccgaacctgg	gccctgcccc	cctacaacaa	ccacctctac	1620
	aagcaaactct	ccaacgggac	atcgggagga	gccaccaacg	acaacaccta	cttcggctac	1680
	agcaccctct	gggggtatct	tgactttaac	agattccact	gccaccttct	accacgtgac	1740
45	tggcagcgac	tcatcaacaa	caactgggga	ttccgaccca	agagactcag	cttcaagctc	1800
	ttcaacatcc	aggtcaagga	ggtcacgcag	aatgaaggca	ccaagaccat	cgccaataac	1860
	ctcaccagca	ccatccaggt	gtttacggac	tcggagtacc	agctgccgta	cgttctcggc	1920
50	tctgtccacc	agggctgcct	gcctccgttc	ccggcggacg	tgttcatgat	tcccagctac	1980
	ggctacctaa	cactcaacaa	cggtagtcag	gccgtgggac	gctcctcctt	ctactgcctg	2040
55	gaatactttc	cttcgcagat	gctgagaacc	ggcaacaact	tccagtttac	ttacaccttc	2100

# EP 1 310 571 B1

5 gaggacgtgc ctttccacag cagctacgcc cacagctaga gcttggaccg gctgatgaat 2160  
 cctctgattg accagtacct gtactacttg tctcggactc aaacaacagg aggcacggca 2220  
 aatacgcaga ctctgggctt cagccaaggt gggcctaata caatggccaa tcaggcaaaag 2280  
 aactggctgc caggaccctg ttaccgccaa caacgcgtct caacgacaac cgggcaaaac 2340  
 aacaatagca actttgcctg gactgctggg accaaatacc atctgaatgg aagaaattca 2400  
 10 ttggctaata ctggcatcgc tatggcaaca cacaagacg acgaggagcg tttttttccc 2460  
 agtaacggga tcctgatttt tggcaaacaa aatgctgcca gagacaatgc ggattacagc 2520  
 gatgtcatgc tcaccagcga ggaagaaatc aaaaccacta accctgtggc tacagaggaa 2580  
 15 tacggtatcg tggcagataa cttgcagcag caaaacacg ctcctcaa at tggaactgtc 2640  
 aacagccagg gggccttacc cggatatggtc tggcagaacc gggacgtgta cctgcagggt 2700  
 cccatctggg ccaagattcc tcacacggac ggcaacttcc acccgtctcc gctgatgggc 2760  
 20 ggctttggcc tgaacatcc tccgcctcag atcctgatca agaacacgcc tgtacctgcg 2820  
 gatectccga ccaccttcaa ccagtcaaag ctgaactctt tcatcacgca atacagcacc 2880  
 ggacagggtca gcgtggaaat tgaatgggag ctgcagaagg aaaacagcaa gcgctggaac 2940  
 25 cccgagatcc agtacacctc caactactac aaatctataa gtgtggactt tgctgttaat 3000  
 acagaaggcg tgtactctga accccgcccc attggcaccc gttacctcac ccgtaatctg 3060  
 taattgcctg ttaatcaata aaccggttga ttcgtttcag ttgaactttg gtctctgcga 3120  
 30 agggcggaatt c 3131

35 <210> 15  
 <211> 3127  
 <212> DNA  
 <213> new AAV serotype, clone 13-3b

40 <400> 15

45

50

55

# EP 1 310 571 B1

	gcggccgcga attcgccctt cgcagagacc aaagttcaac tgaaacgaat caaccggttt	60
	attgattaac atgcaattac agattacggg tgaggtaacg agtgccaata gggcgaggct	120
5	cagagtaaac accctggctg tcaacggcaa agtccacacc agtctgcttt tcaaagttgg	180
	aggtgtactg aatctccggg tcccagecgt tgctgttttc cttctgcagc tcccactcga	240
	tttccacgct gacttgtcg gtgctgtact gtgtgatgaa cgaagcaaac ttggcaggag	300
10	taaacacctc cggaggatta gcgggaacgg gagtgttctt gatcaggatc tgaggaggcg	360
	gatgtttaag tccaaagccg cccatcaaag gagacgggtg aaagttgcca tccgtgtgag	420
	gaatcttggc ccagatggga ccctgcaggt acacgtcccg gttctgccag accatgccag	480
15	gtaaggctcc ctggttggtg acaacttggtg tctgggctgc agtattagcc gcttgtaagt	540
	tgctgctgac tatcccgtat tcttccgtgg ctacaggatt agtaggacga atttcttctt	600
	catttgctcat taacacattt tccaatgtag ttttgtagt tgctccagtt tttccaaaaa	660
20		
25		
30		
35		
40		
45		
50		
55		

EP 1 310 571 B1

	tcaggactcc gctggatggg aaaaagcggg cctcgtcgtc cttgtgagtt gccatggcga	720
5	cgccgggatt aaccaacgag tttctgccgt tcaggtgata tttgggtggca ccagtccaag	780
	caaagttgct gttgttgttt tgatccagcg ttttgagagac cctttgttgc cggaagcagg	840
	gtccaggtaa ccaattcttg gcttgttcgg ccatagttga agggccgccc tggtaaaact	900
10	gcagttcccc attgccagct gtgcctcctg ggctactctg tgttctggcc aggtagtaca	960
	agtactggtc gatgagggga ttcacagcc ggtccaggct ctggctgtgt gcgtagctgc	1020
	tgtggaaagg cacgtcctcg aagctgtagc tgaactcaaa gttgttgccc gttctcagca	1080
15	tctgagaggg gaagtactcc aggcagtaga aggaggaacg tcccacagac tgactgccat	1140
	tgttgagagt caggtagccg tactgaggaa tcatgaagac gtccgcccggg aacggaggca	1200
	ggcagccctg gtgcgcagag ccgaggacgt acggcagctg gtattccgag tccgagaata	1260
20	cctgaatcgt gctggtaagg ttattagcga tggctgtaac gccgtcattc gtcgtgacct	1320
	ccttgacctg gatgttgaag agcttgaacc gcagcttctt gggccggaat cccagttgt	1380
	tgttgatgag tcgctgccag tcacgtggtg agaagtggca gtggaatctg ttaaagtcaa	1440
25	aataccccca ggggggtgctg tagccgaagt aggtgttctg gttggtacta cctgcagttt	1500
	cactggagat ttgctcgtag aggtggttgt tgtaggtggg cagggcccag gttcgggtgc	1560
	tggtggtaat gactctgtcg cccagccatg tggaatcgca atgccaattt cctgagggcat	1620
30	taccactcc gtcggcacct tcgttattgt ctgccattgg tgcgccaccg cctgcagcca	1680
	ctgtaccaga tcccacacta gagggcgctg ctggagggttc tccgagaggt tgagggtcgg	1740
	ggactgactc tgagtcgcca gtctgaccga aattgagtct ctttctggcg ggctgctggc	1800
35	ccttcttgcc gatgcccggtg gaggagtcgg gggaacgctg aggtgacggc tctaccggtc	1860
	tcttctttgc aggagccgtc ttagcgctt cctcaaccag accgagaggt tcgagaaccc	1920
	gcttcttggc ctggaagact gctcgcccga gggtgcccc aaatgacgta tcttcttgca	1980
40	gacgtcctg aaactcggcg tcggcggtgt tataccgcag gtacgggttg tcaccgcat	2040
	tgagctgctg gtcgtaggcc ttgtcgtgct cgagggccgc tgcgtccgcc gcgttgacgg	2100
	gtccccctt gtcgagtcgg ttgaagggtc cgaggtactt gtagccagga agcaccagac	2160
45	ccgggcccgtt gtcctgcttt tgctgggttg ctttgggttt cggggctcca ggtttcaggt	2220
	cccaccactc gcgaatgccc tcagagaggt tgcctcagag ccaatctgga agataacat	2280
	cggcagccat acctgattta aatcatttat tgttcaaaga tgcagtcac caaatccaca	2340
50	ttgaccagat cgcaggcagt gcaagcgtct ggcaccttcc ccatgatatg atgaatgtag	2400
	cacagtttct gatagcctt tttgacgaca gaaacgggtt tagattctga cacgggaaag	2460
	cactctaaac agtctttctg tccgtgagtg aagcagatat ttgaattctg attcattctc	2520
55	tcgcattgtc tgcagggaaa cagcatcaga ttcatgcccc cgtgacgaga acatttgttt	2580

# EP 1 310 571 B1

5      **tggtacctgt ctgcgtagtt gatcgaagct tccgcgtctg acgtcgatgg ctgcgcaact 2640**  
**gactcgcgca cccgtttggg ctcaactata tctgcgtcac tgggggcggg tcttttcttg 2700**  
**gctccaccct ttttgacgta gaattcatgc tccacctcaa ccacgtaatc ctttgccac 2760**  
**cggaaaaagt ctttgacttc ctgcttgggtg accttcccaa agtcatgac cagacggcgg 2820**  
 10    **gtgagttcaa atttgaacat ccggtcttgc aacggctgct ggtgttcgaa ggtcgttgag 2880**  
**ttcccgtcga tcacggcgca catgttgggtg ttggagatga cgatcgcggg agtcgggtct 2940**  
**atctgggccc aggacttgca tttctggtcc acgcgcacct tgcttcctcc gagaatggct 3000**  
 15    **ttggccgact ccacgacctt ggcggtcatc ttcccctcct cccaccagat caccatcttg 3060**  
**tcgacacagt cgttgaaggg aaagttctca ttggtccagt tgacgcagcc gtagaaaggg 3120**  
**cgaattc 3127**

20      <210> 16  
          <211> 3106  
          <212> DNA  
          <213> new AAV serotype, clone 24-1  
 25      <400> 16

30

35

40

45

50

55

# EP 1 310 571 B1

	gcggccgcga attcgccctt cgcagagacc aaagttcaac tgaaacgaat caaccggttt	60
	attgattaac aagtaattac aggttacggg tgaggtaacg ggtgccaatg gggcgaggct	120
5	cagtataaac cccttcgttg ttgacagcaa attccacatt attagacttg gcataatttg	180
	aggtgtactg aatctctgga ttcacagcgtt tgctgttttc tttctgcagt tcccactcga	240
	tctccacgct gacctggccg gtgctgtact gcgtgataaa tgaggcaaac ttggcaggag	300
10	taaacacctc tggaggatta gcaggtagcg ggggtgtttt gatgagaatt tgaggaggcg	360
	ggtgtttgag tccaaatccg cccatcaggg gagacgggtg aaagttgccg tccgtgtgag	420
	gaattttggc ccagatggga ccctgcaggc acacgtcccg gttctgccag accatgccgg	480
15	gcagagcccc ctggctgttg acagtctgtg tctggggtcc ggccgtagac gattgcaggt	540
	tgctggagac cacaccgtat tcttctgtag ccacgggatt ggtggttttg atctcctcct	600
	cgctgggtcat tagcacgttt tccagcgttg tcttgttggc agccccgtt ttgccaaaaa	660
20	ccagcactcc gttgatggga aagaactggg cctcgtcgtc cttgttggtg gccatggcta	720
	cgcccggtt ggttaatgaa tttctaccat tcagatggta tttagtggcc ccggtccagg	780
	caaagttact gttgttggtg ctgtctatgt tttttgacag tctctgctgc cgataacagg	840
25	gtccggggcag ccagttcttt gattgctcgg ccatgggtgtt gggcccagcc tgatggaact	900
	gcagctccct tgtggacccc gtagtgctct ggggccgggc caggtagtac aggtactggt	960
	cgatgagggg attcatcagc cgggtctaggc tctggctgtg cacatagctg ctgtggaaag	1020
30	gcacttcctc aaaggtgtag ctgaattcaa agttattgcc cgttctcagc atctgagaag	1080

35

40

45

50

55

## EP 1 310 571 B1

	gaaagtactc caggcagtag aaggaggaac gtcccacaga ctgactgccg ttgttttagag	1140
	tcagatatcc gtactgagga atcatgaaca cgtccgcagg gaacggaggg aggcagccct	1200
5	ggtgcgcaga gccgaggacg tacggcagtt ggtactccga gtccgagaag acctgaatcg	1260
	tgctggtaag gttattagcg atggtcgtaa cgccgtcggt cgtcgtgacc tccttgacct	1320
	ggatgttgaa caacttgaac cgcagctttc tgggccggaa tcccagttg ttgttgatga	1380
10	gtcgtgcca gtcacgtggt gagaagtggc agtggaatct gttgaagtca aaatagcccc	1440
	agggggtgct gtagctgaag aagtggttgt cgttggtagc cccgctctga cttgatattct	1500
	gcttgtagag gtggttggtg taggtgggca gggcccaggt gcgggtgctg gtggtgatga	1560
15	ctctgtcgcc cagccatgtg gaatcgcaat gccaatttcc ggaggcatta cccactccgt	1620
	cggcgccttc gttattgtct gccattggtg cgccaccgcc tgcagccatt gtaccagatc	1680
	ccagacctga gggcgcggcg ggaggttctc cgagaggttg ggggtcgggc actgactctg	1740
20	agtcgccagt ctgccccaaag ttgagcttct ttttagcggg ctgctggcct ttcttgccga	1800
	tgcccgtgga ggagtcgggg gattctatgg gtctcttctt tccaggagcc gtcttagcga	1860
	cttcctcaac cagaccgaga ggttcgagaa cccgcttctt ggcttgaag actgctcgcc	1920
25	cgaggttgcc cccaaaagac gtatcttctt gaagacgctc ctgaaactcg gcgtcggcgt	1980
	ggttgactt gaggtacggg ttgtccccct gctcgagctg cttgtcgtag gccttgctgt	2040
	gctcgagggc cgcggcgtct gcctcggtga ccggctctcc cttgtcgtgt ccgttgaagg	2100
30	gtctgaggtg cttgtagcca ggaagcacca gaccccgcc gtcgtcctgc ttttgctggt	2160
	tggctttggg tttcggggct ccaggtttca agtcccacca ctcgcgaaatg ccctcagaga	2220
	ggttgtcctc gagccaatct ggaagataac catcggcagc catacctggt ttaagtcatt	2280
35	tattgctcag aaacacagtc atccagggtcc acgttgacca gatcgcaggc cgagcaagca	2340
	atctcgggag cccgccccag cagatgatga atggcacaga gtttccgata cgtcctcttt	2400
	ctgacgaccg gttgagattc tgacacgccg gggaaacatt ctgaacagtc tctggtccccg	2460
40	tgcgtgaagc aaatgttgaa attctgattc actctctcgc atgtcttgca gggaaacagc	2520
	atctgaagca tgcccgcgtg acgagaacat ttgttttggt acctgtcggc aaagtccacc	2580
	ggagctcctt ccgctgtctga cgtcgatgga ttcgcgactg aggggcaggc ccgcttgggc	2640
45	tcgcttttat ccgctcatc gggggcggtt ctcttggtg cccaccctt tctgacgtag	2700
	aacccatgcg ccacctcggt cacgtgatcc tgcgccagc ggaagaacct tttgacttcc	2760
	tgctttgtca ccttgccaaa gttatgtccc agacggcggg tgggttcaaa tttgaacatc	2820
50	cggtcctgca acggctgctg gtgctcgaag gtggcgctgt tcccgtaac cagggcgcac	2880
	atgttggtgt tggaggtgac ggtcacgggg gtggggtcga tctgggcgga cgacttgcac	2940
55	ttttggtcca cgcgcacctt gctgccgccg agaattggcct tggcggactc cagcaccttg	3000



EP 1 310 571 B1

gccgtcatct tgccttcctc ccaccagatc accatcttgt cggcgcaatc gttgaaggga 3060

aagttctcat tgggccagtt gacgcagccg tagaaagggc gaattc 3106

5

<210> 17

<211> 3102

<212> DNA

10 <213> new AAV serotype, clone 27-3

<400> 17

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

gcgggccgcga attcgccctt cgcagagacc aaagttcaac tgaaacgaat caaccggttt 60  
attgattaac aagtaattac aggttacggg tgaggtaacg ggtgccaatg gggcgaggct 120  
5 cagtataaac cccttcgttg ttgacagcaa attccacatt attagacttg gcataatttg 180  
aggtgtactg aatctctgga tccagcgtt tgctgttttc tttctgcagt tccactcga 240  
tctccacgct gacctggccg gtgctgtact gcgtgataaa tgaggcaaac ttggcaggag 300  
10 taaacacctc tggaggatta gcaggtagcg ggggtgtttt gatgagaatt tgaggaggcg 360  
gggtgtttgag tccaaatccg cccatcaggg gagacgggtg aaagttgccg tccgtgtgag 420  
gaatttcggc ccagatggga ccctgcaggt acacgtcccg gttctgccag accatgccgg 480  
15 gcagagcccc ctggctgttg acagtctgtg tccggggtcc ggccgtagac gattgcaggt 540  
tgctggagac cacaccgtat tcttctgtag ccacgggatt ggtggttttg atctcctcct 600  
cgctggtcac tagcacgttt tccagcgttg tcttgttggc agccccgtt ttgccaaaaa 660  
20 ccagcactcc gttgatggga aggaactggt cctcgtcgtc cttgttggtg gccatggcta 720  
cgccccgggtt ggttaatgaa tttctacat tcagatggta tttagtggcc ccggtccagg 780  
caaagttact gttgttggtg ctgtctatgt ttttgacag tctctgctgc cgataacagg 840  
25 gtccgggcag ccagttcttt gattgctcgg ccacgggtgtt gggcccagcc tgatggaaact 900  
gcagctccct tgtggacccc gtagtgctct gggccgggc caggtagtac aggtactggt 960  
cgatgagggg attcatcagc cggccaggc tctggctgtg cgcatagctg ctgtggaaag 1020  
30 gcacttcctc aaaggtgtag ctgaattcaa agttattgcc cgttctcagc atctgagaag 1080  
gaaagtactc caggcagcag aaggaggaac gtccacaga ctgactgccg ttgtttagag 1140  
tcagatatcc gtactgagga atcatgaaca cgtccgcagg gaacggaggg aggcagccct 1200  
35 ggtgcgcaga gccgaggacg tacggcagtt ggtactccga gtccgagaag acctgaatcg 1260  
tgctggtaag gttattagcg atggtcgtaa cgccgtcgtt cgtcgtgacc tccttgacct 1320  
ggatgttgaa caacttgaac cgcagctttc tgggccggaa tcccagttg ttgttgatga 1380  
40 gtcgctgcca gtcacgtggt gagaagtggc agtggaatct gttgaagtca aaatagcccc 1440  
aggggggtgct gtagccgaag aagtggttgt cggtggtagc cccgctctga cttgatatct 1500  
gcttgtagag gtggttggtg taggtgggca gggcccaggt gcgggtgctg gtggtgatga 1560  
45 ctctgtcgcc cagccatgtg gaatcgcaat gccaatcttc ggaggcatta cccactccgt 1620

50

55

EP 1 310 571 B1

	cggcgccttc gttattgtct gccattggtg cgccaccgcc tgcagccatt gtaccagatc	1680
	ccagacctga gggcgcgggc ggaggttctc cgagaggttg ggggtcgggc actgactctg	1740
5	agtcgccagt ctgccc aaag ttgagcttct ttttagcggg ctgctggcct ttcttgccga	1800
	tgcccgtgga ggagtcgggg gattctatgg gtctcttctt tccggaagcc gtcttagcgc	1860
	cttctcaac cagaccgaga ggttcgagaa cccgttctt ggcctggaag actgctcgcc	1920
10	cgaggttgcc cccaaaagac gtatcttctt gaagacgctc ctgaaactcg gcgtcggcgt	1980
	ggttgtaact gaggtacggg ttgtccccct gctcgagctg cttgtcgtag gccttgctgt	2040
	gctcgagggc cgcggcgtct gcctcggtga ccggtctctc cttgtcgagt ccgttgaagg	2100
15	gtccgaggtta cttgtagcca ggaagcacca gacccgggcc gtcgtcctgc ttttgcgtgt	2160
	tggttttggg ttccggggct ccaggtttca agtcccacca ctcgcgaatg ccctcagaga	2220
	ggttgtcctc gagccaatct ggaagataac catcggcagc catacctggt ttaagtcatt	2280
20	tattgctcag aaacacagtc atccaggtcc acgttgacca gatcgaggc cgagcaagca	2340
	atctcgggag cccgccccag cagatgatga atggcacaga gtttccgata cgtcctcttt	2400
	ctgacgaccg gttgagattc tgacacgccg gggaaacatt ctgaacagtc tctggtcccg	2460
25	tgcgtaagc aaatgttgaa attctgattc attctctcgc atgtcttgca gggaaacagc	2520
	atctgaagca tgcccgctg acgagaacat ttgttttggg acctgtcggc aaagtccacc	2580
	ggagctcctt ccgctctga cgtcgatgga tccgcgactg aggggcaagc ccgcttgggc	2640
30	tcgttttat ccgctcatc gggggcgggt ctcttggttg ctcaccctt tctgacgtag	2700
	aactcatgcg ccacctcggg cactgatcc tgcgccagc ggaagaactc tttgacttcc	2760
	tgctttgtca ccttgccaaa gtcatgctc agacggcggg tgagttcaaa tttgaacatc	2820
35	cggctcttgta acggtctgtg gtgctcgaag gtggtgctgt tcccgtaat cacggcgcac	2880
	atgttggtgt tggaagtga gatcacgggg gtgggatcga tctgggaggga cgacttgac	2940
	ttttggtcca cgcgcacctt gctgccgccg agaatggcct tggcggactc cacgacctg	3000
40	gccgtcatct tgccctctc ccaccagatc accatcttgt cgacgcaatc gttgaaggga	3060
	aagttctcat tgggtccagtt gacgcagccg aagggcgaat tc	3102
45	<210> 18	
	<211> 3106	
	<212> DNA	
	<213> new AAV serotype, clone 7-2	
50	<400> 18	
	gcggccgcga attcgccctt cgcagagacc aaagttcaac tgaaacgaat cagccggttt	60
55	attgattaac aagtaattac aggttacggg tgaggtaacg ggtgccaatg gggcgaggct	120
	cagtataaac cccttcgttg ttgacagcaa attccacatt attagacttg gcataatttg	180

## EP 1 310 571 B1

	aggtgtactg aatctctgga ttccagcgtt tgctgttttc tttctgcagt tcccactcga	240
	tctccacgct gacctggccg gtgctgtact gcgtgataaa tgaggcaaac ttggcaggag	300
5	taaacacctc tggaggatta gcaggtagcg ggggtgtttt gatgagaatt tgaggaggcg	360
	gggtgttgag tccaaatccg cccatcaggg gagacgggtg aaagttgccg tccgtgtgag	420
	gaattttggc ccagatggga ccctgcaggt acacgtcccg gttctgccag accatgccgg	480
10	gcagagcccc ctggctgttg acagtctgtg tctggggctc ggccgtagac gattgcaggt	540
	tgctggagac cacaccgtat tcttctgtag ccacgggatt ggtggttttg atctcctcct	600
	cgttggtcat tagcacgttt tccagcgttg tcttgttggc agccccgtt ttgccaaaaa	660
15	ccagcactcc gttgatggga aagaactggc cctcgtcgtc cttgttggtg gccatggcta	720
	cgcccggtt ggttaatgaa tttctacatc tcagatggta tttagtggcc ccggtccagg	780
	caaagttact gttgttggtg ctgtctatgt tttttgacag tctctgtctc cgataacagg	840
20	gtccgggcag ccagttcttt gattgctcgg ccatgggtgtt gggcccagcc tgatggaact	900
	gcagctccct tgtggacccc gtagtgctct gggccgggc caggtagtag aggtactggt	960
	cgatgagggg attcatcagc cgggtccaggc tctggctgtg cgcatactg ctgtggaaaag	1020
25	gcacttcctc aaagggtgtg ctgaattcaa agttatcgcc cgttctcagc atctgagaag	1080
	gaaagtactc caggcagtag aaggaggaaac gtcccacaga ctgactgccg ttgttttagag	1140
	tcagatatcc gtactgagga atcatgaaca cgtccgcagg gaacggaggg aggcagccct	1200
30	gggtgcgcaga gccgaggacg tacggcagtt ggtactccga gtccgagaag acctgaatcg	1260
	tgctggtaag gttattagcg atggtcgtaa cgccgtcgtt cgtcgtgacc tccttgacct	1320
	ggatgttgaa caactgaac cgcagctttc tgggccggaa tccccagttg ttgttgatga	1380
35	gtcgtgccca gtcacgtggt gagaagtggc agtggaatct gttgaagtca aaatagcccc	1440
	aggggggtgct gtagccgaag aagtgggtgt cgttggtagc cccgctctga cttgatattct	1500
	gctttagtag gtggttggtg taggtgggca gggcccaggt gcgggtgctg gtggtgatga	1560
40	ctctgtcgcc cagccatgtg gaatcgcaat gccaatcttc ggaggcatta cccactccgt	1620
	cggcgccttc gttattgtct gccattggtg cgccaccgcc tgcagccatt gtaccagatc	1680
	ccagacctga gggcgcggcg ggaggttctc cgagaggttg ggggtcgggc actgactctg	1740
45	agtcgccagt ctgccccaaag ttgagcttct ttttagcggg cggctggccg ttcttgccga	1800
	tgcccgtgga ggagtcgggg gattctatgg gtctcttctt tccaggagcc gtcttagcgc	1860
	cttcctcaac cagaccgaga ggttcgagaa cccgcttctt ggcctggaag actgctcgcc	1920
50	cgaggttgcc cccaaaagac gtatcttctt gaagacgctc ctgaaactcg gcgtcggcgt	1980
	ggttgtactt gaggtacggg ttgtccccct gctcgagctg cttgtcgtag gccttgctgt	2040
55	gctcgagggc cggggcgtct gcctcgttga ccggtctctc cttgtcgtgt ccgttgaagg	2100

# EP 1 310 571 B1

gtccgaggta cctgtagcca ggaagcacca gaccccggcc gtcgtcctgc ttttgctggt 2160  
 5 tggcctttggg tttcggggct ccagggtttca agtcccacca ctgcggaatg ccctcagaga 2220  
 ggttgccctc gagccaatct ggaagataac catcggcagc catacctggt ttaagtcatt 2280  
 tattgctcag aaacacagtc atccagggtcc acgttggtcca gatcgcaggc cgagcaagca 2340  
 10 atctcgggag cccgccccag cagatgatga atggcacaga gtttccgata cgtcctcttt 2400  
 ctgacgaccg gttgagattc tgacacgccg gggaaacatt ctgaacagtc tctggtcccg 2460  
 tgcgtgaagc aaatgttgaa attctgattc attctctcgc atgtcttgca ggggaacagc 2520  
 15 atctgaagca tgcccgctg acgagaacat ttgttttggg acctgtcggc aaagtccacc 2580  
 ggagctcctt ccgctctga cgtcgtatga tccgcgactg aggggcaggc ccgcttgggc 2640  
 tcgcttttat ccgctcatc gggggcgggt ctcttggttg ctcaccctt tctgacgtag 2700  
 20 aactcatag ccacctcggg cactgatcc tgcgccagc ggaagaactc tttgacttcc 2760  
 tgctttgtca ccttgccaaa gtcattgtcc agacggcggg tgagttcaaa tttgaacatc 2820  
 cggctctgta acggctgctg gtgctcgaag gtggtgctgt tccgtcaat cacggcgcac 2880  
 25 atgttggtgt tggaagtga gatcacgggg gtgggatcga tctgggcgga cgacttgac 2940  
 ttttgggtcca cgcgcacctt gctgccgccg agaattggct tggcggactc cagcaccttg 3000  
 gccgtcatcc tgccctcctc ccaccagatc accatcttgt cgacgcaatc gttgaagggg 3060  
 30 aagttctcat tgggtccagtt gacgcagccg tagaaagggc gaattc 3106

<210> 19

<211> 3105

35 <212> DNA

<213> new AAV serotype, clone C1

<400> 19

40

45

50

55

# EP 1 310 571 B1

	gaattcgccc ttgctgcgtc aactggacca atgagaactt tcccttcaac gattgcgctcg	60
	acaagatggt gatctggtgg gaggagggca agatgaccgc caaggctcgtg gagtccgcca	120
5	aggccattct gggcggaagc aagggtgcgcg tggaccaaaa gtgcaagtca tcggcccaga	180
	tcgacccac gcccgatgatc gtcacctcca acaccaacat gtgcgccgtg atcgacggga	240
	acagcaccac cttcgagcac cagcagccgc tgcaggaccg catgttcaag ttcgagctca	300
10	cccgccgtct ggagcacgac tttggcaagg tgaccaagca ggaagtcaaa gagttcttcc	360
	gctgggctca ggatcacgtg actgaggtgg cgcattgagtt ctacgtcaga aagggcggag	420
	ccacaaaag acccgcccc agtgacgcgg atataagcga gcccaagcgg gcctgcccct	480
15	cagttgcgga gccatcgacg tcagacgcgg aagcaccggt ggactttgcg gacaggtacc	540
	aaaacaaatg ttctcgtcac gcgggcatgc ttcagatgct gtttccctgc aagacatgcg	600
	agagaatgaa tcagaatttc aacgtctgct tcacgcacgg ggtcagagac tgctcagagt	660
20	gcttccccgg cgcgtcagaa tctcaaccg tcgtcagaaa aaagacgtat cagaaactgt	720

25

30

35

40

45

50

55

EP 1 310 571 B1

	gcgcgattca tcattctgctg gggcggggcac ccgagattgc gtgttcggcc cgcgatctcg	780
	tcaacgtgga cttggatgac tgtgtttctg agcaataaat gacttaaac aggtatggct	840
5	gctgacgggtt atcttccaga ttggctcgag gacaacctct ctgagggcat tcgcgagtgg	900
	tgggacctga aacctggagc cccaagccc aaggccaacc agcagaagca ggacgacggc	960
	cggggtctgg tgcttcctgg ctacaagtac ctcggaccct tcaacggact cgacaagggg	1020
10	gagcccgta acgcgggcga cgcagcggcc ctcgagcacg acaaggccta cgaccagcag	1080
	ctcaaagcgg gtgacaatcc gtacctgagg tataaccacg ccgacgccga gtttcaggag	1140
	cgtctgcaag aagatacgtc ttttgggggc aacctcgggc gagcagtctt ccaggccaag	1200
15	aagagggtag tcgaacctct gggcctgggt gaagaagggt ctaagacggc tcctggaaag	1260
	aagagaccgt tagagtcacc acaagagccc gactcctcct caggaatcgg caaaaaaggc	1320
	aaacaaccag ccaaaaagag actcaacttt gaagaggaca ctggagccgg agacggaccc	1380
20	cctgaaggat cagataccag cgccatgtct tcagacattg aaatgcgtgc agcaccgggc	1440
	ggaaatgctg tcgatgcggg acaaggttcc gatggagtgg gtaatgcctc gggtgattgg	1500
	cattgcgatt ccacctggtc tgagggcaag gtcacaacaa cctcgaccag aacctgggtc	1560
25	ttgccacct acaacaacca cttgtacctg cggctcggaa caacatcaa cagcaacacc	1620
	tacaacggat tctccacccc ctggggatac tttgacttta acagattcca ctgtcacttc	1680
	tcaccacgtg actggcaaag actcatcaac aacaactggg gactacgacc aaaagccatg	1740
30	cgcgtaaana tcttcaatat ccaagttaag gaggtcaca cgtcgaacgg cgagactacg	1800
	gtcgctaata accttaccag cagggttcag atatttgagg actcgtcgta tgagctcccg	1860
	tacgtgatgg acgctggaca agagggaagt ctgtctcctt tccccaatga cgtcttcattg	1920
35	gtgcctcaat atggctactg tggcattgtg actggcgaaa atcagaacca gacggacaga	1980
	aatgctttct actgcctgga gtattttcct tcacaaatgc tgagaactgg caataacttt	2040
	gaaatggctt acaactttgg gaagggtgcc ttccactcaa tgtatgctta cagccagagc	2100
40	ccggacagac tgatgaatcc cctcctggac cagtacctgt ggcacttaca gtcgaccacc	2160
	tctggagaga ctctgaatca aggcaatgca gcaaccacat ttggaaaaat caggagtggg	2220
	gactttgcct ttacagaaa gaactggctg cctgggcctt gtgttaaaca gcagagactc	2280
45	tcaaaaactg ccagtcaaaa ttacaagatt cctgccagcg ggggcaacgc tctgttaaag	2340
	tatgacaccc actatacctt aaacaaccgc tggagcaaca tagcgccctg acctccaatg	2400
	gcaacagctg gaccttcaga tggggacttc agcaacgcc agctcatctt ccctggacca	2460
50	tcagtcaccg gaaacacaa aacctcagca aacaatctgt tgtttacatc agaagaagaa	2520
	attgctgcca ccaaccaag agacacggac atgtttggtc agattgctga caataatcag	2580
55	aatgctacaa ctgctcccat aaccggcaac gtgactgcta tgggagtgtc tcctggcatg	2640

# EP 1 310 571 B1

```

gtgtggcaaa acagagacat ttactaccaa gggccaattt gggccaagat cccacacgcg 2700
5  gacggacatt ttcacccctt accgctaatt ggcgggtttg gactgaaaca tccgcctccc 2760
   cagatatatta tcaaaaacac ccccgtaact gccaatcctg cgacaacctt cactgcagcc 2820
   agagtggact ctttcatcac acaatacagc accggccagg tcgctgttca gattgaatgg 2880
10  gaaatcgaaa aggaacgctc caaacgctgg aatcctgaag tgcagtttac ttcaaactat 2940
   ggaaccagt cttctatggt gtgggctccc gatacaactg ggaagtatac agagccgcgg 3000
   gttattggct ctcgttatct gactaatcat ttgtaactgc ctagttaatc aataaaccgt 3060
15  gtgattcggt tcagttgaac tttggtctct gcgaaggcg aattc 3105

```

<210> 20

<211> 3105

20 <212> DNA

<213> new AAV serotype, clone C3

<400> 20

25

30

35

40

45

50

55



# EP 1 310 571 B1

	gaattcgccc ttgctgcgtc aactggacca atgagaactt tcccttcaac gattgcgtcg	60
	acaagatggg gatctggtgg gaggagggca agatgaccgc caaggtcgtg gagtccgcca	120
5	aggccattct gggcggaagc aaggtgcgcg tggaccaaaa gtgcaagtca tcggcccaga	180
	tcgaccccac gcccgatgac gtcacctcca acaccaacat gtgcgccgtg atcgacggga	240
	acagcaccac cttcgagcac cagcagccgc tgcaggaccg catgttcaag ttcgagctca	300
10	cccgccgtct ggagcacgac tttggcaagg tgaccaagca ggaagtcaaa gagttcttcc	360
	gctgggctca ggatcacgtg actgaggtgg cgcattgagtt ctacgtcaga aagggcggag	420
	ccaccaaaaag acccgccccc agtgacgcgg atataagcga gccaagcgg gcctgccctt	480
15	cagttgcgga gccatcgacg tcagacgcgg aagcacccgtt ggactttgcg gacaggtacc	540
	aaaacaaatg ttctcgtcac gcgggcatgc ttcagatgct gtttccttgc aagacatgcg	600
	agagaatgaa tcagaatttc aacgtctgct tcacgcacgg ggtcagagac tgctcagagt	660
20	gcttccccgg cgcgtcagaa tctcaacccg tcgtcagaaa aaagacgtat cagaaactgt	720
	gcgcgattca tcattctgtg gggcgggcac ccgagattgc gtgttcggcc tgcgatctcg	780
	tcaacgtgga cttggatgac tgtgtttctg agcaataaat gacttaaacc aggtatggct	840
25	gctgacgggt atcttccaga ttggtctgag gacaacctct ctgagggcat tcgcgagtgg	900
	tgggacctga aacctggagc cccaagctc aaggccaacc agcagaagca ggacgacggc	960
	cggggtcttg tgcttcttgg ctacaagtac ctcggaacct tccacggact cgacaagggg	1020
30	gagcccgtca acgcggcgga cgcagcgcc ctcgagcacg acaaggccta cgaccagcag	1080
	ctcaaagcgg gtgacaatcc gtacctgcgg tataaccacg ccgacgccga gtttcaggag	1140
	cgtctgcaag aagatacgtc ttttgggggc aacctcgggc gagcagtcct ccaggccaag	1200

35

40

45

50

55

## EP 1 310 571 B1

aagaggggtac tcgaaccact gggcctgggt gaagaagggtg ctaagacggc tcctggaaag 1260  
 aagagaccgt tagagtcacc acaagagccc gactcctcct caggaatcgg caaaaaaggc 1320  
 5 aaacaaccag ccaaaaagag actcaacttt gaagaggaca ctggagccgg agacggaccc 1380  
 cctgaaggat cagataccag cgccatgtct tcagacattg aaatgcgtgc agcaccgggc 1440  
 ggaaatgctg tcgatgcggg acaagggttc gatggagtgg gtaatgcctc gggtgattgg 1500  
 10 cattgcgatt ccacctgggtc tgaggggcaag gtcacaacaa cctcgaccag aacctgggtc 1560  
 ttgcccacct acaacaacca cttgtacctg cggctcggaa caacatcaaa cagcaacacc 1620  
 tacaacggat tctccacccc ctggggatag tttgacttta acagattcca ctgtcacttc 1680  
 15 tcaccacgtg actggcaaag actcatcaac aacaactggg gactacgacc aaaagccatg 1740  
 cgcggttaaaa tcttcaatat ccaagttaag gaggtcacia cgtcgaacgg cgagactacg 1800  
 gtcgctaata accttaccag cagggttcag atatttgctg actcgtcgta tgagctcccg 1860  
 20 tacgtgatgg acgctggaca agaggggaagt ctgcctcctt tccccaatga cgtcttcatg 1920  
 gtgcctcaat atggctactg tggcattgtg actggcgaaa atcagaacca gacggacaga 1980  
 aatgctttct actgcctgga gtattttcct tcacaaatgc tgagaactgg caataacttt 2040  
 25 gaaatggctt acaactttga gaaggtgccg ttccactcaa tgtatgctca cagccagagc 2100  
 ctggacagac tgatgaatcc cctcctggac cagtacctgt ggcacttaca gtcgaccacc 2160  
 tctggagaga ctctgaatca aggcaatgca gcaaccacat ttggaaaaat caggagtggg 2220  
 30 gactttgcct ttacagaaa gaactggctg cctgggcctt gtgttaaaca gcagagattc 2280  
 tcaaaaactg ccagtcaaaa ttacaagatt cctgccagcg ggggcaacgc tctgttaaag 2340  
 tatgacaccc actatacctt aaacaaccgc tggagcaaca tagcgccctg acctccaatg 2400  
 35 gcaacagctg gaccttcaga tggggacttc agcaacgccc agctcatctt ccctggacca 2460  
 tcagtcaccg gaaacacaac aacctcagca aacaatctgt tgtttacatc agaaggagaa 2520  
 attgctgcca ccaacccaag agacacggac atgtttgggtc agattgctga caataatcag 2580  
 40 aatgctacaa ctgctcccat aaccggcaac gtgactgcta tgggagtgtc tcctggcatg 2640  
 gtgtggcaaa acagagacat ttactaccaa gggccaattt gggccaagat cccacacgcg 2700  
 gacggacatt ttcctccttc accgctaatt ggcggttttg gactgaaaca tccgcctccc 2760  
 45 cagatattta tcaaaaacac ccccgtaact gccaatcctg cgacaacctt cactgcagcc 2820  
 agagtggact ctttcatcac acaatacagc accggccagg tcgctgttca gattgaatgg 2880  
 gaaatcgaaa aggaacgctc caaacgccgg aatcctgaag tgcagtttac ttcaaactat 2940  
 50 ggggaaccagt cttctatgtt gtgggctccc gatacaactg ggaagtatac agagccgctg 3000  
 gttattggct ctcgttattt gactaatcat ttgtaactgc ctagttaatc aataaaccgt 3060  
 55 gtgattcggt tcagttgaac tttggtctct gcgaagggcg aattc 3105

EP 1 310 571 B1

<211> 3105

<212> DNA

<213> new AAV serotype, clone C5

5

<400> 21

	gaattcgccc	ttcgcagaga	ccaaagtcca	actgaaacga	atcacacggt	ttattgatta	60
10	actaggcagt	tacaaatgat	tagtcaaata	acgagagcca	ataaccgcg	gctctgtata	120
	cttcccagtt	gtatcgggag	cccacaacat	agaagactgg	ttcccacagt	ttgaagtaaa	180
	ctgcacttca	ggattccagc	gtttggagcg	ttccttttcg	atttcccatt	caatctgaac	240
15	agcgacctgg	cgggtgctgt	attgtgtgat	gaaagagtcc	actctggctg	cagtgaaggt	300
	tgctgcagga	taggcaggta	cgggggtggt	tttgataaat	atctggggag	gcggatgttt	360
	cagtccaaaa	cgcgaatta	gcgggtgaag	atgaaaatgt	ccgtccgcgt	gtgggatctt	420
20	ggcccaaatt	ggcccttggt	agtaaatgtc	tctgttttgc	cacaccatgc	caggaagcac	480
	tcccatagca	gtcacgttgc	cggttatggg	agcagttgta	gcattctgat	tattgtcagc	540
	aatctgacca	aacatgtccg	tgtctcttgg	gttggtggca	gcaatttctt	cttctgatgt	600
25	aaacaacaga	ttgtttgctg	aggttgttgt	gtttccgggtg	actgatggtc	cagggagat	660
	gagctgggcg	ttgctgaagt	ccccatctga	aggccagct	gttgccattg	gaggtccagg	720
	cgtatgttg	ctccagcgg	tgtttaaggt	atagtgggtg	tcatacttta	acagagcgtt	780
30	gcccccgctg	gcaggaatct	tgtaattttg	actggcagtt	tttgagaatc	tctgctgttt	840
	aacacaaggc	ccaggcagcc	agttctttct	gtaaaaggca	aagtctccac	tcctgatttt	900
	tccaaatgtg	gttgctgcat	tgccctgatt	cagagtctct	ccagagggtg	tcgactgtaa	960
35	gtgccacagg	tactggtcca	ggaggggatt	catcagtcg	tccaggctct	ggctgtgagc	1020
	atacattgag	tggaacggca	ccttctcaaa	gttgtaagcc	gtttcaaagt	tattgccagt	1080
	tctcagcatt	tgtgaaggaa	aatactccag	gcagtagaaa	gcatttctgt	ccgtctgggt	1140
40	ctgatttttcg	ccagtcacaa	tgccacagta	gccatattga	ggcaccatga	agacgtcatt	1200
	ggggaaagga	ggcagacttc	cctcttgtcc	agcgtccatc	acgtacggga	gtcctacaga	1260
	caggtccgca	aatatctgaa	ccgtgctggt	aaggttatta	gcgaccgtag	tctcgccgtt	1320
45	cgcgttgtg	acctccttaa	cttggtatatt	gaagatttta	acgcgcatgg	cttttggtcg	1380
	tagtccccag	ttgttggtga	tgagtccttg	ccagtcacgt	ggtgagaagt	gacagtggaa	1440
	tctgttaaag	tcaaagtatc	cccagggggt	ggagaatccg	ttgtaggtgt	tgctgtttga	1500
50	tgttgttccg	agccgcaggt	acaagtgggt	gttgtaggtg	ggcaagacc	aggttctgg	1560
	cgaggttggt	gtgaccttgc	cctcagacca	ggtggaatcg	caatgccaat	caccgaggc	1620
	attaccact	ccatcggaac	cttgctccgc	atcgacagca	tttccgccc	gtgctgcacg	1680
55	catttcaatg	tctgaagaca	tggcgtggt	atctgatcct	tcaggggggc	cgtctccggc	1740

EP 1 310 571 B1

5 tccagtgtcc tcttcaaagt tgagtctctt tttggctggg tgtttgcctt ttttgccgat 1800  
 tcctgaggag gagtcgggct cttgtggtga ctctaacggg ctcttctttc caggagccgt 1860  
 cttagcacct tcttcaacca ggcccagagg ttcgagtacc ctcttcttgg cctggaagac 1920  
 tgctcgcccg aggttgcccc caaaagacgt atcttcttgc agacgctcct gaaactcggc 1980  
 gtcggcgtgg ttataccgca ggtacggatt gtcacccgct ttgagctgct ggtcgtaggc 2040  
 10 cttgtcgtgc tcgagggccg ctgctgccgc cgcgttgacg ggctccccct tgtcagatcc 2100  
 gttgaagggt ccgaggtact cgtagccagg aagcaccaga ccccggccgt cgtcctgctt 2160  
 ctgctgggtg gccttgggct tgggggctcc aggtttcagg tcccaccact cgcgaatgcc 2220  
 15 ctgagagagg ttgtcctcga gccaatctgg aagataaccg tcagcagcca tacctggttt 2280  
 aagtcattta ttgctcagaa acacagtcac ccaagtccac gttgacgaga tcgcaggccg 2340  
 aacacgcaat ctcggttgcc cgcccagca gatgatgaat cgcgcacagt ttctgatacg 2400  
 20 tcttttttct gacgacgggt tgagattctg acgcgccggg gaagcactct gagcagtctc 2460  
 tgaccccggt cgtgaagcag acgttgaaat tctgattcat tctctcgcac gtcttgcagg 2520  
 gaaacagcat ctgaagcatg cccgcgtgac gagaacattt gttttggtac ctgtccgcaa 2580  
 25 ggtccaccgg tgcttcgcgc tctgacgtcg atggctccgc aactgagggg caggcccgct 2640  
 tgggctcgct tatatccgcg tcaactgggg cggttctttt ggtggctccg ccctttctga 2700  
 cgtagaactc atgcgccacc tcagtcacgt gatcctgagc ccagcggag aactctttga 2760  
 30 cttcctgctt ggtcaccttg ccaaagtcgt gctccagacg gcgggtgagc tcgaacttga 2820  
 acatgcggtc ctgcagcggc tgctggtgct cgaagggtgg gctgttcccg tcgatcacgg 2880  
 cgcacatgtt ggtgttggag gtgacgatca cgggcgtggg gtcgatctgg gccgatgact 2940  
 35 tgcacttttg gtccacgcgc accttgcttc cgcccagaat ggcttggcg gactccacga 3000  
 ccttggcggg catcttgccc tcctcccacc agatcaccat cttgtcgacg caatcgttga 3060  
 40 agggaaagtt ctcatgtgtc cagttgacgc agcaagggcg aattc 3105

<210> 22

<211> 3094

<212> DNA

45 <213> new AAV serotype, clone F1

<400> 22

50 gaattcgccc ttgctgcgtc aactggacca agagaacttt cccttcaacg attgcgtcga 60  
 caagatggtg atctggtggg aggagggcaa gatgacggcc aaggctcgtg agtccgccaa 120  
 agccattctg ggcggaagca aggtgcgcgt cgaccaaag tgcaagtcct cggcccagat 180  
 55 cgateccacc cccgtgatcg tcacctccaa caccaacatg tgcgccgtga tcgacgggaa 240  
 cagcaccacc ttcgagcacc agcagccgtt gcaggaccgg atgttcaaat ttgaactcac 300

## EP 1 310 571 B1

5 cgcgcgtctg gaacacgact ttggcaagggt gaccaagcag gaagtcaaag agttcttccg 360  
 ctgggctagt gatcacgtga ctgaggtgac gcatgagttc tacgtcagaa agggcggagc 420  
 cagcaaaaga cccgcccccg atgacgcgga tataagcgag cccaagcggg cctgtccctc 480  
 agtcacggac ccatcgacgt cagacgcgga aggagctccg gtggactttg ccgacaggta 540  
 10 ccaaaacaaa tgttctcgtc acgcgggcat gcttcagatg ctgtttccct gcaaaacgtg 600  
 cgagagaatg aatcagaatt tcaacatttg cttcacgcac ggggtcagag actgtttaga 660  
 atgtttcccc ggcgtgtcag aatctcaacc ggtcgtcaga aaaaagacgt atcggaagct 720  
 15 gtgtgcgatt catcatctgc tggggcgggc acccgagatt gcttgctcgg cctgcgacct 780  
 ggtcaacgtg gacctggacg actgtgtttc tgagcaataa atgacttaaa ccgggtatgy 840  
 ctgccgatgg ttatcttcca gattggctcg aggacaacct ctctgagggc attcgcgagt 900  
 20 ggtgggacct gaaacctgga gccccgaaac ccaaagccaa ccagcaaaag caggacgacg 960  
 gccgggggtct ggtgcttccct ggctacaagt acctcggacc cttcaacgga ctcgacaagg 1020  
 gggagcccggt caacgcggcg gacgcagcgg ccctcgagca cgacaaggcc tacgaccagc 1080  
 25 agctcaaagc gggtgacaat ccgtacctgc ggtataacca cgccgacgcc gagtttcagg 1140  
 agcgtctgca agaagatacg tcatttgggg gcaacctcgg gcgagcagtc ttccaggcca 1200  
 agaagcgggt tctcgaacct ctcggctctgg ttgaggaagg cgctaagacg gtccttgga 1260  
 30 agaagagacc catagactct ccagactcct ccacgggcat cggcaaaaaa ggccagcagc 1320  
 ccgctaaaaa gaagctcaat ttggtcaga ctggcgactc agagtcagtc cccgaccctc 1380  
 aacctcttg agaacctcca gcagcgcct ctagtggtgg atctggtaca atggtgcag 1440  
 35 gcggtggcgc accaatggca gacaataacg aagggtgccga cggagtgggt aatgcctcag 1500  
 gaaattggca ttgcgattcc acatggctgg gcgacagagt catcaccacc agcaccagaa 1560  
 cctgggacct cccacctac aacaaccacc tctacaagca aatctccagc agcagctcag 1620  
 40 gagccaccaa tgacaaccac tacttcggct acagcaccct ctgggggtat ttgacttta 1680  
 acagattcca ctgccacttc tcaccacgtg actggcagcg actcatcaac aacaactggg 1740  
 gattccggcc caagaagctg cggttcaagc tcttcaacat ccaggtaag gaggtcacia 1800  
 45 cgaatgacgg cgtcacgacc atcgctaata accttaccag cacggttcag gtcttctcgg 1860  
 actcggataa ccagctgccg tacgtcctcg gctctgcgca ccagggtgc ctgcctccgt 1920  
 tcccggcgga cgtcttcatg attcctcagt acggctacct gactctgaac aacggcagcc 1980  
 50 aatcgggtgg ccgttccctc ttctactgcc tggaatattt cccctctcaa atgctgagaa 2040  
 cgggcaacaa ctttgagttc agttacagct tcgaggacgt gcctttccac agcagctacg 2100  
 cgcacagcca gagcctagac cggctgatga accctctcat cgaccagtac ctgtactacc 2160  
 55 tggccccgac ccagagcacc acgggttcca ccagggaact gcaatttcat caagctgggc 2220

# EP 1 310 571 B1

	ccaatactat ggccgagcag tcaaagaact ggctgcctgg accctgctat aggcaacagg	2280
	gactgtcaaa gaacttggac ttttaacaaca acagcaatTTt tgcctggact gctgccacta	2340
5	aatatcatct gaatggcaga aactcTTtga ccaatcctgg cattcccatg gcaaccaaca	2400
	aggatgatga ggaccagttc tttcccatca acggggTact ggTTTTtggc aagacggggag	2460
	ctgccaacaa aactacgctg gaaaacgttc tgatgaccag cgaggaggag atcaagacca	2520
10	ctaaccctgt ggctacagaa gaatacggTg tggTctccag caacctgcag ccgtctacag	2580
	ccgggcctca atcacagact atcaacagcc agggagcact gcctggcatg gtctggcaga	2640
	accgggacgt gtatctgcag ggtcccatct gggccaaaat tcctcacacg gatggcaact	2700
15	ttcaccctgc tcctctgatg ggcggtTTtTg gactcaaaca cccgcctcca cagatcctga	2760
	tcaaaaacac acctgtacct gctaatcctc cggaggTgtt tactcctgcc aagTTtgcct	2820
	ccttcatcac gcagtacagc accggacaag tcagcgtgga aatcgagtgg gagctgcaga	2880
20	aagaaaacag caagcgctgg aaccagaaa ttcagtatac ttccaattat gccaagtcta	2940
	ataatgttga atttgctgtg aaccctgatg gtgtttatac tgagcctcgc ccattggca	3000
	ctcgttacct cccccgtaat ctgtaattgc ttgttaatca ataaaccggt tgattcgTTt	3060
25	cagttgaact ttggTctctg cgaagggcga attc	3094

30 <210> 23  
 <211> 3095  
 <212> DNA  
 <213> new AAV serotype, clone F3

35 <400> 23

40

45

50

55

# EP 1 310 571 B1

	gaattcgccc ttcgcagaga ccaaagttca actgaaacga atcaaccggt ttattgatta	60
	acaagcaatt acagattacg ggtgaggtaa cgagtgccaa tggggcgagg ctcaagtataa	120
5	acaccatcag ggttcacagc aaattcaaca ttattagact tggcataatt ggaagtatac	180
	tgaatttctg ggttccagcg cttgctgttt tctttctgca gctcccactc gatttccacg	240
	ctgacttgtc cggtgctgta ctgcgtgatg aaggaggcaa acttggcagg agtaaacacc	300
10	tccggaggat tagcaggtac aggtgtgttt ttgatcagga tctgtggagg cgggtgtttg	360
	agtccaaaac cgcccatcag aggagacggg tgaaagttgc catccgtgtg aggaattttg	420
	gcccagatgg gaccctgcag atacacgtcc cggttctgcc agaccatgcc aggcagtgtc	480
15	ccctggctgt tgatagtctg tgattgaggc ccggctgtag acgactgcag gttgctggag	540
	accacaccgt attcttctgt agccacaggg ttagtgggtc tgatctctc ctcgctggtc	600
	atcagaacgt tttccagcgt agttttgttg gcagctcccg tcttgccaaa aaccagtacc	660
20	ccgttgatgg gaaagaactg gtcctcatca tccttgttgg ttgccatggg aatgccagga	720
	ttggtcaaag agtttctgcc attcagatga tatttagtgg cagcagtcca ggcaaaaattg	780

25

30

35

40

45

50

55

## EP 1 310 571 B1

ctgttggtgt taaagtccaa gttcttttgac agtctctgtt gcctatagca ggggtccaggc 840  
 agccagttct ttgactgctc ggccatagta ttgggccag cttgatgaaa ttgcagttcc 900  
 5 ctggtggaac cgtggtgct ctgggtccgg gccaggtagt acaggtagt gtcgatgaga 960  
 gggttcatca gccgggtctag gctctggctg tgcgcgtagc tgctgtggaa aggcacgtcc 1020  
 tcgaagctgt aactgaactc aaagttgttg cccgttctca gcatttgaga ggggaaatat 1080  
 10 tccaggcagt agaaggagga acggcccacc gattggctgc cgttggtccag agtcaggtag 1140  
 ccgtactgag gaatcatgaa gacgtccgcc gggaacggag gcaggcagcc ctggtgcgca 1200  
 gagccgagga cgtacggcag ctggtattcc gagtccgaga agacctgaac cgtgctggta 1260  
 15 aggttattag cgatggtcgt gacgccgtca ttcgttgtga cctccttgac ctggatgttg 1320  
 aggagcttga accgcagctt cttgggccgg aatccccagt tgttgttgat gagtcgtgc 1380  
 cagtcacgtg gtgagaagtg gcagtggaat ctgttaaagt caaaataccc ccaggggggtg 1440  
 20 ctgtagccga agtagtggtt gtcattggtg gctcctgagc tgctgctgga gatttgcttg 1500  
 tagaggtggt tgttgtaggt ggggagggcc caggttctgg tgctggtggt gatgactctg 1560  
 tcgcccagcc atgtggaatc gcaatgccaa tttcctgagg cattaccac tccgtcggca 1620  
 25 ccttcgttat tgtctgccat tgggtgcgcca ccgcctgcag ccattgtacc agatcccaca 1680  
 ctagagggcg ctgctggagg ttctccaaga gggtgagggc cggggactga ctctgagtcg 1740  
 ccagtctgac caaaattgag cttcttttta gcgggctgct ggcctttttt gccgatgccc 1800  
 30 gtggaggagt ctggagagcc tatgggtctc ttctttccag gagccgtctt agcgccttcc 1860  
 tcaaccagac cgagagggtc gagaacccgc ttcttggcct ggaagactgc tcgcccaggg 1920  
 ttgccccaa atgacgtatc ttcttgca ga cgtcctgaa actcggcgtc ggcgtggtta 1980  
 35 taccgcaggt acggattgtc acccgctttg agctgctggt cgtaggcctt gtcgtgctcg 2040  
 agggccgctg cgtccgccgc gttgacgggc tcccccttgt cgagtcctgt gaaggggtccg 2100  
 aggtacttgt agccaggaag caccagaccc cggccgtcgt cctgcttttg ctggttggt 2160  
 40 ttgggtttcg gggctccagg tttcaggctc caccactcgc gaatgccctc agagaggttg 2220  
 tcctcgagcc aatctggaag ataaccatcg gcagccatac ctggtttaag tcatttattg 2280  
 45 ctcaaaaaca cagtcgtcca ggtccacgtt gaccaggctc caggccgagc aagcaatctc 2340  
 ggggtgccgc cccagcagat gatgaatcgc acacagcttc cgatacgtct tttttctgac 2400  
 gaccggttga gattctgaca cgccggggaa acattctaaa cagtctctga ccccggtgcgt 2460  
 50 gaagcaaatg ttgaaattct gattcattct ctgcacgtt ttgcaggga acagcacctg 2520  
 aagcatgccc gcgtgacgag aacatttgtt ttggtacctg tcggcaaagt ccaccggagc 2580  
 tccttcgcgc tctgacgtcg atgggtccgt gactgagga cgggcccgt tgggctcgct 2640  
 55 tatatccgcg tcatcggggg cgggtctttt gctggctccg ccctttctga cgtagaactc 2700



# EP 1 310 571 B1

atgcgtcacc tcagtcacgt gatcactagc ccagcggaag aactctttga cttcctgctt 2760  
 5 tgtcaccttg ccaaagtcgt gttccagacg gcgggtgagt tcaaatttga acatccggtc 2820  
 ctgcaacggt tgctgggtgt cgaagggtgg gctgttcccg tcgatcacgg cgcacatggt 2880  
 ggtgttgagg gtgacgatca cgggggtggg atcgatctgg gcggacgact tgcacttttg 2940  
 10 gtccacgcgc accttgctgc cgccgagaat ggccttgggc gactccacga ccttggccgt 3000  
 catcttgccc tcctcccacc agatcaccat cttgtcgacg caatcgttga agggaaagtt 3060  
 ctcatgggtc cagttgacgc agcaagggcg aattc 3095

15

<210> 24

<211> 3095

<212> DNA

<213> new AAV serotype, clone F5

20

<400> 24

25

30

35

40

45

50

55

EP 1 310 571 B1

	gaattcgccc	ttcgcagaga	ccaaagttca	actgaaacga	atcaaccggt	ttattgatta	60
	acaagcaatt	acagattacg	ggtgaggtaa	cgagtgccaa	tggggcgagg	ctcagtataa	120
5	acaccatcag	ggttcacagc	aaattcaaca	ttattagact	tggcataatt	ggaagtatac	180
	tgaatttctg	ggttccagcg	cttgctgttt	tctttctgca	gctcccactc	gatttccacg	240
	ctgacttgtc	cggtgctgta	ctgcgtgatg	aaggaggcaa	acttggcagg	agtaaacacc	300
10	tccggaggat	tagcaggtag	aggtgtgttt	ttgatcagga	tctgtggagg	cgggtgttcg	360
	agtccaaaac	cgcccatcag	aggagacggg	tgaaagtgtc	catccgtgtg	aggaattttg	420
	gccagatgg	gaccctgcag	atacacgtcc	cggttctgcc	agaccatgcc	aggcagtgtc	480
15	ccctggctgt	tgatagtctg	tgattgaggc	cgggctgtag	acgactgcag	gttgtctggag	540
	accacaccgt	attcttctgt	agccacaggg	ttagtgggtc	tgatctcctc	ctcgtctggc	600
	atcagaacgt	tttccagcgt	agttttgttg	gcagctcccg	tcttgccaaa	aaccagtacc	660
20	ccgttgatgg	gaaagaactg	gtcctcatca	tccttggttg	ttgccatggg	aatgccagga	720
	ttggtcaaag	agtttctgcc	attcagatga	tatttagtgg	cagcagtcca	ggcaaaattg	780
	ctgttggtgt	taaagtccaa	gttctttgac	agtctctgtt	gcctatagca	gggtccaggc	840
25	agccagttct	ttgactgctc	ggccatagta	ttgggccag	cttgatgaaa	ttgcagttcc	900
	ctggtggaac	ccgtggtgct	ctgggtccgg	gccaggtagt	acagggtactg	gtcgtatgaga	960
	gggttcatca	gccgggtctag	gctctggctg	tgcgcgtagc	tgctgtggaa	aggcacgtcc	1020
30	tcgaagctgt	aactgaactc	aaagtgtgtg	cccgttctca	gcatttgaga	ggggaaatat	1080
	tccaggcagt	agaaggagga	acggcccacc	gattggctgc	cgttggttcag	agtcaggtag	1140
	ccgtactgag	gaatcatgaa	gacgtccgcc	gggaacggag	gcaggcagcc	ctggtgcgca	1200
35	gagccgagga	cgtacggcag	ctggtattcc	gagtcggaga	agacctgaac	cgtgctggta	1260
	aggttattag	cgatgggtcgt	gacgccgtca	ttcgttgtga	cctccttgac	ctggatgttg	1320

40

45

50

55

EP 1 310 571 B1

	aagagcttga accgcagctt cttggggccgg aatccccagt tgttggtgat gagtcgctgc	1380
	cagtcacgtg gtgagaagtg gcagtggaaat ctgttaaagt caaaataccc ccaggggggtg	1440
5	ctgtagccga agtagtggtt gtcattggtg gtcctgagc tgctgctgga gatttgcttg	1500
	tagagggtgt tgttgtaggt ggggagggcc caggttcttg tgctggtggt gatgactctg	1560
	tcgcccagcc atgtggaatc gcaatgccaa tttcctgagg cattaccac tccgtcggca	1620
10	ccttcgttat tgtctgccgt tggtagcgca ccgcctgcag ccattgtacc agatcccaca	1680
	ctagagggcg ctgctggagg ttctccaaga ggttgagggt cggggactga ctctgagtcg	1740
	ccagtctgac caaaattgag cttcttttta gcgggctgct ggcctttttt gccgatgccc	1800
15	gtggaggagt ctggagagtc tatgggtctc ttctttccag gagccgtctt agcgccttcc	1860
	tcaaccagac cgagagggtc gagaaccgc ttcttgccct ggaagactgc tcgcccaggg	1920
	ttgcccccaa atgacgtatc ttcttgacag cgctcctgaa actcggcgctc ggcgtggtta	1980
20	taccgcaggt acggattgtc acccgctttg agctgctggt cgtaggcctt gtcgtgctcg	2040
	agggcgctg cgtccgccgc gttgacgggc tcccccttgt cgagtccgtt gaagggtccg	2100
	aggtacttgt agccaggaag caccagacct cggccgctgt cctgcttttg ctggttggtc	2160
25	ttgggtttcg gggctccagg ttccaggtcc caccactcgc gaatgccctc agagagggtg	2220
	tcctcgagcc aatctggaag ataaccatcg gcagccatac ctggtttaag ccattttattg	2280
	ctcagaaaca cagtcgtcca ggtccacgtt gaccagggtc caggccgagc aggcaatctc	2340
30	gggtgcccgc cccagcagat gatgaatcgc acacagcttc cgatacgtct tttttctgac	2400
	gaccggttga gattctgaca cgccggggaa acattctaaa cagtctctga ccccgctgct	2460
	gaagcaaagt ttgaaattct gattcattct ctgcacggtt ttgcaggga acagcatctg	2520
35	aagcatgccc gcgtggcgag aacatttgtt ttggtacctg tcggcaaagt ccaccggagc	2580
	tccttcgcgc tctgacgtcg atgggtccgt gactgagga caggccgct tgggctcgtc	2640
	tatatccgcg tcatcggggg cgggtctttt gctggctccg ccctttctga cgtagaactc	2700
40	atgcgtcacc tcagtcacgt gatcactagc ccagcggaag aactctttga cttcctgctt	2760
	tgtcaccttg ccaaagtcgt gttccagacg gcgggtgagt tcaaatttga acatccggtc	2820
	ctgcaacggc tgctggtgct cgaagggtgt gctgttcccg tcgatcacgg cgcgcatgtt	2880
45	ggtgttgag gtgacgatca cgggggtggg atcgatctgg gcggacgact tgcacttttg	2940
	gtccacgcgc accttgctgc cgccgagaat ggccttggcg gactccacga ccttggccgt	3000
	catcttgccc tcctcccacc agatcaccat cttgtcgacg caatcgttga agggaaagtt	3060
50	ctcattggtc cagttgacgc agcaagggcg aattc	3095

<210> 25

<211> 3142

<212> DNA

<213> new AAV serotype, clone H6

## EP 1 310 571 B1

&lt;400&gt; 25

	aaaacgacgg gccagtgatt gtaatacgac tcactatagg gcgaaattga aattagcggc	60
5	cgcgaattcg cctttcgcag agaccaaagt tcaactgaaa cgaattaaac ggtttattga	120
	ttaacaagca attacagatt acgagtcagg tatctggtgc caatggggcg aggctctgaa	180
	tacacaccat tagtgctccac agtaaagtcc acattaacag acttggtgta gttggaagtg	240
10	tactgaattt cgggattcca gcgtttgctg ttctccttct gcagctccca ctcgatctcc	300
	acgctgacct gtcccggtga atactgtgtg atgaaagaag caaacttggc agaactgaag	360
	tttgtgggag gattggctgg aacgggagtg tttttgatca tgatctgagg aggcgggtgt	420
15	ttgagtcгаа aacctcccat cagtggagaa ggatgaaagt gtccatcggg gtgaggaatc	480
	ttggcccaaa tgggtccctg caggtacacg tctcgatcct gccacaccat accaggtaac	540
	gctccttggg gattgacagt tccagtagtt ggaccagtgt ttgagttttg caaattatct	600
20	gacacagtcc cgtactgctc cgtagccacg ggattggtgg ccctgatttc ttcttcatct	660
	gtaatcatga ctttttccaa atccgcgtcg ttggcatttg ttccttgttt accaaatctc	720
	agggttccat gcatggggaa aaacttttct tcgtcatcct tgtgactggc catagctggt	780
25	cctggattaa ccaacgagtc ccggccattt agatgatact ttgtagctgc agtccaggga	840
	aagttgctgt tgttgttgtc gtttgctgtt tttgacagac gctgctgtct gtagcaagg	900
	ccaggcagcc agtttttagc ttgaagagac atgttggttg gtccagcttg gctaaacagt	960
30	agccgagact gctgaagagt tccactatct gtttgtgtct tgttcagata atacaggtag	1020
	tggtcgatca gaggattcat cagccgatcc agactctggc tgtgagcgta gctgctgtgg	1080
	aaaggcacgt cttcaaaagt gtagctgaac tgaaagtgtt ttccagtacg cagcatctga	1140
35	gaaggaaagt actccaggca gtaaaaggaa gagcgtccta ccgcctgact cccgttggtc	1200
	agggtgaggt atccatactg tgggaccatg aagacgtccg ctggaaacgg cgggagggcat	1260
	ccttgatgcg ccgagcccag gacgtacggg agctggtagt ccgagtcagt aaacacctga	1320
40	accgtgctgg taaggttatt ggcaatcgtc gtcgtaccgt cattctgctg gacctctttg	1380
	acttgaatat taaagagctt gaagttgagt cttttgggcc ggaatccccg gttgttgttg	1440
	acgagtcttt gccagtcacg tggtgaaaag tggcagtggg atctgttgaa gtcaaaatac	1500
45	ccccaggggg tgctgtagcc aaagtagtgg ttgtcgttgc tggctcctga ttggctggag	1560
	atttgcttgt agaggtggtt gttgtatgtg ggcagggccc aggttcgggt gctgggtggtg	1620
	atgactctgt cggccagcca ttgggaatcg caatgccaat ttcctgagga attaccact	1680
50	ccatcggcac cctcgttatt gtctgccatt ggtgcgccac tgcctgtagc cattgtagta	1740

55

EP 1 310 571 B1

gatcccagac cagagggggc tgctggtggc tgtccgagag gctggggggtc aggtacggag 1800  
 tctgcgtctc cagtctgacc aaaatttaat ctttttcttg caggctgctg gcccgctttt 1860  
 5 ccggttcccc aggaggagtc tggctccaca ggagagtgtc ctaccggcct cttttttccc 1920  
 ggagccgtct taacaggctc ctcaaccagg cccagagggt caagaaccct ctttttcgcc 1980  
 tggaagactg ctcgctccgag gttgccccca aaagacgtat cttctttaag gcgctcctga 2040  
 10 aactctgcgt cggcgtggtt gtacttgagg tacgggttgt ctccgctgtc gagctgccgg 2100  
 tcgtaggcct tgcgtgctc gagggccgcy gcgtctgcct cgttgaccgg ctcccccttg 2160  
 tcgagtcctg tgaagggtcc gaggtacttg taccaggaa gcacaagacc cctgctgtcg 2220  
 15 tccttatgcc gctctgcggg ctttggtggt ggtgggccag gtttgagctt ccaccactgt 2280  
 cttattcctt cagagagagt gtcctcgagc caatctggaa gataaccatc ggcagccata 2340  
 cctgatttaa atcatttatt gttcagagat gcagtcaccc aaatccacat tgaccagatc 2400  
 20 gcaggcagtg caagcgtctg gcacctttcc catgatatga tgaatgtagc acagtttctg 2460  
 atacgccttt ttgacgacag aaacggggtg agattctgac acgggaaagc actctaaaca 2520  
 gtctttctgt ccgtgagtga agcagatatt tgaattctga ttcattctct cgcattgtct 2580  
 25 gcagggaac agcatcagat tcatgccac gtgacgagaa catttgtttt ggtacctgtc 2640  
 cgcgtagtgt atcgaagctt ccgcgtctga cgtcgatggc tgcgcaactg actcgcgcgc 2700  
 ccgtttgggc tcacttatat ctgcgtcact gggggcgggg cttttcttag ctccaccctt 2760  
 30 tttgacgtag aattcatgct ccacctcaac cacgtgatcc tttgccacc ggaaaaagtc 2820  
 tttcacttcc tgcttggtga cttttccaaa gtcgatgcc agacggcggg taagttcaaa 2880  
 tttgaacatc cggctctgca acggtctgtg gtgctcgaag gtcgttgagt tcccgtcaat 2940  
 35 cacggcgcac atgttggtgt tggagggtgac gatcacggga gtcgggtcta tctgggccga 3000  
 ggacttgcat ttctggtcca cagcacctt gcttctcca agaattggtt tggccgactc 3060  
 cacgacctg gcggtcatct tcccctctc ccaccagatc accatcttgt cgacgcaatg 3120  
 40 gtaaaaggaa agttctcatt gg 3142

<210> 26

<211> 3075

45 <212> DNA

<213> new AAV serotype, clone H2

<400> 26

50 tgagaacttt cctttcaacg attgcgtcgg acaagatggt gatctggtgg gaggagggga 60  
 agatgaccgc caaggctcgtg gagtcggcca aagccattct tggaggaagc aagggtgcgtg 120  
 tggaccagaa atgcaagtcc tcggcccaga tagaccgac tcccgtgatc gtcacctcca 180  
 55 acaccaacat gtgcgccgtg attgacggga actcaacgac cttecgagcac cagcagccgt 240  
 tgcaagaccg gatgttcaaa tttgaactta cccgccgtct ggatcatgac tttggaaagg 300

## EP 1 310 571 B1

tcaccaagca ggaagtgaaa gactttttcc ggtgggcaaa ggatcacgtg gttgaggtgg 360  
 agcatgaatt ctacgtcaaa aaggggtggag ctaagaaaag acccgcccc agtgacgcag 420  
 5 atataagtga gcccacacgg gcgcgcgagt cagttgcgca gccatcaacg tcagacgcgg 480  
 aagcttcgat caactacgag gacaggtacc aaaaacaaat gttctcgtca cgtgggcatg 540  
 aatctgatgc tgtttccctg cagacaatgc gagagaatga atcagaattc aaatatctgc 600  
 10 ttcactcacg gacagaaaga ctgttttagag tgctttcccg tgtcagaatc tcaaccggtt 660  
 tctgtcgtca aaaaggcgta tcagaaactg tgctacattc atcatatcat gggaaaggtg 720  
 ccagacgctt gcaactgctg cgatctgggtc aatgtggatt tggatgactg catctctgaa 780  
 15 caataaatga tttaaatcag gtatggctgc cgatgggttat cctccagatt ggctcgagga 840  
 cactctctct gaagggataa gacagtgggtg gaagctcaaa cctggccac caccaccaa 900  
 gcccgcagag cggcataagg acgacagcag ggtcttctgt cttcctgggt acaagtacct 960  
 20 cggacccttc aacggactcg acaaggggga gccggtcaac gaggcagacg ccgcgccct 1020  
 cgagcacgac aaggcctacg accggcagct cgacagcgga gacaaccgt acctcaagta 1080  
 caaccacgcc gacgcagagt ttcaggagcg ccttaaagaa gatacgtctt ttgggggcaa 1140  
 25 cctcgagcga gcagtcttcc aggcgaaaaa gagggttctt gaacctctgg gcctggttga 1200  
 ggaacctgtt aagacggctc cgggaaaaaa gaggccggta gagcactctc ctgtggagcc 1260  
 agactcctcc tcgggaaccg gaaaagcggg ccagcggcct gcaagaaaaa gattaaattt 1320  
 30 tggtcagact ggagacgcag actccgtacc tgacccccag cctctcggac agccaccagc 1380  
 agccccctct ggtctgggat ctactacaat ggctacaggc agtggcgcac caatggcaga 1440  
 caataacgag ggtgccgatg gagtgggtaa ttctcagga aattggcatt gcgattccca 1500  
 35 atggctgggc gacagagtca tcaccaccag caccgaacc tgggccctgc ccacatacaa 1560  
 caaccacctc tacaagcaaa tctccagcca atcaggagcc agcaacgaca accactactt 1620  
 tggctacagc acccctggg ggtattttga cttcaacaga ttccactgcc acttttcacc 1680  
 40 acgtgactgg caaagactca tcaacaacaa ctggggattc cggcccaaaa gactcaactt 1740  
 caagctcttt aatattcaag tcaaagaggt cacgcagaat gacggtacga cgacgattgc 1800  
 caataacctt accagcacgg ttcaggtgtt tactgactcg gactaccagc tcccgtacgt 1860  
 45 cctgggctcg gcgcacaaag gatgcctccc gccgtttcca gcggacgtct tcatggtccc 1920  
 acagtatgga tacctcacc tgaacaacgg gagtcaggcg gtaggacgct cttcctttta 1980  
 ctgcctggag tactttcctt ctcatgct gcgtactgga aacaactttc agttcagcta 2040  
 50 cacttttgaa gacgtgcctt tccacagcag ctacgtcac agccagagtc tggatcggt 2100  
 gatgaatcct ctgatcgacc agtacctgta ttatctgaac aagacacaaa caaatagtgg 2160  
 aactcttcag cagtctcggc tactgtttag ccaagctgga ccaaccaaca tgtctcttca 2220  
 55

# EP 1 310 571 B1

	agctaaaaac	tggetgcctg	gaccttgcta	cagacagcag	cgtctgtcaa	aacaggcaaa	2280
	cgacaacaac	aacagcaact	ttccctggac	tgcagctaca	aagtatcatc	taaatggccg	2340
5	ggactcgttg	gttaatccag	gaccagctat	ggccagtcac	aaggatgacg	aagaaaagtt	2400
	tttcccatg	catggaaccc	tgatatttgg	taaacaagga	acaaatgcca	acgacgcgga	2460
	tttgaaaaat	gtcatgatta	cagatgaaga	agaaatcagg	gccaccaatc	ccgtggctac	2520
10	ggagcagtac	gggactgtgt	caaataattt	gcaaaactca	aacactgggc	caactactgg	2580
	aactgtcaat	cgccaaggag	cgttacctgg	tatgggtgtg	caggatcgag	acgtgtacct	2640
	gcagggaccc	atttgggcca	agattcctca	caccgatgga	cactttcatc	cttctccact	2700
15	gatgggaggt	tttggactca	aacacccgcc	tcctcagatc	atgatcaaaa	acactcccgt	2760
	tccagccaat	cctcccacaa	acttcagttc	tgccaagttt	gcttctttca	tcacacagta	2820
	ttccacggga	caggtcagcg	tgagatcga	gtgggagctg	cagaaggaga	acagcaaacg	2880
20	ctggaatccc	gaaattcagt	acacttccaa	ctacaacaag	tctgttaatg	tggactttac	2940
	tgtggacact	aatgggtgtg	attcagagcc	tcgccccatt	ggcaccagat	acctgactcg	3000
	taatctgtaa	ttgcttggtt	atcaataaac	cgtttaattc	gtttcagttg	aactttgggc	3060
25	tctgcgaagg	gcgaa					3075

	<210> 27
30	<211> 3128
	<212> DNA
	<213> new AAV serotype, clone 42.8

35	<400> 27
----	----------

40

45

50

55

# EP 1 310 571 B1

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
	gcgtcgacaa gatggtgata tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
5	ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcttccg	180
	cccagatcga tcccaccccc gtgatcgtca cttccaacac caacatgtgc gccgtgattg	240
	acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatg ttcaaatttg	300
10	aactcaccgg ccgtctggag cagcactttg gcaagggtgac aaagcaggaa gtcaaagagt	360
	tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctac gtcagaaagg	420
	gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggcct	480
15	gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg	540
	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
	agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact	660
20	gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc	720
	ggaaactctg tgccattcat catctgctag ggcgggctcc cgagattgct tgctcggcct	780

25

30

35

40

45

50

55



EP 1 310 571 B1

	gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca	840
	ggtatggctg ccgatggtta tcttccagat tggctcgagg acaacctctc tgagggcatt	900
5	cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaagcag	960
	gacgacggcc ggggtctggt gcttctctggc tacaagtacc tcggaccctt caacggactc	1020
	gacaaggggg agcccgtcaa cgcggcggac gcagcggccc tcgagcacga caaggcctac	1080
10	gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc cgacgccgag	1140
	tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggcg agcagtcctc	1200
	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
15	cctggaaaga agagaccggt agagccatca cccagcggt ctccagactc ctctacgggc	1320
	atcggcaaga caggccagca gcccgcgaaa aagagactca actttgggca gactggcgac	1380
	tcagagtcag tgcccgacct tcaaccaatc ggagaacccc ccgcaggccc ctctggtctg	1440
20	ggatctggta caatggctgc aggcggtggc gctccaatgg cagacaataa cgaaggcgcc	1500
	gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggct gggcgacaga	1560
	gtcatcacca ccagcacccg aacctgggccc ctccccacct acaacaacca cctctacaag	1620
25	caaatctcca acgggacatc gggaggaagc accaacgaca acacctactt cggctacagc	1680
	accccttggg ggtattttga ctttaacaga ttccactgcc acttctcacc acgtgactgg	1740
	cagcgactca tcaacaacaa ctgggggattc cggcccaaga gactcaactt caagctcttc	1800
30	aacatccagg tcaaggagggt cacgcagaat gaaggcacca agaccatcgc caataacctt	1860
	accagcacga ttacggtctt tacggactcg gaataccagc tcccgtagct cctcggtctt	1920
	gcgccaccagg gctgcctgcc tccgttcccc gcggacgtct tcatgatgcc tcagtacggg	1980
35	tacctgactc tgaacaacgg cagtcaggcc gtgggcccgtt cctccttcta ctgcctggag	2040
	tactttcctt ctcaaagctt gagaacgggc aacaactttg agttcagcta ccagtttgag	2100
	gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggct gatgaacccc	2160
40	ctcatcgacc agtacctgta ctacctgtct cggactcagt ccacgggagg taccgcagga	2220
	actcagcagt tgctattttc tcaggccggg cctaataaca tgtcgggtca ggccaaaaac	2280
	tggctacccg ggccctgcta ccggcagcaa cgcgtctcca cgacactgtc gcaaaataac	2340
45	aacagcaact ttgcttgga cgggtgccacc aagtatcatc tgaatggcag agactctctg	2400
	gtaaatcccc gtgtcgctat ggcaacgcac aaggacgacg aagagcgatt ttttccatcc	2460
	agcggagtct tgatgtttgg gaaacagga gctggaaaag acaacgtgga ctatagcagc	2520
50	gttatgctaa ccagtgagga agaaatcaaa accaccaacc cagtggccac agaacagtac	2580
	ggcgtggtgg ccgataacct gcaacagcaa aacgccgctc ctattgtagg ggccgtcaac	2640
55	agtcaaggag ccttacctgg catggtctgg cagaaccggg acgtgtacct gcagggtcct	2700

# EP 1 310 571 B1

	atctgggcca agattcctca cacggacggc aactttcatc cttcgccgct gatgggaggc	2760
	tttggaactga aacacccgcc tcctcagatc ctgattaaga atacacctgt tcccgcggat	2820
5	cctccaacta ccttcagtca agccaagctg gcgtcgttca tcacgcagta cagcaccgga	2880
	caggtcagcg tggaaattga atgggagctg cagaaagaga acagcaagcg ctggaaccca	2940
	gagattcagt atacttccaa ctactacaaa tctacaaatg tggactttgc tgtcaatact	3000
10	gagggtaactt attcagagcc tcgccccatt ggcaccggtt acctcaccg taacctgtaa	3060
	ttgcctgtta atcaataaac cggctaattc gtttcagttg aactttggtc tctgcgaagg	3120
	gcgaattc	3128

15

<210> 28

<211> 3128

<212> DNA

20

<213> new AAV serotype, clone 42.15

<400> 28

25

30

35

40

45

50

55

# EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
5 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180  
cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240  
acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatg ttcaaatttg 300  
10 aactcaccgg ccgtctggag catgactttg gcaaggtgac aaagcaggaa gtcaaagagt 360  
tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagtcttac gtcagaaagg 420  
gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggcct 480  
15 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540  
acaggtagca aaacaaatgt tctcgtcagc cgggcatgct tcagatgctg tttccctgca 600  
agacatgcga gagaatgaat cagaatttca acatttgctt cacgcgcggg accagagact 660  
20 gttcagaatg tttcccgggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc 720  
ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct 780  
gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca 840  
25 ggtatggctg ccgatgggta tcttcagat tggctcgagg acaacctctc tgagggcatt 900  
cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag 960  
gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc 1020  
30 gacaaggggg agcccgtaaa cgcggcggac gcagcggccc tcgagcacga caaggcctac 1080  
gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc cgacgccgag 1140  
tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggag agcagtcttc 1200  
35 caggccaaga agcgggttct cgaacctctc ggtctgggtg aggaaggcgc taagacggct 1260

40

45

50

55

EP 1 310 571 B1

	cctggaaaga agagaccggt agagccatca cccagcggt ctccagactc ctctacgggc	1320
	atcggcaaga caggccagca gcccgcgaaa aagagactca actttgggca gactggcgac	1380
5	tcagagtcag tgcccgaccc tcaaccaatc ggagaacccc ccgcaggccc ctctgggtctg	1440
	ggatctggta caatggctgc aggcgggtggc gctccaatgg cagacaataa cgaaggcgcc	1500
	gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggct gggcgacaga	1560
10	gtcatcacca ccagcacccg aacctggggc ctccccacct acaacaacca cctctacaag	1620
	caaatctcca acgggacatc gggaggaagc accaacgaca acacctactt cggctacagc	1680
	acccccctggg ggtattttga ctttaacaga ttccactgcc acttctcacc acgtgactgg	1740
15	cagcgactca tcaacaacaa ctggggattc cggccaaga gactcaactt caagctcttc	1800
	aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgc caataacctt	1860
	accagcacga ttcagggtctt tacggactcg gaataccagc tcccgtacgt cctcggtctt	1920
20	gcgcaccagg gctgcccgcc tccgttcccg gcggacgtct tcatgattcc tcagtacggg	1980
	tacctgactc tgaacaacgg cagtcaggcc gtgggcccgtt cctccttcta ctgcctggag	2040
	tactttcctt ctcaaattgcg gagaacgggc aacaactttg agttcagcta ccagtttgag	2100
25	gacgtgcctt ttcacagcag ctacgcgcat agccaaagcc tggaccggct gatgaacccc	2160
	ctcatcgacc agtacctgta ctacctgtct cggactcagt ccacgggagg taccgcagga	2220
	actcagcagt tgctattttc tcaggccggg cctaataaca tgtcgggtca ggccaaaaac	2280
30	tggctacccg ggccctgcta ccggcagcaa cgcgtctcca cgacactgtc gcaaaaataac	2340
	aacagcaact ttgcttgga cggtgccacc aagtatcatc tgaatggcag agactctctg	2400
	gtaaattccc gtgtcgctat ggcaacgcac aaggacgacg aagagcgatt ttttccatcc	2460
35	agcggagtct tgatgtttgg gaaacagggg gctggaaaag acaacgtgga ctatagcagc	2520
	gttatgctaa ccagtgagga agaaatcaaa accaccaacc cagtggccac agaacagtac	2580
	ggcgtggtgg ccgataacct gcaacagcaa aacgcgcctc ctattgtagg ggccgtcaac	2640
40	agtcaaggag ccttacctgg catggtctgg cagaaccggg acgtgtacct gcagggtcct	2700
	atctgggcca agattcctca cacggacggc aactttcatc cttcgccgct gatgggaggc	2760
	tttggactga aacacccgcc tcctcagatc ctgattaaga atacacctgt tcccgcggat	2820
45	cctccaacta ccttcagtca agccaagctg gcgtcggttca tcacgcagta cagcaccgga	2880
	caggtcagcg tggaaattga atgggagctg cagaaagaga acagcaagcg ctggaaccca	2940
	gagattcagt atacttccaa ctactacaaa tctacaaatg tggactttgc tgtcaatact	3000
50	gagggtactt attcagagcc tcgccccatt ggcacccgtt acctacccg taacctgtaa	3060
	ttgcctgtta atcaataaac cggttaattc gtttcagttg aactttggtc tctgcgaagg	3120
55	gcgaattc	3128

EP 1 310 571 B1

<211> 3197

<212> DNA

<213> new AAV serotype. clone 42.5b

5

<400> 29

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
10	gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
	ccgccaaggc cattctcggc ggagcaagg tgcgctgga ccaaaagtgc aagtcgtccg	180
	cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg	240
15	acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatg ttcaaatttg	300
	aactcaccgc ccgtctggag cacgactttg gcaagggtgac aaagcaggaa gtcaaagagt	360
	tcttcgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctac gtcagaaagg	420
20	gtggagccaa caagagaccc gcccccgatg acgcgataa aagcgagccc aagcgggcct	480
	gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg	540
	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
25	agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact	660
	gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc	720
	ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct	780
30	gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca	840
	ggtatggctg ccgatgggta tcttcagat tggctcgagg acaacctctc tgagggcatt	900
	cgcgagtggg gggacttgaa acctggagcc ccgaaaccca aagccaacca gcaaaagcag	960
35	gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc	1020
	gacaagggag agccgggtcaa cgaggcagac gccgcggccc tcgagcacga caaggcctac	1080
	gacaagcagc tcgagcaggg ggacaacccg tacctcaagt acaaccacgc cgacgccgag	1140
40	tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcggggc agcagtcttc	1200
	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
	cctggaaaga agagaccggt agagccatca cccagcgtt ctccagactc ctctacgggc	1320
45	atcggcaaga caggccagca gccgcgaaa aagagactca actttgggca gactggcgac	1380
	tcagagtcag tgcccagacc tcaaccaatc ggagaacccc ccgcaggccc ctctgggtctg	1440
	ggatctggta caatggctgc aggcggtggc gctccaatgg cagacaataa cgaaggcgcc	1500
50	gacggagtgg gtagttcctc aggaaatttg cattgcgatt ccacatggct gggcgacaga	1560
	gtcatcacca ccagcaccgc aacctgggccc ctccccacct acaacaacca cctctacaag	1620
	caaatctcca acgggacatc gggaggaagc accaacgaca acacctactt cggctacagc	1680
55	acccctggg ggtattttga cttaacaga ttccactgcc acttctcacc acgtgactgg	1740

# EP 1 310 571 B1

	cagcgactca tcaacaacaa ctggggattc cggcccaaga gactcaactt caagctcttc	1800
	aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgc caataacctt	1860
5	accagcacga ttcaggtctt tacggactcg gaataccagc tcccgtacgt cctcggctct	1920
	gcgcaccagg gctgcctgcc tccgttcccc gcggacgtct tcatgattcc tcagtacggg	1980
	tacctgactc tgaacaacgg cagtcaggcc gtggggccgtt cctccttcta ctgcctggag	2040
10	tactttcctt ctcaaatgct gagaacgggc aacaactttg agttcagcta ccagtttgag	2100
	gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggct gatgaacccc	2160
	ctcatcgacc agtacctgta ctacctgtct cggactcagt ccacgggagg taccgcagga	2220
15	actcagcagt tgctattttc tcaggccggg cctaataaca tgtcggctca ggccaaaaac	2280
	tggtaccg cgccctgcta ccggcagcaa cgcgtctcca cgacactgtc gcaaaaataac	2340
	aacagcaact ttgcttgga cggtgccacc aagtatcatc tgaatggcag agactctctg	2400
20	gtaaatcccg gtgtcgctat ggcaacgcac aaggacgacg aagagcgatt ttttccatcc	2460
	agcggagtct tgatgtttgg gaaacaggga gctggaaaag acaacgtgga ctatagcagc	2520
	gttatgctaa ccagtgagga agaaatcaaa accaccaacc cagtggccac agaacagtac	2580
25	ggcgtggtgg ccgataacct gcaacagcaa aacgccgctc ctattgtagg ggccgtcaac	2640
	agtcaaggag ccttacctgg catggtctgg cagaaccggg acgtgtacct gcagggtcct	2700
	atctgggcca agattcctca cacggacggc aactttcatc cttcgccgct gatgggaggc	2760
30	tttggactga aacacccgcc tcctcagatc ctgattaaga atacacctgt tcccgcggat	2820
	cctccaacta ccttcagtca agccaagctg gcgtcgttca tcacgcagta cagcaccgga	2880
	caggtcagcg tggaaattga atgggagctg cagaaagaga acagcaagcg ctggaaccca	2940
35	gagattcagt atacttccaa ctactacaaa tctacaaatg tggactttgc tgtcaatact	3000
	gagggtactt attcagagcc tcgccccatt ggcaccggtt acctcaccg taacctgtaa	3060
	ttgcctgtta atcaataaac cggttaattc gtttcagttg aactttggtc tctgcgaagg	3120
40	gcgaattcgt ttaaacctgc aggactagtc cctttagtga gggttaattc tgagcttggc	3180
	gtaatcatgg gtcatag	3197
45	<210> 30	
	<211> 2501	
	<212> DNA	
	<213> new AAV serotype, clone 42.1b	
50	<400> 30	
	gaattcgccc ttggtgcgt caactggacc aatgagaact ttcccttcaa cgattgcgtc	60
	gacaagatgg tgatctggtg ggaggagggc aagatgacgg ccaaggtcgt ggagtccgcc	120
55	aaggccattc atcatctgct gggggcgggt cccgagattg cttgctcggc ctgcgatctg	180
	gtcaacgtgg acctggatga ctgtgtttct gagcaataaa tgacttaaac caggatatggc	240

EP 1 310 571 B1

	tgccgatggt tatcttccag attggctcga ggacaacctc tctgagggca ttcgcgagtg	300
	gtgggacttg agacctggag ccccgaaacc caaagccaac cagcaaaagc aggacgacgg	360
5	ccggggtctg gtgcttcctg gctacaagta cctcggaccc ttcaacggac tcgacaaggg	420
	agagccggtc aacgaggcag acgccgcggc cctcgagcac gacaaggcct acgacaagca	480
	gctcgagcag ggggacaacc cgtacctcaa gtacaaccac gccgacgccg agtttcagga	540
10	gcgtcttcaa gaagatacgt cttttggggg caacctcggg cgagcagtct tccaggccaa	600
	gaagcggggt ctcgaacctc tcgggtctggt tgaggaaggc gctaagacgg ctccctggaaa	660
	gaagagaccc atagaatccc ccgactcctc cacgggcatc ggcaagaaaag gccagcagcc	720
15	cgctaaaaag agactcaact ttgggcagac tggcgactca gagtcaagtgc ccgacctca	780
	accaatcgga gaaccccccg caggccccctc tgggtctggga tctggcacia tggctgcagg	840
	cggtggcgct ccaatggcag acaataacga aggcgccgac ggagtgggta gttcctcagg	900
20	aaattggcat tgcgattcca catggctggg cgacagagtc atcaccacca gcacccgaac	960
	ctgggcccctc cccacctaca acaaccacct ctacaagcaa atctccaacg ggacatcggg	1020
	aggaagcacc aacgacaaca cctacttcgg ctacagcacc ccctgggggt attttgactt	1080
25	taacagattc cactgccact tctcaccag tgactggcag cgactcatca acaacaactg	1140
	gggattccgg cccaagagac tcaacttcaa gctcttcaac atccagggtca aggaggtcac	1200
	gcagaatgaa ggcaccaaga ccatcgccaa taaccttacc agcacgattc aggtctttac	1260
30	ggactcggaa taccagctcc cgtacgtcct cggctctgcg caccagggct gcctgcctcc	1320
	gttcccggcg gacgtcttca tgattcctca gtacgggtac ctgactctga acaacggcag	1380
	tcaggccgtg ggcggttctt ccttctactg cctggagtac tttccttctc aaatgctgag	1440
35	aacgggcaac aactttgagt tcagctacca gtttgaggac gtgccttttc acagcagcta	1500
	tgcgcacagc caaagcctgg accggctgat gaacccccctc atcgaccagt acctgtacta	1560
	cctgtctcgg actcagttca cgggaggtac cgcaggaact cagcagttgc tattttctca	1620
40	ggccgggcct aataacatgt cggctcaggc caaaaactgg ctacccgggc cctgctaccg	1680
	gcagcaacgc gtctccacga cagtgtcgca aaataacaac agcaactttg cttggaccgg	1740
45	tgccaccaag tatcatctga atggcagaga ctctctggta aatcccgggtg tcgctatggc	1800
	aacgcacaag ggcgacgaag agcgattttt tccatccagc ggagtcttga tgtttgggaa	1860
	acagggagct ggaaaagaca acgtagacta tagcagcgtt atgctaacca gtgaggaaga	1920
50	aatcaaaaacc accaaccacg tggccacaga acagtacggc gtgggtggccg ataacctgca	1980
	acagcaaaaac gccgctccta ttgtaggggc cgtcaacagt caaggagcct tacctggcat	2040
	ggctctggcag aaccgggacg tgtacctgca gggtcctatc tgggccaaga ttcttcacac	2100
55	ggacggcaac tttcatcctt cgccgctgat gggaggcttt ggactgaaac accgcctcc	2160

EP 1 310 571 B1

tcagatcctg attaagaata cacctgttcc cgcggatcct ccaactacct tcagtcaagc 2220  
caagctggcg tcgttcatca cgcagtacag caccggacag gtcagcgtgg aaattgaatg 2280  
5 ggagctgcag aaagagaaca gcaagcgctg gaacccagag attcagtata cttccaacta 2340  
ctacaaatct acaaattgtgg actttgctgt caatactgag ggtacttatt cagagcctcg 2400  
ccccattggc acccgttacc tcacccgtaa cctgtaattg cctgttaatc aataaaccgg 2460  
10 ttgattcggt tcagttgaac tttggtctca agggcgaatt c 2501

15 <210> 31  
<211> 3113  
<212> DNA  
<213> new AAV serotype, clone 42.13

20 <400> 31

25

30

35

40

45

50

55



EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
gcgctcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
5 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180  
cccagatcga tcccaccccc gtgatcgtca cttccaacac caacatgtgc gccgtgattg 240  
acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatg ttcaaatttg 300  
10 aactcacccg ccgtctggag catgactttg gcaagggtgac aaagcaggaa gtcaaagagt 360  
tcttcgcgtg gggcgaggat cacgtgaccg aggtggcgca tgagttctac gtcagaaagg 420  
gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagccc aagcgggcct 480  
15 gccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540  
acaggtagca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca 600  
agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact 660  
20 gttcagaatg tttccccggc gtgtcagaat ctcaaccggg cgtcagaaag aggacgtatc 720  
ggaaactctg tgccattcat catctgctgg ggccgggctc cgagattgct tgctcggcct 780  
gcatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca 840  
25 ggtatggctg ccgatggta tcttcagat tggctcgagg acaacctctc tgagggcatt 900  
cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag 960  
gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc 1020  
30 gacaaggggg agcccgtaaa cgcggcggac gcagcggccc tcgagcacga caaggcctac 1080  
gaccagcagc tcaaagcggg tgacaatccg tacctgcggg ataaccacgc cgacgcccag 1140  
tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg agcagtcctc 1200  
35 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct 1260  
cctggaaaaga agagacccat agaatcccc gactcctcca cgggcatcgg caagaaaggc 1320  
cagcagcccg ctaaaaagaa gctcaacttt gggcagactg gcgactcaga gtcagtgcgc 1380  
40

45

50

55

EP 1 310 571 B1

	gaccctcaac caatcggaga acccccccga gggccctctg gtctgggata tggtagaatg	1440
	gctgcaggcg gtggcgctcc aatggcagac aataacgaag gcgccgacgg agtgggtagt	1500
5	tcctcaggaa attggcattg cgattccaca tggtcggcg acagagtcac caccaccagc	1560
	accggaacct gggccctccc cacctacaac aaccacctct acaagcaaatt ctccaacggg	1620
	acatcgggag gaagcaccaa cgacaacacc tacttcgggt acagcacccc ctgggggtat	1680
10	tttgacttta acagattcca ctgccacttc tcaccacgtg actggcagcg actcatcaac	1740
	aacaactggg gattccggcc caagagactc aacttcaagc tcttcaacat ccagggtcaag	1800
	gaggtcacgc agaataagg caccaagacc atcgccaata accttaccag caggttcag	1860
15	gtctttacgg actcggata ccagctcccg tacgtcctcg gctctgcga ccagggtgc	1920
	ctgcctccgt tcccggcgga cgtcttcacg attcctcagt acgggtacct gactctgaac	1980
	aacggcagtc aggccgtggg ccgttcctcc ttctactgcc tggagtactt tccttctcaa	2040
20	atgctgagaa cgggcaacaa ctttgagttc agctaccagt ttgaggacgt gccttttcac	2100
	agcagctatg cgcacagcca aagcctggac cggctgatga acccctcat cgaccagtac	2160
	ctgtactacc tgtctcggac tcagtccacg ggaggtaccg caggaactca gcagttgcta	2220
25	ttttctcagg ccgggcctaa taacatgtcg gctcaggcca aaaactggct acccgggccc	2280
	tgctaccggc agcaacgcgt ctccacgaca gtgtcgcaaa ataacaacag caactttgct	2340
	tggaccggtg ccaccaagta tcatctgaat ggcagagact ctctggtaaa tcccgggtgc	2400
30	gctatggcaa cgcacaaggg cgacgaagag cgattttttc catccagcgg agtcttgatg	2460
	tttgggaaac agggagctgg aaaagacaac gtggactata gcagcgttat gctaaccagt	2520
	gaggaagaaa tcaaaaccac caaccagtg gccacagaac agtacggcgt ggtggccgat	2580
35	aacctgcaac agcaaaacgc cgctcctatt gtaggggccc tcaacagtca aggagcctta	2640
	cctggcatgg tctggcagaa ccgggacgtg tacctgcagg gtcctatctg ggccaagatt	2700
	cctcacacgg acggcaactt tcatccttcg ccgctgatgg gaggctttgg actgaaacac	2760
40	ccgcctcctc agatcctgat taagaatata cctgttcccg cggtacctcc aactaccttc	2820
	agtaagcca agctggcgtc gttcatcacg cagtacagca ccggacaggt cagcgtggaa	2880
	attgaatggg agctgcagaa agagaacagc aagcgttggg acccagagat tcagtatact	2940
45	tccaactact acaaatctac aaatgtggac ttgctgtca atactgaggg tacttattca	3000
	gagcctcgcc ccattggcac ccgttacctc acccgtagcc tgtaattgcc tgttaatcaa	3060
50	taaaccgggt gattcgtttc agttgaactt tggctctctg gaaggcgaa ttc	3113

<210> 32

<211> 3113

<212> DNA

55 <213> new AAV serotype, clone 42.3a

<400> 32

EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
gcgctcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
5 cgcgaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180  
cccagatcga tccccacccc gtgatcgtca cttccaacac caacatgtgc gccgtgattg 240  
acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatg ttcaaatttg 300  
10 aactcacccg ccgtctggag catgactttg gcaaggtgac aaagcaggaa gtcaaagagt 360  
tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagtcttac gtcagaaagg 420  
gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagccc aagcgggcct 480  
15 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccc 540  
acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg cttccctgca 600  
agacatgcga gagaatgaat cagaatttca gcatttgctt cacgcacggg accagagact 660  
20 gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc 720  
ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct 780  
gcatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca 840  
25 ggtatggctg ccgatggtca tcttccagat tggctcgagg acaacctctc tgagggcatt 900  
cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag 960  
gacgacggcc ggggtctggt gcttctctggc tacaagtacc tcggaccctt caacggactc 1020  
30 gacaaggggg agcccgtcaa cgcggcggac gcagcggccc tcgagcacga caaggcctac 1080  
gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc cgacgccgag 1140  
tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcggggc agcagtcttc 1200  
35 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct 1260  
cctggaaaga agagacccat agaatcccc gactcctcca cgggcatcgg caagaaaggc 1320  
cagcagcccg ctaaaaagaa gctcaacttt ggcagactg gcgactcaga gtcagtgcc 1380  
40 gacctcaac caatcggaga accccccgca gggcctctg gtctgggatc tgggtacaatg 1440  
gctgcaggcg gtggcgctcc aatggcagac aataacgaag gcgccgacgg agtgggtagt 1500  
tcctcaggaa attggcattg cgattccaca tagctgggag acagagtcac caccaccagc 1560  
45 acccgaacct gggccctccc cacctacaac aaccacctct acaagcaaat ctccaacggg 1620  
acatcgggag gaagcaccaa cgacaacacc tacttcggct acagcaccac ctgggggtat 1680  
tttgacttta acagattcca ctgccacttc tcaccacgtg actggcagcg actcatcaac 1740  
50 aacagctggg gattccggcc caagagactc aacttcaagc tcttcaacat ccaggtcaag 1800  
gaggtcacgc agaataagg caccaagacc atcgccaata accttaccag cagattcag 1860  
gtctttacgg actcgggaata ccagctccc tagctcctcg gctctgcgca ccagggctgc 1920

# EP 1 310 571 B1

ctgcctccgt tcccggcgga cgtcttcattg attcctcagt acgggtacct gactctgaac 1980  
 aacggcagtc agggcgtggg ccgttcctcc ttctactgcc tggagtactt tccttctcaa 2040  
 5 atgctgagaa cgggcaacaa ctttgagttc agctaccagt ttgaggacgt gccttttcac 2100  
 agcagctacg cgcacagcca aagcctggac cggctgatga accccctcat cgaccagtac 2160  
 ctgtactacc tgtctcggac tcagtccacg ggaggtaccg caggaactca gcagttgcta 2220  
 10 ttttctcagg ccgggcctaa taacatgtcg gctcaggcca aaaactggct acccgggccc 2280  
 tgctaccggc agcaacgcgt ctccacgaca ctgtcgcaaa ataacaacag caactttgct 2340  
 tggaccggtg ccaccaagta tcattctgaat ggcagagact ctctggtaaa tcccgggtgc 2400  
 15 gctatggcaa cgcacaagga cgacgaagag cgattttttc catccagcgg agtcttgatg 2460  
 tttgggaaac agggagctgg aaaagacaac gtggactata gcagcgttat gctaaccagt 2520  
 gaggaagaaa tcaaaaccac caaccagtg gccacagaac agtacggcgt ggtggccgat 2580  
 20 aacctgcaac agcaaaacgc cgctcctatt gtaggggccc tcaacagtca aggagcctta 2640  
 cctggcatgg tctggcagaa ccgggacgtg tacctgcagg gtcctatctg ggccaagatt 2700  
 cctcacacgg acggcaactt tcattccttcg ccgtgatgg gaggttttg actgaaacac 2760  
 25 ccgcctcctc agatcctgat taagaataca cctgttcccg cggatcctcc aactaccttc 2820  
 agtcaagcca agctggcgtc gttcatcacg cagtacagca ccggacaggt cagcgtggaa 2880  
 attgaatggg agctgcagaa agagaacagc aagcgtgga acccagagat tcagtatact 2940  
 30 tccaactact acaaactctac aaatgtggac tttgctgtca atactgaggg tacttattca 3000  
 gagcctcgcc ccattggcac ccgttacctc acccgtaacc tgtaattgcc tgtaaatcaa 3060  
 taaaccggtt aattcgtttc agttgaactt tggctctctgc gaagggcgaa ttc 3113  
 35

<210> 33

<211> 2504

<212> DNA

40 <213> new AAV serotype, clone 42.4

<400> 33

45

50

55

# EP 1 310 571 B1

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
	gcgtcgacaa gatggtgatc tggtagggagg agggcaagat gacggccaag gtcgtggagt	120
5	ccgccaaggc cattcatcat ctgctggggc gggtcccga gattgcttgc tcggcctgcg	180
	atctggtcaa cgtggacctg gatgactgtg tttctgagca ataaatgact taaaccaggt	240
	atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc	300
10	gagtggtaggg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac	360
	gacggccggg gtctggtgct tcttggtac aagtacctcg gacccttcaa cggactcgac	420
	aagggagagc cggatcaacga ggcagacgcc gcggccctcg agcacgacaa ggcctacgac	480
15	aagcagctcg agcaggggga caaccgtac ctcaagtaca accacgccga cgccgagttt	540

20

25

30

35

40

45

50

55

EP 1 310 571 B1

	caggagcgtc ttcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag	600
	gccaagaagc ggggttctcga acctctcggt ctgggtgagg aaggcgctaa gacggctcct	660
5	ggaaagaaga gacctataga atcccccgac tcctccacgg gcatcggcaa gaaaggccag	720
	cagcccgtc aaaagaagct caactttggg cagactggcg actcagagtc agtgcccgc	780
	cctcaaccaa tcggagaacc ccccgagggc ccctctggtc tgggatctgg tacaatggct	840
10	gcaggcggtg gcgctccaat ggcagacaat aacgaaggcg ccgacggagt gggtaatgcc	900
	tccggaaatt ggcattgcga ttccacatgg ctgggcgaca gagtcatcac caccagcacc	960
	cgcacctggg ccctgcccac ctacaacaac cacctctaca agcagatata aagtcagagc	1020
15	ggggctacca acgacaacca cttcttcggc tacagcacc cctggggcta ttttgacttc	1080
	aacagattcc actgccactt ctcatcacgt gactggcagc gactcatcaa caacaactgg	1140
	ggattccggc ccaagagact caacttcaag ctcttcaaca tccagggtcaa ggaggtcacg	1200
20	cagaatgaag gcaccaagac catcgccaat aaccttacca gcacgattca ggtctttacg	1260
	gactcggaat accggctccc gtacgtcctc ggctctgcgc accagggctg cctgcctccg	1320
	ttcccggcgg acgtcttcat gattcctcag tacgggtacc tgactctgaa caacggcagt	1380
25	caggccgtgg gccgttcctc cttctactgc ctggagtact ttccttctca aatgctgaga	1440
	acgggcaaca actttgagtt cagctaccag tttgaggacg tgccttttca cagcagctac	1500
	gcgcacagcc aaagcctgga ccggctgatg aacccccca tcgaccagta cctgtactac	1560
30	ctgtctcggc ctcatctgaa gggagggtacc gcaggaactc agcagttgct attttctcag	1620
	gccgggccta ataacatgtc ggctcaggcc aaaaactggc taccggggcc ctgctaccgg	1680
	cagcaacgcg tctccacgac actgtcgcaa aataacaaca gcaactttgc ttggaccggt	1740
35	gccaccaagt atcatctgaa tggcagagac tctctggtaa atcccgggtg cgctatggca	1800
	acgcacaagg acgacgaaga gcgatttttt ccatccagcg gactcttgat gtttgggaaa	1860
	caggagctg gaaaagacaa cgtggactat agcagcgta tgctaaccag tgaggaagaa	1920
40	atcaaaaacca ccaaccaggt ggccacagaa cagtacggcg tggtagggcga taacctgcaa	1980
	cagcaaaacg ccgctcctat tgtagggggc gtcaacagtc aaggagcctt acctggcatg	2040
	gtctggcaga accgggacgt gtacctgcag ggtcctatct gggccaagat tcctcacacg	2100
45	gacggcaact ttcattcctc gccgctgatg ggaggctttg gactgaaaca cccgcctcct	2160
	cagatcctga ttaagaatac acctgttccc gcggatcctc caactacctt cagtcaagcc	2220
	aagccggcgt cgttcatcac gcagtacagc accggacagg tcagcgtgga aattgaatgg	2280
50	gagctgcaga aagagaacag caagcgctgg aaccagaga ttcagtatac ttccaactac	2340
	tacaaatcta caaatgtgga ctttgctgtc aatactgagg gtacttattc agagcctcgc	2400
55	cccattggca cccgttacct caccgtaac ctgtaattgc ctgttaatca ataaaccggt	2460

taattcgttt cagttgaact ttggtctctg cgaagggcga attc

2504

5

<210> 34

<211> 3106

<212> DNA

<213> new AAV serotype, clone 42.5a

10

<400> 34

15

20

25

30

35

40

45

50

55

## EP 1 310 571 B1

gaattcgccc ttctacggct gcgtaactg gaccaatgag aactttccct tcaacgattg 60  
 cgtcgacaag atggtgatct ggtgggagga gggcaagatg acggccaagg tcgtggagtc 120  
 5 cgccaaggcc attctcggcg gcagcaaggt gcgcgtggac caaaagtgca agtcgtccgc 180  
 ccagatcgac cccacccccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga 240  
 cgggaacagc accaccttcg agcaccagca gccgttgacg gaccggatgt tcaaatttga 300  
 10 actcaccgcg cgtctggagc atgacttttg caaggcgaca aagcaggaag tcaaagagtt 360  
 cttccgctgg gcgcaggatc acgtgaccga ggtggcgcat gagttctacg tcagaaaggg 420  
 tggagccaac aagagacccg ccccgatga cgcggataaa agcgagccca agcgggcccg 480  
 15 cccctcagtc gcggatccat cgacgtcaga cgcggaagga gctccggtgg actttgccga 540  
 caggtagcaa aacaaatgtt ctcgtcacgc gggcatgctt cagatgctgt ttccctgcaa 600  
 aacatgcgag agaatgaatc agaatttcaa catttgcttc acgcacggga ccagagactg 660  
 20 ttcagaatgt ttccccggcg tgtcagaatc tcaaccggtc gtcagaaaga ggacgtatcg 720  
 gaaactctgt gccattcatc atctgctggg gcgggctccc gagattgctt gctcggcctg 780  
 cgatctggtc aacgtggacc tggatgactg tgtttctgag caataaatga cttaaaccag 840  
 25 gtatggctgc cgatggttat cttccagatt ggctcgagga caacctctct gagggcattc 900  
 gcgagtgggtg ggacttgaaa cctggagccc cgaaacccaa agccaaccag caaaagcagg 960  
 acgacggccg gggctctggtg ctctctggct acaagtacct cggacccttc aacggactcg 1020  
 30 acaagggaga gccggtcaac gaggcagacg ccgcggccct cgagcacgac aaggcctacg 1080  
 acaagcagct cgagcagggg gacaaccctg acctcaagta caaccacgcc gacgccgagt 1140  
 ttcaggagcg tcttcaagaa gatacgtctt ttgggggcaa cctcggggcg gcagtcttcc 1200  
 35 gggccaagaa gcgggttctc gaacctctcg gtctggttga ggaaggcgct aagacggctc 1260  
 ctggaaagaa gagaccata gaatcccccg actcctccac gggcatcggc aagaaaggcc 1320  
 agcagcccg ctaaaagaag ctcaactttg ggcagactgg cgactcagag tcagtgcccg 1380  
 40 accccaacc tctcggagaa cctcccgccg cgccctcagg tctgggatct ggtacaatgg 1440  
 ctgcaggcgg tggcgacca atggcagaca ataacgaagg cgccgacgga gtgggtaatg 1500  
 cctccgaaa ttggcattgc gattccacat ggctggggcg cagagtcac accaccagca 1560  
 45 cccgcacctg ggccctgcc acctacaaca accacctcta caagcagata tcaagtcaga 1620  
 gcggggctac caacgacaac cacttcttcg gctacagcac cccctggggc tattttgact 1680

50

55



# EP 1 310 571 B1

	tcaacagatt ccactgccac ttctcaccac gtgactggca gcgactcatc aacaacaacc	1740
	ggggattccg gcccagaaag ctgcggttca agttgttcaa catccaggtc aaggagggtca	1800
5	cgacgaacga cggcgttacg accatcgcta ataaccttac cagcaagatt caggctcttct	1860
	cggactcggg gtaccaactg ccgtacgtcc tcggctctgc gcaccagggc tgcctccctc	1920
	cgttccctgc ggacgtgttc atgattcctc agtacggata tctgactcta aacaacggca	1980
10	gtcagtctgt gggacgttcc tccttctact gcctggagta ctttccttct cagatgctga	2040
	gaacgggcaa taactttgaa ttcagctacc agtttgagga cgtgcccttt cacagcagct	2100
	acgcgcacag ccaaagcctg gaccggctga tgaacccct catcgaccag tacctgtact	2160
15	acctgtctcg gactcagtc acgggaggta ccgcaggaac tcagcagttg ctatcttctc	2220
	aggccggggc taataacatg tcggctcagg ccaaaaactg gctaccggg ccctgctacc	2280
	ggcagcaacg cgtctccacg aactgtcgc aaaataacaa cagcaacttt gcttgaccg	2340
20	gtgccaccaa gtatcatctg aatggcagag actctctggt aaatcccggg gtcgctatgg	2400
	caacgcacaa ggacgacgaa gagcgatttt ttccatccag cggagtcttg atgtttggga	2460
	aacagggagc tggaaaagac aacgtggact atagcagcgt tatgctaacc agtgagggaag	2520
25	aaatcaaaac caccaacca gtggccacag aacagtacgg cgtggtggcc gataacctgc	2580
	aacagcaaaa cgccgctcct attgtagggg ccgtcaacag tcaaggagcc ttacctggca	2640
	tggcctggca gaaccgggac gtgtacctgc agggctctat ctgggccaag attcctcaca	2700
30	cggacggcaa ctttcatect tcgccgctga tgggaggctt tggactgaaa caccgcctc	2760
	ctcagatcct gattaagaat acacctgttc ccgcggatcc tccaactacc ttcagtcaag	2820
	ccaagctggc gtcgttcac acgcagtaca gcaccggaca ggtcagcgtg gaaattgaat	2880
35	gggagctgca gaaagagaac agcaagcgtt ggaaccaga gattcagtat acttccaact	2940
	actacaaatc tacaaatgtg gactttgctg tcaatactga gggacttat tcagagcctc	3000
	gccccattgg caccggttac ctcaccgta acctgtaatt gcctgttaat caataaaccg	3060
40	gttaattcgt ttcagttgaa ctttggtctc tgcgaagggc gaattc	3106

	<210> 35
45	<211> 2489
	<212> DNA
	<213> new AAV serotype, clone 42.10

	<400> 35
50	

55

# EP 1 310 571 B1

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
	gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtgaagt	120
5	ccgccaaggc cattcatcat ctgctggggc gggctcccga gattgcttgc tcggcctgcg	180
	atctggtcaa cgtggacctg gatgactgtg tttctgagca ataaatgact taaaccaggt	240
	atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc	300

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

gagtgggtggg acttgaaacc tggagccccc aaacccaaag ccaaccagca aaagcaggac 360  
 gacggccggg gtctgggtgt tcttgggtac aagtacctcg gacccttcaa cggactcgac 420  
 5 aagggagagc cgggtcaacga ggcagacgcc gcggccctcg agcacgacaa ggcctacgac 480  
 aagcagctcg agcaggggga caacccttac ctcaagtaca accacgccga cgccgagttt 540  
 caggagcgtc ttcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 600  
 10 gccaaagaagc gggttctcga acctctcggg ctggttgagg aaggcgctaa gacggctcct 660  
 ggaaagaaga gacccataga atccccgac tcctccacgg gcatcggcag gaaaggccag 720  
 cagcccgcta aaaagaagct caactttggg cagactggcg actcagagtc agtgcccgac 780  
 15 cctcaaccaa tcggagaacc ccccgagggc ccctctggtc tgggatctgg tacaatggct 840  
 gcaggcggty gcgctccaat ggcagacaat aacgaaggcg ccgacggagt gggtaatgcc 900  
 tccggaaatt ggcattgcga ttccacatgg ctgggcgaca gagtcatcac caccagcacc 960  
 20 cgcacctggg ccctgcccac ctacaacaac cacctctaca agcagatata aagtcagagc 1020  
 ggggctacca acgacaacca cttcttcggc tacagcacc cctggggcta ttttgacttc 1080  
 aacagattcc actgccactt ctcaccacgt gactggcagc gactcatcaa caacaactgg 1140  
 25 ggattccggc ccagaaagct gcggttcaag ttgttcaaca tccagggtcaa ggaggtcacg 1200  
 acgaacgacg gcgttacgac catcgccaat aaccttacca gcacgattca ggtcttctcg 1260  
 gactcggagt accaactgcc gtacgtctc ggctctgcgc accagggctg cctccctccg 1320  
 30 ttccctgcgg acgtgttcat gattcctcag tacggatata tgactctaaa caacggcagt 1380  
 cagtctgtgg gacgttcctc cttctactgc ctggagtact ttcttctca gatgctgaga 1440  
 acgggcaata actttgaatt cagctacacc tttgaggaag tgcctttcca cagcagctat 1500  
 35 gcgcacagcc agagcctgga cgggctgatg aatccctca tcgaccagta cctgtactac 1560  
 ctggccccga ccagagcac tacgggggtcc acaagggagc tgcagttcca tcaggctggg 1620  
 cccaacacca tggccgagca atcaaagaac tggctgcccg gaccctgtta tcggcagcag 1680  
 40 agactgtcaa aaaacataga cagcaacaac aacagtaact ttgcctggac cggggccact 1740  
 aaataccatc tgaatggtag aaattcatta accaaccgg gcgtagccat ggccaccaac 1800  
 aaggacgacg aggaccagtt ctttcccatc aacggagtgc tggtttttgg caaaacgggg 1860  
 45 gctgccaca agacaacgct ggaaaacgtg ctaatgacca gcgaggagga gatcaaaacc 1920  
 accaatcccg tggctacaga agaatacggg gtgggtctcca gcaacctgca atcgtctacg 1980  
 gccggacccc agacacagac tgtcaacagc cagggggctc tgcccggcat ggtctggcag 2040  
 50 aaccgggacg tgtacctgca gggctccatc tgggcaaaa ttctctcacac ggacggcaac 2100  
 tttcacccgt ctcccctgat gggcggtatt ggactcaaac acccgctcc tcaaattctc 2160  
 atcaaaaaca ccccggtacc tgctaatact ccagaggtgt ttactcctgc caagtttgcc 2220

EP 1 310 571 B1

tcatttatca cgcagtacag caccggccag gtcagcgtgg agatcgagtg ggaactgcag 2280  
aaagaaaaca gcaaacgctg gaatccagag attcagtaca cctcaaatta tgccaagtct 2340  
5 aataatgtgg aatttgctgt caacaacgaa ggggtttata ctgagcctcg ccccatggc 2400  
accggttacc tcaccgtaa cctgtaattg cctgttaatc aataaaccgg ttaattcggt 2460  
tcagttgaac tttggtcaag ggcgaattc 2489

10 <210> 36

<211> 2495

<212> DNA

15 <213> new AAV serotype, clone 42.3b

<400> 36

20

25

30

35

40

45

50

55

EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact agaccaatga gaactttccc ttcaacgatt 60  
gcgtcgacaa gatggatgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
5 cgcgcaaggc cattcatcat ctgctggggc gggctcccga gattgcttgc tcggcctgcg 180  
atctggtcaa cgtggacctg gatgactgtg tttctgagca ataatgact taaaccaggt 240  
atggctgccg atggttatct tccagattgg ctgaggaca acctctctga gggcattcgc 300  
10 gagtgggtggg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 360  
gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac 420  
aagggagagc cgttcaacga ggcagacgcc gcggccctcg agcacgacaa ggcctacgac 480  
15 aagcagctcg agcaggggga caaccctgac ctcaagtaca accacgccga cgccgagttt 540  
caggagcgtc ttcaagaaga tacgtctttt gggggcaacc tcgggagagc agtcttccag 600  
gccaaagaagc ggggttctcga acctctcggg ctggttgagg aaggcgctaa gacggctcct 660  
20 ggaaagaaga gacccataga atccccgac tcctccacgg gcatcggcaa gaaaggccag 720  
cagcccgtca aaaagaagct caactttggg cagactggcg actcagagtc agtgcccgac 780  
cctcaaccaa tcggagaacc ccccgagggc ccctctggtc tgggatctgg tacaatggct 840  
25 gcaggcggtg gcgctccaat ggcagacaat aacgaaggcg ccgacggagt gggtaatgcc 900  
tccggaaatt ggcattgca ttccacatgg ctgggagaca gagtcacac caccagcacc 960  
cgcacctggg ccctgcccac ctacaacaac cacctctaca agcagatata aagtcagagc 1020  
30 ggggctacca acgacaacca cttcttcggc tacagcacc cctggggcta ttttgacttc 1080  
aacagattcc actgccactt ctcaccaggt gactggcagc gactcatcaa caacaactgg 1140  
ggattccggc ccagaaagct gcggttcaag ttgttcaaca tccaggtcaa ggaggtcacg 1200  
35 acgaacgagc gcgttacgac catcgctaataaaccttacca gcacgattca ggtcttctcg 1260  
gactcggagt accaactgcc gtacgtcttc ggctctgccc accagggtcg cctccctccg 1320  
ttccctgagg acgtgttcat gattcctcag tacggatata tgactctaaa caacggcagt 1380  
40 cagtctgtgg gacgttcctc cttctactgc ctggagtact ttccttctca gatgctgaga 1440

45

50

55

EP 1 310 571 B1

	acggggcaata actttgaatt cagctacacc tttgaggaag tgcctttcca cagcagctat	1500
	gcgcacagcc agagcctgga cgggctgatg aatcccctca tcgaccagta cctgtactac	1560
5	ctggccccgga cccagagcac tacgggggtcc acaagggagc tgcagttcca tcaggctggg	1620
	cccaacacca tggccgagca atcaaagaac tggctgcccc gaccctgtta tcggcagcag	1680
	agactgtcaa aaaacataga cagcaacaac accagtaact ttgcctggac cggggccact	1740
10	aaataccatc tgaatggtag aaattcatta accaaccggg gcgtagccat ggccaccaac	1800
	aaggacgacg aggaccagtt ctttcccatc aacggagtg cgggtttttgg caaaacgggg	1860
	gctgccaaca agacaacgct ggaaaacgtg ctaatgacca gcgaggagga gatcaaaacc	1920
15	accaatcccg tggctacaga acagtacgt gtggtctcca gcaacctgca atcgtctacg	1980
	gccggacccc agacacagac tgtcaacage cagggggctc tgcccggcat ggtctggcag	2040
	aaccgggacg tgtacctgca gggctccatc tgggcaaaa ttcctcacac ggacggcaac	2100
20	tttcaccgt ctccctgat gggcggattt ggactcaaac acccgctcc tcaaattctc	2160
	atcaaaaaca ccccggtacc tgctaactct ccagagggtgt ttactcctgc caagtttgcc	2220
	tcatttatca cgcagtacag caccggccag gtcagcgtgg agatcgagtg ggaactgcag	2280
25	aaagaaaaca gcaaacgctg gaatccagag attcagtaca cctcaaatta tgccaagtct	2340
	aataatgtgg aatttgctgt caacaacgaa ggggtttata ctgagcctcg cccattggc	2400
	accggttacc tcaccgtaa cctgtaattg cctgttaatc aataaacgg ttaattcgtt	2460
30	tcagttgaac tttggtctct gcgaaggggc aattc	2495

<210> 37

<211> 3098

35 <212> DNA

<213> new AAV serotype, clone 42.11

<400> 37

40	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
	gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
	ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga caaaagtgc aagtcttccg	180
45	cccagatcga tcccaccccc gtgatcgtca cttccaacac caacatgtgc gccgtgattg	240
	acgggaacag caccacctc gagcaccagc agccgttaca agaccggatg ttcaaatttg	300
	aactcaccgg ccgtctggag cagcactttg gcaaggtgac aaagcaggaa gtcaaagagt	360
50	tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctac gtcagaaagg	420
	gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggctt	480
	gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg	540
55	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
	agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accggagact	660

## EP 1 310 571 B1

	gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc	720
	ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct	780
5	gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca	840
	ggtatggctg ccgatggtta tcttcagat tggctcgagg acaacctctc tgagggcatt	900
	cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag	960
10	gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc	1020
	gacaagggag agccggtcaa cgcggcggac gcagcggccc tcgagcacga caaggcctac	1080
	gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc cgacgccgag	1140
15	tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg agcagtcttc	1200
	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
	cctggaaaga agagacccat agaatcccc gactcctcca cgggcatcgg caagaaaggc	1320
20	cagcagcccc ctaaaaagaa gctcaacttt gggcagactg gcgactcaga gtcagtgcc	1380
	gacctcaac caatcgga acccccgca ggccctctg gtctgggatc tggtaaatg	1440
	gctgcaggcg gtggcgctcc aatggcagac aataacgaag gcgccgacgg agtgggtaat	1500
25	gcctccggaa attggcattg cgattccaca tggctgggcg acagagtcac caccaccagc	1560
	acccgcacct gggccctgcc cacctacaac aaccacctct acaagcagat atcaagtcag	1620
	agcggggcta ccaacgacaa ccacttcttc ggctacagca cccctgggg ctattttgac	1680
30	ttcaacagat tccactgcca cttctacca cgtgactggc agcgactcat caacaacaac	1740
	tggggattcc ggcccagaaa gctgcggttc aagttgttca acatccaggt caaggaggtc	1800
	acgacgaacg acggcgttac gaccatcgct aataacctta ccagcacgat tcaggctctc	1860
35	tcggactcgg agtaccact gccgtacgtc ctcggtctg cgcaccaggg ctgcctccct	1920
	ccgttccctg cggacgtggt catgattcct cagtacggat atctgactct aaacaacggc	1980
	agtcagtctg tgggacgttc ctcttctac tgcctggagt actttccttc tcagatgctg	2040
40	agaacgggca ataactttga attcagctac acctttgagg aagtgccttt ccacagcagc	2100
	tatgcgcaca gccagagcct ggaccggctg atgaatcccc tcatcgacca gtacctgtac	2160
	tacctggccc ggaccagag cactacgggg tccacaaggg agctgcagtt ccatcaggct	2220
45	gggccaaca ccatggccga gcaatcaaag aactggctgc ccggaccctg ttatcggcgg	2280
	cagagactgt caaaagacat agacagcaac aacaacagta actttgcctg gaccggggcc	2340
	actaaatacc atctgaatgg tagaaattca ttaaccaacc cgggcgtagc catggccacc	2400
50	aacaaggacg acgaggacca gttctttccc atcaacggag tgctggtttt tggcaaacg	2460
	ggggctgcca acaagacaac gctggaaaac gtgctaataa ccagcgagga ggagatcaaa	2520
55	accaccaatc ccgtggctac agaagaatac ggtgtggtct ccagcaacct gcaatcgtct	2580

# EP 1 310 571 B1

```

acggccggac cccagacaca gactgtcaac agccaggggg ctctgcccg catggtctgg 2640
cagaaccggg acgtgtacct gcaggggtccc atctggggcca aaattcctca cacggacggc 2700
5 aactttcacc cgtctcccct gatggggcgga tttggactca aacacccgcc tcctcaaatt 2760
ctcatcaaaa acaccccggt acctgctaata cctccagagg tgtttactcc tgccaagttt 2820
gcctcattta tcacgcagta cagcaccggc caggtcagcg tggagatcga gtgggaactg 2880
10 cagaaagaga acagcaaact ctggaatcca gagattcagt acacctcaaa ttatgccaag 2940
tctaataatg tggaatttgc tgtcaacaac gaaggggttt atactgagcc tcgccccatt 3000
ggcaccggtt acctcaccgg taacctgtaa ttacttggtta atcaataaac cggttgattc 3060
15 gtttcagttg aactttggtc tctgcgaagg gcgaattc 3098

```

<210> 38

<211> 3276

<212> DNA

<213> new AAV serotype, clone 42.6a

<400> 38



EP 1 310 571 B1

	gaattcgccc ttcgcagaga ccaaagttca actgaaacga attaacgggt ttattgatta	60
	acaggcaatt acaggttacg ggtgaggtaa cgggtgccaa tggggcgagg ctcaagtataa	120
5	accccttcgt tgttgacagc aaattccaca ttattagact tggcataatt tgaggtgtac	180
	tgaatctctg gattccagcg tttgctgttt tctttctgca gttcccactc gatctccacg	240
	ctgacctggc cgggtgctgta ctgcgtgata aatgaggcaa acttggcagg agtaaacc	300
10	tctggaggat tagcaggtag cggggtgttt ttgatgagaa tttgaggagg cgggtgtttg	360
	agtccaaatc cgtccatcag gggagacggg tgaaagttgc cgtccgtgtg aggaattttg	420
	gccagatgg gacctgcag gtacacgtcc cggttctgcc agaccatgcc gggcagagcc	480
15	ccctggctgt tgacagtctg tgtctggggg ccggccgtag acgattgcag gttgctggag	540
	accacaccgt attcttctgt agccacggga ttggtggttt tgatctctc ctcgtggtc	600
	attagcacgt tttccagcgt tgtcttgttg gcagcccccg ttttgccaaa aaccagcact	660
20	ccgttgatgg gaaagaactg gtcctcgtcg tccttggttg tggccatggc tacgccggg	720
	ttggttaatg aatttctacc attcagatgg tatttagtgg ccccggtcca ggcaaagtta	780
	ctgttggtgt tgctgtctat gttttttgac agtctctgct gccgataaca gggtcggggc	840
25	agccagttct ttgattgctc ggccatgggt ttggggccag cctgatggaa ctgcagctcc	900
	cttgtggacc ccgtagtgt ctgggtccgg gccaggtagt acaggtagt gtcgatgagg	960
	ggattcatca gccgggtccag gctctggcta tgcgcatagc tgctgtggaa aggcaattcc	1020
30	tcaaagggtg agctgaattc aaagttattg cccgttctca gcattctgaga aggaaagtac	1080
	tccaggcagt agaaggagga acgtcccaca gactgactgc cgttgtttag agtcagatat	1140
35	ccgtactgag gaatcatgaa cacgtccgca gggaacggag ggaggcagcc ctggtgcgca	1200

40

45

50

55

EP 1 310 571 B1

	gagccgagga cgtacggcag ttggtactcc gagtccgaga agacctgaat cgtgctggtg	1260
	aggttattag cgatggtcgt aacgccgtcg tccgtcgtga cctccttgac ctggatggtg	1320
5	aacaacttga accgcagctt tctgggccgg aatccccagt tgttggtgat gagtcgctgc	1380
	cagtcacgtg gtgagaagtg gcagtggaat ctgttaaagt caaaatacc ccagggggtg	1440
	ctgtagccga agtaggtgtt gtcgttggtg ctctctcccg atgtcccgtt ggagatttgc	1500
10	ttgtagaggt ggttggtgta ggtggggagg gcccagggtc ggggtgctggt ggtgatgact	1560
	ctgtcgccca gccatgtgga atcgcaatgc caatttcctg aggaactacc cactccgtcg	1620
	gcgccttcgt tattgtctgc cattggagcg ccaccgcctg cagccattgt accagatccc	1680
15	agaccagagg ggcctgcggg gggttctccg attgggtgag ggtcgggcac tgactctgag	1740
	tcgccagtct gcccaaagt gagtctcttt ttcgcgggct gctggcctgt cttgccgatg	1800
	cccgtagagg agtctggaga acgctgggt gatggctcta ccggtctctt ctttccagga	1860
20	gccgtcttag cgccttcctc aaccagaccg agagggtcga gaaccgcctt cttggcctgg	1920
	aagactgctc gcccgagggt gcccccacaa gacgtatctt cttgaagacg ctctgaaac	1980
	tcggcgctcg cgtggttgta cttgaggtag gggttgtccc cctgctcgag ctgcttgctg	2040
25	taggccttgt cgtgctcgag ggccgcggcg tctgcctcgt tgaccggctc tcccttgctg	2100
	agtccgttga agggcccgag gtactttag ccaggaagca ccagaccccg gccgtcgctc	2160
	tgcttttgct ggttggtctt gggtttcggg gctccagggt tcaagtccca ccactcgca	2220
30	atgccctcag agagggtgtc ctcgagccaa tctggaagat aaccatcggc agccatacct	2280
	ggtttaagtc atttattgct cagaaacaca gtcatccagg tccacgttga ccagatcgca	2340
	ggccgagcaa gcaatctcg gagcccgccc cagcagatga tgaatggcac agagtctccg	2400
35	atacgtcctc tttctgacga ccggttgaga ttctgacacg ccggggaaac attctgaaca	2460
	gtctctgggt ccgtgcgtga agcaaatgtt gaaattctga ttcattctct cgcattgctt	2520
	gcagggaaac agcatctgaa gcatgccgc gtgacgagaa cacttggttt ggtacctgtc	2580
40	ggcaaagtcc accggagctc cttccgcgtc tgacgtcgat ggatgcaaaa tgtcgcaaaa	2640
	gcactcacgt gacagctaatacaggaccac tcccctatga cgtgatttac gtcagcgcta	2700
	tgcccgctg acgagaacat ttgttttggt acctgtcggc aaagtccacc ggagctcctt	2760
45	ccgcgtctga cgtcgatgga tccgcgactg aggggcaggc ccgcttgggc tcgcttttat	2820
	ccgcgtcatc gggggcgggt ctcttggttg ctccaccctt tctgacgtag aactcatgcg	2880
	ccacctcggt cacgtgatcc tgccgccagc ggaagaactc tttgacttcc tgctttgtca	2940
50	ccttgccaaa gtcatgctcc agacggcggg tgagttcaaa tttgaacatc cggctctgca	3000
	acggctgctg gtgctcgaag gtgggtgctgt tcccgtaac caccggcgac atgttggtgt	3060
55	tggaagtgc gatcacgggg gtgggagcga tctggcgga agacttgac ttttggtcca	3120

# EP 1 310 571 B1

cgcgcacctt gctgccgccg agaatggcct tggcggactc cacgaccttg gccgtcatct 3180  
tgccctcctc ccaccagatc accatcttgt cgacgcaatc gttgaaggga aagttctcat 3240  
5 tgggccagtt gacgcagccg tagaaagggc gaattc 3276

<210> 39

10 <211> 3084

<212> DNA

<213> new AAV serotype, clone 43.1

<400> 39

15

20

25

30

35

40

45

50

55

## EP 1 310 571 B1

gaattcgccc tttctacggc tgcacaaact ggaccaatga gaactttccc ttcaacgatt 60  
 gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
 5 cgcgcaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180  
 cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240  
 acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatg ttcaagttcg 300  
 10 aactcaccgg cgtctcggag cagcactttg gcaagggtgac caagcaggaa gtcaaagagt 360  
 tcttcgctg ggcgcaggat cagtgaccg aggtggcgca tgagttctac gtcagaaagg 420  
 gcggagccag caaaagacc gcccccgatg acgcggatat aagcgagccc aagcgggcct 480  
 15 gccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540  
 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca 600  
 aaacgtgcga gaaaatgaat cagaatttca acatttgctt cacgcacggg gtcagagact 660  
 20 gctcagaatg tttccccggg gcatcagaat ctcaaccggg cgtcagaaaa aaaacgtatc 720  
 agaaactgtg tgccattcat catctgctgg ggcgggcacc cgagattgct tgctcggcct 780  
 gcgatctggt caacgtggac ctggacgact gtgtttctga gcaataaatg acttaaacca 840  
 25 ggtatggctg ccgatgggta tcttcagat tggcttgagg acaacctctc tgagggcatt 900  
 cgcgagtggg gggacctgaa acctggagcc ccgaaaccca aagccaacca gcaaaagcag 960  
 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc 1020  
 30 gacaaggggg agcccgtaa cgcggcggac gcagcggccc tcgagcacga caaggcctac 1080  
 gaccagcagc tcaaagcggg tgacaatccg tacctgcggg ataaccacgc cgacgccgag 1140  
 tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggcy agcagtcttc 1200  
 35 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct 1260  
 cctggaaaga agagaccggg agagccatca cctcagcgtt cccccgactc ctccacgggc 1320  
 atcggcaaga aaggccacca gcccgcgaga aagagactga actttgggca gactggcgac 1380  
 40 tcggagtcag tccccgacct tcaaccaatc ggagaaccac cagcaggccc ctctggtctg 1440  
 ggatctggtg caatggctgc aggcgggtgc gctccaatgg cagacaataa cgaaggcgcc 1500  
 gacggagtgg gtagttcctc aggaaattgg cattgagatt ccacatggct gggcgacaga 1560

45

50

55

EP 1 310 571 B1

gtcatcacca ccagcaccg aacctgggccc ctgcccacct acaacaacca tctctacaag 1620  
 caaatctcca acgggacatc gggaggaagc actaacgaca acacctactt tggctacagc 1680  
 5 accccctggg ggtatttttga cttcaacaga ttccactgcc acttctcacc acgtgactgg 1740  
 cagcgactca tcaacaataa ctgggggattc cggcccaaga gactcaactt caagctcttc 1800  
 aacatccagg tcaaggagggt cacgcagaat gaaggcacca agaccatcgc caataacctt 1860  
 10 accagcacga ttcagggtgtt tacggactcg gaataccagc tcccgtacgt ccccggtctt 1920  
 gcgcaccagg gctgcctccc tccgttcccg gcggacgtct tcatgattcc tcagtacggg 1980  
 tatctgaccc taaacaatgg cagtcagggt gtggggccgtt cctccttcta ctgcctggaa 2040  
 15 tacttccctt ctcaaagtgt gaggacgggc aacaactttg aattcagcta caccttcgag 2100  
 gacgtgcctt tccacagcag ctacgcgcac agccagagcc tggaccgggt gatgaaccct 2160  
 ctcatcgacc agtacctgta ttacttatcc agaactcagt ccacaggagg aactcaagggt 2220  
 20 actcagcaat tggtattttc tcaagccggg cccgcaaaca tgtcgggtca ggccaagaac 2280  
 tggctacctg gaccgtgtta ccgtcagcaa cgagtttcca cgacactgtc gcaaaacaac 2340  
 aacagcaatt ttgcttggaac cgggtgccacc aagtatcacc tgaatggcag agactccctg 2400  
 25 gttaatcccg gcgttgccat ggctaccac aaggacgacg aggagcgctt cttcccgta 2460  
 agcggagttc taatgtttgg caagcagggg gctggaaaag acaatgtgga ctacagcagc 2520  
 gtgatgctca ccagcgaaga agaaattaaa actactaacc cagtggctac agagcagtat 2580  
 30 ggtgtggtgg cagacaacct gcagcagacc aacggagctc ccattgtggg aactgtcaac 2640  
 agccaggggg ccttacctgg tatggtctgg caaaaccggg acgtgtacct gcagggcccc 2700  
 atctgggcca aaattcctca cacggacggc aactttcatc cttcgccgt gatgggaggc 2760  
 35 tttggactga aacaccgcc tcctcagatc ctggtgaaaa acactcctgt tcctgcggat 2820  
 cctccgacca ccttcagcca ggccaagctg gcttctttta tcacgcagta cagcaccgga 2880  
 caggtcagcg tggaaatcga atgggagctg cagaaagaaa acagcaagcg ctggaacca 2940  
 40 gagattcagt atacttccaa ctactacaaa tctacaaatg tggactttgc tgtcaatact 3000  
 gagggctactt attcagagcc tcgccccatt ggcactcggt atctcaccg taatctgtaa 3060  
 ttgcttgta atcaataaac cgg 3084

45

<210> 40

<211> 2370

<212> DNA

50

<213> new AAV serotype, clone 43.5

<400> 40

55

EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
gcgtcgacaa gatggtgac tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
5 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaagtgc aagtcgtccg 180

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

	cccagatcga cccacacccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg	240
	acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatg ttcaagttcg	300
5	aactcacccg ccgtctggag cacgactttg gcaagggtgac caagcaggaa gtcaaagagt	360
	tcttccgctg ggcgaggat cacgtgaccg aggtggcgca tgagttctac gtcagaaagg	420
	gcgagaccag caaaagaccc gccccgatg acgcggatat aagcgagccc aagcgggcct	480
10	gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg	540
	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagacgctg tttccctgca	600
	aaacgtgcga gagaatgaat cagaatttca acatttgctt cacgcacggg gtcagagact	660
15	gctcagaatg tttccccggt gcatcagaat ctcaaccggt cgtcagaaaa aaaacgtatc	720
	agaaactgtg tgccattcat catctgctgg ggcgggcacc cgagattgct tgctcggcct	780
	gcgatctggt caacgtggac ctggacgact gtgtttctga gcaataaatg acttaaacca	840
20	ggtatggctg ccgatggtta tcttccagat tggcttgagg acaacctctc tgagggcatt	900
	cgcgagtggg gggacctgaa acctggagcc ccgaaaccca aagccaacca gcaaaagcag	960
	gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc	1020
25	gacaaggggg agcccgtcaa cgcgggcgac gcagcgcccc tcgagcacga caaggcctac	1080
	gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc cgacgccgag	1140
	tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggag agcagtcttc	1200
30	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
	cctggaaaga agagaccggt agagccatca cctcagcgtt cccccgactc ctccacgggc	1320
	atcggcaaga aaggccacca gcccgcgaga aagagactga actttgggca gactggcgac	1380
35	tcggagtacg tccccgacct tcaaccaatc ggagaaccac cagcaggccc ctctggctctg	1440
	ggatctggta caatggctgc aggcgggtggc gctccaatgg cagacaataa cgaaggcgcc	1500
	gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggct gggcgacaga	1560
40	gtcatcacca ccagcacccg aacctgggac ctgcccacct acaacaacca tctctacaag	1620
	caaattctca acgggacatc gggaggaagc actaacgaca acacctactt tggctacagc	1680
	accccctggg ggtattttga cttcaacaga ttccactgcc acttctcacc acgtgactgg	1740
45	cagcgactca tcaacaataa ctggggattc cgggccaaga gactcaactt caagctcttc	1800
	aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgc caataacctt	1860
	accagcacga ttcaggtggt tacggactcg gaataccagc tcccgtacgt cctcggctct	1920
50	gcgcaccagg gctgcctccc tccgttcccc gcggacgtct tcatgattcc tcagtacggg	1980
	tatctgacct taaacaatgg cagtcaggct gtgggccgtt cctccttcta ctgcctggaa	2040
55	tacttccctt ctcaaatgct gaggacgggc aacaactttg aattcagcta caccttcgag	2100

# EP 1 310 571 B1

gacgtgcctt tccacagcag ctacgcgcac agccagagcc tggaccgggt gatgaaccct 2160  
5 ctcacgcacc agtacctgta ttacttatcc agaactcagt ccacaggagg aactcaaggt 2220  
actcagcaat tgttattttc tcaagccggg cccgcaaaca tgtygggtca ggccaagaac 2280  
tggctacctg gaccgtgcta ccgtcagcaa cgagtttcca cgacactgtc gcaaaacaac 2340  
10 aacagcaatt ttgctggacc ggtgccacca 2370

<210> 41

<211> 3123

15 <212> DNA

<213> new AAV serotype, clone 43.12

<400> 41

20

25

30

35

40

45

50

55



## EP 1 310 571 B1

	gaattcgccc ttggctgcgt caactggacc aatgagaact ttccttcaa cgattgcgtc	60
	gacaagatgg tgatctggtg ggaggagggc aagatgacgg ccaaggtcgt ggagtccgcc	120
5	aaggccattc tcggcggcag caaggtgcgc gtggaccaa agtgcaagtc gtccgcccag	180
	atcgacccca ccccgatgat cgtcacctcc aacaccaaca tgtgcgccgt gattgacggg	240
	aacagcacca ccttcgagca ccagcagccg ttgcaggacc ggatgttcaa gttcgaactc	300
10	acccgccgtc tggagcacga ctttggcaag gtgaccaagc aggaagtcaa agagtctctc	360
	cgctgggcgc aggatcacgt gaccgaggtg gcgcatgagt tctacgtcag aaagggcgga	420
	gccagcaaaa gaccgcgcc cgatgacgcg gatataagcg agcccaagcg ggctgcccc	480
15	tcagtcgcgg atccatcgac gtcagacgcg gaaggagctc cgggtggactt tgccgacagg	540
	tacaaaaaca aatgttctcg tcacgcgggc atgctccaga tgctgtttcc ctgcaaaacg	600
	tgcgagagaa tgaatcagaa tttcaacatt tgcttcacgc acggggtcag agactgctca	660
20	gaatgtttcc ccggtgcac agaactctcaa ccggtcgtca gaaaaaaaaac gtatcagaaa	720
	ctgtgtgcca ttcacatct gctggggcgg gcacccgaga ttgcttgctc ggctgcgat	780
	ctggtcaacg tggacctgga cgactgtgtt tctgagcaat aaatgactta aaccagggtat	840
25	ggctgcccga ggttatcttc cagattggct tgaggacaac ctctctgagg gcattcgcga	900
	gtggtgggac ctgaaacctg gagccccgaa acccaaagcc aaccagcaaa agcaggacga	960
	cggccggggg ctggtgcttc ctggctacaa gtacctcgga cccttcaacg gactcgacaa	1020
30	gggggagccc gtcaacgcgg cggacgcagc ggccctcgag cacgacaagg cctacgacca	1080
	gcagctcaaa gggggtgaca atccgtacct gcggtataac cagcccgacg ccgagtttca	1140
	ggagcgtctg caagaagata cgtcttttgg gggcaacctc gggcgagcag tcttccaggc	1200
35	caagaagcgg gttctcgaac ctctcggtct ggttgaggaa ggcgctaaga cggtcctgg	1260
	aaagaagaga ccggtagagc catcacctca gcgttcccc gactcctcca cgggcatcgg	1320
	caagaaaggc caccagcccg cgagaaagag actgaacttt gggcagactg gcgactcgga	1380
40	gtcagtcccc gacctcaac caatcggaga accaccagca ggcccctctg gtctgggatc	1440

45

50

55

EP 1 310 571 B1

	tggtacaatg gctgcaggcg gtggcgctcc aatggcagac aataacgaag gcgccgacgg	1500
	agtgggtagt tcctcaggaa attggcattg cgattccaca tggctgggcg acagagtcac	1560
5	caccaccagc acccgaacct gggccctgcc cacctacaac aaccatctct acaagcaa	1620
	ctccaacggg acatcgggag gaagcactaa cgacaacacc tactttggct acagcacc	1680
	ctgggggtat tttgacttca acagattcca ctgccacttc tcaccacgtg actggcag	1740
10	actcatcaac aataactggg gattccggcc caagagactc aacttcaagc tcttcaac	1800
	ccagggtcaag gaggtcacgc agaatgaagg caccaagacc atcgccaata accttacc	1860
	cacgattcag gtgtttacgg actcgggaata ccagctcccg tacgtcctcg gctctgcg	1920
15	ccagggctgc ctccctccgt tcccggcgga cgtcttcatg attcctcagt acgggtat	1980
	gaccctaaac aatggcagtc aggtgtggg ccgttcctcc ttctactgcc tggaatact	2040
	cccttctcaa atgctgagga cgggcaacaa ctttgaattc agctacacct tcgaggac	2100
20	gcctttccac agcagctacg cgcacagcca gagcctggac cggctgatga accctctc	2160
	cgaccagtac ctgtattact tatccagaac tcagtccaca ggaggaaactc aaggta	2220
	gcaattgtta ttttctcaag cggggccgcg aaacatgtcg gctcaggcca agaactg	2280
25	acctggaccg tgttaccgtc agcaacgagt ttccacgaca ctgtcgcaaa acaaca	2340
	caatthttgct tggaccggtg ccaccaagta tcacctgaat ggcagagact ccctg	2400
	tcccggcggt gccatggcta cccacaagga cgacgaggag cgcttcttcc cgtcaag	2460
30	agttctaatg tttggcaagc agggggctgg aaaagacaat gtggactaca gcagcg	2520
	gctcaccagc gaagaagaaa ttaaaactac taaccagtg gctacagagc agtatgg	2580
	ggtggcagac aacctgcagc agaccaacgg agctccatt gtgggaactg tcaacag	2640
35	gggggcctta cctgggatgg tctggcaaaa cgggacgtg tacctgcagg gccccat	2700
	ggccaaaatt cctcacacgg acggcaactt tcctccttcg ccgctgatgg gaggct	2760
	actgaaacac ccgcctctc agatcctggg gaaaaaact cctgttcctg cggatc	2820
40	gaccaccttc agccaggcca agctggcttc ttttatcacg cagtacagca ccggac	2880
	cagcgtggaa atcgaatggg agctgcagaa agaaaacagc aagcgtgga acccag	2940
	tcagtatact tccaactact acaaatctac aaatgtggac tttgctgtca atactg	3000
45	tacttattca gagcctcgcc ccattggcac tcgttatctc acccgtaatc tgtaatt	3060
	tgtaaatcaa taaaccggtt aattcgtttc agttgaactt tggctctctgc gaagg	3120
50	ttc	3123

<210> 42

<211> 3122

<212> DNA

55 <213> new AAV serotype, clone 43.20

<400> 42

EP 1 310 571 B1

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
	gcgctcgacaa gatgggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
5	ccgccaaggc cattctcggc ggcagcaagg tgcgtgtgga ccaaaagtgc aagtcttcg	180
	cccagatcga tcccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg	240
	acgggaacag cgccaccttc gagcaccagc agcgttgca ggaccggatg ttcaaatttg	300
10	aactcaccgg ccgtctggag catgactttg gcaaggtgac gaagcaggaa gtcaaagagt	360
	tcttcgctg ggcgaggat cacgtgaccg aggtggcgca tgagttccac gtcagaaagg	420
	gtggagccaa caagagaccc gccccgatg acgcygatat aagcgagccc aagcgggcct	480
15	gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg	540
	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
	agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact	660
20	gttcagaatg tttccccggc gtgtcagaat ctcaaccggg cgtcagaaag aggacgtatc	720
	ggaaactctg tgcgattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct	780
	gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca	840
25	ggtatggctg ccgatgggta tcttcagat tggctcgagg acaacctctc tgagggcatt	900
	cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag	960
	gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc	1020
30	gacaaggggg agcccgtaaa cgcgggcgac gcagcggccc tcgagcacga caaagcctac	1080
	gaccagcagc tcaaagcggg tgacaatccg tacctgagggt ataatacgc cgacgccgag	1140
	tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggag agcagtcttc	1200
35	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
	cctggaaaga agagactggg agagcagtcg ccacaagagc cagactcctc ctcgggcac	1320
	ggcaagacag gccagcagcc cgctaaaaag agactcaatt ttggtcagac tggcgactca	1380
40	gagtcagtc ccgaccaca acctctcgga gaacctccag cagccccctc aggtctggga	1440
	cctaatacaa tggtctcagg cgggtggcgt ccaatggcag acaataacga aggcgccgac	1500
	ggagtgggta attcctcggg aaattggcat tgcgattcca catggctggg ggacagagtc	1560
45	atcaccacca gcaccgaac ctggggcctg cccacctaca acaaccacct ctacaagcaa	1620
	atctccaacg gcacctcggg aggaagcacc aacgacaaca cctatcttgg ctacagcacc	1680
	ccctgggggt attttgactt caacagattc cactgtcact tttaccacg tgactggcaa	1740
50	cgactcatca acaacaattg gggattccgg cccaaaagac tcaacttcaa gctgttcaac	1800
	atccaggtca aggaagtcac gacgaacgaa ggcaccaaga ccatcgccaa taatctcacc	1860
	agcaccgtgc aggtctttac ggactcggag taccagttac cgtacgtgct aggatccgct	1920

EP 1 310 571 B1

	caccagggat gtctgcctcc gttcccggcg gacgtcttca cggttcctca gtacggctat	1980
	ttaactttaa acaatggaag ccaagccctg ggacgttctt ccttctactg tctggagtat	2040
5	ttcccatcgc agatgctgag aaccggcaac aactttcagt tcagctacac cttcgaggac	2100
	gtgcctttcc acagcagcta cgcgcacagc cagagcctgg acaggctgat gaatcccctc	2160
	atcgaccagt acctgtacta cctggtcaga acgcaaacga ctggaactgg agggacgcag	2220
10	actctggcat tcagccaagc gggctcctagc tcaatggcca accaggctag aaattgggtg	2280
	cccggacctt gctaccggca gcagcgcgtc tccacgacaa ccaaccagaa caacaacagc	2340
	aactttgcct ggacgggagc tgccaagttt aagctgaacg gccgagactc tctaataaat	2400
15	ccgggctgtg caatggcttc ccacaaggat gacgacgacc gcttcttccc ttcgagcggg	2460
	gtcctgattt ttggcaagca aggagccggg aacgatggag tggattacag ccaagtgtctg	2520
	attacagatg aggaagaaat caaggctacc aaccccggtg ccacagaaga atatggagca	2580
20	gtggccatca acaaccaggc cgccaatacg caggcgcaga ccggactcgt gcacaaccag	2640
	ggggtgattc ccggcatggt gtggcagaat agagacgtgt acctgcaggg tcccatctgg	2700
	gccaaaattc ctcacacgga cggcaacttt caccgcgtc ccctgatggg cggcttttga	2760
25	ctgaagcacc cgcctcctca aattctcatc aagaacacac cggttccagc ggaccgcgcg	2820
	cttaccttca accaggccaa gctgaactct ttcatcacgc agtacagcac cggacaggtc	2880
	agcgtggaaa tcgagtggga gctgcagaaa gaaaacagca aacgctggaa tccagagatt	2940
30	caatacactt ccaactacta caaatctaca aatgtggact ttgctgtcaa cacggaagga	3000
	gtttatagcg agcctcgccc cattggcacc cgttacctca cccgcaacct gtaattacat	3060
	gttaatcaat aaaccggtta attcgtttca gttgaacttt ggtctctgcg aagggcgaat	3120
35	tc	3122

<210> 43  
 <211> 3117  
 <212> DNA  
 <213> new AAV serotype, clone 43.21

<400> 43

	gaattcgccc ttggctgcgt caactggacc aatgagaact ttcccttcaa cgattgcgtc	60
	gacaagatgg tgatctggtg ggaggagggc aagatgacgg ccaaggctcg ggagtccgcc	120
50	aaggccattc tcggcggcag caaggctcgt gtggaccaa agtgcaagtc ttccgcccag	180
	atcgatccca ccccgctgat cgtcacctcc aacaccaaca tgtgcgccgt gattgacggg	240
	aacagcacca ccttcgagca ccagcagccg ttgcaggacc ggatgttcaa atttgaactc	300
55	acccgcgcgtc tggagcatga ctttggaag gtgacgaagc aggaagtcaa agagttcttc	360
	cgctgggcgc aggatcacgt gaccgaggtg gcgcatgagt tccacgtcag aaagggtgga	420

EP 1 310 571 B1

	gccaacaaga gacccgcccc cgatgacgcg gatataagcg agcccaagcg ggctgcccc	480
	tcagtcgchg atccatcgac gtcagacgcg gaaggagctc cgggtggactt tgccgacagg	540
5	tacaaaaaca aatgtttctcg tcacgcgggc atgcttcaga tgctgtttcc ctgcaagaca	600
	tgcgagagaa tgaatcagaa tttcaacatt tgcttcacgc acgggaccag agactgttca	660
	gaatgtttcc ccggcggtgc agaattctcaa ccggctcgta gaaagaggac gtatcggaaa	720
10	ctctgtgcga ttcattcatct gctggggcgg gctcccgaga ttgcttgctc ggctgcgat	780
	ctggtcaacg tggacctgga tgactgtgtt tctgagcaat aaatgactta aaccaggat	840
	ggctgccgat gggtattcttc cagattggct cgaggacaac ctctctgagg gcattcgcga	900
15	gtggtgggac ttgaaacctg gagccccgaa acccaaagcc aaccagcaaa agcaggacga	960
	cggccgggggt ctggtgcttc ctggctacaa gtacctcgga cccttcaacg gactcgacaa	1020
	gggggagccc gtcaacgcgg cggacgcagc ggccctcgag cagacaaaag cctacgacca	1080
20	gcagctcaaa gcgggtgaca atccgtacct gcggtataat cagcccgacg ccgagtttca	1140
	ggagcgtctg caagaagata cgtcttttg gggaacctc gggcgagcag tcttcaggc	1200
	caagaagcgg gttctcgaac ctctcgggtc ggttgaggaa ggcgctaaga cggctcctgg	1260
25	aaagaagaga ccggtagagc agtcgccaca agagccagac tcctcctcgg gcatcgga	1320
	gacaggccag cagcccgcta aaaagagact caattttggt cagactggcg actcagagtc	1380
	agtccccgac ccacaacctc tcggagaacc tccagcagcc ccctcaggtc tgggacctaa	1440
30	tacaatggct tcaggcgggtg gcgctccaat ggcagacaat aacgaaggcg ccgacggagt	1500
	gggtaattcc tcgggaaatt ggcattgcga ttccacatgg ctgggggaca gagtcattcac	1560
	caccagcacc cgaacctggg ccctgcccac ctacaacaac cacctctaca agcaaattctc	1620
35	caacggcacc tcgggaggaa gcaccaacga caacacctat tttggctaca gcacccctg	1680
	gggggtatatt gacttcaaca gattccactg tcaattttca ccacgtgact ggcaacgact	1740
	catcaacaac aattggggat tccggcccaa aagactcaac ttcaagctgt tcaacatcca	1800
40	ggtcaaggaa gtcacgacga acgaaggcac caagaccatc gccataatc tcaccagcac	1860
	cgtgcgggtc tttacggact cggagtacca gttaccgtac gtgctaggat ccgtcacca	1920
	gggatgtctg cctccgttcc cggcggacgt cttcatggtt cctcagtacg gctatttaac	1980
45	tttaaacat ggaagccaag ccctgggacg ttctccttc tactgtctgg agtatttccc	2040
	atcgcatag ctgagaaccg gcaacaactt tcagttcagc tacaccttcg aggacgtgcc	2100
	tttcacagc agctacgagc acagccagag cctggacagg ctgatgaatc ccctcatcga	2160
50	ccagtacctg tactacctgg tcagaacgca aacgactgga actggaggga cgcagactct	2220
	ggcattcagc caagcgggtc ctgactcaat ggccaaccag gctagaaatt ggggtgccgg	2280
55	accttgctac cggcagcagc gcgtctccac gacaaccaac cagagcaaca acagcaactt	2340

# EP 1 310 571 B1

	tgcttgacg ggagctgcc agtttaagct gaacggccga gactctctaa tgaatccggg	2400
5	cgtggcaatg gcttcccaca aggatgacga cgaccgcttc tcccttcga gcggggctct	2460
	gatttttggc aagcaaggag ccgggaacga tggagtggat tacagccaag tgctgattac	2520
	agatgaggaa gaaatcaagg ctaccaaccc cgtggccaca gaagaatatg gagcagtggc	2580
10	catcaacaac caggccgcca atacgcaggc gcagaccgga ctctgtcaca accagggggt	2640
	gattcccggc atggtgtggc agaatagaga cgtgtacctg caggggtcca tctgggcca	2700
	aattcctcac acggacggca actttcacc gtctcccctg atggggggct ttggactgaa	2760
15	gcacccgctt cctcaaattc tcatcaagaa cacaccggtt ccagcggacc cgccgcttac	2820
	cttcaaccag gccaagctga actctttcat cacgcagtac agcaccggac aggtcagcgt	2880
	ggaaatcgag tgggagctgc agaaagaaaa cagcaaacgc tggaatccag agattcaata	2940
20	cacttccaac tactacaaat ctacaaatgt ggactttgct gtcaacacgg aaggagttaa	3000
	tagcgagcct cgccccattg gcaccggtta cctcaccgc aacctgtaat tacatgttaa	3060
	tcaataaacc ggttaattcg tttcagttga actttggtct ctgcgaaggg cgaattc	3117

25

<210> 44

<211> 3121

<212> DNA

<213> new AAV serotype, clone 43.23

30

<400> 44

35

40

45

50

55

EP 1 310 571 B1

	gaattcgccc ttctacggct gcgtcaactg gaccaatgag aactttccct tcaacgattg	60
	cgtcgacaag atggtgatct ggtgggagga gggcaagatg acggccaagg tcgtggagtc	120
5	cgccaaggcc attctcggcg gcagcaagggt gcgtgtggac caaaagtgc agtcttccgc	180
	ccagatcgat cccacccccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga	240
	cggaacagc accaccttcg agcaccagca gccgttgag gaccggatgt tcaaatttga	300
10	actcaccgc cgtctggagc atgactttgg caaggtagc aagcaggaag tcaaagagt	360
	cttccgctgg gcgcaggatc acgtgaccga ggtggcgcac gagttccacg tcagaaagg	420
	tggcgccaac aagagaccg ccccgatga cgcgatata agcgagcca agcgggcctg	480
15	cccctcagtc gcggatccat cgacgtcaga cgcggaagga gctccggtg actttgccga	540
	caggtaccaa aacaaatgtt ctgcgcacgc gggcatgctt cagatgctgt ttccctgcaa	600
	gacatgcgag agaatgaatc agaatttcaa catttgcttc acgcacggga ccagagactg	660
20	ttcagaatgt ttccccggcg tgtcagaatc tcaaccggtc gtcagaaaga ggacgtatcg	720
	gaaactctgt gcgattcatc atctgctggg gcgggctccc gagattgctt gctcggcctg	780
	cgatctggtc aacgtggacc tggatgactg tgtttctgag caataaatga cttaaaccag	840
25	gtatggctgc cgatggttat cttccagatt ggctcgagga caacctctct gagggcattc	900
	gcgagtgggt ggacttgaaa cctggagccc cgaaaccaa agccaaccag caaaagcagg	960

30

35

40

45

50

55

EP 1 310 571 B1

	acgacggccg gggctctggg cttcctgggt acaagtacct cggacccttc aacggactcg	1020
	acaaggggga gcccgtcaac gcggcggacg cagcggccct cgagcacgac aaagcctacg	1080
5	accagcagct caaagcgggt gacaatccgt acctgcggta taatcacgcc gacgccgagt	1140
	ttcaggagcg tctgcaagaa gatacgtcct ttgggggcaa cctcgggcga gcagtcttcc	1200
	aggccaagaa gcgggttctc gaacctctcg gtctgggtga ggaaggcgct aagacggctc	1260
10	ctggaaagaa gagaccggtg gagcagtcgc cacaagagcc agactcctcc tcgggcatcg	1320
	gcaagacagg ccagcagccc gctaaaaaga gactcaattt tggtcagact ggcgactcag	1380
	agtcagtccc cgaccacaaa cctctcggag aacctccagc agccccctca ggtctgggac	1440
15	ctaatacaat ggcttcaggc ggtggcgctc caatggcaga caataacgaa ggcgccgacg	1500
	gagtgggtaa ttcctcggga aattggcatt gcgattccac atggctgggg gacagagtca	1560
	tcaccaccag caccgaacc tgggccctgc ccacctacaa caaccacctc tacaagcaaa	1620
20	tctccaacgg cacctcggga ggaagcacca acgacaacac ctattttggc tacagcaccc	1680
	cctgggggta ttttgacttc aacagattcc actgtcactt ttcaccacgt gactggcaac	1740
	gactcatcaa caacaattgg ggattccggc caaaagact caacttcaag ctgttcaaca	1800
25	tccaggtcaa ggaagtcacg acgaacgaag gcaccaagac catcgccaat aatctacca	1860
	gcaccgtgca ggtctttacg gacttggagt accagttacc gtacgtgcta ggatccgctc	1920
	accagggatg tctgcctccg ttcccggcgg acgtcttcat ggttcctcag tacggctatt	1980
30	taactttaaa caatggaagc caagccctgg gacgttcctc cttctactgt ctggagtatt	2040
	tcccatcgca gatgccgaga accggcaaca actttcagtt cagctacacc ttcgaggacg	2100
	tgcctttcca cagcagctac gcgcacagcc agagcctgga caggctgatg aatcccctca	2160
35	tcgaccagta cctgtactac ctggtcagaa cgcaaagcag tggaactgga gggacgcaga	2220
	ctctggcatt cagccaagcg ggtcctagct caatggccaa ccaggctaga aattgggtgc	2280
	ccggaccttg ctaccggcag cagcgcgtct ccacgacaac caaccagaac aacaacagca	2340
40	actttgcctg gacgggagct gccaaagttta agctgaacgg ccgagactct ctaatgaatc	2400
	cgggcgtggc aatggcttcc cacaaggatg acgacgaccg cttcttccct tcgagcgggg	2460
	tcctgatttt tggcaagcaa ggagccggga acgatggagt ggattacagc caagtgctga	2520
45	ttacagatga ggaagaaatc aaggctacca accccgtggc cacagaagaa tatggagcag	2580
	tggccatcaa caaccaggcc gccaatacgc aggcgcagac cggactcgtg cacaaccagg	2640
	gggtgattcc cggcatgggt tggcagaata gagacgtgta cctgcagggt cccatctggg	2700
50	ccaaaattcc tcacacggac ggcaactttc acccgtctcc cctgatgggc ggctttggac	2760
	tgaagcaccg gcctcctcaa attctcatca agaacacacc ggttccagcg gaccgcgcg	2820
55	ttaccttcaa ccaggccaag ctgaactctt tcatcacgca gtacagcacc ggacagggtca	2880



# EP 1 310 571 B1

	gcgtggaaat cgagtgggag ctgcagaaag aaaacagcaa acgctggaat ccagagattc	2940
	aatacacttc caactactac aaatctacaa atgtggactt tgctgtcaac acggaaggag	3000
5	tttatagcga gcctcgcccc attggcacc cgttacctcac ccgcaacctg taattacatg	3060
	ttaatcaata aaccgggttaa ttcgtttcag ttgaactctg gtctctgcga agggcgaatt	3120
	c	3121
10	<210> 45 <211> 3122 <212> DNA <213> new AAV serotype, clone 43.25	
15	<400> 45	
	gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt	60
20	gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
	ccgccaaggc cattctcggc ggcagcaagg tgcgtgtgga ccaaaagtgc aagtcttccg	180
	cccagatcga tcccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg	240
25	acgggaacag caccaccttc gagcaccagc agcgtttgca ggaccggatg ttcaaatttg	300
	aactcaccgc ccgtctggag catgactttg gcaaggtgac gaagcaggaa gtcaaagggg	360
	tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagtccac gtgcgagccc	420
30	aagcgggctt gcccctcagt cgcggatcca tcgacgtcag accagaaagg gtggagccaa	480
	caagagaccc gccccgatg acgcggatat aagcggagg agctccgggt gactttgccg	540
	acaggtagca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
35	agacatgcga gagaatgaat cagaatttca acattttgctt cacgcacggg accagagact	660
	gttcagaatg tttccccggc gtgtcagaat ctcaaccggg cgtcagaaag aggacgtatc	720
	ggaaactctg tgcgattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct	780
40	gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca	840
	ggtatggctg ccgatgggta tcttccagat tggctcgagg acaacctctc tgagggcatt	900
	cgcgagtggg gggacttgaa acctggagcc ccgaaaccca aagccaacca gcaaaagcag	960
45	gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc	1020
	gacaaggggg agcccgtaa cgcggcggac gcagcggccc tcgagcacga caaagcctac	1080
	gaccagcagc tcaaagcggg tgacaatccg tacctgcggg ataatcacgc cgacgccgag	1140
50	tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcggggc agcagtcttc	1200
	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
	cctggaaaga agagaccggg agagcagtcg ccacaagagc cagactcctc ctcgggcac	1320
55	ggcaagacag gccagcagcc cgctaaaaag agactcaatt ttggtcagac tggcgactca	1380
	gagtcagtc ccgacccaca acctctcgga gaacctccag cagccccctc aggtctggga	1440

EP 1 310 571 B1

5 cctaatacaa tggcttcagg cgggtggcgct ccaatggcag acaataacga aggcgccgac 1500  
 ggagtgggta attcctcggg aaattggcat tgcgattcca catggctggg ggacagagtc 1560  
 10 atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa 1620  
 atctccaacg gcacctcggg aggaagcacc aacgacaaca cctatTTTTgG ctacagcacc 1680  
 ccctgggggt atTTtgactt caacagattc cactgtcact tttcaccacg tgactggcaa 1740  
 15 cgactcatca acaacaattg gggattccgg cccaaaagac tcaacttcaa gctgttcaac 1800  
 atccaggTca aggaagTcac gacgaacgaa ggaccaaga ccatcgccaa taatctcacc 1860  
 agcaccgtgc aggtctttac ggactcggag taccagttac cgtacgtgct aggatccgct 1920  
 20 caccagggat gtctgcctcc gttcccggcg gacgtcttca tggTtctctca gtacggctat 1980  
 ttaactttaa acaatggaag ccaagccctg ggacgttctt cctTctactg tctggagtat 2040  
 ttcccatcgc agatgctgag aaccggcaac aactttcagt tcagctacac cttcgaggac 2100  
 25 gtgcctttcc acagcagcta cgcgcacagc cagagcctgg acaggctgat gaatccccctc 2160  
 atcgaccagt acctgtacta cctggtcaga acgcaaacga ctggaactgg agggacgcag 2220  
 actctggcat tcagccaagc gggTcctagc tcaatggcca accaggctag aaattgggtg 2280  
 30 cccggacctt gctaccggca gcagcgcgtc tccacgacaa ccaaccagaa caacaacagc 2340  
 aactttgcct ggacgggagc tgccaagttt aagctgaacg gccgagactc tctaataaat 2400  
 ccgggcggtg caatggcttc ccacaaggat gacgacgacc gcttcttccc ttcgagcggg 2460  
 35 gtcttgattt ttggcaagca aggagccggg aacgatggag tggattacag ccaagtgtg 2520  
 attacagatg aggaagaaat caaggctacc aaccccgTgg ccacagaaga atatggagca 2580  
 gtggccatca acaaccaggc cgccaatacg caggcgcaga ccggactcgt gcacaaccag 2640  
 40 ggggtgattc ccggcatggt gtggcagaat agagacgtgt acctgcaggg tcccatctgg 2700  
 gccaaaattc ctacacgga cggcaacttt caccgctctc ccctgatggg cggctttgga 2760  
 ctgaagcacc cgcctcctca aattctcatc aagaacacac cggTtccagc ggacccgccg 2820  
 45 cttaccttca accaggccaa gctgaactct ttcattcagc agtacagcac cggacaggtc 2880  
 agcgtggaaa tcgagtggga gctgcagaaa gaaaacagca aacgctggaa tccagagatt 2940  
 caatacactt ccaactacta caaatctaca aatgtggact ttgctgtcaa cacggagggg 3000  
 50 gtttatagcg agcctcgccc cattggcacc cgttacctca cccgcaacct gtaattacat 3060  
 gttaatcaat aaaccggTta attcgTttca gttgaacttt ggtctctgcg aagggcgaat 3120  
 tc 3122

<210> 46

<211> 3128

<212> DNA

<213> new AAV serotype, clone 44.1

<400> 46

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
 gcgtcgacaa gatgttgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
 5 ccgccaaggc cattctcggc ggcagcaaag tgcgcgtgga ccaaaagtgc aagccgtccg 180  
 cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240  
 acgggaacag caccaccttc gagcaccagc agccgttgcg ggaccggatg ttcaagtttg 300  
 10 aactcaccgg ccgtctggag cacgactttg gcaagggtgac aaagcaggaa gtcagagagt 360  
 tcttcgcgtg ggcgagagat cacgtgaccg aggtggcgca cgagttctac gtcagaaagg 420  
 gtggagccaa caagagaccc gccccgatg acgcgataa aagcgagccc aagcgggcct 480  
 15 gccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540  
 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca 600  
 aaacatgcga gagaatgaat cagaatttca acatttgctt cagcacggg accagagact 660  
 20 gttcagaatg tttccccggc gtgtcagaat ctcaaccggg cgtcagaaaa aagacgtatc 720  
 ggaaactctg tgcgattcat catctgctgg ggcgggcacc cgagattgct tgctcggcct 780  
 gcgatctggt caacgtggac ctagatgact gtgtttctga gcaataaatg acttaaacca 840  
 25 ggtatggctg ccgatggta tcttcagat tggctcgagg acaacctctc tgagggcatt 900  
 cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag 960  
 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc 1020  
 30 gacaaggggg agcccgtaaa cgcggcggac gcagcggccc tcgagcacga caaggcctac 1080  
 gaccagcagc tcaaagcggg tgacaatccg tacctgcggg ataaccacgc cgacgccgag 1140  
 tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggag agcagtcttc 1200  
 35 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct 1260  
 cctggaaaga agagaccggg agagccatca cccagcgtt ctccagactc ctctacgggc 1320  
 atcggcaaga aaggccagca gcccgcgaaa aagagactca actttgggca gactggcgac 1380  
 40 tcagagttag tgcccgaccc tcaaccaatc ggagaacccc ccgcaggccc ctctgggtctg 1440  
 ggatctggta caatggctgc aggcgggtgg gctccaatgg cagacaataa cgaaggcgcc 1500  
 gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggct gggcgacaga 1560  
 45 gtcatcacca ccagcaccgg aacctgggac ctccccacct acaacaacca cctctacaag 1620  
 caaatctcca acgggacttc gggaggaagc accaacgaca acacctactt cggctacagc 1680  
 accccctggg ggtattttga ctttaacaga ttccactgcc acttctcacc acgtgactgg 1740  
 50 cagcgactca tcaacaacaa ctggggatc cggcccaaga gactcaactt caagctcttc 1800  
 aacatccagg tcaaggaggc cagcgagaat gaaggacca agaccatcgc caataacctt 1860  
 accagcacga ttcaggctct tacggactcg gaataccagc tcccgtagct cctcggctct 1920  
 55

EP 1 310 571 B1

5 ggcgaccagg gctgcctgcc tccgttcccc gcggacgtct tcatgattcc tcagtacggg 1980  
 tacctgactc tgaacaatgg cagtcaggcc gtggggccgtt cctccttcta ctgcctggag 2040  
 tactttcett ctcaaagtct gagaacgggc aacaactttg agttcagcta ccagtttgag 2100  
 gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggct gatgaacccc 2160  
 ctcacgcacc agtacctgta ctacctgtct cggactcagt ccacgggagg taccgcagga 2220  
 10 actcagcagt tgctattttc tcaggccggg cctaataaca tgtcggctca ggccaaaaac 2280  
 tggctacccg ggccctgcta ccggcagcaa cgcgtctcca cgacactgtc gcaaaataac 2340  
 aacagcaact gtaaateccg gtgtcgctat ggcaaccac aaggacgacg aagagcgatt 2400  
 15 ttgcctggac cgggtgccacc aagtatcatc tgaatggcag agactctctg ttttccgtcc 2460  
 agcggagtct taatgtttgg gaaacaggga gctggaaaag acaacgtgga ctatagcagc 2520  
 gttatgctaa ccagtgagga agaaattaaa accaccaacc cagtggccac ggaacagtac 2580  
 20 ggcgtggtgg ccgataacct gcaacagcaa aacgccgctc ctattgtagg ggccgtcaac 2640  
 agtcaaggag ccttacctgg catggtctgg cagaaccggg acgtgtacct gcagggtcct 2700  
 atctgggcca agattcctca cacggacgga aactttcatc cctcgccgct gatgggagggc 2760  
 25 tttggactga aacacccgcc tcctcagatc ctgattaaga atacacctgt tcccgcggat 2820  
 cctccaacta ccttcagtca agctaagctg gcgtcgttca tcacgcagta cagcaccgga 2880  
 caggtcagcg tggaaattga atgggagctg cagaaagaaa acagcaaacg ctggaaccca 2940  
 30 gagattcaat acacttccaa ctactacaaa tctacaaatg tggacttcgc tgtaaacaca 3000  
 gatggcactt attctgagcc tcgccccatt ggcaccggtt acctcaccgg taatctgtaa 3060  
 ttgctcgtta atcaataaac cggttgattc gtttcagttg aactttggtc tctgcgaagg 3120  
 35 gcgaattc 3128

<210> 47

<211> 3128

40 <212> DNA

<213> new AAV serotype, clone 44.5

<400> 47

45 gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
 gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
 ccgccaaggc cattctcggc ggcagcaaag tgcgcgtgga ccaaaagtgc aagtcgtccg 180  
 50 cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240  
 acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatg ttcaagtttg 300  
 aactcaccgg ccgtctggag cagactttg gcaagggtgac aaagcaggaa gtcagagagt 360  
 55 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca cgagttctac gtcagaaagg 420  
 gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggcct 480

EP 1 310 571 B1

	gccccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccgggtg gacttttgccg	540
5	acagggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
	aaacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact	660
	gttcagaatg tttccccggc gtgtcagaat ctcaaccggg tgtcagaaaa aagacgtatc	720
10	ggaaactctg tgcgattcat catctgctgg ggcgggcacc cgagattgct tgctcggcct	780
	gcgatctggt caacgtggac ctagatgact gtgtttctga gcaataaatg acttaaacca	840
	ggatatggctg ccgatgggta tcttccagat tggctcagagg acaacctctc tgagggcatt	900
15	cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag	960
	gacgacggcc ggggtctggt gcttctctggc tacaagtacc tcggaccctt caacggactc	1020
	gacaaggggg agcccgtaa cgcggcggac gcagcggccc tcgagcacga caaggcctac	1080
20	gaccagcagc tcaaagcggg tgacaatccg tacctgcggg ataaccacgc cgacgccgag	1140
	tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggag agcagtcttc	1200
	caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct	1260
25	cctggaaaga agagaccggt agagccatca cccagcggt ctccagactc ctctacgggc	1320
	atcggcaaga aaggccagca gcccgcgaaa aagagactca actttgggca gactggcgac	1380
	tcagagtcag tgcccgaccc tcaaccaatc ggagaacccc ccgcaggccc ctctggtctg	1440
30	ggatctggta caatggctgc aggcggtggc gctccaatgg cagacaataa cgaaggcgcc	1500
	gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggct gggcgacaga	1560
	gtcatcacca ccagcacccg aacctgggccc ctccccacct acaacaacca cctctacaag	1620
35	caaatctcca acgggacttc gggaggaagc accaacgaca acacctactt cggctacagc	1680
	accccctggg ggtattttga ctttaacaga ttccactgcc acttctcacc acgtgactgg	1740
	cagcgactca tcaacaacaa ctggggattc cggcccaaga gacccaactt caagctcttc	1800
40	aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgc caataacctt	1860
	accagcacga ttcagggtctt tacggactcg gaataccagc tcccgtacgt cctcggctct	1920
	gcgcaccagg gctgcctgcc tccgttcccg gcggacgtct tcatgattcc tcagtacggg	1980
45	tacctgactc tgaacaatgg cagtcaggcc gtggggcgtt cctccttcta ctgcctggag	2040
	tactttcctt ctcaaatgct gagaacgggc aacaactttg agttcagcta ccagtttgag	2100
	gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggct gatgaacccc	2160
50	ctcatcgacc agtacctgta ctacctgtct cggactcagt ccacgggagg taccgcagga	2220
	actcagcagt tgctattttc tcaggccggg cctaataaca tgcgggtca ggccaaaaac	2280
	tggtacccg ggccctgcta ccggcagcaa cgcgtctcca cgacactgtc gcaaaataac	2340
55	aacagcaact ttgcctggac cgggtgccacc aagtatcatc tgaatggcag agactctctg	2400

# EP 1 310 571 B1

```

gtaaatcccg gtgtcgctat ggcaaccac aaggacgacg aagagcgatt tttccgtcc 2460
agcggagtct taatgtttgg gaaacagggg gctggaaaag acaacgtgga ctatagcagc 2520
5 gttatgctaa ccagtgagga agaaattaaa accaccaacc cagtggccac agaacagtac 2580
ggcgtggtgg ccgataacct gcaacagcaa aacgccgctc ctattgtagg ggccgtcaac 2640
agtcaaggag ccttacctgg catggtctgg cagaaccggg acgtgtacct gcagggtcct 2700
10 atctgggcca agattcctca cacggacgga aactttcatc cctcgccgct gatgggaggc 2760
tttggactga aacacccgcc tcctcagatc ctgattaaga atacacctgt tcccgcggat 2820
cctccaacta ccttcagtca agctaagctg gcgtcgttca tcacgcagta cagcaccgga 2880
15 caggtcagcg tggaaattga atgggagctg cagaaagaaa acagcaaacg ctggaaccca 2940
gagattcaat acacttccaa ctactacaaa tctacaaatg tggactttgc tgtaacaca 3000
gatggcactt attctgagcc tcgccccatt ggcacccggt acctcacccg taatctgtaa 3060
20 ttgcttgtaa atcaataaac cggttgattc gtttcagttg aactttggtc tctgcgaagg 3120
gcgaattc 3128

```

```

<210> 48
<211> 1933
<212> DNA
<213> new AAV serotype, clone 223.10

```

```

<220>
<221> misc_feature
<222> (1302)..(1302)
<223> can be a, c, g or t

```

```

<400> 48

```

# EP 1 310 571 B1

	caaggcctac gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc	60
	cgacgccgag tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg	120
5	agcagtcttc caggccaaaa agcgggttct cgaacctctt ggtctggttg agacgccagc	180
	taagacggca cctggaaaga agcgaccggt agactcgcca gactccacct cgggcatcgg	240
	caagaaaggc cagcagcccg cgaaaaagag actcaacttt gggcagactg gcgactcaga	300
10	gtcagtcccc gaccctcaac caatcggaga accaccagca ggcccctctg gtctgggac	360
	tggtacaatg gctgcaggcg gtggcgacc aatggctgac aataacgagg gcgccgacgg	420
	agtgggtaat gcctcaggaa attggcattg cgattccaca tggctgggcg acagagtc	480
15	caccaccagc acccgaacct gggccctgcc cacctacaac aaccacctct acaagcaa	540
	ctccagtcag tcagcaggga gcaccaacga taactctat ttcggctaca gcaccccc	600
	ggggtat ttt gacttcaaca gattccattg ccacttctca ccacgtgact ggcagcg	660
20	tatcaacaac aactggggat tccggcccaa gaagctcaac ttcaagctct tcaacatcca	720
	ggtcaaggag gtcacgacga atgacggtgt cacaaccatc gctaataacc ttaccagcac	780
25		
30		
35		
40		
45		
50		
55		

# EP 1 310 571 B1

5  
 10  
 15  
 20  
 25  
 30  
 35

ggttcagggtc	ttttcggact	cggaatatca	actgccgtac	gtcctcggct	ccgcgcacca	840
gggctgcctg	cctccgttcc	cggcagacgt	gttcatgatt	ccgcagtagc	gatacctgac	900
tctgaacaat	ggcagccaat	cggtaggccg	ttcctccttc	tactgcctgg	agtactttcc	960
ttctcagatg	ctgagaacgg	gcaacaactt	caccttttagc	tacaccttcg	aggacgtgcc	1020
tttccacagc	agctacgcgc	acagccagag	tctggaccgg	ctgatgaatc	ccctcatcga	1080
ccagtacctg	tactacttgg	ccagaacaca	gagcaacgca	ggaggtagct	ctggcaatcg	1140
ggaactgcag	ttttatcagg	gcggacctac	caccatggcc	gaacaagcaa	agaactggct	1200
gcccggacct	tgcttccggc	aacagagagt	atccaagacg	ctggatcaaa	ataacaacag	1260
caactttgcc	tggactggtg	ccacaaaata	ccattttaat	gnaagaaatt	cattgggttaa	1320
tcccgggtgc	gccatggcaa	cccacaagga	cgacgaggaa	cgcttcttcc	cttcgagcgg	1380
agttctaatt	tttgcaaaa	ctggagcagc	taataaaact	acattagaaa	acgtgctcat	1440
gacaaatgaa	gaagaaattc	gtcctacca	cccggtagct	accgaggaat	acgggattgt	1500
aagcagcaac	ttgcaggcgg	ctagcaccgc	agcccagaca	caagttgtta	acaaccaggg	1560
agccttacct	ggcatggtct	ggcagaaccg	ggacgtgtac	ctgcaaggtc	ccatttgggc	1620
caagattcct	cacacggacg	gcaactttca	cccgtctcct	ctaattgggtg	gctttggact	1680
gaaacacccg	cctccccaga	tcctgatcaa	aaacacaccg	gtacctgcta	atcctccaga	1740
agtgtttact	cctgccaaagt	ttgcttcctt	catcacgcag	tacagcaccg	ggcaagtcag	1800
cgttgagatc	gagtgggagc	tgcaaaaaga	gaacagcaag	cgctggaacc	cagagattca	1860
gtacacctcc	aactttgaca	aacagactgg	agtggacttt	gctgttgaca	gccagggtgt	1920
ttactctgag	cct					1933

<210> 49

<211> 1933

<212> DNA

<213> new AAV serotype, clone 223.2

<400> 49



# EP 1 310 571 B1

	caaggcctac gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc	60
	cgacgccgag ttccaggagt gtcttcaaga agatacgtct ttggggggca acctcgggcg	120
5	agcagtcttc caggccaaaa agcgggttct cgaacctctt ggtctggttg agacgccagc	180
	taagacggca cctggaaaga agcgaccggt agactcgcca gactccacct cgggcatcgg	240
	caagaaaggc cagcagcccg cgaaaaagag actcaacttt gggcagactg gcgactcaga	300
10	gtcagteccc gacctcaac caatcgga accaccagca ggccccctctg gtctgggatc	360
	tgggtacaatg gttgcaggcg gtggcgacc aatggctgac aataacgagg gcgccgacgg	420
	agtgggtaat gcctcaggaa attggcattg cgattccaca tggctgggcg acagagtcac	480
15	caccaccagc acccgaacct gggccctgcc cacctacaac aaccacctct acaagcaa	540
20		
25		
30		
35		
40		
45		
50		
55		

# EP 1 310 571 B1

ctccagtcag tcagcagggg gcaccaacga taacgtctat ttcgggtaca gcacccctg 600  
 5 ggggtatatt gacttcaaca gattccattg ccacttctca ccacgtgact ggcagcgact 660  
 tatcaacaac aactggggat tccggcccaa gaagctcaac ttcaagctct tcaacatcca 720  
 ggtcaaggag gtcacgacga atgacggtgt cacaaccatc gctaataacc ttaccagcac 780  
 10 ggttcaggtc ttttcggact cggaatatca actgccgtac gtcctcggct ccgcgcacca 840  
 gggctgcctg cctcgttcc cggcagacgt gttcatgatt ccgcagtacg gatacctgac 900  
 tctgaacaat ggcagccaat cggtaggccg ttcctccttc tactgcctgg agtactttcc 960  
 15 ttctcagatg ctgagaacgg gcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020  
 tttccacagc agctacgcg acagccagag tctggaccgg ctgatgaatc ccctcatcga 1080  
 ccagtacctg tactacttgg ccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140  
 20 ggaactgcag ttttatcagg gcgacacctac caccatggcc gaacaagcaa agaactggct 1200  
 gcccggacct tgcttcggc aacagagagt atccaagacg ctggatcaaa ataacaacag 1260  
 caactttgcc tggactggtg ccacaaaata ccatttaaatt ggaagaaatt cattgggttaa 1320  
 25 tcccgggtgc gccatggcaa ccacaaagga cgacgaggaa cgcttctccc cttcgagcgg 1380  
 agttctaatt tttggcaaaa ctggagcagc taataaaact acattagaaa acgtgctcat 1440  
 gacaaatgaa gaagaaattc gtcctaccaa cccggtagct accgaggaat acgggattgt 1500  
 30 aagcagcaac ttgcaggcgg ctagcaccgc agcccagaca caagttgtta acaaccaggg 1560  
 agccttacct ggcattggtc ggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620  
 caagattcct cacacggacg gcaactttca cccgtctcct ctaatgggtg gctttggact 1680  
 35 gaaacacccg cctccccaga tcctgatcaa aaacacgccg gtacctgcta atcctccaga 1740  
 agtgtttact cctgccaagt ttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800  
 cgttgagatc gagtgggagc tgcagaaaga gaacagcaag cgctggaacc cagagattca 1860  
 40 gtacacctcc aactttgaca aacagactgg agtggacttt gctgttgaca gccagggtgt 1920  
 ttactctgag cct 1933

45 <210> 50  
 <211> 1933  
 <212> DNA  
 <213> new AAV serotype, clone 223.4

50 <400> 50

55

EP 1 310 571 B1

	caaggcctac gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc	60
	cgacgccgag tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg	120
5	agcagtcttc caggccaaaa agcgggttct cgaacctctt ggtctggttg agacgccagc	180
	taagacggca cctggaaaga agcgaccggt agactcgcca gactccacct cgggcatcgg	240
	caagaaaggc cagcagcccg cgaaaaagag actcaacttt gggcagactg gcgactcaga	300
10		
	gccagtcccc gaccctcaac caatcggaga accaccagca ggccccctctg gtctggggtc	360
	tggtacaatg gctgcaggcg gtggcgcacc aatggctgac aataacgagg gcgccgacgg	420
15	agtgggtaat gcctcaggaa attggcattg cgattccaca cggctgggcg acagagtcac	480
	caccaccagc acccgaacct gggccctgcc cacctacaac aaccacctct acaagcaaat	540
	ctccagtcag tcagcaggga gcaccaacga taacgtctat ttcggctaca gaacccccctg	600
20	gggggtathtt gacttcaaca gattccattg ccacttctca ccacgtgact ggcagcgact	660
	tatcaacaac aactggggat tccggcccaa gaagctcaac ttcaagctct tcaacatcca	720
	ggtcaaggag gtcacgacga atgacggcgt cacaaccatc gctaataacc ttaccagcac	780
25	ggttcaggtc ttttcggact cggaatatca actgccgtac gtcctcggct ccgcgcacca	840
	gggctgcctg cctccgttcc cggcagacgt gttcatgatt ccgcagtagc gatacctgac	900
	tctgaacaat ggcagccaat cggtaggccg ttcctccttc tactgcctgg agtactttcc	960
30	ttctcagatg ctgagaacgg gcaacaactt caccttttagc tacaccttcg aggacgtgcc	1020
	tttccacagc agctacgcgc acagccagag tctgggccgg ctgatgaatc ccctcatcga	1080
	ccagtacctg tactacttgg ccagaacaca gagcaacgca ggaggtactg ctggcaatcg	1140
35	ggaactgcag ttttatcagg gcggacctac caccatggcc gaacaagcaa agaactggct	1200
	gcccggacct tgcttccggc aacagagagt atccaagacg ctggatcaaa ataacaacag	1260
	caactttgcc tggactggtg ccacaaaata ccatttaaat ggaagaaatt cattgggtta	1320
40	tcccgggtgc gccatggcaa ccacaaagga cgacgaggaa cgcttcttcc cttcgagcgg	1380
	agttctaatt tttggcaaaa ctggagcagc taataaaact acattagaaa acgtgctcat	1440
	gacaaatgaa gaagaaattc gtcctaccaa cccggtagct accgaggaat acgggattgt	1500
45	aagcagcaac ttgcaggcgg ctagcaccgc agcccagaca caagttgtta acaaccaggg	1560
	agccttacct ggcatggtct ggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc	1620
	caagattcct cacacggacg gcaactttca cccgtctcct ctaatgggtg gctttggact	1680
50	gaaacacccg cctccccaga tcctgatcaa aaacacaccg gtacctgcta atcctccaga	1740
	agtgtttact cctgccaaagt ttgcttcctt catcacgcag tacagcaccg ggcaagtcag	1800
	cgttgagatc gaatgggagc tgcagaaaaga gaacagcaag cgctggaacc cagagattca	1860
55	gtacacctcc aactttgaca aacagactgg agtggacttt gctgttgaca gccagggtgt	1920
	ttactctgag cct	1933

EP 1 310 571 B1

<210> 51  
<211> 1933  
<212> DNA  
<213> new AAV serotype, clone 223.5

5

<400> 51

caaggcctac gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60

10

15

20

25

30

35

40

45

50

55

	cgacgccgag tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg	120
	agcagtcttc caggccaaaa agcgggttct cgaacctctt ggtctggttg agacgccagc	180
5	taagacggca cctggaaaga agcgaccggt agactcgcca gactccacct cgggcatcgg	240
	caagaaaggc cagcagcccg cgaaaaagag actcaacttt gggcagactg gcgactcaga	300
	gccagtcccc gacctcaac caatcgga accaccagca ggccccctctg gtctgggac	360
10	tggtacaatg gctgcaggcg gtggcgacc aatggctgac aataacgagg gcgccgacgg	420
	agtgggtaat gcctcaggaa attggcattg cgattccaca cggctgggcg acagagtc	480
	caccaccagc acccgaacct gggccccctg cacctacaac aaccacctct acaagcaaat	540
15	ctccagtcag tcagcagggg gcaccaacga taacgtctat ttcggctaca gacccccctg	600
	ggggatatttt gacttcaaca gattccattg ccacttctca ccacgtgact ggcagcgact	660
	tatcaacaac aactggggat tccggcccaa gaagctcaac ttcaagctct tcaacatcca	720
20	ggtcaaggag gtcacgacga atgacggcgt cacaaccatc gctaataacc ttaccagcac	780
	ggttcaggtc ttttcggact cggaatatca actgccgtac gtccctcggct ccgcgcacca	840
	gggctgcctg cctccgttcc cggcagacgt gttcatgatt ccgcagtagc gatacctgac	900
25	tctgaacaat ggcagccaat cggtaggcg ttcctccttc tactgcctgg agtactttcc	960
	ttctcagatg ctgagaacgg gcaacaactt cacccttagc tacaccttcg aggacgtgcc	1020
	tttccacagc agctacgcgc acagccagag tctgggccgg ctgatgaatc ccctcatcga	1080
30	ccagtacctg tactacttgg ccagaacaca gagcaacgca ggaggtagct ctggcaatcg	1140
	ggaactgcag ttttatcagg gcggacctac caccatggcc gaacaagcaa agaactggct	1200
	gcccggacct tgcttccggc aacagagagt atccaagacg ctggatcaaa ataacaacag	1260
35	caactttgdc tggactggtg ccacaaaata ccatttaaat ggaagaaatt cattgggtta	1320
	tcccggtgtc gccatggcaa ccacaaagga cgacgaggaa cgcttcttcc cttcagagcg	1380
	agttctaatt tttggcaaaa ctggagcagc taataaaact acattagaaa acgtgctcat	1440
40	gacaaatgaa gaagaaattc gtcctaccaa cccggtagct accgaggaat acgggattgt	1500
	aagcagcaac ttgcaggcgg ctagcaccgc agcccagaca caagttgta acaaccaggg	1560
	agccttacct ggcattggtc ggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc	1620
45	caagattcct cacacggacg gcaacttca cccgtctcct ctaatgggtg gctttggact	1680
	gaaacacccg cctcccaga tcctgatcaa aaacacaccg gtacctgcta atcctccaga	1740
	agtgtttact cctgccaaagt ttgcttctt catcacgcag tacagcaccg ggcaagtcag	1800
50	cgttgagatc gaatgggagc tgcagaaaga gaacagcaag cgctggaacc cagagattca	1860
	gtacacctcc aactttgaca aacagactgg agtggacttt gctgttgaca gccaggggtg	1920
55	ttactctgag cct	1933

# EP 1 310 571 B1

<211> 1933

<212> DNA

<213> new AAV serotype, clone 223.6

5 <400> 52

	caaggcctac gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc	60
10	cgacgccgag tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcg	120
	agcagtcttc caggccaaaa agcgggttct cgaacctctt ggtctggttg agacgccagc	180
	taagacggca cctggaaaga agcgaccggt agactcgcca gactccacct cgggcatcgg	240
15	caagaaaggc cagcagcccg cgaaaaagag actcaacttt gggcagactg gcgactcaga	300
	gtcagtcccc gacctcaac caatcggaga accaccagca ggccccctctg gtctgggatac	360
	tggtacaatg gctgcaggcg gtggcgcacc aatggctgac aatagcgagg gcgccgacgg	420
20	agtgggtaat gcctcaggaa attggcattg cgattccaca tggctgggcg acagagtcac	480
	caccaccagc acccgaacct gggccctgcc cacctacaac aaccacctct acaagcaa	540
	ctccagtcag tcagcaggga gcaccaacga taacgtctat ttcggctaca gcacccccctg	600
25	ggggatatttt gacttcaaca gattccattg ccacttctca ccacgtgact ggcagcgact	660
	tatcaacaac aactggggat tccggcccaa gaagctcaac ttcaagctct tcaacatcca	720
	ggtcaaggag gtcacgacga atgacggtgt cacaaccatc gctaataacc ttaccagcac	780
30	ggttcagggtc ttttcggact cggaatatca actgccgtac gtctcgggt ccgcgcacca	840
	ggggtgcctg cctccgttcc cggcagacgt gttcatgatt ccgcagtacg gatacctgac	900
	tctgaacaat ggcagccaat cggtagggcg ttctctcttc tactgcctgg agtactttcc	960
35	ttctcagatg ctgagaacgg gcaacaactt cacctttagc tacaccttcg aggacgtgcc	1020
	tttccacagc agctacgcgc acagccagag tctggaccgg ctgatgaatc ccctcatcga	1080
	ccagtacctg tactacttgg ccagaacaca gagcaacgca ggaggtactg ctggcaatcg	1140
40	ggaactgcag ttttatcagg gcggacctac caccatggcc gaacaagcaa agaactggct	1200
	gcccggacct tgcttccggc aacagagagt atccaagacg ctggatcaaa ataacaacag	1260
	caactttgcc tggactggtg ccacaaaata ccatttaa	1320
45	ttccgggtgtc gccatggcaa cccacaagga cgacgaggaa cgcttcttcc cttcgagcgg	1380
	agttctaatt tttggcaaaa ctggagcagc taataaaact acattagaaa acgtgctcat	1440
	gacaaatgaa gaagaaattc gtcctaccaa cccggtagct accgaggaat acgggattgt	1500
50	aagcagcaac ttgcaggcgg ctagcaccgc agcccagaca caagttgtta acaaccaggg	1560
	agccttacct ggcattggtc ggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc	1620
	caagattcct cacacggacg gcaactttca cccgtctcct ctaatgggtg gctttggact	1680
55	gaaacacccg cctccccaga tctgatcaa aaacacaccg gtacctgcta atcctccaga	1740

EP 1 310 571 B1

agtgtttact cctgccaaagc ttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800  
 cgttgagatc gagtgggagc tgcagaaaga gaacagcaag cgctggaacc cagagattca 1860  
 5 gtaacacctcc aactttgaca aacagactgg agtggacttt gctgttgaca gccaggggtgt 1920  
 ttactctgag cct 1933

10 <210> 53  
 <211> 1933  
 <212> DNA  
 <213> new AAV serotype, clone 223.7

15 <400> 53

caaggcctac gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60  
 cgacgccgag ttccaggagc gtcttcaaga agatacgtct tttgggggca acctcggggc 120  
 20 agcagtcttc caggccaaaa agcgggttct cgaacctctt ggtctggttg agacgccagc 180  
 taagacggca cctggaaaga agcgaccggt agactcgcca gactccacct cgggcacatcg 240  
 caagaaaggc cagcagcccg cgaaaaagag actcaacttt gggcagactg gcgactcaga 300  
 25 gtcagtcccc gacctcaac caatcggaga accaccagca ggcccctctg gtctgggatac 360  
 tgggtacaatg gctgcaggcg gtggcgccacc aatggctgac aataacgagg gcgccgacgg 420  
 agtgggtaat gcctcaggaa attggcattg cgattccaca tggctgggag acagagtcac 480  
 30 caccaccagc acccgaacct gggccctgcc cacctacaac aaccacctct acaagcaaat 540  
 ctccagtcag tcagcagggg gcaccaacga taacgtctat ttcggctaca gacccccctg 600  
 ggggtatttt gacttcaaca gattccattg ccacttctca ccacgtgact ggcagcgact 660  
 35 tatcaacaac aactggggat tccggcccaa gaagctcaac ttcaagctct tcaacatcca 720  
 ggtcaaggag gtcacgacga atgacggcgt cacaaccatc gctaataacc ttaccagcac 780  
 ggttcaggtc ttttcggacc cggaatatca actgccgtac gtctcgggt ccgcgcacca 840  
 40 gggctgcctg cctccgttcc cggcagacgt gttcatgatt ccgcagtagc gatacctgac 900  
 tctgaacaat ggcagccaat cggtaggccg ttctctcttc tactgcctgg agtactttcc 960  
 ttctcagatg ctgagaacgg gcaacaactt caccttttagc tacaccttcg aggacgtgcc 1020  
 45 tttccacagc agctacgcgc acagccagag tctggaccgg ctgatgaatc ccctcatcga 1080  
 ccagtacctg tactacttgg ccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140  
 ggaactgcag ttttatcagg gcggacctac caccatggcc gaacaagcaa agaactgggt 1200  
 50 gcccggacct tgcttccggc aacagagagt atccaagacg ctggatcaaa ataacaacag 1260  
 caactttgcc tggactgggt ccacaaaata ccatttaaatt ggaagaaatt cattgggttaa 1320  
 tcccgggtgc gccatggcaa ccacaaagga cgacgaggaa cgcttcttcc ctccgagcgg 1380  
 55 agttctaatt tttggcaaaa ctggagcagc taataaaact acattagaaa acgtgctcat 1440  
 gacaaatgaa gaagaaattc gtcctaccaa cccggtagct accgaggaat acgggattgt 1500

# EP 1 310 571 B1

aagcagcaac ttgcaggcgg ctagcaccgc agcccagaca caagttgtta acaaccaggg 1560  
 agcettacct ggcatggtct ggcagaaccg ggacgtgtac ctgcaaggte ccatttgggc 1620  
 5 caagattcct cacacggacg gcaactttca cccgtctcct ctaatgggtg gctttggact 1680  
 gaaacacccg cctccccaga tcctgatcaa aaacacaccg gtacctgcta atcctccaga 1740  
 agtggtttact cctgccaaaga ttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800  
 10 cgttgagatc gagtgggagc tgcagaaaga gaacagcaag cgctggaacc cagagattca 1860  
 gtacacctcc aactttgaca aacagactgg agtggacttt gctgttgaca gccagggtgt 1920  
 ttactctgag cct 1933

<210> 54

<211> 3123

<212> DNA

<213> new AAV serotype, clone A3.4

<400> 54

gaattcgccc tttctacggc tgcgtcaact ggaccaatga aaactttccc ttcaacgatt 60  
 25 gcgtcgacaa gatggtgatc tgggtgggagg agggaaagat gaccgccaag gtcgtggaat 120  
 ctgccaaagc cattctgggt ggaagcaagg ttcgtgtgga ccagaaatgc aagtcttcgg 180  
 cccagatcga cccgactccg gtgattgtca cctctaacac caacatgtgc gccgtgattg 240  
 30 acggaaactc gaccaccttc gagcaccagc agccgttgca agaccggatg ttcaaatttg 300  
 aacttacccg ccgtttggat catgactttg ggaaggtcac caagcaggaa gtcaaagact 360  
 ttttccggtg ggctcaagat cacgtgactg aggtggagca tgagttctac gtcaaaaagg 420  
 35 gtggagccaa gaaaaggccc gccccgatg atgtatatat aaatgagccc aagcgggagc 480  
 gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgataaac tacgcgggca 540  
 ggtacaaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgtcgac 600  
 40 aatgcgaaag aatgaatcag aattcaaata tctgcttcac acacgggcaa aaagactgtt 660  
 tggaatgctt tcccgtgtca gaatctcaac ccgtttctgt cgtcagaaaa acgtatcaga 720  
 aactttgtta cattcatcat atcatgggaa aagaaccaga cgctgcact gcctgcgacc 780  
 45 tggtaaagtgt ggacttggat gactgtattt ctgagcaata aatgacttaa atcaggtatg 840  
 gctgctgacg gttatcttcc agattggctc gaggacactc tctctgaagg aatcagacag 900  
 tgggtggaagc tcaaacctgg cccaccaccg ccgaaacctt accaacaaca ccggggacgac 960  
 50 agtaggggtc ttgtgcttcc tgggtacaag tacctcggac ctttcaacgg actcgacaaa 1020  
 ggagagccgg tcaacgaggc agacgccgcg gccctcgagc acgacaaagc ctacgaccac 1080  
 cagctcaagc aagggggacaa cccgtacctc aaatacaacc acgcgggacg tgaatttcag 1140  
 55 gagcgtcttc aagaagatac gtctttcggg ggcaacctcg ggcgagcagt cttccaggcc 1200  
 aaaaagaggg tactcgagcc tcttggctct gttgaggaag ctgttaagac ggctcctgga 1260



## EP 1 310 571 B1

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

aaaaagagac ctatagagca gtctcctgca gaaccggact cttcctcggg catcggcgaa 1320  
 tcaggccagc agcccgctaa gaaaagactc aattttgggc agactggcga cacagagtca 1380  
 gtcccagacc ctcaaccaat cggagaaccc cccgcagccc cctctgggtg gggatctaata 1440  
 acaatggctt caggcgggtg ggcaccaatg gcagacgata acgaaggcgc cgacgggagt 1500  
 ggtaattcct cgggaaattg gcattgcgat tccacatgga tgggcgacag agttatcacc 1560  
 accagcacia gaacctgggc cctccccacc tacaataatc acctctacia gcaaatctec 1620  
 agcgaatcgg gagccaccaa cgacaaccac tacttcgggt acagcacccc ctgggggtat 1680  
 tttgacttta acagattcca ctgtcacttc tcaccacgtg actggcagcg actcatcaac 1740  
 aacaactggg gatttagacc caagaaactc aatttcaagc tcttcaacat ccaagtcaag 1800  
 gaggtcacgc agaattgatg aaccacgacc atcgccaata accttaccag cacgggtgcag 1860  
 gtcttcacag actctgagta ccagctgccc tacgtcctcg gttcgggtca ccagggtgc 1920  
 cttccgccgt tcccagcaga cgtcttcatg attcctcagt acggctactt gactctgaac 1980  
 aatggcagcc aagcggtagg acgttcttca ttctactgtc tagagtattt tccctctcag 2040  
 atgctgagga cgggaaacaa cttcaccttc agctacactt ttgaagacgt gcctttccac 2100  
 agcagctacg cgcacagcca gagtctggat cggctgatga atcctctcat tgaccagtac 2160  
 ctgtattacc tgagcaaaac tcagggtaca agtggaaaca cgcagcaatc gagactgcag 2220  
 ttcagccaag ctgggcctag ctccatgggt cagcaggcca aaaactgggt accgggaccc 2280  
 agctaccgac agcagcgaat gtctaagacg gctaataaca acaacaacag tgaatttgct 2340  
 tggactgcag ccaccaaata ttacctgaat ggaagaaatt ctctgggtcaa tcccgggccc 2400  
 ccaatggcca gtcacaagga cgatgaggaa aagtatttcc ccatgcacgg aaatctcatc 2460  
 tttggaaaac aaggcacagg aactaccaat gtggacattg aatcagtgct tattacagac 2520  
 gaagaagaaa tcagaacaac taatcctgtg gctacagaac aatacggaca ggttgccacc 2580  
 aaccatcaga gtcaggacac cacagcttcc tatggaagtg tggacagcca gggaatctta 2640  
 cctggaatgg tgtggcagga ccgcgatgtc tatcttcaag gtcccatttg ggccaaaact 2700  
 cctcacacgg acggacactt tcaccttctt ccgctcatgg gaggttttg actgaaacac 2760  
 cctcctcccc agatcctgat caaaaacaca cctgtgccag cgaatccgc gaccactttc 2820  
 actcctggaa agtttgcttc gttcattacc cagtattcca ccggacaggt cagcgtggaa 2880  
 atagagtggg agctgcagaa agaaaacagc aaacgctgga acccagaaat tcagtacacc 2940  
 tccaactaca acaagtccgt gaatgtggag tttaccgtgg acgcaaacgg tgtttattct 3000  
 gaaccccgcc ctattggcac tcgttacctt acccggaact tgtaatttcc tgtaaatgaa 3060  
 taaaccgatt tatgcgttcc agttgaactt tggctctctgc gaaggcgaa ttcgcggccg 3120  
 cta 3123

&lt;210&gt; 55

&lt;211&gt; 3113

# EP 1 310 571 B1

<212> DNA

<213> new AAV serotype, clone A3.5

<400> 55

5

```

gaattcgccc tttctacggc tgcgtcaact ggaccaatga aaactttccc ttcaacgatt      60
gcgtcgacaa gatggtgata tgggtgggagg agggaaagat gaccgccaag gtcgtggaat      120
ctgccaaagc cattctgggt ggaagcaagg ttcgtgtgga ccagaaatgc aagtcttcgg      180
cccagatcga cccgactccg gtgattgtca cctctaacac caacatgtgc gccgtgattg      240
acggaaactc gaccaccttc gagcaccagc agccgttgca agaccggatg ttcaaatttg      300
aacttacccg ccgtttggat catgactttg ggaagggtcac caagcaggaa gtcaaagact      360
ttttccggtg ggctcaagat cacgtgactg aggtggagca tgagttctac gtcaaaaagg      420
gtggagccaa gaaaaggccc gccccgatg atgtatatat aaatgagccc aagcgggagc      480
gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgataaac tacgaggaca      540
ggtacaaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgtcgac      600
aatgcgaaag aatgaatcag aattcaaata tctgcttcac acacgggcaa aaagactgtt      660
tggaatgctt tcccggtgca gaatctcaac ccgttcctgt cgtcagaaaa acgtatcaga      720
aactttgtta cattcatcat atcatgggaa aagtaccaga cgctgcact gcctgcgacc      780
tggtaaatgt ggacttggat gactgtatct ctgagcaata aatgacttaa atcaggtatg      840
gctgctgacg gttatcttcc agattggctc gaggacactc tctctgaagg aatcagacag      900
tgggtggaagc tcaaacctgg cccaccaccg ccgaaacctt accaacaaca ccgggacgac      960
agtaggggtc ttgtgcttcc tgggtacaag tacctcggac ccttcaacgg actcgacaam     1020
ggagagccgg tcaacgaggc agacgccgag gccctcgagc acgacaaagc ctacgaccac     1080
cagctcaagc aaggggacaa cccgtacctc aaatacaacc acgaggacgc tgaatttcag     1140
gagcgtcttc aagaagatac gtctttcggg ggcaacctcg ggcgagcagt cttccaggcc     1200
aaaaagaggg tactcgagcc tcttggtctg gttgaggaag ctgttaagac ggctcctgga     1260
aaaaagagac ctatagagca gtctcctgca gaaccggact cttcctcggg catcggcaaa     1320
tcaggccagc agcccgttaa gaaaagactc aattttggtc agactggcga cacagagtca     1380
gtcccagacc ctcaaccaat cggagaacct cccgcagccc cctctggtgt gggatctaata     1440
acaatggctt caggcgggtg ggcaccaatg gcagacaata acgaaggcgc cgacggagtg     1500
ggtaattcct cgggaaattg gcattgcgat tccacatgga tgggagacag agttatcacc     1560
accagcacia gaacctgggc cctccccacc tacaataatc acctctacia gaaaatctcc     1620
agcgaatcgg gagccaccaa cgacaaccac tacttcggct acagcacccc ctgggggtat     1680
tttgacttta acagattcca ctgtcacttc tcaccacgtg actggcagcg actcatcaat     1740

```

55

5 aacaactggg gatttagacc caagaaactc aatttcaagc tcttcaacat ccaagtcaag 1800  
 gaggtcacgc agaattgatgg aaccacgacc atcgccaata accttaccag cacgggtgcag 1860  
 gtcttcacag actctgagta ccagctgccc tacgtcctcg gttcggtca ccagggtgc 1920  
 ctcccgccgt tcccagcaga cgtcttcatg attcctcagt acggctactt gactctgaac 1980  
 aatggcagcc aagcggtagg acgttcttca ttctactgtc tagagtattt tccctctcag 2040  
 10 atgctgagga cgggaaacaa cttcaccttc agctacactt ttgaagacgt gcctttccac 2100  
 agcagctacg cgcacagcca gagtctggat cggctgatga atcctctcat tgaccagtac 2160  
 ctgtattacc tgagcaaaac tcagggtaca agtgaacaa cgcagcaatc gagactgcag 2220  
 15 ttcaaccaag ctgggcctag ctccatggct cagcaggcca aaaactggct accgggaccc 2280  
 agctaccgac agcagcgaat gtctaagacg gctaatacaca acaacaacag tgaatttgct 2340  
 tggactgcag ccaccaaata ttacccgaat ggaagaaatt ctctgggtcaa tcccgggccc 2400  
 20 ccaatggcca gtcacaagga cgatgaggaa aagtatttcc ccatgcacgg aaatctcatc 2460  
 tttggaanaa aaggcacagg aactaccaat gtggacattg aatcagtgct tattacagac 2520  
 gaagaagaaa tcagaacgac taatcctgtg gctacagaac aatacggaca ggttgccacc 2580  
 25 aaccgtcaga gtcagaacac cacagcttcc tatggaagtg tggacagcca gggaatctta 2640  
 cctggaatgg tgtggcagga ccgcgatgtc tatcttcaag gtcccatttg ggccaaaact 2700  
 cctcacacgg acggacactt tcatccttct ccgctcatgg gaggttttg actgaaacac 2760  
 30 cctcctcccc agatcctgat caaaaacaca cctgtgccag cgaatccgc gaccacttcc 2820  
 actcctggaa agtttgcttc gttcattacc cagtattcca ccggacaggt cagcgtggaa 2880  
 atagagtggg agctgcagaa agaaaacagc aaacgctgga acccggaat tcagtacacc 2940  
 35 tccaactaca acaagtcggg gaatgtggag ttaccgtgg acgcaaacgg tgtttattct 3000  
 gaaccccgcc ctattggcac tcgttacctt acccggaact tgtaatttcc tgttaatgaa 3060  
 40 taaaccgatt tatgcgtttc agttgaactt tggctctctgc gaaggcgaa ttc 3113

&lt;210&gt; 56

&lt;211&gt; 3122

&lt;212&gt; DNA

45 <213> new AAV serotype, clone A3.7

&lt;400&gt; 56

50

55

# EP 1 310 571 B1

	agcggccgcg aattcgccct ttctacggct gcgtcaactg gaccaatgaa aactttccct	60
	tcaacgattg cgtcgacaag atggtgatct ggtgggagga gggaaagatg accgccaagg	120
5	tcgtggaatc tgccaaagcc attctgggtg gaagcaaggc tcgtgtggac cagaaatgca	180
	ggtcttcggc ccagatcgac ccgactccgg tgattgtcac ctctaacacc aacatgtgcg	240
	ccgtgattga cggaaactcg accaccttcg agcaccagca gccgttgcaa gaccggatgt	300
10	tcaaatttga acttaccgcg cgtttggatc atgactttgg gaaggtcacc aagcaggaag	360

15

20

25

30

35

40

45

50

55

## EP 1 310 571 B1

	tcaaagactt tttccggtgg gctcaagatc acgtgactga ggtggagcat gagttctacg	420
	tcaaaaaggg tggagccaag aaaaggcccg ccccgatga tgtatatata aatgagccca	480
5	agcgggcgcg cgagtcagtt gcgcagccat cgacgtcaga cgcggaagct tcgataaact	540
	acgcggacag gtacccaaac aaatgttctc gtcacgtggg catgaatctg atgctgtttc	600
	cctgtcgaca atgcgaaaga atgaatcaga attcaaatat ctgcttcaca cacgggcaaa	660
10	aagactgttt ggaatgcttt cccgtgtcag aatctcaacc cgtttctgtc gtcagaaaaa	720
	cgtatcagaa actttgttac attcatcata tcatgggaaa agtaccagac gcctgcactg	780
	cctgcgacct ggtaaatgtg gacttggatg actgtatttc tgagcaataa atgacttaaa	840
15	tcaggtatgg ctgctgacgg ttatcttcca gattggctcg aggacactct ctctgaagga	900
	atcagacagt ggtggaagct caaacctggc ccaccaccgc cgaaacctaa ccaacaacac	960
	cgggacgaca gtaggggtct tgtgcttcct gggtagaagt acctcggacc cttcaacgga	1020
20	ctcgacaaag gagagccggt caacgaggca gacgccgagg ccctcgagca cgacaaagcc	1080
	tacgaccacc agctcaagca aggggacaac ccgtacctca aatacaacca cgcggacgct	1140
	gaatttcagg agcgtcttca agaagatacg tctttcgggg gcaacctcgg gcgagcagtc	1200
25	ttccaggcca aaaagagggg actcgagcct cttggtctgg ttgaggaagc tgttaagacg	1260
	gctcctggaa aaaagagacc tatagagcag tctcctgcag aaccggactc ttcctcgggc	1320
	atcggcaaat caggccagca gcccgctaag aaaagactca attttggtca gactggcgac	1380
30	acagagtcag tcccagaccc tcaaccaatc ggagaacccc ccgcagcccc ctctggtgtg	1440
	ggatctaata caatggcttc aggcggtggg gcaccaatgy cagacaataa cgaaggcgcc	1500
	gacggagtgg gtaattcctc gggaaattgg cattgcgatt ccacatggat gggcgacaga	1560
35	gttatcacca ccagcacaag aacctgggcc ctccccacct acaataatcg cctctacaag	1620
	caaatctcca gcgaatcggg agccaccaac gacaaccact acttcggcta cagcaccccc	1680
	tgggggtatt ttgactttaa cagattccac tgtcacttct caccacgtga ctggcagcga	1740
40	ctcatcaaca acaactgggg atttagaccc aagaaactca atttcaagct cttcaacatc	1800
	caagtcaagg aggtcacgca gaatgatgga accacgacca tcgccaataa ccttaccagc	1860
	acggtgcagg tcttcacaga ctctgagtac cagctgccct acgtcctcgg ttcggctcac	1920
45	cagggctgcc ttccgccgtt cccagcagac gtcttcatga ttccctcagta cggctacttg	1980
	actctgaaca atggcagcca agcggtagga cgttcttcat tctactgtct agagtatttt	2040
	ccctctcaga tgctgaggac gggaaacaac ttcaccttca gctacacttt tgaagacgtg	2100
50	cctttccaca gcagctacgc gcacagccag agtctggatc ggctgatgaa tcctctcatt	2160
	gaccagtacc tgtattacct gagcaaaact cagggtagaa gtggaacaac gcagcaatcg	2220
55	agactgcagt tcagccaagc tgggcctagc tccatggctc agcaggccaa aaactggcta	2280

# EP 1 310 571 B1

	ccgggaccca gctaccgaca gcagcgaatg tctaagacgg ctaatgacaa caacaacagt	2340
	gaatttgctt ggactgcagc caccaaatac tacctgaatg gaagaaattc tctggtcaat	2400
5	cccgggcccc caatggccag tcacaaggac gatgaggaaa agtatttccc catgcacgga	2460
	aatctcatct ttggaaaaca aggcacagga actaccaatg tggacattga atcagtgtt	2520
	attacagacg aagaagaaat cagaacaact aatcctgtgg ctacagaaca atacggacag	2580
10	gttgccacca accatcagag tcagaacacc acagcttcct atggaagtgt ggacagccag	2640
	ggaatcttac ctggaatggt gtggcaggac cgcgatgtct atcttcaagg tcccatttgg	2700
	gccaaaactc ctcacacgga cggacacttt catccttctc cgctcatggg aggctttgga	2760
15	ctgaaacacc ctctcccca gatcctgac aaaaacacac ctgtgccagc gaatcccgcg	2820
	accactttca ctcttgaaa gtttgcttcg ttcattaccc agtattccac cggacaggtc	2880
	agcgtggaaa tagagtggga gctgcagaaa gaaaacagca aacgctggaa cccagaaatt	2940
20	cagtacacct ccaactacaa caagtcggtg aatgtggagt ttaccgtgga cgcaaacggt	3000
	gtttattctg .aaccgcccc tattggcact cgttacctta cccggaactt gtaatttctt	3060
	gttaatgaat aaaccgattt atgcgtttca gttgaacttt ggtctctgcg aagggcgaat	3120
25	tc	3122

	<210> 57
30	<211> 3123
	<212> DNA
	<213> new AAV serotype, clone A3.3

35	<400> 57
----	----------

40

45

50

55

# EP 1 310 571 B1

	gaattcgccc tttctacggc tgcgtcaact ggaccaatga aaactttccc ttcaacgatt	60
	gcgtcgacaa gatggtgatc tgggtgggagg agggaaagat gaccgccaag gtcgtggaat	120
5	ctgccaaagc cattctgggt ggaggcaagg ttcgtgtgga ccagaaatgc aagtcttcgg	180
	cccagatcga cccgactccg gtgattgtca cctctaacac caacatgtgc gccgtgattg	240
	acggaaactc gaccaccttc gagcaccagc agccgttgca agaccggatg ttcaaatttg	300
10	aacttaccgg ccgtttggat catgactttg ggaaggtcac caagcaggaa gtcaaagact	360
	ttttccggtg ggctcaagat cacgtgactg aggtggagca tgagttctac gtcaaaaagg	420
	gtggagccaa gaaaaggccc gccccgatg atgtatatat aaatgagccc aagcgggcgc	480
15	gcgagtcagt tgcgcagcca tcgacgtcag acgcggaagc ttcgataaac tacgcggaca	540
	ggtaccaaaa caaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgtcgac	600
	aatgcgaaag aatgaatcag aattcaaata tctgcttcac acacgggcaa aaagactgtt	660
20	tggaatgctt tcccgtgtca gaatctcaac ccgtttctgt cgtcagaaaa acgtatcaga	720
	aactttgtta cattcatcat atcatgggaa aagtaccaga cgctgcact gcctgcgacc	780
	tggtaaatgt ggacttggat gactgtattt ctgagcaata aatgacttaa atcaggtagt	840
25		
30		
35		
40		
45		
50		
55		

	gctgctgacg gttatcttcc agattggctc gaggacactc tctctgaagg aatcagacag	900
	tggtggaagc tcaaacctgg cccaccaccg ccgaaaccta accaacaaca ccgggacgac	960
5	agtaggggtc ttgtgcttcc tgggtacaag tacctcggac ccttcaacgg actcgacaaa	1020
	ggagagccgg tcaacgaggc agacgccgcg gccctcgagc acgacaaagc ctacgaccac	1080
	cagctcaagc aaggggacaa cccgtacctc aaatacaacc acgcgagcgc tgaatttcag	1140
10	gagcgtcttc aagaagatac gtctttcggg ggcaacctcg ggcgagcagt cttccaggcc	1200
	aaaaagaggg tactcgagcc tcttggtctg gttgaggaag ctgttaagac ggctcctgga	1260
	aaaaagagac ctatagagca gtctcctgca gaaccggact cttcctcggg catcggcaaa	1320
15	tcaggccagc agcccgctaa gaaaagactc aattttggtc agactggcga cacagagtca	1380
	gtcccaggcc ctcaaccaat cggagaaccc cccgcagccc cctctggtgt gggatctaata	1440
	acaatggctt caggcggtgg ggcaccaatg gcagacaata acgaaggcgc cgacggagtg	1500
20	ggtaattcct cgggaaattg gcattgcgat tccacatgga tgggcgacag agttatcacc	1560
	accagcaciaa gaacctgggc cctccccacc tacaataatc acctctacaa gcaaattctc	1620
	agcgaatcgg gagccaccaa cgacaaccac tacttcggct acagcacccc ctgggggtat	1680
25	tttgacttta acagattcca ctgtcacttc tcaccacgtg actggcagcg actcatcaac	1740
	aacaactggg gatttagacc caagaaactc aatttcaagc tcttcaacat ccaagtcaag	1800
	gaggtcacgc agaatgatgg aaccacgacc atcgccaata accttaccag cgcggtgcag	1860
30	gtcttcacag actctgagta ccagctgccc tacgtcctcg gttcgggtca ccagggtgc	1920
	cttcgcgcgt tcccagcaga cgtcttcgat attcctcagt acggctactt gactctgaac	1980
	aatggcagcc aagcggtagg acgttcttca ttctactgtc tagagtattt tccctctcag	2040
35	atgctgagga cgggaaacaa cttcaccttc agctacactt ttgaagacgt gcctttccac	2100
	agcagctacg cgcacagcca gagtctggat cggctgatga atcctctcat tgaccagtac	2160
	ctgtattacc tgagcaaac tcagggtaca agtgaacaa cgcagcaatc gagactgcag	2220
40	ttcagccaag ctgggcctag ctccatggct cagcaggcca aaaactggct accgggaccc	2280
	agctaccgac agcagcgaat gtctaagacg gctaatagaca acaacaacag tgaatttgct	2340
	tggactgcag ccaccaata ttacctgaat ggaagaaatt ctctgggtcaa tcccgggccc	2400
45	ccagtggcca gtcacaagga cgatgaggaa aagtatttcc ccatgcacgg aaatctcatc	2460
	tttggaatac aaggcacagg aactaccaat gtggacattg aatcagtgct tattacagac	2520
	gaagaagaaa tcagaacaac taatcctgtg gctacagaac aatacggaca gggtgccacc	2580
50	aaccatcaga gtcagaacac cacagcttcc tatggaagtg tggacagcca ggaatctta	2640
	cctggaatgg tgtggcagga ccgcgatgtc tatcttcaag gtcccatttg ggccaaaact	2700
55	cctcacacgg acggacactt tcatacttct ccgtcatgg gaggttttg actgaaacac	2760



# EP 1 310 571 B1

```

cctcctcccc agatcctgat caaaaacaca cctgtgccag cgaatcccgc gaccactttc 2820
actcctggaa agtttgcttc gttcattacc cagtattcca cctgacaggt cagcgtggaa 2880
5 atagagtggg agctgcagaa agaaaacagc aaacgctgga acccagaaat tcagtacacc 2940
tccaactaca acaagtcggt gaatgtggag tttaccgtgg acgcaaacgg tgttttattct 3000
gaaccccgcc ctattggcac tcgttacctt acccggaact tgtaatttcc tgттаатgaa 3060
10 taagccgatt tatgcgtttc agttgaactt tggctctctgc gaagggcgaa ttcgttttaa 3120
cct 3123

```

```

15 <210> 58
    <211> 2969
    <212> DNA
    <213> new AAV serotype, clone 42.12

```

```

20 <400> 58

```

25

30

35

40

45

50

55

# EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60  
gcgctgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt 120  
5 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180  
cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240  
acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatg ttcaaatttg 300  
10 aactcaccgg ccgtctggag cagcactttg gcaagggtgac aaagcaggaa gtcaaagagt 360  
tcttccgctg ggcgaggat cagctgaccg aggtggcgca tgagttctac gtcagaaagg 420  
gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggcct 480  
15 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540  
acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca 600  
agacatgcga gagaatgaat cagaatttca acatttgctt cagcacagg accagagact 660  
20 gttcagaatg tttccccggc gtgtcagaat ctcaaccggg cgtcagaaag aggacgtatc 720  
ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct 780  
gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca 840  
25 ggtatggctg ccgatggtta tcttccagat tggtctgagg acaacctctc tgagggcatc 900  
cgcgagtggg gggacttgaa acctggagcc ccgaaacca aagccaacca gcaaaagcag 960  
gacgacggcc ggggtctggt gcttcttgge tacaagtacc tcggaccctt caacggactc 1020  
30 gacaaggag agccggtcaa cgaggcagac gccgcggccc tcgagcacga caaggcctac 1080  
gacaagcagc tcgagcaggg ggacaaccgg tacctcaagt acaaccacgc cgacgccgag 1140  
tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcggggc agcagtcttc 1200  
35 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct 1260  
cctggaaaga agagaccggg agagccatca cccagcgtt ctccagactc ctctacgggc 1320

40

45

50

55

EP 1 310 571 B1

atcggcaaga caggccagca gcccgcgaaa aagagactca actttgggca gactggcgac 1380  
 tcagagtcag tgcccgaccc tcaaccaatc ggagaacccc ccgcaggccc ctctggtctg 1440  
 5 ggatctggta caatggctgc aggcgggtggc gctccaatgg cagacaataa cgaaggcgcc 1500  
 gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggct gggcgacaga 1560  
 gtcacacca ccagcaccgc aacctggggc ctccccacct acaacaacca cctctacaag 1620  
 10 caaatctcca acgggacatc gggaggaagc accaacgaca acacctactt cggctacagc 1680  
 accccctggg ggtattttga ctttaacaga ttccactgcc acttctcacc acgtgactgg 1740  
 cagcgactca tcaacaacaa ctggggattc cggcccaaga gactcaactt caagctcttc 1800  
 15 aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgc caataacctt 1860  
 accagcacga ttcaggctctt tacggactcg gaataccagc tcccgtagct cctcggctct 1920  
 gcgcaccagg gctgcctgcc tccgttcccg gcggacgtct tcatgattcc tcagtacggg 1980  
 20 tacctgactc tgaacaacgg cagtcaggcc gtgggccgtt cctccttcta ctgcctggag 2040  
 tactttcctt ctcaaagtct gagaacgggc aacaactttg agttcagcta ccagtttgag 2100  
 gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggct gacgaacccc 2160  
 25 ctcatcgacc agtacctgta ctacctggcc cggaccaga gcactacggg gtccacaagg 2220  
 gggctgcagt tccatcaggc tgggcccac accatggccg agcaatcaaa gaactggctg 2280  
 cccggaccct gttatcgga gcagagactg tcaaaaaaca tagacagcaa caacaacagt 2340  
 30 aactttgcct ggaccggggc cactaaatac catctgaatg gtagaaattc attaaccaac 2400  
 cggggcgtag ccatggccac caacaaggac gacgaggacc agttctttcc catcaacgga 2460  
 gtgctgggtt ttggcaaac gggggctgcc aacaagacaa cgctggaaaa cgtgctaatt 2520  
 35 accagcgagg aggagatcaa aaccaccaat cccgtggcta cagaagaata cgggtgtggtc 2580  
 tccagcaacc tgcaatcgtc tacggccgga cccagacac agactgtcaa cagccagggg 2640  
 gctctgcccg gcatggtctg gcagaaccgg gacgtgtacc tgcagggtcc catctggggc 2700  
 40 aaaattcctc acacggacgg caactttcac cgtctcccc tgatggggcg atttgactc 2760  
 aaacaccgc ctcctcaaat tctcatcaag tatacttcca actactaaa atctacaaat 2820  
 gtggactttg ctgtcaatac tgagggtact tattcagagc ctgccccat tggcacccgt 2880  
 45 tacctcaccg gtaacctgta attgcctgtt aatcaataaa ccggttaatt cgtttcagtt 2940  
 gaactttggt ctctgcgaag ggcgaattc 2969

50 <210> 59  
 <211> 3129  
 <212> DNA  
 <213> new AAV serotype, clone 44.2

55 <400> 59

EP 1 310 571 B1

gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60

5

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

	gcgtcgacaa gatggtgatc tgggtgggagg agggcaagat gacggccaag gtcgtggagt	120
	ccgccaaggc cattctcggc ggcagcaaag tgcgcgtgga ccaaaagtgc aagtcgtccg	180
5	cccagatcga cccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg	240
	acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatg ttcaagtttg	300
	aactcaccgc cgtctggag cagcactttg gcaaggtgac aaagcaggaa gtcagagagt	360
10	tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca cgagtctctac gtcagaaagg	420
	gtggagccaa caagagaccc gccccgatg acgcggataa aagcgagccc aagcgggcct	480
	gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg	540
15	acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca	600
	aaacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact	660
	gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaaa aagacgtatc	720
20	ggaaactctg tgcgattcat catctgctgg gggcgggcac ccgagattgc ttgctcggcc	780
	tgcgatctgg tcaacgtgga cctagatgac tgtgtttctg agcaataaat gacttaaacc	840
	aggtatggct gccgatgggt atcttccaga ttggtctgag gacaacctct ctgagggcat	900
25	tcgcgagtgg tgggacttga aacctggagc cccgaaaccc aaagccaacc agcaaaagca	960
	ggacgacggc cggggtctgg tgcttcctgg ctacaagtac ctcggaccct tcaacggact	1020
	cgacaagggg gagcccgtca acgcggcgga cgcagcggcc ctcgagcacg acaaggccta	1080
30	cgaccagcag ctcaaagcgg gtgacaatcc gtacctgagg tataaccacg ccgacgccga	1140
	gtttcaggag cgtctgcaag aagatacgtc ttttgggggc aacctcgggc gagcagtctt	1200
	ccaggccaag aagcgggttc tcgaacctct cggctctggtt gaggaaggcg ctaagacggc	1260
35	tcctggaaag aagagaccgg tagagccatc accccagcgt tctccagact cctctacggg	1320
	catcggcaag aaaggccagc agcccgcgaa aaagagactc aactttgggc agactggcga	1380
	ctcagagtca gtgcccgacc ctcaaccaat cggagaaccc ccgcaggcc cctctggtct	1440
40	gggatctggt acaatggctg caggcgggtg cgctccaatg gcagacaata acgaaggcgc	1500
	cgacggagtg ggtagttcct caggaaattg gcattgcatg tccacatggc tgggcgacag	1560
	agtcatcacc accagcacc gaacctgggc cctccccacc tacaacaacc acctctacaa	1620
45	gcaaatctcc aacgggactt cgggaggaag caccaacgac aacacctact tcggctacag	1680
	caccccctgg gggatatttg actttaacag attccactgc cacttctcac cagtgactg	1740
	gcagcgactc atcaacaaca actggggatt ccggcccaag agactcaact tcaagctctt	1800
50	caacatccag gtcaaggagg tcacgcagaa tgaaggcacc aagaccatcg ccaataacct	1860
	taccagcacg attcaggtct ttacggactc ggaataccag ctcccgtacg tcctcggctc	1920
55	tgcgcaccag ggctgcctgc ctccgttccc ggcggacgtc ttcattgatc ctcagtacgg	1980

# EP 1 310 571 B1

gtacctgact ctgaacaatg gcagtcaggc cgtgggcccgt tcctccttct actgcctgga 2040  
 gtactttcct tctcaaatgc tgagaacggg caacaacttt gagttcagct accagtttga 2100  
 5 ggacgtgcct tttcacagca gctacgcgca cagccaaagc ctggaccggc tgatgaaccc 2160  
 cctcatcgac cagtacctgt actacctgtc tcggactcag tccacgggag gtaccgcagg 2220  
 aactcagcag ttgctatttt ctcaggccgg gcctaataac atgtcggctc aggccaaaaa 2280  
 10 ctggctaccc gggccctgct accggcagca acgcgtctcc acgacactgt cgcaaaataa 2340  
 caacagcaac tttgcctgga ccggtgccac caagtatcat ctgaatggca gagactctct 2400  
 ggtaaattccc ggtgtcgcta tggcaaccca caaggacgac gaagagcgat tttttccgtc 2460  
 15 cagcggagtc ttaatgtttg ggaaacaggg agctggaaaa gacaacgtgg actatagcag 2520  
 cgttatgcta accagtgagg aagaaattaa aaccaccaac ccagtggcca cagaacagta 2580  
 cggcgtgggt gccgataacc tgcaacagca aaacgccgct cctattgtag gggccgtcaa 2640  
 20 cagtcaagga gccttacctg gcatggctct gcagaaccgg gacgtgtacc tgcagggtcc 2700  
 tatctggggc aagattcctc acacggacgg aaactttcat ccctcgccgc tgatgggagg 2760  
 ctttgactg aaacacccgc ctcctcagat cctgattaag aatacacctg tccccgcgga 2820  
 25 tcctccaact accttcagtc aagctaagct ggcgtcgctc atcacgcagt acagcaccgg 2880  
 acaggtcagc gtggaaattg aatgggagct gcagaaagaa aacagcaaac gctggaaccc 2940  
 agagattcaa tacacttcca actactacaa atctacaaat gtggactttg ctgttaacac 3000  
 30 agatggcact tattctgagc ctcgccccat cggcaccggt tacctcacc gtaatctgta 3060  
 attgcttggt aatcaataaa ccggttgatt cgtttcagtt gaactttggt ctctgcgaag 3120  
 35 ggcgaaattc 3129

<210> 60

<211> 733

<212> PRT

<213> capsid protein of AAV serotype, clone C1VP1

<400> 60

# EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5  
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

10  
Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

5 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

10 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

15 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

20 Pro Leu Glu Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys  
145 150 155 160

Lys Gly Lys Gln Pro Ala Lys Lys Arg Leu Asn Phe Glu Glu Asp Thr  
165 170 175

25 Gly Ala Gly Asp Gly Pro Pro Glu Gly Ser Asp Thr Ser Ala Met Ser  
180 185 190

30 Ser Asp Ile Glu Met Arg Ala Ala Pro Gly Gly Asn Ala Val Asp Ala  
195 200 205

Gly Gln Gly Ser Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys  
210 215 220

35 Asp Ser Thr Trp Ser Glu Gly Lys Val Thr Thr Thr Ser Thr Arg Thr  
225 230 235 240

40 Trp Val Leu Pro Thr Tyr Asn Asn His Leu Tyr Leu Arg Leu Gly Thr  
245 250 255

Thr Ser Asn Ser Asn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr  
260 265 270

45 Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln  
275 280 285

Arg Leu Ile Asn Asn Asn Trp Gly Leu Arg Pro Lys Ala Met Arg Val  
290 295 300

50 Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Thr Ser Asn Gly Glu  
305 310 315 320

55



## EP 1 310 571 B1

5

Thr Thr Val Ala Asn Asn Leu Thr Ser Thr Val Gln Ile Phe Ala Asp  
325 330 335

Ser Ser Tyr Glu Leu Pro Tyr Val Met Asp Ala Gly Gln Glu Gly Ser  
340 345 350

10

Leu Ser Pro Phe Pro Asn Asp Val Phe Met Val Pro Gln Tyr Gly Tyr  
355 360 365

15

Cys Gly Ile Val Thr Gly Glu Asn Gln Asn Gln Thr Asp Arg Asn Ala  
370 375 380

Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn  
385 390 395 400

20

Asn Phe Glu Met Ala Tyr Asn Phe Gly Lys Val Pro Phe His Ser Met  
405 410 415

25

Tyr Ala Tyr Ser Gln Ser Pro Asp Arg Leu Met Asn Pro Leu Leu Asp  
420 425 430

Gln Tyr Leu Trp His Leu Gln Ser Thr Thr Ser Gly Glu Thr Leu Asn  
435 440 445

30

Gln Gly Asn Ala Ala Thr Thr Phe Gly Lys Ile Arg Ser Gly Asp Phe  
450 455 460

35

Ala Phe Tyr Arg Lys Asn Trp Leu Pro Gly Pro Cys Val Lys Gln Gln  
465 470 475 480

Arg Leu Ser Lys Thr Ala Ser Gln Asn Tyr Lys Ile Pro Ala Ser Gly  
485 490 495

40

Gly Asn Ala Leu Leu Lys Tyr Asp Thr His Tyr Thr Leu Asn Asn Arg  
500 505 510

45

Trp Ser Asn Ile Ala Pro Gly Pro Pro Met Ala Thr Ala Gly Pro Ser  
515 520 525

Asp Gly Asp Phe Ser Asn Ala Gln Leu Ile Phe Pro Gly Pro Ser Val  
530 535 540

50

Thr Gly Asn Thr Thr Thr Ser Ala Asn Asn Leu Leu Phe Thr Ser Glu  
545 550 555 560

55

Glu Glu Ile Ala Ala Thr Asn Pro Arg Asp Thr Asp Met Phe Gly Gln  
565 570 575

EP 1 310 571 B1

Ile Ala Asp Asn Asn Gln Asn Ala Thr Thr Ala Pro Ile Thr Gly Asn  
580 585 590

Val Thr Ala Met Gly Val Leu Pro Gly Met Val Trp Gln Asn Arg Asp  
595 600 605

Ile Tyr Tyr Gln Gly Pro Ile Trp Ala Lys Ile Pro His Ala Asp Gly  
610 615 620

His Phe His Pro Ser Pro Leu Ile Gly Gly Phe Gly Leu Lys His Pro  
625 630 635 640

Pro Pro Gln Ile Phe Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Ala  
645 650 655

Thr Thr Phe Thr Ala Ala Arg Val Asp Ser Phe Ile Thr Gln Tyr Ser  
660 665 670

Thr Gly Gln Val Ala Val Gln Ile Glu Trp Glu Ile Glu Lys Glu Arg  
675 680 685

Ser Lys Arg Trp Asn Pro Glu Val Gln Phe Thr Ser Asn Tyr Gly Asn  
690 695 700

Gln Ser Ser Met Leu Trp Ala Pro Asp Thr Thr Gly Lys Tyr Thr Glu  
705 710 715 720

Pro Arg Val Ile Gly Ser Arg Tyr Leu Thr Asn His Leu  
725 730

<210> 61

<211> 733

<212> PRT

<213> capsid protein of AAV serotype, clone C2VP1

<400> 61

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Leu  
20 25 30

10 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe His Gly Leu Asp Lys Gly Glu Pro  
50 55 60

15 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

20

25

30

35

40

45

50

55

EP 1 310 571 B1

5 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
 85 90 95  
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110  
 10 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140  
 15 Pro Leu Glu Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys  
 145 150 155 160  
 20 Lys Gly Lys Gln Pro Ala Lys Lys Arg Leu Asn Phe Glu Glu Asp Thr  
 165 170 175  
 Gly Ala Gly Asp Gly Pro Pro Glu Gly Ser Asp Thr Ser Ala Met Ser  
 180 185 190  
 25 Ser Asp Ile Glu Met Arg Ala Ala Pro Gly Gly Asn Ala Val Asp Ala  
 195 200 205  
 30 Gly Gln Gly Ser Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys  
 210 215 220  
 Asp Ser Thr Trp Ser Glu Gly Lys Val Thr Thr Thr Ser Thr Arg Thr  
 225 230 235 240  
 35 Trp Val Leu Pro Thr Tyr Asn Asn His Leu Tyr Leu Arg Leu Gly Thr  
 245 250 255  
 40 Thr Ser Asn Ser Asn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr  
 260 265 270  
 Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln  
 275 280 285  
 45 Arg Leu Ile Asn Asn Asn Trp Gly Leu Arg Pro Lys Ala Met Arg Val  
 290 295 300  
 50 Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Thr Ser Asn Gly Glu  
 305 310 315 320  
 Thr Thr Val Ala Asn Asn Leu Thr Ser Thr Val Gln Ile Phe Ala Asp  
 325 330 335  
 55

EP 1 310 571 B1

Ser Ser Tyr Glu Leu Pro Tyr Val Met Asp Ala Gly Gln Glu Gly Ser  
340 345 350

Leu Pro Pro Phe Pro Asn Asp Val Phe Met Val Pro Gln Tyr Gly Tyr  
355 360 365

Cys Gly Ile Val Thr Gly Glu Asn Gln Asn Gln Thr Asp Arg Asn Ala  
370 375 380

Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn  
385 390 395 400

Asn Phe Glu Met Ala Tyr Asn Phe Glu Lys Val Pro Phe His Ser Met  
405 410 415

Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Leu Asp  
420 425 430

Gln Tyr Leu Trp His Leu Gln Ser Thr Thr Ser Gly Glu Thr Leu Asn  
435 440 445

Gln Gly Asn Ala Ala Thr Thr Phe Gly Lys Ile Arg Ser Gly Asp Phe  
450 455 460

Ala Phe Tyr Arg Lys Asn Trp Leu Pro Gly Pro Cys Val Lys Gln Gln  
465 470 475 480

Arg Phe Ser Lys Thr Ala Ser Gln Asn Tyr Lys Ile Pro Ala Ser Gly  
485 490 495

Gly Asn Ala Leu Leu Lys Tyr Asp Thr His Tyr Thr Leu Asn Asn Arg  
500 505 510

Trp Ser Asn Ile Ala Pro Gly Pro Pro Met Ala Thr Ala Gly Pro Ser  
515 520 525

Asp Gly Asp Phe Ser Asn Ala Gln Leu Ile Phe Pro Gly Pro Ser Val  
530 535 540

Thr Gly Asn Thr Thr Thr Ser Ala Asn Asn Leu Leu Phe Thr Ser Glu  
545 550 555 560

Gly Glu Ile Ala Ala Thr Asn Pro Arg Asp Thr Asp Met Phe Gly Gln  
565 570 575

Ile Ala Asp Asn Asn Gln Asn Ala Thr Thr Ala Pro Ile Thr Gly Asn  
580 585 590

EP 1 310 571 B1

Val Thr Ala Met Gly Val Leu Pro Gly Met Val Trp Gln Asn Arg Asp  
595 600 605

Ile Tyr Tyr Gln Gly Pro Ile Trp Ala Lys Ile Pro His Ala Asp Gly  
610 615 620

His Phe His Pro Ser Pro Leu Ile Gly Gly Phe Gly Leu Lys His Pro  
625 630 635 640

Pro Pro Gln Ile Phe Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Ala  
645 650 655

Thr Thr Phe Thr Ala Ala Arg Val Asp Ser Phe Ile Thr Gln Tyr Ser  
660 665 670

Thr Gly Gln Val Ala Val Gln Ile Glu Trp Glu Ile Glu Lys Glu Arg  
675 680 685

Ser Lys Arg Arg Asn Pro Glu Val Gln Phe Thr Ser Asn Tyr Gly Asn  
690 695 700

Gln Ser Ser Met Leu Trp Ala Pro Asp Thr Thr Gly Lys Tyr Thr Glu  
705 710 715 720

Pro Arg Val Ile Gly Ser Arg Tyr Leu Thr Asn His Leu  
725 730

<210> 62

<211> 733

<212> PRT

<213> capsid protein of AAV serotype, clone C5VP1@2

<400> 62

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Glu Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

5

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110  
 5  
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 10  
 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140  
 Pro Leu Glu Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys  
 145 150 155 160  
 15  
 Lys Gly Lys Gln Pro Ala Lys Lys Arg Leu Asn Phe Glu Glu Asp Thr  
 165 170 175  
 20  
 Gly Ala Gly Asp Gly Pro Pro Glu Gly Ser Asp Thr Ser Ala Met Ser  
 180 185 190  
 Ser Asp Ile Glu Met Arg Ala Ala Pro Gly Gly Asn Ala Val Asp Ala  
 195 200 205  
 25  
 Gly Gln Gly Ser Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys  
 210 215 220  
 30  
 Asp Ser Thr Trp Ser Glu Gly Lys Val Thr Thr Thr Ser Thr Arg Thr  
 225 230 235 240  
 Trp Val Leu Pro Thr Tyr Asn Asn His Leu Tyr Leu Arg Leu Gly Thr  
 245 250 255  
 35  
 Thr Ser Asn Ser Asn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr  
 260 265 270  
 40  
 Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln  
 275 280 285  
 Arg Leu Ile Asn Asn Asn Trp Gly Leu Arg Pro Lys Ala Met Arg Val  
 290 295 300  
 45  
 Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Thr Ser Asn Gly Glu  
 305 310 315 320  
 50  
 Thr Thr Val Ala Asn Asn Leu Thr Ser Thr Val Gln Ile Phe Ala Asp  
 325 330 335  
 Ser Ser Tyr Glu Leu Pro Tyr Val Met Asp Ala Gly Gln Glu Gly Ser  
 340 345 350  
 55



EP 1 310 571 B1

Leu Pro Pro Phe Pro Asn Asp Val Phe Met Val Pro Gln Tyr Gly Tyr  
355 360 365

Cys Gly Ile Val Thr Gly Glu Asn Gln Asn Gln Thr Asp Arg Asn Ala  
370 375 380

Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn  
385 390 395 400

Asn Phe Glu Thr Ala Tyr Asn Phe Glu Lys Val Pro Phe His Ser Met  
405 410 415

Tyr Ala His Ser Gln Ser Leu Asp Gly Leu Met Asn Pro Leu Leu Asp  
420 425 430

Gln Tyr Leu Trp His Leu Gln Ser Thr Thr Ser Gly Glu Thr Leu Asn  
435 440 445

Gln Gly Asn Ala Ala Thr Thr Phe Gly Lys Ile Arg Ser Gly Asp Phe  
450 455 460

Ala Phe Tyr Arg Lys Asn Trp Leu Pro Gly Pro Cys Val Lys Gln Gln  
465 470 475 480

Arg Phe Ser Lys Thr Ala Ser Gln Asn Tyr Lys Ile Pro Ala Ser Gly  
485 490 495

Gly Asn Ala Leu Leu Lys Tyr Asp Thr His Tyr Thr Leu Asn Asn Arg  
500 505 510

Trp Ser Asn Ile Ala Pro Gly Pro Pro Met Ala Thr Ala Gly Pro Ser  
515 520 525

Asp Gly Asp Phe Ser Asn Ala Gln Leu Ile Phe Pro Gly Pro Ser Val  
530 535 540

Thr Gly Asn Thr Thr Thr Ser Ala Asn Asn Leu Leu Phe Thr Ser Glu  
545 550 555 560

Glu Glu Ile Ala Ala Thr Asn Pro Arg Asp Thr Asp Met Phe Gly Gln  
565 570 575

Ile Ala Asp Asn Asn Gln Asn Ala Thr Thr Ala Pro Ile Thr Gly Asn  
580 585 590

Val Thr Ala Met Gly Val Leu Pro Gly Met Val Trp Gln Asn Arg Asp  
595 600 605

# EP 1 310 571 B1

Ile Tyr Tyr Gln Gly Pro Ile Trp Ala Lys Ile Pro His Ala Asp Gly  
610 615 620

5 His Phe His Pro Ser Pro Leu Ile Gly Gly Phe Gly Leu Lys His Pro  
625 630 635 640

10 Pro Pro Gln Ile Phe Ile Lys Asn Thr Pro Val Pro Ala Tyr Pro Ala  
645 650 655

Thr Thr Phe Thr Ala Ala Arg Val Asp Ser Phe Ile Thr Gln Tyr Ser  
660 665 670

15 Thr Gly Gln Val Ala Val Gln Ile Glu Trp Glu Ile Glu Lys Glu Arg  
675 680 685

20 Ser Lys Arg Trp Asn Pro Glu Val Gln Phe Thr Ser Asn Cys Gly Asn  
690 695 700

Gln Ser Ser Met Leu Trp Ala Pro Asp Thr Thr Gly Lys Tyr Thr Glu  
705 710 715 720

25 Pro Arg Val Ile Gly Ser Arg Tyr Leu Thr Asn His Leu  
725 730

<210> 63

30 <211> 734

<212> PRT

<213> capsid protein of AAV serotype, clone AAV4VP1

<400> 63

35

40

45

50

55

EP 1 310 571 B1

Met Thr Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser Glu  
1 5 10 15

Gly Val Arg Glu Trp Trp Ala Leu Gln Pro Gly Ala Pro Lys Pro Lys  
20 25 30

Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro Gly  
35 40 45

Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro Val  
50 55 60

Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln  
65 70 75 80

Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp  
85 90 95

Ala Glu Phe Gln Gln Arg Leu Gln Gly Asp Thr Ser Phe Gly Gly Asn  
100 105 110

EP 1 310 571 B1

Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu  
 115 120 125

5

Gly Leu Val Glu Gln Ala Gly Glu Thr Ala Pro Gly Lys Lys Arg Pro  
 130 135 140

10

Leu Ile Glu Ser Pro Gln Gln Pro Asp Ser Ser Thr Gly Ile Gly Lys  
 145 150 155 160

Lys Gly Lys Gln Pro Ala Lys Lys Lys Leu Val Phe Glu Asp Glu Thr  
 165 170 175

15

Gly Ala Gly Asp Gly Pro Pro Glu Gly Ser Thr Ser Gly Ala Met Ser  
 180 185 190

20

Asp Asp Ser Glu Met Arg Ala Ala Ala Gly Gly Ala Ala Val Glu Gly  
 195 200 205

Gly Gln Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys  
 210 215 220

25

Asp Ser Thr Trp Ser Glu Gly His Val Thr Thr Thr Ser Thr Arg Thr  
 225 230 235 240

30

Trp Val Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Arg Leu Gly Glu  
 245 250 255

Ser Leu Gln Ser Asn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr  
 260 265 270

35

Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln  
 275 280 285

40

Arg Leu Ile Asn Asn Asn Trp Gly Met Arg Pro Lys Ala Met Arg Val  
 290 295 300

Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Thr Ser Asn Gly Glu  
 305 310 315 320

45

Thr Thr Val Ala Asn Asn Leu Thr Ser Thr Val Gln Ile Phe Ala Asp  
 325 330 335

50

Ser Ser Tyr Glu Leu Pro Tyr Val Met Asp Ala Gly Gln Glu Gly Ser  
 340 345 350

Leu Pro Pro Phe Pro Asn Asp Val Phe Met Val Pro Gln Tyr Gly Tyr  
 355 360 365

55

EP 1 310 571 B1

5 Cys Gly Leu Val Thr Gly Asn Thr Ser Gln Gln Gln Thr Asp Arg Asn  
370 375 380

10 Ala Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly  
385 390 395 400

15 Asn Asn Phe Glu Ile Thr Tyr Ser Phe Glu Lys Val Pro Phe His Ser  
405 410 415

20 Met Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile  
420 425 430

25 Asp Gln Tyr Leu Trp Gly Leu Gln Ser Thr Thr Thr Gly Thr Thr Leu  
435 440 445

30 Asn Ala Gly Thr Ala Thr Thr Asn Phe Thr Lys Leu Arg Pro Thr Asn  
450 455 460

35 Phe Ser Asn Phe Lys Lys Asn Trp Leu Pro Gly Pro Ser Ile Lys Gln  
465 470 475 480

40 Gln Gly Phe Ser Lys Thr Ala Asn Gln Asn Tyr Lys Ile Pro Ala Thr  
485 490 495

45 Gly Ser Asp Ser Leu Ile Lys Tyr Glu Thr His Ser Thr Leu Asp Gly  
500 505 510

50 Arg Trp Ser Ala Leu Thr Pro Gly Pro Pro Met Ala Thr Ala Gly Pro  
515 520 525

55 Ala Asp Ser Lys Phe Ser Asn Ser Gln Leu Ile Phe Ala Gly Pro Lys  
530 535 540

60 Gln Asn Gly Asn Thr Ala Thr Val Pro Gly Thr Leu Ile Phe Thr Ser  
545 550 555 560

65 Glu Glu Glu Leu Ala Ala Thr Asn Ala Thr Asp Thr Asp Met Trp Gly  
565 570 575

70 Asn Leu Pro Gly Gly Asp Gln Ser Asn Ser Asn Leu Pro Thr Val Asp  
580 585 590

75 Arg Leu Thr Ala Leu Gly Ala Val Pro Gly Met Val Trp Gln Asn Arg  
595 600 605

80 Asp Ile Tyr Tyr Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp  
610 615 620

EP 1 310 571 B1

Gly His Phe His Pro Ser Pro Leu Ile Gly Gly Phe Gly Leu Lys His  
625 630 635 640

Pro Pro Pro Gln Ile Phe Ile Lys Asn Thr Pro Val Pro Ala Asn Pro  
645 650 655

Ala Thr Thr Phe Ser Ser Thr Pro Val Asn Ser Phe Ile Thr Gln Tyr  
660 665 670

Ser Thr Gly Gln Val Ser Val Gln Ile Asp Trp Glu Ile Gln Lys Glu  
675 680 685

Arg Ser Lys Arg Trp Asn Pro Glu Val Gln Phe Thr Ser Asn Tyr Gly  
690 695 700

Gln Gln Asn Ser Leu Leu Trp Ala Pro Asp Ala Ala Gly Lys Tyr Thr  
705 710 715 720

Glu Pro Arg Ala Ile Gly Thr Arg Tyr Leu Thr His His Leu  
725 730

<210> 64

<211> 736

<212> PRT

<213> capsid protein of AAV serotype, clone AAV1

<400> 64

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

EP 1 310 571 B1

5 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140  
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
 145 150 155 160  
 10 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
 165 170 175  
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
 180 185 190  
 15 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly  
 195 200 205  
 20 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
 210 215 220  
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
 225 230 235 240  
 25 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
 245 250 255  
 30 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His  
 260 265 270  
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
 275 280 285  
 35 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
 290 295 300  
 40 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln  
 305 310 315 320  
 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
 325 330 335  
 45 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
 340 345 350  
 50 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
 355 360 365  
 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
 370 375 380  
 55

## EP 1 310 571 B1

5

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
405 410 415

10

Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp  
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg  
435 440 445

15

Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser  
450 455 460

20

Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro  
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn  
485 490 495

25

Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn  
500 505 510

30

Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys  
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly  
530 535 540

35

Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile  
545 550 555 560

40

Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg  
565 570 575

Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala  
580 585 590

45

Thr Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln  
595 600 605

50

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
625 630 635 640

55



# EP 1 310 571 B1

Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
645 650 655

5

Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr  
660 665 670

10

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn  
690 695 700

15

Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu  
705 710 715 720

20

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu  
725 730 735

<210> 65

<211> 736

25

<212> PRT

<213> capsid protein of AAV serotype, clone AAV6VP1

<400> 65

30

35

40

45

50

55

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

EP 1 310 571 B1

5

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

10

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
180 185 190

Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly  
195 200 205

15

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
210 215 220

20

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

25

Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His  
260 265 270

30

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
290 295 300

35

Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln  
305 310 315 320

40

Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
340 345 350

45

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
355 360 365

50

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
370 375 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
385 390 395 400

55

## EP 1 310 571 B1

5

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
 405 410 415

10

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp  
 420 425 430

15

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg  
 435 440 445

Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser  
 450 455 460

20

Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro  
 465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn  
 485 490 495

25

Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn  
 500 505 510

Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys  
 515 520 525

30

Asp Asp Lys Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly  
 530 535 540

Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile  
 545 550 555 560

35

Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg  
 565 570 575

40

Phe Gly Thr Val Ala Val Asn Leu Gln Ser Ser Ser Thr Asp Pro Ala  
 580 585 590

Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln  
 595 600 605

45

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
 610 615 620

50

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
 625 630 635 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
 645 650 655

55

EP 1 310 571 B1

Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr  
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn  
690 695 700

Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu  
705 710 715 720

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu  
725 730 735

<210> 66

<211> 735

<212> PRT

<213> capsid protein of AAV serotype, clone A3.3

<400> 66

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser  
1 5 10 15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro  
20 25 30

Lys Pro Asn Gln Gln His Arg Asp Asp Ser Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

His Gln Leu Lys Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Ala Val Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

EP 1 310 571 B1

5

Pro Ile Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

10

Gly Asp Thr Glu Ser Val Pro Gly Pro Gln Pro Ile Gly Glu Pro Pro  
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205

15

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

20

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile  
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

25

Tyr Lys Gln Ile Ser Ser Glu Ser Gly Ala Thr Asn Asp Asn His Tyr  
260 265 270

30

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His  
275 280 285

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp  
290 295 300

35

Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val  
305 310 315 320

40

Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu  
325 330 335

Thr Ser Ala Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr  
340 345 350

45

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp  
355 360 365

50

Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser  
370 375 380

55

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser  
385 390 395 400

## EP 1 310 571 B1

5

Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu  
405 410 415

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg  
420 425 430

10

Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr  
435 440 445

Gln Gly Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln Phe Ser Gln  
450 455 460

15

Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn Trp Leu Pro Gly  
465 470 475 480

20

Pro Ser Tyr Arg Gln Gln Arg Met Ser Lys Thr Ala Asn Asp Asn Asn  
485 490 495

Asn Ser Glu Phe Ala Trp Thr Ala Ala Thr Lys Tyr Tyr Leu Asn Gly  
500 505 510

25

Arg Asn Ser Leu Val Asn Pro Gly Pro Pro Val Ala Ser His Lys Asp  
515 520 525

30

Asp Glu Glu Lys Tyr Phe Pro Met His Gly Asn Leu Ile Phe Gly Lys  
530 535 540

Gln Gly Thr Gly Thr Thr Asn Val Asp Ile Glu Ser Val Leu Ile Thr  
545 550 555 560

35

Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr  
565 570 575

40

Gly Gln Val Ala Thr Asn His Gln Ser Gln Asn Thr Thr Ala Ser Tyr  
580 585 590

Gly Ser Val Asp Ser Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp  
595 600 605

45

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Thr Pro His Thr  
610 615 620

50

Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys  
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn  
645 650 655

55



EP 1 310 571 B1

Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe Ala Ser Phe Ile Thr Gln  
660 665 670

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys  
675 680 685

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr  
690 695 700

Asn Lys Ser Val Asn Val Glu Phe Thr Val Asp Ala Asn Gly Val Tyr  
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 67

<211> 735

<212> PRT

<213> capsid protein of AAV serotype, clone A3.7

<400> 67

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser  
1 5 10 15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro  
20 25 30

Lys Pro Asn Gln Gln His Arg Asp Asp Ser Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

His Gln Leu Lys Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Ala Val Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

EP 1 310 571 B1

5 Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
 165 170 175  
 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
 180 185 190  
 10 Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly  
 195 200 205  
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
 210 215 220  
 15 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile  
 225 230 235 240  
 20 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn Arg Leu  
 245 250 255  
 Tyr Lys Gln Ile Ser Ser Glu Ser Gly Ala Thr Asn Asp Asn His Tyr  
 260 265 270  
 25 Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His  
 275 280 285  
 30 Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp  
 290 295 300  
 Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val  
 305 310 315 320  
 35 Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu  
 325 330 335  
 40 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr  
 340 345 350  
 Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp  
 355 360 365  
 45 Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser  
 370 375 380  
 50 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser  
 385 390 395 400  
 Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu  
 405 410 415  
 55

EP 1 310 571 B1

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg  
 420 425 430

5 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr  
 435 440 445

10 Gln Gly Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln Phe Ser Gln  
 450 455 460

Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn Trp Leu Pro Gly  
 465 470 475 480

15 Pro Ser Tyr Arg Gln Gln Arg Met Ser Lys Thr Ala Asn Asp Asn Asn  
 485 490 495

20 Asn Ser Glu Phe Ala Trp Thr Ala Ala Thr Lys Tyr Tyr Leu Asn Gly  
 500 505 510

Arg Asn Ser Leu Val Asn Pro Gly Pro Pro Met Ala Ser His Lys Asp  
 515 520 525

25 Asp Glu Glu Lys Tyr Phe Pro Met His Gly Asn Leu Ile Phe Gly Lys  
 530 535 540

30 Gln Gly Thr Gly Thr Thr Asn Val Asp Ile Glu Ser Val Leu Ile Thr  
 545 550 555 560

Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr  
 565 570 575

35 Gly Gln Val Ala Thr Asn His Gln Ser Gln Asn Thr Thr Ala Ser Tyr  
 580 585 590

40 Gly Ser Val Asp Ser Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp  
 595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Thr Pro His Thr  
 610 615 620

45 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys  
 625 630 635 640

50 His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn  
 645 650 655

Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe Ala Ser Phe Ile Thr Gln  
 660 665 670

55

EP 1 310 571 B1

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys  
675 680 685

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr  
690 695 700

Asn Lys Ser Val Asn Val Glu Phe Thr Val Asp Ala Asn Gly Val Tyr  
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 68

<211> 735

<212> PRT

<213> capsid protein of AAV serotype, clone A3.4

<400> 68

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser  
1 5 10 15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro  
20 25 30

Lys Pro Asn Gln Gln His Arg Asp Asp Ser Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

His Gln Leu Lys Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Ala Val Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

Glu Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

EP 1 310 571 B1

5 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205

10 Ala Pro Met Ala Asp Asp Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile  
225 230 235 240

15 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

20 Tyr Lys Gln Ile Ser Ser Glu Ser Gly Ala Thr Asn Asp Asn His Tyr  
260 265 270

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His  
275 280 285

25 Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp  
290 295 300

30 Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val  
305 310 315 320

Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu  
325 330 335

35 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr  
340 345 350

40 Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp  
355 360 365

Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser  
370 375 380

45 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser  
385 390 395 400

50 Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu  
405 410 415

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg  
420 425 430

55

EP 1 310 571 B1

5 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr  
435 440 445

Gln Gly Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln Phe Ser Gln  
450 455 460

10 Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn Trp Leu Pro Gly  
465 470 475 480

Pro Ser Tyr Arg Gln Gln Arg Met Ser Lys Thr Ala Asn Asp Asn Asn  
485 490 495

15 Asn Ser Glu Phe Ala Trp Thr Ala Ala Thr Lys Tyr Tyr Leu Asn Gly  
500 505 510

20 Arg Asn Ser Leu Val Asn Pro Gly Pro Pro Met Ala Ser His Lys Asp  
515 520 525

25 Asp Glu Glu Lys Tyr Phe Pro Met His Gly Asn Leu Ile Phe Gly Lys  
530 535 540

Gln Gly Thr Gly Thr Thr Asn Val Asp Ile Glu Ser Val Leu Ile Thr  
545 550 555 560

30 Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr  
565 570 575

Gly Gln Val Ala Thr Asn His Gln Ser Gln Asp Thr Thr Ala Ser Tyr  
580 585 590

35 Gly Ser Val Asp Ser Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp  
595 600 605

40 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Thr Pro His Thr  
610 615 620

45 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys  
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn  
645 650 655

50 Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe Ala Ser Phe Ile Thr Gln  
660 665 670

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys  
675 680 685

55

EP 1 310 571 B1

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr  
690 695 700

Asn Lys Ser Val Asn Val Glu Phe Thr Val Asp Ala Asn Gly Val Tyr  
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 69

<211> 735

<212> PRT

<213> capsid protein of AAV serotype, clone A3.5

<400> 69



EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser  
1 5 10 15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro  
20 25 30

Lys Pro Asn Gln Gln His Arg Asp Asp Ser Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

His Gln Leu Lys Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Ala Val Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
180 185 190

EP 1 310 571 B1

5

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205

10

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile  
225 230 235 240

15

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

Tyr Lys Gln Ile Ser Ser Glu Ser Gly Ala Thr Asn Asp Asn His Tyr  
260 265 270

20

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His  
275 280 285

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp  
290 295 300

25

Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val  
305 310 315 320

30

Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu  
325 330 335

Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr  
340 345 350

35

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp  
355 360 365

40

Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser  
370 375 380

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser  
385 390 395 400

45

Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu  
405 410 415

50

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg  
420 425 430

Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr  
435 440 445

55

EP 1 310 571 B1

Gln Gly Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln Phe Asn Gln  
450 455 460

Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn Trp Leu Pro Gly  
465 470 475 480

Pro Ser Tyr Arg Gln Gln Arg Met Ser Lys Thr Ala Asn Asp Asn Asn  
485 490 495

Asn Ser Glu Phe Ala Trp Thr Ala Ala Thr Lys Tyr Tyr Pro Asn Gly  
500 505 510

Arg Asn Ser Leu Val Asn Pro Gly Pro Pro Met Ala Ser His Lys Asp  
515 520 525

Asp Glu Glu Lys Tyr Phe Pro Met His Gly Asn Leu Ile Phe Gly Lys  
530 535 540

Gln Gly Thr Gly Thr Thr Asn Val Asp Ile Glu Ser Val Leu Ile Thr  
545 550 555 560

Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr  
565 570 575

Gly Gln Val Ala Thr Asn Arg Gln Ser Gln Asn Thr Thr Ala Ser Tyr  
580 585 590

Gly Ser Val Asp Ser Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp  
595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Thr Pro His Thr  
610 615 620

Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys  
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn  
645 650 655

Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe Ala Ser Phe Ile Thr Gln  
660 665 670

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys  
675 680 685

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr  
690 695 700

EP 1 310 571 B1

Asn Lys Ser Val Asn Val Glu Phe Thr Val Asp Ala Asn Gly Val Tyr  
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 70

<211> 735

<212> PRT

<213> capsid protein of AAV serotype, clone AAV2

<400> 70

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser  
1 5 10 15

Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro  
20 25 30

Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Arg Gln Leu Asp Ser Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Pro Val Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu His Ser Pro Val Glu Pro Asp Ser Ser Ser Gly Thr Gly  
145 150 155 160

Lys Ala Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

Gly Asp Ala Asp Ser Val Pro Asp Pro Gln Pro Leu Gly Gln Pro Pro  
180 185 190

EP 1 310 571 B1

5

Ala Ala Pro Ser Gly Leu Gly Thr Asn Thr Met Ala Thr Gly Ser Gly  
195 200 205

10

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

15

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile  
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr  
260 265 270

20

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His  
275 280 285

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp  
290 295 300

25

Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val  
305 310 315 320

30

Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu  
325 330 335

Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr  
340 345 350

35

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp  
355 360 365

40

Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser  
370 375 380

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser  
385 390 395 400

45

Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu  
405 410 415

50

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg  
420 425 430

Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr  
435 440 445

55

EP 1 310 571 B1

5 Asn Thr Pro Ser Gly Thr Thr Thr Gln Ser Arg Leu Gln Phe Ser Gln  
 450 455 460  
 Ala Gly Ala Ser Asp Ile Arg Asp Gln Ser Arg Asn Trp Leu Pro Gly  
 465 470 475 480  
 10 Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ser Ala Asp Asn Asn  
 485 490 495  
 Asn Ser Glu Tyr Ser Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly  
 500 505 510  
 15 Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp  
 515 520 525  
 20 Asp Glu Glu Lys Phe Phe Pro Gln Ser Gly Val Leu Ile Phe Gly Lys  
 530 535 540  
 Gln Gly Ser Glu Lys Thr Asn Val Asp Ile Glu Lys Val Met Ile Thr  
 545 550 555 560  
 25 Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr  
 565 570 575  
 30 Gly Ser Val Ser Thr Asn Leu Gln Arg Gly Asn Arg Gln Ala Ala Thr  
 580 585 590  
 Ala Asp Val Asn Thr Gln Gly Val Leu Pro Gly Met Val Trp Gln Asp  
 595 600 605  
 35 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr  
 610 615 620  
 40 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys  
 625 630 635 640  
 His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn  
 645 650 655  
 45 Pro Ser Thr Thr Phe Ser Ala Ala Lys Phe Ala Ser Phe Ile Thr Gln  
 660 665 670  
 50 Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys  
 675 680 685  
 Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr  
 690 695 700  
 55

EP 1 310 571 B1

Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr  
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 71

<211> 736

<212> PRT

<213> capsid protein of AAV serotype, clone AAV3

<400> 71

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Val Pro Gln Pro  
20 25 30

Lys Ala Asn Gln Gln His Gln Asp Asn Arg Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Ile Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Gly  
130 135 140

Ala Val Asp Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Val Gly  
145 150 155 160

Lys Ser Gly Lys Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
180 185 190

Ala Ala Pro Thr Ser Leu Gly Ser Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205



EP 1 310 571 B1

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

5 Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile  
225 230 235 240

10 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr  
260 265 270

15 Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His  
275 280 285

20 Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp  
290 295 300

Gly Phe Arg Pro Lys Lys Leu Ser Phe Lys Leu Phe Asn Ile Gln Val  
305 310 315 320

25 Arg Gly Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu  
325 330 335

30 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr  
340 345 350

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp  
355 360 365

35 Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser  
370 375 380

40 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser  
385 390 395 400

Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr Phe Glu  
405 410 415

45 Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg  
420 425 430

50 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg Thr  
435 440 445

Gln Gly Thr Thr Ser Gly Thr Thr Asn Gln Ser Arg Leu Leu Phe Ser  
450 455 460

55

## EP 1 310 571 B1

5 Gln Ala Gly Pro Gln Ser Met Ser Leu Gln Ala Arg Asn Trp Leu Pro  
 465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Leu Ser Lys Thr Ala Asn Asp Asn  
 485 490 495

10 Asn Asn Ser Asn Phe Pro Trp Thr Ala Ala Ser Lys Tyr His Leu Asn  
 500 505 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys  
 515 520 525

15 Asp Asp Glu Glu Lys Phe Phe Pro Met His Gly Asn Leu Ile Phe Gly  
 530 535 540

20 Lys Glu Gly Thr Thr Ala Ser Asn Ala Glu Leu Asp Asn Val Met Ile  
 545 550 555 560

25 Thr Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln  
 565 570 575

Tyr Gly Thr Val Ala Asn Asn Leu Gln Ser Ser Asn Thr Ala Pro Thr  
 580 585 590

30 Thr Gly Thr Val Asn His Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
 595 600 605

35 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
 610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
 625 630 635 640

40 Lys His Pro Pro Pro Gln Ile Met Ile Lys Asn Thr Pro Val Pro Ala  
 645 650 655

45 Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr  
 660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
 675 680 685

50 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
 690 695 700

55 Tyr Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val  
 705 710 715 720

EP 1 310 571 B1

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 72  
<211> 737  
<212> PRT  
<213> capsid protein of AAV serotype, clone 3.3bVP1  
<400> 72

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asn Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Asn Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Ala Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro  
180 185 190

Pro Ala Ala Pro Ser Ser Val Gly Ser Gly Thr Val Ala Ala Gly Gly  
195 200 205

EP 1 310 571 B1

5

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn  
210 215 220

Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

10

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

Leu Tyr Glu Gln Ile Ser Ser Glu Thr Ala Gly Ser Thr Asn Asp Asn  
260 265 270

15

Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
275 280 285

20

Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
290 295 300

Asn Trp Gly Phe Arg Pro Lys Lys Leu Arg Phe Lys Leu Phe Asn Ile  
305 310 315 320

25

Gln Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn  
325 330 335

30

Asn Leu Thr Ser Thr Ile Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu  
340 345 350

Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
355 360 365

35

Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
370 375 380

40

Gly Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
385 390 395 400

Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser  
405 410 415

45

Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
420 425 430

Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala  
435 440 445

50

Arg Thr Gln Ser Asp Pro Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln  
450 455 460

55

EP 1 310 571 B1

5  
Phe Tyr Gln Gly Gly Pro Ser Thr Met Ala Glu Gln Ala Lys Asn Trp  
465 470 475 480

10  
Leu Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp  
485 490 495

15  
Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

20  
Leu Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

25  
His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile  
530 535 540

30  
Phe Gly Lys Thr Gly Ala Thr Asn Lys Thr Thr Leu Glu Asn Val Leu  
545 550 555 560

35  
Met Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu  
565 570 575

40  
Glu Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Asn Thr Ala Ala  
580 585 590

45  
Gln Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp  
595 600 605

50  
Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro  
610 615 620

55  
His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly  
625 630 635 640

60  
Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro  
645 650 655

65  
Ala Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile  
660 665 670

70  
Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu  
675 680 685

75  
Gln Lys Glu Asn Ser Lys Arg Trp Asp Pro Glu Ile Gln Tyr Thr Ser  
690 695 700

80  
Asn Phe Glu Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly  
705 710 715 720

EP 1 310 571 B1

Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn  
725 730 735

Leu

<210> 73

<211> 644

<212> PRT

<213> capsid protein of AAV serotype, clone 223-4

<400> 73

Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg  
1 5 10 15

Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr  
20 25 30

Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg  
35 40 45

Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro  
50 55 60

Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly  
65 70 75 80

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
85 90 95

Gly Asp Ser Glu Pro Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
100 105 110

Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly  
115 120 125

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
130 135 140

Ser Gly Asn Trp His Cys Asp Ser Thr Arg Leu Gly Asp Arg Val Ile  
145 150 155 160

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
165 170 175

Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val  
180 185 190

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
195 200 205

EP 1 310 571 B1

5

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
210 215 220

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln  
225 230 235 240

10

Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
245 250 255

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
260 265 270

15

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
275 280 285

20

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
290 295 300

Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
305 310 315 320

25

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
325 330 335

30

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Gly  
340 345 350

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg  
355 360 365

35

Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe  
370 375 380

40

Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu  
385 390 395 400

Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln  
405 410 415

45

Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu  
420 425 430

50

Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His  
435 440 445

Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe  
450 455 460

55

EP 1 310 571 B1

5 Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met  
465 470 475 480

Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu  
485 490 495

10 Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln  
500 505 510

Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
515 520 525

15 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
530 535 540

20 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
545 550 555 560

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
565 570 575

25 Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr  
580 585 590

30 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
595 600 605

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
610 615 620

35 Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val  
625 630 635 640

40 Tyr Ser Glu Pro

<210> 74

<211> 644

45 <212> PRT

<213> capsid protein of AAV serotype, clone 223.5

<400> 74

50

55



EP 1 310 571 B1

Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg  
 1 5 10 15

Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr  
 20 25 30

Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg  
 35 40 45

5

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro  
50 55 60

5 Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly  
65 70 75 80

10 Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
85 90 95

Gly Asp Ser Glu Pro Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
100 105 110

15 Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly  
115 120 125

20 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
130 135 140

Ser Gly Asn Trp His Cys Asp Ser Thr Arg Leu Gly Asp Arg Val Ile  
145 150 155 160

25 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
165 170 175

30 Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val  
180 185 190

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
195 200 205

35 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
210 215 220

40 Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln  
225 230 235 240

Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
245 250 255

45 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
260 265 270

50 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
275 280 285

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
290 295 300

55

EP 1 310 571 B1

Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
305 310 315 320

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
325 330 335

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Gly  
340 345 350

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg  
355 360 365

Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe  
370 375 380

Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu  
385 390 395 400

Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln  
405 410 415

Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu  
420 425 430

Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His  
435 440 445

Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe  
450 455 460

Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met  
465 470 475 480

Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu  
485 490 495

Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln  
500 505 510

Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
515 520 525

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
530 535 540

Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
545 550 555 560

EP 1 310 571 B1

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
565 570 575

Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr  
580 585 590

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
595 600 605

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
610 615 620

Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val  
625 630 635 640

Tyr Ser Glu Pro

<210> 75

<211> 644

<212> PRT

<213> capsid protein of AAV serotype, clone 223.10

<220>

<221> MISC\_FEATURE

<222> (434)..(434)

<223> can be any amino acid

<400> 75

Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg  
1 5 10 15

Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr  
20 25 30

Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg  
35 40 45

Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro  
50 55 60

Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly  
65 70 75 80

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
85 90 95

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
100 105 110

## EP 1 310 571 B1

Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly  
115 120 125

5

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
130 135 140

10

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
145 150 155 160

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
165 170 175

15

Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val  
180 185 190

20

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
195 200 205

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
210 215 220

25

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln  
225 230 235 240

30

Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
245 250 255

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
260 265 270

35

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
275 280 285

40

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
290 295 300

Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
305 310 315 320

45

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
325 330 335

50

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp  
340 345 350

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg  
355 360 365

55

EP 1 310 571 B1

5 Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe  
370 375 380

Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu  
385 390 395 400

10 Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln  
405 410 415

Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu  
420 425 430

15 Asn Xaa Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His  
435 440 445

20 Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe  
450 455 460

Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met  
465 470 475 480

25 Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu  
485 490 495

30 Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln  
500 505 510

Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
515 520 525

35 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
530 535 540

40 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
545 550 555 560

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
565 570 575

45 Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr  
580 585 590

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
595 600 605

50 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
610 615 620

55

EP 1 310 571 B1

Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val  
625 630 635 640

Tyr Ser Glu Pro

<210> 76

<211> 644

<212> PRT

<213> capsid protein of AAV serotype, clone 223.2

<400> 76

Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg  
1 5 10 15

Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Cys Leu Gln Glu Asp Thr  
20 25 30

Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg  
35 40 45

Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro  
50 55 60

Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly  
65 70 75 80

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
85 90 95

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
100 105 110

Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Val Ala Gly Gly Gly  
115 120 125

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
130 135 140

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
145 150 155 160

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
165 170 175

Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val  
180 185 190

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
195 200 205

EP 1 310 571 B1

5 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
210 215 220

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln  
225 230 235 240

10 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
245 250 255

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
260 265 270

15 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
275 280 285

20 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
290 295 300

Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
305 310 315 320

25 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
325 330 335

30 Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp  
340 345 350

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg  
355 360 365

35 Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe  
370 375 380

40 Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu  
385 390 395 400

Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln  
405 410 415

45 Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu  
420 425 430

50 Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His  
435 440 445

Lys Asp Asp Glu Glu Arg Phe Ser Pro Ser Ser Gly Val Leu Ile Phe  
450 455 460

55



EP 1 310 571 B1

Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met  
465 470 475 480

Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu  
485 490 495

Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln  
500 505 510

Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
515 520 525

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
530 535 540

Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
545 550 555 560

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
565 570 575

Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr  
580 585 590

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
595 600 605

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
610 615 620

Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val  
625 630 635 640

Tyr Ser Glu Pro

<210> 77

<211> 644

<212> PRT

<213> capsid protein of AAV serotype, clone 223.7

<400> 77

Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg  
1 5 10 15

Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr  
20 25 30

EP 1 310 571 B1

5 Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg  
 35 40 45  
 Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro  
 50 55 60  
 10 Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly  
 65 70 75 80  
 Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
 85 90 95  
 15 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
 100 105 110  
 Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly  
 115 120 125  
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
 130 135 140  
 25 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
 145 150 155 160  
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
 165 170 175  
 Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val  
 180 185 190  
 35 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
 195 200 205  
 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
 210 215 220  
 Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln  
 225 230 235 240  
 45 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
 245 250 255  
 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Pro Glu Tyr Gln Leu Pro  
 260 265 270  
 50 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
 275 280 285  
 55

EP 1 310 571 B1

5

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
290 295 300

10

Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
305 310 315 320

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
325 330 335

15

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp  
340 345 350

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg  
355 360 365

20

Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe  
370 375 380

Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu  
385 390 395 400

25

Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln  
405 410 415

30

Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu  
420 425 430

Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His  
435 440 445

35

Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe  
450 455 460

40

Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met  
465 470 475 480

Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu  
485 490 495

45

Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln  
500 505 510

50

Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
515 520 525

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
530 535 540

55

EP 1 310 571 B1

Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
545 550 555 560

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
565 570 575

Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Ile Ala Ser Phe Ile Thr  
580 585 590

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
595 600 605

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
610 615 620

Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val  
625 630 635 640

Tyr Ser Glu Pro

<210> 78

<211> 644

<212> PRT

<213> capsid protein of AAV serotype, clone 223.6

<400> 78

Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg  
1 5 10 15

Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr  
20 25 30

Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg  
35 40 45

Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro  
50 55 60

Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly  
65 70 75 80

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
85 90 95

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro  
100 105 110

Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly  
115 120 125

EP 1 310 571 B1

Ala Pro Met Ala Asp Asn Ser Glu Gly Ala Asp Gly Val Gly Asn Ala  
130 135 140

5 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
145 150 155 160

10 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
165 170 175

Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val  
180 185 190

15 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe  
195 200 205

20 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn  
210 215 220

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln  
225 230 235 240

25 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn  
245 250 255

30 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro  
260 265 270

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala  
275 280 285

35 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly  
290 295 300

40 Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro  
305 310 315 320

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe  
325 330 335

45 Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp  
340 345 350

50 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg  
355 360 365

Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe  
370 375 380

55

EP 1 310 571 B1

Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu  
385 390 395 400

Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln  
405 410 415

Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu  
420 425 430

Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His  
435 440 445

Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe  
450 455 460

Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met  
465 470 475 480

Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu  
485 490 495

Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln  
500 505 510

Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln  
515 520 525

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
530 535 540

Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
545 550 555 560

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
565 570 575

Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Leu Ala Ser Phe Ile Thr  
580 585 590

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
595 600 605

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
610 615 620

Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val  
625 630 635 640

Tyr Ser Glu Pro

5

&lt;210&gt; 79

&lt;211&gt; 738

&lt;212&gt; PRT

10

&lt;213&gt; capsid protein of AAV serotype, clone 44.1

&lt;400&gt; 79

15

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

20

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

25

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

30

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

35

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

40

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

45

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
165 170 175

50

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

55

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

EP 1 310 571 B1

5

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

10

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

15

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

20

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
305 310 315 320

25

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

30

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

35

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

40

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

45

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

50

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
450 455 460

55



EP 1 310 571 B1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
580 585 590

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp  
705 710 715 720

EP 1 310 571 B1

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

5

Asn Leu

<210> 80

10

<211> 738

<212> PRT

<213> capsid protein of AAV serotype, clone 44.5

<400> 80

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

EP 1 310 571 B1

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Pro Asn Phe Lys Leu Phe Asn  
305 310 315 320

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
450 455 460

EP 1 310 571 B1

Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
580 585 590

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp  
705 710 715 720

EP 1 310 571 B1

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

5

Asn Leu

<210> 81

10

<211> 738

<212> PRT

<213> capsid protein of AAV serotype, clone 44.2

<400> 81

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

EP 1 310 571 B1

5

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

10

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

15

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

20

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
305 310 315 320

25

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

30

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

35

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

40

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

45

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

50

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
450 455 460

55



EP 1 310 571 B1

5

Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

10

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

15

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

20

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

25

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
580 585 590

30

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

35

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

40

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

45

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

50

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp  
705 710 715 720

55

EP 1 310 571 B1

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

5

Asn Leu

10

<210> 82

<211> 738

<212> PRT

<213> capsid protein of AAV serotype, clone 29.3VP1

15

<400> 82

20

25

30

35

40

45

50

55

**EP 1 310 571 B1**

	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
	1				5					10					15		
5	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Ala	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro	
			20						25					30			
	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				
10	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
15		65				70					75					80	
	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala	
					85					90					95		
20	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105					110			
	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
25			115					120					125				
	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
		130					135					140					
30	Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Thr	Thr	Gly	Ile	
	145					150					155					160	
	Gly	Lys	Lys	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	
35					165					170					175		
	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Ile	Gly	Glu	Pro	
				180					185					190			
40	Pro	Ala	Gly	Pro	Ser	Gly	Leu	Gly	Ser	Gly	Thr	Met	Ala	Ala	Gly	Gly	
			195					200					205				

## EP 1 310 571 B1

5 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
 210 215 220  
 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
 225 230 235 240  
 10 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
 245 250 255  
 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
 260 265 270  
 15 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
 275 280 285  
 20 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
 290 295 300  
 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
 305 310 315 320  
 25 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
 325 330 335  
 30 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
 340 345 350  
 Leu Pro Tyr Val Leu Gly Ser Ala Arg Gln Gly Cys Leu Pro Pro Phe  
 355 360 365  
 35 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
 370 375 380  
 40 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
 385 390 395 400  
 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
 405 410 415  
 45 Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
 420 425 430  
 50 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
 435 440 445  
 Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
 450 455 460  
 55

EP 1 310 571 B1

5 Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

10 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

15 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

20 Phe Gly Lys Gln Gly Ala Gly Lys Gly Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

25 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
580 585 590

30 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

35 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

40 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

45 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

50 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp  
705 710 715 720

55

EP 1 310 571 B1

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

Asn Leu

<210> 83  
<211> 738  
<212> PRT  
<213> capsid protein of AAV serotype, clone 29.5VP1

<400> 83

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
25 35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
30 50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
35 65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
35 85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
40 100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
40 115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
45 130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
50 145 150 155 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
50 165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
55 180 185 190

EP 1 310 571 B1

5

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

10

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Gly Val  
225 230 235 240

15

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

20

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

25

Asn Asn Trp Gly Phe Arg Pro Lys Ser Leu Asn Phe Lys Leu Phe Asn  
305 310 315 320

30

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

35

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

40

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

45

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

50

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

55

EP 1 310 571 B1

5

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
450 455 460

Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

10

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

Gln Asn Asp Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

15

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

20

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

25

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

30

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
580 585 590

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

35

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

40

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
645 650 655

45

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

50

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

55



EP 1 310 571 B1

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp  
705 710 715 720

5

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

Asn Leu

10

<210> 84

<211> 738

<212> PRT

15

<213> capsid protein of AAV serotype, clone 42.15

<400> 84

20

25

30

35

40

45

50

55

**EP 1 310 571 B1**

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile
145					150					155					160

Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

EP 1 310 571 B1

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

5 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

10 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

15 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

20 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

25 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
305 310 315 320

30 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

35 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Pro Pro Pro Phe  
355 360 365

40 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

45 Phe Pro Ser Gln Met Arg Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

50 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

55

EP 1 310 571 B1

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
 450 455 460  
 5  
 Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
 465 470 475 480  
 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
 485 490 495  
 10  
 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
 500 505 510  
 15  
 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
 515 520 525  
 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
 530 535 540  
 20  
 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
 545 550 555 560  
 25  
 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
 565 570 575  
 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
 580 585 590  
 30  
 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
 595 600 605  
 35  
 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
 610 615 620  
 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
 625 630 635 640  
 40  
 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
 645 650 655  
 45  
 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
 660 665 670  
 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
 675 680 685  
 50  
 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
 690 695 700  
 55

EP 1 310 571 B1

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu  
705 710 715 720

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

Asn Leu

<210> 85

<211> 738

<212> PRT

<213> capsid protein of AAV serotype, clone 42.8

<400> 85

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
165 170 175

## EP 1 310 571 B1

5

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
 180 185 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
 195 200 205

10

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
 210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
 225 230 235 240

15

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
 245 250 255

20

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
 260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
 275 280 285

25

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
 290 295 300

30

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
 305 310 315 320

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
 325 330 335

35

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
 340 345 350

40

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
 355 360 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
 370 375 380

45

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
 385 390 395 400

50

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
 405 410 415

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
 420 425 430

55

EP 1 310 571 B1

5 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
 435 440 445  
 Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
 450 455 460  
 10 Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
 465 470 475 480  
 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
 485 490 495  
 15 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
 500 505 510  
 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
 515 520 525  
 20 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
 530 535 540  
 25 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
 545 550 555 560  
 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
 565 570 575  
 30 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
 580 585 590  
 35 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
 595 600 605  
 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
 610 615 620  
 40 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
 625 630 635 640  
 45 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
 645 650 655  
 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
 660 665 670  
 50 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
 675 680 685  
 55

EP 1 310 571 B1

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

5

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu  
705 710 715 720

10

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

Asn Leu

15

<210> 86

<211> 733

<212> PRT

20 <213> amino acid of AAV serotype, clone 42.13

<400> 86

25

30

35

40

45

50

55



EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

EP 1 310 571 B1

Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190

Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp  
210 215 220

His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn Thr Tyr Phe Gly  
260 265 270

Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His  
275 280 285

Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe  
290 295 300

Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu  
305 310 315 320

Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser  
325 330 335

Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu  
340 345 350

Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe  
355 360 365

Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala  
370 375 380

Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met  
385 390 395 400

Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val  
405 410 415

Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met  
420 425 430

EP 1 310 571 B1

5 Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser  
 435 440 445  
 Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly  
 450 455 460  
 10 Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys  
 465 470 475 480  
 Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Ser Gln Asn Asn Asn Ser  
 485 490 495  
 15 Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp  
 500 505 510  
 20 Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His Lys Gly Asp Glu  
 515 520 525  
 Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly  
 530 535 540  
 25 Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu  
 545 550 555 560  
 30 Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val  
 565 570 575  
 Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala  
 580 585 590  
 35 Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp  
 595 600 605  
 40 Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly  
 610 615 620  
 Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro  
 625 630 635 640  
 45 Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro  
 645 650 655  
 50 Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe Ile Thr Gln Tyr Ser  
 660 665 670  
 Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn  
 675 680 685

EP 1 310 571 B1

Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys  
690 695 700

Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu  
705 710 715 720

Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Ser Leu  
725 730

<210> 87

<211> 733

<212> PRT

<213> capsid protein of AAV serotype, clone 42.3A

<400> 87

EP 1 310 571 B1

Met Ala Ala Asp Gly His Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190

EP 1 310 571 B1

5 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp  
210 215 220

10 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

15 Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn Thr Tyr Phe Gly  
260 265 270

20 Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His  
275 280 285

Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Ser Trp Gly Phe  
290 295 300

25 Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu  
305 310 315 320

30 Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser  
325 330 335

Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu  
340 345 350

35 Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe  
355 360 365

40 Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala  
370 375 380

Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met  
385 390 395 400

45 Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val  
405 410 415

50 Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met  
420 425 430

Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser  
435 440 445

55

EP 1 310 571 B1

5

Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly  
450 455 460

Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys  
465 470 475 480

10

Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser Gln Asn Asn Asn Ser  
485 490 495

Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp  
500 505 510

15

Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His Lys Asp Asp Glu  
515 520 525

20

Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly  
530 535 540

Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu  
545 550 555 560

25

Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val  
565 570 575

30

Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala  
580 585 590

Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp  
595 600 605

35

Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly  
610 615 620

40

Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro  
625 630 635 640

Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro  
645 650 655

45

Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe Ile Thr Gln Tyr Ser  
660 665 670

50

Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn  
675 680 685

Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys  
690 695 700

55

EP 1 310 571 B1

Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu  
705 710 715 720

Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730

<210> 88  
<211> 731  
<212> PRT  
<213> capsid protein of AAV serotype, clone 42.4

<400> 88

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190



EP 1 310 571 B1

Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
 195 200 205  
 5  
 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
 210 215 220  
 10  
 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
 225 230 235 240  
 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
 245 250 255  
 15  
 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
 260 265 270  
 20  
 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
 275 280 285  
 Ser Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
 290 295 300  
 25  
 Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
 305 310 315 320  
 30  
 Gln Asn Glu Gly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
 325 330 335  
 Gln Val Phe Thr Asp Ser Glu Tyr Arg Leu Pro Tyr Val Leu Gly Ser  
 340 345 350  
 35  
 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
 355 360 365  
 40  
 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly  
 370 375 380  
 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
 385 390 395 400  
 45  
 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val Pro Phe  
 405 410 415  
 50  
 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
 420 425 430  
 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser Thr Gly  
 435 440 445  
 55

EP 1 310 571 B1

5 Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly Pro Asn  
450 455 460

Asn Met Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg  
465 470 475 480

10 Gln Gln Arg Val Ser Thr Thr Leu Ser Gln Asn Asn Asn Ser Asn Phe  
485 490 495

Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp Ser Leu  
500 505 510

15 Val Asn Pro Gly Val Ala Met Ala Thr His Lys Asp Asp Glu Glu Arg  
515 520 525

20 Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly Ala Gly  
530 535 540

Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu Glu Glu  
545 550 555 560

25 Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val Val Ala  
565 570 575

30 Asp Asn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala Val Asn  
580 585 590

Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr  
595 600 605

35 Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe  
610 615 620

40 His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro  
625 630 635 640

Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Thr  
645 650 655

45 Phe Ser Gln Ala Lys Pro Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly  
660 665 670

50 Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys  
675 680 685

Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Thr  
690 695 700

55

EP 1 310 571 B1

Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu Pro Arg  
705 710 715 720

5

Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730

10

<210> 89

<211> 731

<212> PRT

<213> capsid protein of AAV serotype, clone 42.5A

15

<400> 89

20

25

30

35

40

45

50

55

EP 1 310 571 B1

	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
	1				5					10				15			
5	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Asp	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro	
				20					25					30			
	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				
10	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
15	Val	Asn	Glu	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
	65					70					75					80	
	Lys	Gln	Leu	Glu	Gln	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala	
					85					90					95		
20	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105					110			
25	Asn	Leu	Gly	Arg	Ala	Val	Phe	Arg	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				
	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
		130					135					140					
30	Pro	Ile	Glu	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile	Gly	Lys	Lys	Gly	Gln	
	145					150					155					160	
35	Gln	Pro	Ala	Lys	Lys	Lys	Leu	Asn	Phe	Gly	Gln	Thr	Gly	Asp	Ser	Glu	
					165					170					175		
	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro	Ala	Ala	Pro	Ser	
				180					185					190			
40	Gly	Leu	Gly	Ser	Gly	Thr	Met	Ala	Ala	Gly	Gly	Gly	Ala	Pro	Met	Ala	
			195					200					205				

45

50

55

EP 1 310 571 B1

5 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

10 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

15 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
260 265 270

Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

20 Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Arg Gly Phe Arg Pro  
290 295 300

25 Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

30 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

35 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
370 375 380

40 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

45 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val Pro Phe  
405 410 415

His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

50 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser Thr Gly  
435 440 445

Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly Pro Asn  
450 455 460

55

EP 1 310 571 B1

Asn Met Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg  
465 470 475 480

5

Gln Gln Arg Val Ser Thr Thr Leu Ser Gln Asn Asn Asn Ser Asn Phe  
485 490 495

10

Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp Ser Leu  
500 505 510

Val Asn Pro Gly Val Ala Met Ala Thr His Lys Asp Asp Glu Glu Arg  
515 520 525

15

Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly Ala Gly  
530 535 540

20

Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu Glu Glu  
545 550 555 560

Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val Val Ala  
565 570 575

25

Asp Asn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala Val Asn  
580 585 590

30

Ser Gln Gly Ala Leu Pro Gly Met Ala Trp Gln Asn Arg Asp Val Tyr  
595 600 605

Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe  
610 615 620

35

His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro  
625 630 635 640

40

Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Thr  
645 650 655

Phe Ser Gln Ala Lys Leu Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly  
660 665 670

45

Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys  
675 680 685

50

Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Thr  
690 695 700

Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu Pro Arg  
705 710 715 720

55

EP 1 310 571 B1

Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730

<210> 90  
<211> 733  
<212> PRT  
<213> capsid protein of AAV serotype, clone 42.1B

<400> 90

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Arg Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190

Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp  
210 215 220

EP 1 310 571 B1

5  
 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
 225 230 235 240  
 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
 245 250 255  
 10 Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn Thr Tyr Phe Gly  
 260 265 270  
 Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His  
 275 280 285  
 15 Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe  
 290 295 300  
 20 Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu  
 305 310 315 320  
 Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser  
 325 330 335  
 25 Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu  
 340 345 350  
 Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe  
 355 360 365  
 30 Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala  
 370 375 380  
 35 Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met  
 385 390 395 400  
 Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val  
 405 410 415  
 40 Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met  
 420 425 430  
 45 Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser  
 435 440 445  
 Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly  
 450 455 460  
 50 Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys  
 465 470 475 480  
 55



EP 1 310 571 B1

Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Ser Gln Asn Asn Asn Ser  
 485 490 495  
 5  
 Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp  
 500 505 510  
 10  
 Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His Lys Gly Asp Glu  
 515 520 525  
 Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly  
 530 535 540  
 15  
 Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu  
 545 550 555 560  
 20  
 Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val  
 565 570 575  
 Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala  
 580 585 590  
 25  
 Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp  
 595 600 605  
 30  
 Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly  
 610 615 620  
 Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro  
 625 630 635 640  
 35  
 Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro  
 645 650 655  
 40  
 Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe Ile Thr Gln Tyr Ser  
 660 665 670  
 Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn  
 675 680 685  
 45  
 Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys  
 690 695 700  
 50  
 Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu  
 705 710 715 720  
 Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
 725 730  
 55

## EP 1 310 571 B1

&lt;211&gt; 738

&lt;212&gt; PRT

&lt;213&gt; capsid protein of AAV serotype, clone 42.5B

5 &lt;400&gt; 91

```

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1           5           10           15

10 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
           20           25           30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
           35           40           45

15 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
           50           55           60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65           70           75           80

20 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
           85           90           95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
25           100          105          110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
           115          120          125

30 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
           130          135          140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile
35 145          150          155          160

Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln
           165          170          175

40 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro
           180          185          190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly
45 195          200          205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser
210          215          220

50 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
225          230          235          240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
55 245          250          255

```

EP 1 310 571 B1

5

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

10

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
305 310 315 320

15

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

20

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

25

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

30

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

35

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

40

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu  
450 455 460

45

Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

50

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

55

EP 1 310 571 B1

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
515 520 525

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala  
580 585 590

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

Gly Leu Lys His Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu  
705 710 715 720

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

Asn Leu

<210> 92

<211> 738

<212> PRT

<213> capsid protein of AAV serotype, clone 43.1

<400> 92

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

10 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

15 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

20 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

25 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

30 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

35 Gly Lys Lys Gly His Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

40 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

45 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

50 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

55

EP 1 310 571 B1

5 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
 260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
 275 280 285

10 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
 290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
 305 310 315 320

15 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
 325 330 335

20 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
 340 345 350

Leu Pro Tyr Val Pro Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
 355 360 365

25 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
 370 375 380

30 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
 385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
 405 410 415

35 Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
 420 425 430

40 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
 435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Gln Gly Thr Gln Gln Leu Leu  
 450 455 460

45 Phe Ser Gln Ala Gly Pro Ala Asn Met Ser Ala Gln Ala Lys Asn Trp  
 465 470 475 480

50 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
 485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
 500 505 510

55 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
 515 520 525

EP 1 310 571 B1

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
565 570 575

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Thr Asn Gly Ala  
580 585 590

Pro Ile Val Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
610 615 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
625 630 635 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Val Lys Asn Thr Pro Val  
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
660 665 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu  
705 710 715 720

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
725 730 735

Asn Leu

<210> 93

<211> 738

<212> PRT

<213> capsid protein of AAV serotype, clone 43.12

<400> 93

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Lys Gly His Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255



EP 1 310 571 B1

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
 260 265 270  
 5  
 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
 275 280 285  
 10  
 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
 290 295 300  
 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
 305 310 315 320  
 15  
 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
 325 330 335  
 20  
 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
 340 345 350  
 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
 355 360 365  
 25  
 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
 370 375 380  
 30  
 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
 385 390 395 400  
 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
 405 410 415  
 35  
 Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
 420 425 430  
 40  
 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
 435 440 445  
 Ser Arg Thr Gln Ser Thr Gly Gly Thr Gln Gly Thr Gln Gln Leu Leu  
 450 455 460  
 45  
 Phe Ser Gln Ala Gly Pro Ala Asn Met Ser Ala Gln Ala Lys Asn Trp  
 465 470 475 480  
 50  
 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
 485 490 495  
 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
 500 505 510

EP 1 310 571 B1

5 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr  
 515 520 525  
 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met  
 530 535 540  
 10 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val  
 545 550 555 560  
 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
 565 570 575  
 15 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Thr Asn Gly Ala  
 580 585 590  
 20 Pro Ile Val Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
 595 600 605  
 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
 610 615 620  
 25 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
 625 630 635 640  
 30 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Val Lys Asn Thr Pro Val  
 645 650 655  
 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe  
 660 665 670  
 35 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
 675 680 685  
 40 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
 690 695 700  
 Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu  
 705 710 715 720  
 45 Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
 725 730 735  
 50 Asn Leu

<210> 94

<211> 738

<212> PRT

55 <213> capsid protein of AAV serotype, clone 43.5

<400> 94

## EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
145 150 155 160

Gly Lys Lys Gly His Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln  
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
180 185 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
195 200 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
225 230 235 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

EP 1 310 571 B1

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
260 265 270

5

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

10

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
305 310 315 320

15

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

20

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

25

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

30

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

35

Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

40

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Gln Gly Thr Gln Gln Leu Leu  
450 455 460

45

Phe Ser Gln Ala Gly Pro Ala Asn Met Ser Ala Gln Ala Lys Asn Trp  
465 470 475 480

50

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser  
485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His  
500 505 510

55

EP 1 310 571 B1

	Leu	Asn	Gly	Arg	Asp	Ser	Leu	Val	Asn	Pro	Gly	Val	Ala	Met	Ala	Thr	
			515					520					525				
5	His	Lys	Asp	Asp	Glu	Glu	Arg	Phe	Phe	Pro	Ser	Ser	Gly	Val	Leu	Met	
		530					535					540					
10	Phe	Gly	Lys	Gln	Gly	Ala	Gly	Lys	Asp	Asn	Val	Asp	Tyr	Ser	Ser	Val	
	545					550					555					560	
	Met	Leu	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	
					565					570					575		
15	Glu	Gln	Tyr	Gly	Val	Val	Ala	Asp	Asn	Leu	Gln	Gln	Thr	Asn	Gly	Ala	
				580					585					590			
20	Pro	Ile	Val	Gly	Thr	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	
			595					600					605				
	Trp	Gln	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	
		610					615					620					
25	Pro	His	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	
	625					630					635					640	
30	Gly	Leu	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Val	Lys	Asn	Thr	Pro	Val	
					645					650					655		
	Pro	Ala	Asp	Pro	Pro	Thr	Thr	Phe	Ser	Gln	Ala	Lys	Leu	Ala	Ser	Phe	
				660					665					670			
35	Ile	Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	
			675					680					685				
40	Leu	Gln	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	
	690						695					700					
	Ser	Asn	Tyr	Tyr	Lys	Ser	Thr	Asn	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu	
	705					710					715					720	
45	Gly	Thr	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	
					725					730					735		
50	Asn	Leu															

<210> 95

<211> 738

55 <212> PRT

<213> capsid protein of AAV serotype, clone AAV8

<400> 95

EP 1 310 571 B1

1	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
					5					10					15		
5	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Ala	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro	
				20					25					30			
10	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				
15	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
20	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
		65				70					75					80	
25	Gln	Gln	Leu	Gln	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala	
				85						90				95			
30	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
			100						105					110			
35	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				
40	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
		130					135					140					
45	Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile	
		145				150					155					160	
50	Gly	Lys	Lys	Gly	Gln	Gln	Pro	Ala	Arg	Lys	Arg	Leu	Asn	Phe	Gly	Gln	
				165					170						175		
55	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	
			180						185					190			
60	Pro	Ala	Ala	Pro	Ser	Gly	Val	Gly	Pro	Asn	Thr	Met	Ala	Ala	Gly	Gly	
			195					200					205				
65	Gly	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	
		210					215					220					
70	Ser	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	
				225		230					235					240	

EP 1 310 571 B1

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ala Thr Asn Asp  
260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Ser Phe Lys Leu Phe Asn  
305 310 315 320

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
355 360 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Thr Tyr  
405 410 415

Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala Asn Thr Gln Thr Leu Gly  
450 455 460

Phe Ser Gln Gly Gly Pro Asn Thr Met Ala Asn Gln Ala Lys Asn Trp  
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Gly  
485 490 495

EP 1 310 571 B1

5 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Ala Gly Thr Lys Tyr His  
 500 505 510  
 Leu Asn Gly Arg Asn Ser Leu Ala Asn Pro Gly Ile Ala Met Ala Thr  
 515 520 525  
 10 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Asn Gly Ile Leu Ile  
 530 535 540  
 Phe Gly Lys Gln Asn Ala Ala Arg Asp Asn Ala Asp Tyr Ser Asp Val  
 545 550 555 560  
 15 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr  
 565 570 575  
 20 Glu Glu Tyr Gly Ile Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala  
 580 585 590  
 Pro Gln Ile Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val  
 595 600 605  
 25 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile  
 610 615 620  
 30 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe  
 625 630 635 640  
 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val  
 645 650 655  
 35 Pro Ala Asp Pro Pro Thr Thr Phe Asn Gln Ser Lys Leu Asn Ser Phe  
 660 665 670  
 40 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu  
 675 680 685  
 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr  
 690 695 700  
 45 Ser Asn Tyr Tyr Lys Ser Thr Ser Val Asp Phe Ala Val Asn Thr Glu  
 705 710 715 720  
 50 Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg  
 725 730 735  
 Asn Leu

55



EP 1 310 571 B1

<212> PRT

<213> capsid protein of AAV serotype, clone 43.21

<400> 96

5

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

10

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

15

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

20

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

25

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

30

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

35

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

40

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

45

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
180 185 190

Ala Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205

50

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

55

EP 1 310 571 B1

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
 225 230 235 240  
 5  
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
 245 250 255  
 Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn  
 10 260 265 270  
 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
 275 280 285  
 15  
 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
 290 295 300  
 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile  
 20 305 310 315 320  
 Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn  
 325 330 335  
 25  
 Asn Leu Thr Ser Thr Val Arg Val Phe Thr Asp Ser Glu Tyr Gln Leu  
 340 345 350  
 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
 30 355 360 365  
 Ala Asp Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
 370 375 380  
 35  
 Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
 385 390 395 400  
 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr  
 40 405 410 415  
 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
 420 425 430  
 45  
 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val  
 435 440 445  
 Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser  
 50 450 455 460  
 Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp Val Pro  
 465 470 475 480  
 55

EP 1 310 571 B1

	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Thr	Asn	Gln	Ser	
					485					490					495		
5	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Gly	Ala	Ala	Lys	Phe	Lys	Leu	Asn	
				500					505					510			
	Gly	Arg	Asp	Ser	Leu	Met	Asn	Pro	Gly	Val	Ala	Met	Ala	Ser	His	Lys	
10			515					520					525				
	Asp	Asp	Asp	Asp	Arg	Phe	Phe	Pro	Ser	Ser	Gly	Val	Leu	Ile	Phe	Gly	
		530					535					540					
15	Lys	Gln	Gly	Ala	Gly	Asn	Asp	Gly	Val	Asp	Tyr	Ser	Gln	Val	Leu	Ile	
	545					550					555					560	
	Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Glu	
20					565					570					575		
	Tyr	Gly	Ala	Val	Ala	Ile	Asn	Asn	Gln	Ala	Ala	Asn	Thr	Gln	Ala	Gln	
				580					585					590			
25	Thr	Gly	Leu	Val	His	Asn	Gln	Gly	Val	Ile	Pro	Gly	Met	Val	Trp	Gln	
			595					600					605				
	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	
30		610					615					620					
	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	
	625					630					635					640	
35	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
					645					650					655		
	Asp	Pro	Pro	Leu	Thr	Phe	Asn	Gln	Ala	Lys	Leu	Asn	Ser	Phe	Ile	Thr	
40				660					665					670			
	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	
			675					680					685				
45	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn	
	690						695					700					
	Tyr	Tyr	Lys	Ser	Thr	Asn	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu	Gly	Val	
50	705					710					715					720	
	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Asn	Leu	
					725					730					735		

55

<210> 97  
<211> 736

EP 1 310 571 B1

<212> PRT

<213> capsid protein of AAV serotype, clone 43.25

<400> 97

5

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

10

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

15

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

20

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

25

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

30

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

35

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

40

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
180 185 190

45

Ala Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205

50

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
225 230 235 240

55

EP 1 310 571 B1

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
 245 250 255  
 5  
 Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn  
 260 265 270  
 10  
 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
 275 280 285  
 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
 290 295 300  
 15  
 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile  
 305 310 315 320  
 20  
 Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn  
 325 330 335  
 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu  
 340 345 350  
 25  
 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
 355 360 365  
 30  
 Ala Asp Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
 370 375 380  
 Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
 385 390 395 400  
 35  
 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr  
 405 410 415  
 40  
 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
 420 425 430  
 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val  
 435 440 445  
 45  
 Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser  
 450 455 460  
 50  
 Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp Val Pro  
 465 470 475 480  
 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn Gln Asn  
 485 490 495  
 55

EP 1 310 571 B1

5 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn  
 500 505 510  
 Gly Arg Asp Ser Leu Met Asn Pro Gly Val Ala Met Ala Ser His Lys  
 515 520 525  
 10 Asp Asp Asp Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe Gly  
 530 535 540  
 Lys Gln Gly Ala Gly Asn Asp Gly Val Asp Tyr Ser Gln Val Leu Ile  
 545 550 555 560  
 15 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Glu  
 565 570 575  
 20 Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala Ala Asn Thr Gln Ala Gln  
 580 585 590  
 Thr Gly Leu Val His Asn Gln Gly Val Ile Pro Gly Met Val Trp Gln  
 595 600 605  
 25 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
 610 615 620  
 30 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
 625 630 635 640  
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
 645 650 655  
 35 Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe Ile Thr  
 660 665 670  
 40 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
 675 680 685  
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
 690 695 700  
 45 Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Val  
 705 710 715 720  
 50 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
 725 730 735

<210> 98

<211> 736

<212> PRT

<213> capsid protein of AAV serotype, clone 43.23

&lt;400&gt; 98

5 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
 1 5 10 15  
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30  
 10 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45  
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
 50 55 60  
 15 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
 65 70 75 80  
 20 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
 85 90 95  
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110  
 25 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 30 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140  
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
 145 150 155 160  
 35 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
 165 170 175  
 40 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
 180 185 190  
 Ala Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly  
 195 200 205  
 45 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
 210 215 220  
 50 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
 225 230 235 240  
 55

## EP 1 310 571 B1

5 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
 245 250 255

Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn  
 260 265 270

10 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
 275 280 285

Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
 290 295 300

15 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile  
 305 310 315 320

20 Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn  
 325 330 335

Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Leu Glu Tyr Gln Leu  
 340 345 350

25 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
 355 360 365

30 Ala Asp Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
 370 375 380

Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
 385 390 395 400

35 Pro Ser Gln Met Pro Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr  
 405 410 415

40 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
 420 425 430

Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val  
 435 440 445

45 Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser  
 450 455 460

50 Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp Val Pro  
 465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn Gln Asn  
 485 490 495

55



EP 1 310 571 B1

5 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn  
 500 505 510  
 Gly Arg Asp Ser Leu Met Asn Pro Gly Val Ala Met Ala Ser His Lys  
 515 520 525  
 10 Asp Asp Asp Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe Gly  
 530 535 540  
 Lys Gln Gly Ala Gly Asn Asp Gly Val Asp Tyr Ser Gln Val Leu Ile  
 545 550 555 560  
 15 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Glu  
 565 570 575  
 20 Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala Ala Asn Thr Gln Ala Gln  
 580 585 590  
 Thr Gly Leu Val His Asn Gln Gly Val Ile Pro Gly Met Val Trp Gln  
 595 600 605  
 25 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
 610 615 620  
 30 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
 625 630 635 640  
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
 645 650 655  
 35 Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe Ile Thr  
 660 665 670  
 40 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
 675 680 685  
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
 690 695 700  
 45 Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Val  
 705 710 715 720  
 50 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
 725 730 735

<210> 99

<211> 736

<212> PRT

<213> capsid protein of AAV serotype, clone 43.20

&lt;400&gt; 99

5 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
 1 5 10 15  
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30  
 10 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45  
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
 50 55 60  
 15 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
 65 70 75 80  
 20 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
 85 90 95  
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110  
 25 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 30 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140  
 Leu Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
 145 150 155 160  
 35 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
 165 170 175  
 40 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
 180 185 190  
 Ala Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly  
 195 200 205  
 45 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
 210 215 220  
 50 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
 225 230 235 240  
 55

EP 1 310 571 B1

5 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn  
260 265 270

10 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
275 280 285

Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
290 295 300

15 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile  
305 310 315 320

20 Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn  
325 330 335

Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu  
340 345 350

25 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
355 360 365

30 Ala Asp Val Phe Thr Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
370 375 380

Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
385 390 395 400

35 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr  
405 410 415

40 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
420 425 430

Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val  
435 440 445

45 Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser  
450 455 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp Val Pro  
465 470 475 480

50 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn Gln Asn  
485 490 495

55

EP 1 310 571 B1

5 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn  
 500 505 510  
 Gly Arg Asp Ser Leu Met Asn Pro Gly Val Ala Met Ala Ser His Lys  
 515 520 525  
 10 Asp Asp Asp Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe Gly  
 530 535 540  
 Lys Gln Gly Ala Gly Asn Asp Gly Val Asp Tyr Ser Gln Val Leu Ile  
 545 550 555 560  
 15 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Glu  
 565 570 575  
 20 Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala Ala Asn Thr Gln Ala Gln  
 580 585 590  
 Thr Gly Leu Val His Asn Gln Gly Val Ile Pro Gly Met Val Trp Gln  
 595 600 605  
 25 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
 610 615 620  
 30 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
 625 630 635 640  
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
 645 650 655  
 35 Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe Ile Thr  
 660 665 670  
 40 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
 675 680 685  
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
 690 695 700  
 45 Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Val  
 705 710 715 720  
 50 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
 725 730 735

<210> 100

<211> 736

55 <212> PRT

<213> capsid protein of AAV serotype, clone AAV9

400> 100

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

10 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

15 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

20 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

25 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

30 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

35 Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
180 185 190

40 Glu Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly  
195 200 205

45 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser  
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
225 230 235 240

50 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
245 250 255

55

EP 1 310 571 B1

5 Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn  
260 265 270

Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg  
275 280 285

10 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn  
290 295 300

Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile  
305 310 315 320

15 Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn  
325 330 335

20 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu  
340 345 350

Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro  
355 360 365

25 Ala Asp Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn  
370 375 380

30 Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe  
385 390 395 400

Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr  
405 410 415

35 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu  
420 425 430

40 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val  
435 440 445

Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser  
450 455 460

45 Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp Val Pro  
465 470 475 480

50 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn Gln Asn  
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn  
500 505 510

55

EP 1 310 571 B1

5 Gly Arg Asp Ser Leu Met Asn Pro Gly Val Ala Met Ala Ser His Lys  
515 520 525

Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe Gly  
530 535 540

10 Lys Gln Gly Ala Gly Asn Asp Gly Val Asp Tyr Ser Gln Val Leu Ile  
545 550 555 560

Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Glu  
565 570 575

15 Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala Ala Asn Thr Gln Ala Gln  
580 585 590

20 Thr Gly Leu Val His Asn Gln Gly Val Ile Pro Gly Met Val Trp Gln  
595 600 605

25 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
610 615 620

Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
625 630 635 640

30 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
645 650 655

35 Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe Ile Thr  
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
675 680 685

40 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn  
690 695 700

45 Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Val  
705 710 715 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 101

<211> 728

<212> PRT

<213> capsid protein of AAV serotype, clone 24.1

<400> 101

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5

10

15

20

25

30

35

40

45

50

55



EP 1 310 571 B1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Arg Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Val Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
180 185 190

Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Ser Tyr Ser  
260 265 270

## EP 1 310 571 B1

5

Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

10

Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

15

Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

20

Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
370 375 380

25

Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

30

Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
405 410 415

His Ser Ser Tyr Val His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

35

Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
435 440 445

40

Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
450 455 460

Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
465 470 475 480

45

Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
485 490 495

50

Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
500 505 510

Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe  
515 520 525

55

EP 1 310 571 B1

Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
530 535 540

5

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560

10

Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
565 570 575

Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

15

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Cys Leu Gln Gly  
595 600 605

20

Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

25

Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

30

Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

35

Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

40

Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

45

<210> 102

<211> 728

<212> PRT

<213> capsid protein of AAV serotype, clone 42.2REAL

50

<400> 102

55

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

## EP 1 310 571 B1

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30

5 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45

10 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
 50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
 65 70 75 80

15 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
 85 90 95

20 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125

25 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140

30 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
 145 150 155 160

Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
 165 170 175

35 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
 180 185 190

40 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
 195 200 205

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
 210 215 220

45 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
 225 230 235 240

50 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
 245 250 255

Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
 260 265 270

55

## EP 1 310 571 B1

5

Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

10

Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

15

Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

20

Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

25

Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
370 375 380

Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

30

Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
405 410 415

35

His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
435 440 445

40

Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
450 455 460

45

Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
465 470 475 480

Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
485 490 495

50

Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
500 505 510

55

Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe  
515 520 525

Pro Ile Asn Gly Val Leu Val Phe Gly Glu Thr Gly Ala Ala Asn Lys  
530 535 540

5

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560

10

Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
565 570 575

Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

15

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
595 600 605

20

Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

25

Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

30

Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

35

Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

40

Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

45

<210> 103

<211> 728

<212> PRT

50

<213> capsid protein of AAV serotype, clone 7.2VP1

<400> 103

55

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Gly Asn Leu Ser  
1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

5

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

10

Gly Tyr Arg Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

15

Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

20

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

25

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Asn Gly Gln  
145 150 155 160

30

Pro Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
180 185 190

35

Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

40

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

45

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

50

Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
260 265 270

Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

55



EP 1 310 571 B1

5 Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

10 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

15 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

20 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
370 375 380

Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

25 Thr Gly Asp Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
405 410 415

30 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
435 440 445

35 Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
450 455 460

40 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
465 470 475 480

Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
485 490 495

45 Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
500 505 510

50 Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe  
515 520 525

Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
530 535 540

55

EP 1 310 571 B1

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560

Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
565 570 575

Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
595 600 605

Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

<210> 104

<211> 728

<212> PRT

<213> capsid protein of AAV serotype, clone 27.3VP1

<400> 104

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

EP 1 310 571 B1

5 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45  
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
 50 55 60  
 10 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
 65 70 75 80  
 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
 85 90 95  
 15 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110  
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 20 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Ser Gly Lys Lys Arg  
 130 135 140  
 25 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
 145 150 155 160  
 30 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
 165 170 175  
 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
 180 185 190  
 35 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
 195 200 205  
 40 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
 210 215 220  
 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
 225 230 235 240  
 45 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
 245 250 255  
 50 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
 260 265 270  
 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
 275 280 285

EP 1 310 571 B1

5 Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
 290 295 300  
 Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
 305 310 315 320  
 10 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
 325 330 335  
 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
 340 345 350  
 15 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
 355 360 365  
 20 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
 370 375 380  
 Arg Ser Ser Phe Cys Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
 385 390 395 400  
 25 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
 405 410 415  
 30 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
 420 425 430  
 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
 435 440 445  
 35 Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Val  
 450 455 460  
 40 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
 465 470 475 480  
 Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
 485 490 495  
 45 Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
 500 505 510  
 50 Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Leu  
 515 520 525  
 55 Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
 530 535 540

EP 1 310 571 B1

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560

Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
565 570 575

Gln Ser Ser Thr Ala Gly Pro Arg Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
595 600 605

Pro Ile Trp Ala Glu Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

<210> 105

<211> 728

<212> PRT

<213> capsid protein of AAV serotype, clone 16.3VP1

<400> 105

# EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
 1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30

10 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

5 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

10 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

15 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

20 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

25 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

30 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
180 185 190

Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

35 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

40 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

45 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
260 265 270

50 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

55

EP 1 310 571 B1

Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Met Gly  
370 375 380

Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
405 410 415

His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
435 440 445

Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
450 455 460

Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
465 470 475 480

Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
485 490 495

Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
500 505 510

Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Gly Gln Phe Phe  
515 520 525

Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
530 535 540

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560



EP 1 310 571 B1

Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
 565 570 575  
 5  
 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
 580 585 590  
 10  
 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
 595 600 605  
 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
 610 615 620  
 15  
 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
 625 630 635 640  
 20  
 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Gly Val Phe Thr Pro  
 645 650 655  
 Ala Leu Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
 660 665 670  
 25  
 Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
 675 680 685  
 30  
 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
 690 695 700  
 Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
 705 710 715 720  
 35  
 Thr Arg Tyr Leu Thr Arg Asn Leu  
 725  
 40  
 <210> 106  
 <211> 728  
 <212> PRT  
 <213> capsid protein of AAV serotype, clone 42.10  
 45  
 <400> 106  
 50  
 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
 1 5 10 15  
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30  
 55  
 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45

EP 1 310 571 B1

5 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

10 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

15 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

20 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

25 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

30 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

35 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Arg Lys Gly Gln  
145 150 155 160

40 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

45 Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190

50 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

55 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

60 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

65 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

70 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
260 265 270

75 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

80 Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

EP 1 310 571 B1

5 Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

10 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

15 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
370 375 380

20 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
405 410 415

25 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

30 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
435 440 445

Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
450 455 460

35 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
465 470 475 480

40 Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
485 490 495

Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
500 505 510

45 Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe  
515 520 525

50 Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
530 535 540

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560

55

EP 1 310 571 B1

Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
565 570 575

5

Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

10

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
595 600 605

Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

15

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

20

Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

25

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

30

Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

35

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

40

<210> 107

<211> 728

<212> PRT

<213> capsid protein of AAV serotype, clone 42.3B

45

<400> 107

50

55

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

10 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

5 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

10 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

15 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

20 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

25 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

30 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

35 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

40 Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190

45 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

50 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

55 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

60 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

65 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
260 265 270

70 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

75 Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

80 Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

5

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
325 330 335

10

Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
340 345 350

15

Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
355 360 365

Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
370 375 380

20

Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
385 390 395 400

Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
405 410 415

25

His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
420 425 430

Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
435 440 445

30

Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
450 455 460

35

Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln  
465 470 475 480

Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Thr Ser Asn Phe Ala Trp  
485 490 495

40

Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
500 505 510

45

Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe  
515 520 525

Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
530 535 540

50

Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
545 550 555 560

55

Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val Val Ser Ser Asn Leu  
565 570 575

EP 1 310 571 B1

5 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
595 600 605

10 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

15 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

20 Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

25 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

30 Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

35

<210> 108  
<211> 728  
<212> PRT  
40 <213> capsid protein of AAV serotype, clone 42.11

<400> 108

45 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

50 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

55 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60



EP 1 310 571 B1

5 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

10 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

15 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

20 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

25 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

30 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

35 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

40 Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser  
180 185 190

45 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

50 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

55 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser  
260 265 270

Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser  
275 280 285

Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro  
290 295 300

Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr  
305 310 315 320

EP 1 310 571 B1

Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile  
 325 330 335  
 5  
 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser  
 340 345 350  
 10  
 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile  
 355 360 365  
 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly  
 370 375 380  
 15  
 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg  
 385 390 395 400  
 20  
 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe  
 405 410 415  
 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro  
 420 425 430  
 25  
 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr  
 435 440 445  
 30  
 Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met  
 450 455 460  
 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Arg Gln  
 465 470 475 480  
 35  
 Arg Leu Ser Lys Asp Ile Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp  
 485 490 495  
 40  
 Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn  
 500 505 510  
 Pro Gly Val Ala Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe  
 515 520 525  
 45  
 Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys  
 530 535 540  
 50  
 Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr  
 545 550 555 560  
 Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu  
 565 570 575  
 55

EP 1 310 571 B1

5 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly  
580 585 590

Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly  
595 600 605

10 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser  
610 615 620

Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu  
625 630 635 640

15 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro  
645 650 655

20 Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser  
660 665 670

Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn  
675 680 685

25 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu  
690 695 700

30 Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro Ile Gly  
705 710 715 720

Thr Arg Tyr Leu Thr Arg Asn Leu  
725

35

<210> 109  
<211> 729  
<212> PRT

40 <213> capsid protein of AAV serotype, clone F1VP1

<400> 109

45 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

50 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

55 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

EP 1 310 571 B1

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
 85 90 95

5 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110

10 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140

15 Pro Ile Asp Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
 145 150 155 160

20 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
 165 170 175

Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
 180 185 190

25 Ser Val Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
 195 200 205

30 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
 210 215 220

His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
 225 230 235 240

35 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
 245 250 255

40 Ser Ser Ser Ser Ser Gly Ala Thr Asn Asp Asn His Tyr Phe Gly Tyr  
 260 265 270

Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe  
 275 280 285

45 Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg  
 290 295 300

50 Pro Lys Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val  
 305 310 315 320

Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr  
 325 330 335

55

EP 1 310 571 B1

Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly  
340 345 350

5 Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met  
355 360 365

10 Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val  
370 375 380

Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu  
385 390 395 400

15 Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser Phe Glu Asp Val Pro  
405 410 415

20 Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn  
420 425 430

Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr  
435 440 445

25 Thr Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr  
450 455 460

30 Met Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln  
465 470 475 480

Gln Gly Leu Ser Lys Asn Leu Asp Phe Asn Asn Asn Ser Asn Phe Ala  
485 490 495

35 Trp Thr Ala Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr  
500 505 510

40 Asn Pro Gly Ile Pro Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe  
515 520 525

Phe Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn  
530 535 540

45 Lys Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys  
545 550 555 560

50 Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn  
565 570 575

Leu Gln Pro Ser Thr Ala Gly Pro Gln Ser Gln Thr Ile Asn Ser Gln  
580 585 590

55

EP 1 310 571 B1

Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln  
595 600 605

5

Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro  
610 615 620

10

Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile  
625 630 635 640

Leu Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr  
645 650 655

15

Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val  
660 665 670

20

Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp  
675 680 685

Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val  
690 695 700

25

Glu Phe Ala Val Asn Pro Asp Gly Val Tyr Thr Glu Pro Arg Pro Ile  
705 710 715 720

30

Gly Thr Arg Tyr Leu Pro Arg Asn Leu  
725

<210> 110

35

<211> 729

<212> PRT

<213> capsid protein of AAV serotype, clone F5VP1@3

<400> 110

40

45

50

55

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

5

10

15

20

25

30

35

40

45

50

55

EP 1 310 571 B1

5 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110  
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 10 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140  
 Pro Ile Asp Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
 145 150 155 160  
 15 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
 165 170 175  
 20 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
 180 185 190  
 Ser Val Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Thr Ala  
 195 200 205  
 25 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
 210 215 220  
 30 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
 225 230 235 240  
 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
 245 250 255  
 35 Ser Ser Ser Ser Ser Gly Ala Thr Asn Asp Asn His Tyr Phe Gly Tyr  
 260 265 270  
 40 Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe  
 275 280 285  
 Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg  
 290 295 300  
 45 Pro Lys Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val  
 305 310 315 320  
 50 Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr  
 325 330 335  
 55 Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly  
 340 345 350



## EP 1 310 571 B1

5

Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met  
355 360 365

10

Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val  
370 375 380

15

Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu  
385 390 395 400

Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser Phe Glu Asp Val Pro  
405 410 415

20

Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn  
420 425 430

Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr  
435 440 445

25

Thr Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr  
450 455 460

Met Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln  
465 470 475 480

30

Gln Arg Leu Ser Lys Asn Leu Asp Phe Asn Asn Asn Ser Asn Phe Ala  
485 490 495

Trp Thr Ala Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr  
500 505 510

35

Asn Pro Gly Ile Pro Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe  
515 520 525

40

Phe Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn  
530 535 540

Lys Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys  
545 550 555 560

45

Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn  
565 570 575

50

Leu Gln Ser Ser Thr Ala Gly Pro Gln Ser Gln Thr Ile Asn Ser Gln  
580 585 590

55

Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln  
595 600 605

EP 1 310 571 B1

Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro  
 610 615 620

5

Ser Pro Leu Met Gly Gly Phe Gly Leu Glu His Pro Pro Pro Gln Ile  
 625 630 635 640

10

Leu Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr  
 645 650 655

Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val  
 660 665 670

15

Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp  
 675 680 685

20

Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val  
 690 695 700

Glu Phe Ala Val Asn Pro Asp Gly Val Tyr Thr Glu Pro Arg Pro Ile  
 705 710 715 720

25

Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
 725

30

<210> 111  
 <211> 729  
 <212> PRT  
 <213> capsid protein of AAV serotype, clone F3VP1

35

<400> 111

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
 1 5 10 15

40

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30

45

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
 50 55 60

50

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
 65 70 75 80

55

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
 85 90 95

EP 1 310 571 B1

5

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

10

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

15

Pro Ile Gly Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln  
145 150 155 160

Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu  
165 170 175

20

Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser  
180 185 190

Ser Val Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala  
195 200 205

25

Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp  
210 215 220

30

His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr  
225 230 235 240

Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile  
245 250 255

35

Ser Ser Ser Ser Ser Gly Ala Thr Asn Asp Asn His Tyr Phe Gly Tyr  
260 265 270

40

Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe  
275 280 285

Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg  
290 295 300

45

Pro Lys Lys Leu Arg Phe Lys Leu Leu Asn Ile Gln Val Lys Glu Val  
305 310 315 320

50

Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr  
325 330 335

Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly  
340 345 350

55

EP 1 310 571 B1

Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met  
355 360 365

Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asp Asn Gly Ser Gln Ser Val  
370 375 380

Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu  
385 390 395 400

Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser Phe Glu Asp Val Pro  
405 410 415

Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn  
420 425 430

Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr  
435 440 445

Thr Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr  
450 455 460

Met Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln  
465 470 475 480

Gln Arg Leu Ser Lys Asn Leu Asp Phe Asn Asn Asn Ser Asn Phe Ala  
485 490 495

Trp Thr Ala Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr  
500 505 510

Asn Pro Gly Ile Pro Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe  
515 520 525

Phe Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn  
530 535 540

Lys Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys  
545 550 555 560

Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn  
565 570 575

Leu Gln Ser Ser Thr Ala Gly Pro Gln Ser Gln Thr Ile Asn Ser Gln  
580 585 590

Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln  
595 600 605

EP 1 310 571 B1

Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro  
610 615 620

Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile  
625 630 635 640

Leu Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr  
645 650 655

Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val  
660 665 670

Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp  
675 680 685

Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val  
690 695 700

Glu Phe Ala Val Asn Pro Asp Gly Val Tyr Thr Glu Pro Arg Pro Ile  
705 710 715 720

Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725

<210> 112  
<211> 735  
<212> PRT  
<213> capsid protein of AAV serotype, clone 42.6B

<400> 112

EP 1 310 571 B1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

5 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

10 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

15 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

20 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

25

30

35

40

45

50

55

EP 1 310 571 B1

5 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125  
 10 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
 145 150 155 160  
 15 Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
 165 170 175  
 20 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
 180 185 190  
 25 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
 195 200 205  
 30 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
 210 215 220  
 35 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
 225 230 235 240  
 40 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
 245 250 255  
 45 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
 260 265 270  
 50 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
 275 280 285  
 55 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
 290 295 300  
 60 Asn Asn Trp Gly Phe Arg Pro Arg Lys Leu Arg Phe Lys Leu Phe Asn  
 305 310 315 320  
 65 Ile Gln Val Lys Glu Val Thr Thr Asp Asp Gly Val Thr Thr Ile Ala  
 325 330 335  
 70 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Ser Asp Ser Glu Tyr Gln  
 340 345 350  
 75 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
 355 360 365

EP 1 310 571 B1

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

5 Asn Gly Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr  
385 390 395 400

10 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

15 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

20 Ala Arg Thr Gln Ser Thr Thr Gly Ser Thr Arg Glu Leu Gln Phe His  
450 455 460

Gln Ala Gly Pro Asn Thr Met Ala Glu Gln Ser Lys Asn Trp Leu Pro  
465 470 475 480

25 Gly Pro Cys Tyr Arg Gln Gln Arg Leu Ser Lys Asn Ile Asp Ser Asn  
485 490 495

30 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn  
500 505 510

Gly Arg Asn Ser Leu Thr Asn Pro Gly Val Ala Met Ala Thr Asn Lys  
515 520 525

35 Asp Asp Glu Asp Gln Phe Phe Pro Ile Asn Gly Val Leu Val Phe Gly  
530 535 540

40 Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met Thr  
545 550 555 560

Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr  
565 570 575

45 Gly Val Val Ser Ser Asn Leu Gln Ser Ser Thr Ala Gly Pro Gln Thr  
580 585 590

50 Gln Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn  
595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr  
610 615 620

55



EP 1 310 571 B1

Asp Gly Asn Phe His Pro Ser Pro Leu Met Asp Gly Phe Gly Leu Lys  
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn  
645 650 655

Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln  
660 665 670

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys  
675 680 685

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr  
690 695 700

Ala Lys Ser Asn Asn Val Glu Phe Ala Val Asn Asn Glu Gly Val Tyr  
705 710 715 720

Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
725 730 735

<210> 113

<211> 685

<212> PRT

<213> capsid protein of AAV serotype, clone 42.12

<400> 113

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

## EP 1 310 571 B1

5

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125

10

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140

15

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile  
 145 150 155 160

Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln  
 165 170 175

20

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro  
 180 185 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly  
 195 200 205

25

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser  
 210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val  
 225 230 235 240

30

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His  
 245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp  
 260 265 270

35

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn  
 275 280 285

40

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn  
 290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn  
 305 310 315 320

45

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala  
 325 330 335

50

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln  
 340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe  
 355 360 365

55

**EP 1 310 571 B1**

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn  
370 375 380

Asn	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr
385					390					395					400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr  
405 410 415

Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser  
420 425 430

Leu Asp Arg Leu Thr Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu  
435 440 445

Ala Arg Thr Gln Ser Thr Thr Gly Ser Thr Arg Gly Leu Gln Phe His  
450 455 460

Gln Ala Gly Pro Asn Thr Met Ala Glu Gln Ser Lys Asn Trp Leu Pro  
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Leu Ser Lys Asn Ile Asp Ser Asn  
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn  
500 505 510

Gly Arg Asn Ser Leu Thr Asn Pro Gly Val Ala Met Ala Thr Asn Lys  
515 520 525

Asp Asp Glu Asp Gln Phe Phe Pro Ile Asn Gly Val Leu Val Phe Gly  
530 535 540

Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met Thr  
545 550 555 560

Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr  
565 570 575

Gly Val Val Ser Ser Asn Leu Gln Ser Ser Thr Ala Gly Pro Gln Thr  
580 585 590

Gln Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn  
595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr  
610 615 620

EP 1 310 571 B1

Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys  
625 630 635 640

5

His Pro Pro Pro Gln Ile Leu Ile Lys Tyr Thr Ser Asn Tyr Tyr Lys  
645 650 655

10

Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu  
660 665 670

15

Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu  
675 680 685

<210> 114

<211> 724

<212> PRT

20

<213> capsid protein of AAV serotype, clone AAV5CAP

<400> 114

25

30

35

40

45

50

55

EP 1 310 571 B1

Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu  
1 5 10 15

5 Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys  
20 25 30

10 Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly  
35 40 45

Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val  
50 55 60

15 Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu  
65 70 75 80

20 Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp  
85 90 95

Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn  
100 105 110

25 Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe  
115 120 125

30 Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile  
130 135 140

Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser  
145 150 155 160

35 Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln  
165 170 175

40

45

50

55

EP 1 310 571 B1

5

Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr  
180 185 190

Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala  
195 200 205

10

Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp  
210 215 220

Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu Pro  
225 230 235 240

15

Ser Tyr Asn Asn His Gln Tyr Arg Glu Ile Lys Ser Gly Ser Val Asp  
245 250 255

20

Gly Ser Asn Ala Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr  
260 265 270

Phe Asp Phe Asn Arg Phe His Ser His Trp Ser Pro Arg Asp Trp Gln  
275 280 285

25

Arg Leu Ile Asn Asn Tyr Trp Gly Phe Arg Pro Arg Ser Leu Arg Val  
290 295 300

30

Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Val Gln Asp Ser Thr  
305 310 315 320

Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp  
325 330 335

35

Asp Asp Tyr Gln Leu Pro Tyr Val Val Gly Asn Gly Thr Glu Gly Cys  
340 345 350

40

Leu Pro Ala Phe Pro Pro Gln Val Phe Thr Leu Pro Gln Tyr Gly Tyr  
355 360 365

Ala Thr Leu Asn Arg Asp Asn Thr Glu Asn Pro Thr Glu Arg Ser Ser  
370 375 380

45

Phe Phe Cys Leu Glu Tyr Phe Pro Ser Lys Met Leu Arg Thr Gly Asn  
385 390 395 400

50

Asn Phe Glu Phe Thr Tyr Asn Phe Glu Glu Val Pro Phe His Ser Ser  
405 410 415

Phe Ala Pro Ser Gln Asn Leu Phe Lys Leu Ala Asn Pro Leu Val Asp  
420 425 430

55

## EP 1 310 571 B1

Gln Tyr Leu Tyr Arg Phe Val Ser Thr Asn Asn Thr Gly Gly Val Gln  
 435 440 445

5

Phe Asn Lys Asn Leu Ala Gly Arg Tyr Ala Asn Thr Tyr Lys Asn Trp  
 450 455 460

10

Phe Pro Gly Pro Met Gly Arg Thr Gln Gly Trp Asn Leu Gly Ser Gly  
 465 470 475 480

Val Asn Arg Ala Ser Val Ser Ala Phe Ala Thr Thr Asn Arg Met Glu  
 485 490 495

15

Leu Glu Gly Ala Ser Tyr Gln Val Pro Pro Gln Pro Asn Gly Met Thr  
 500 505 510

20

Asn Asn Leu Gln Gly Ser Asn Thr Tyr Ala Leu Glu Asn Thr Met Ile  
 515 520 525

Phe Asn Ser Gln Pro Ala Asn Pro Gly Thr Thr Ala Thr Tyr Leu Glu  
 530 535 540

25

Gly Asn Met Leu Ile Thr Ser Glu Ser Glu Thr Gln Pro Val Asn Arg  
 545 550 555 560

30

Val Ala Tyr Asn Val Gly Gly Gln Met Ala Thr Asn Asn Gln Ser Ser  
 565 570 575

Thr Thr Ala Pro Ala Thr Gly Thr Tyr Asn Leu Gln Glu Ile Val Pro  
 580 585 590

35

Gly Ser Val Trp Met Glu Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp  
 595 600 605

40

Ala Lys Ile Pro Glu Thr Gly Ala His Phe His Pro Ser Pro Ala Met  
 610 615 620

Gly Gly Phe Gly Leu Lys His Pro Pro Pro Met Met Leu Ile Lys Asn  
 625 630 635 640

45

Thr Pro Val Pro Gly Asn Ile Thr Ser Phe Ser Asp Val Pro Val Ser  
 645 650 655

50

Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met Glu  
 660 665 670

Trp Glu Leu Lys Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln  
 675 680 685

55

# EP 1 310 571 B1

Tyr Thr Asn Asn Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp  
690 695 700

5

Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu  
705 710 715 720

Thr Arg Pro Leu

10

<210> 115

<211> 9

15

<212> DNA

<213> Dralll restriction enzyme site

<400> 115

20

caccacgtc

9

<210> 116

25

<211> 28

<212> DNA

<213> AV2cas

<400> 116

30

cgcagagacc aaagttcaac tgaaacga

28

35

<210> 117

<211> 255

<212> DNA

<213> adeno-associated virus serotype 10

40

<400> 117

ggtaattcct ccggaattg gcattgcgat tccacatggc tgggacgacag agtcatcacc 60

45

accagcaccc gaacctgggt cctgccacc tacaacaacc acatctacaa gcaaattctcc 120

agcgagacag gagccaccaa cgacaaccac tacttcgggt acagcacccc ctgggggtat 180

tttgacttta acagattcca ctgccacttt tcaccacgtg actggcagcg actcatcaac 240

50

aacaactggg gattc 255

55

<210> 118

<211> 258

<212> DNA

<213> adeno-associated virus serotype 11



# EP 1 310 571 B1

<400> 118

	ggtaattcct cgggaaattg gcattgcatg tccacatggc tgggcgacag agtcattacc	60
5	accagcacc cgaacctgggc cctgccaacc tacaacaacc acctctacaa acaaattctcc	120
	agcgcttcaa cggggggccag caacgacaac cactactttg gctacagcac cccctggggg	180
10	tattttgact ttaacagatt ccactgccac ttctcaccac gtgactggca gcgactcatc	240
	aacaacaact ggggattc	258

15 <210> 119  
 <211> 255  
 <212> DNA  
 <213> adeno-associated virus serotype 12

20 <400> 119

	ggtaattcct cgggaaattg gcattgcatg tccacatggc tgggcgaccg agtcattacc	60
25	accagcacc cgaacctgggc cctgccaacc tacaacaacc acctctacaa gcaaattctcc	120
	agccaatcgg gtgccaccaa cgacaaccac tacttcggct acagcaccac ttgggggtat	180
	tttgatttca acagattcca ctgccatttc tcaccacgtg actggcagcg actcatcaac	240
30	aacaactggg gattc	255

35 <210> 120  
 <211> 2205  
 <212> DNA  
 <213> adeno-associated virus serotype, clone A3.1vp1

<400> 120

40

45

50

55

EP 1 310 571 B1

	atggctgccg atggttatct tccagattgg ctcgaggaca ctctctctga aggaatcaga	60
	cagtgggtgga agctcaaacc tggcccacca ccgccgaaac ctaaccaaca acaccgggac	120
5	gacagtaggg gtcttgtgct tcctgggtac aagtacctcg gacccttcaa cggactcgac	180
	aaaggagagc cgggtcaacga ggcagacgcc gcggccctcg agcacgacaa agcctacgac	240
	caccagctca agcaagggga caaccctgtac ctcaaataca accacgcgga cgctgaattt	300
10	caggagcgct ttcaagaaga tacgtctttc gggggcaacc tcgggcgagc agtcttccag	360
	gccaaaaaga ggggtactcga gcctcttggc ctggttgagg aagctgttaa gacggctcct	420
	ggaaaaaaga gacctataga gcagtctcct gcagaaccgg actcttctc ggcatcggc	480
15	aatcaggcc agcagccgc taagaaaaga ctcaattttg gtcagactgg cgacacagag	540
	tcagtcccag accctcaacc aatcggagaa cccccgcag cccctctgg tgtgggatct	600
	aatacaatgg cttcaggcgg tggggcacca atggcagaca ataacgaagg cgccgacgga	660
20	gtgggtaatt cctcgggaaa ttggcattgc gattccacat ggatgggcga cagagttatc	720
	accaccagca caagaacctg ggccctcccc acctacaata atcacctcta caagcaaadc	780
	tccagcgaat cgggagccac caacgacaac cactacttcg gctacagcac cccctggggg	840
25	tattttgact ttaacagatt ccactgtcac ttctcaccac gtgactggca gcgactcatc	900
	aacaacaact ggggatttag acccaagaaa ctcaatttca agctcttcaa catccaagtc	960
30	aaggaggtca cgcagaatga tggaaccacg accatcgcca ataaccttac cagcacggtg	1020
35		
40		
45		
50		
55		

5 caggtcttca cagactctga gtaccagctg ccctacgtcc tcggttcggc tcaccagggc 1080  
 tgccttccgc cgttcccagc agacgtcttc atgattcctc agtacggcta cttgactctg 1140  
 aacaatggca gccaaagcgtt aggacgttct tcattctact gtctagagta ttttccctct 1200  
 cagatgctga ggacgggaaa caacttcacc ttcagctaca cttttgaaga cgtgcctttc 1260  
 10 cacagcagct acgcgcacag ccagagtctg gatcggctga tgaatcctct cattgaccag 1320  
 tacctgtatt acctgagcaa aactcagggg acaagtggaa caacgcagca atcgagactg 1380  
 cagttcagcc aagctgggcc tagctccatg gctcagcagg ccaaaaactg gctaccggga 1440  
 15 cccagctacc gacagcagcg aatgtctaag acggctaatt acaacaacaa cagtgaattt 1500  
 gcttggactg cagccaccaa atattacctg aatggaagaa attctctggt caatcccggg 1560  
 cccccaatgg ccagtcacaa ggacgatgag gaaaagtatt tccccatgca cggaaatctc 1620  
 20 atctttggaa aacaaggcac aggaactacc aatgtggaca ttgaatcagt gcttattaca 1680  
 gacgaagaag aaatcagaac aactaatcct gtggctacag aacaatacgg acaggttgcc 1740  
 accaaccatc agagtcagaa caccacagct tcctatggaa gtgtggacag ccagggaatc 1800  
 25 ttacctggaa tgggtgtggc ggaccgcgat gtctatcttc aagggtcccat ttgggcaaaa 1860  
 actcctcaca cggacggaca ctttcacctt tctccgctca tgggaggctt tggactgaaa 1920  
 caccctcctc cccagatcct gatcaaaaac acacctgtgc cagcgaatcc cgcgaccact 1980  
 30 ttcactcctg gaaagtttgc ttcgttcatt acccagtatt ccaccggaca ggtcagcgtg 2040  
 gaaatagagt gggagctgca gaaagaaaac agcaaacgct ggaaccaga aattcagtac 2100  
 acctccaact acaacaagtc ggtgaatgtg gagtttaccg tggacgcaaa cgggtgtttat 2160  
 35 tctgaacccc gccctattgg cactcgttac cttaccggga acttg 2205

#### 40 Claims

1. A method of identifying unknown adeno-associated virus (AAV) sequences in a sample suspected of containing AAV from a latent infection, said method comprising the steps of:

- 45 (a) subjecting the sample containing DNA to amplification via polymerase chain reaction (PCR) using a first set of primers which specifically amplify a first AAV region comprising at least 250 bp of AAV capsid nucleic acid sequences, said first region having a variable sequence flanked by at least 18 base pairs of highly conserved sequence at its 5' end and at least 18 base pairs of highly conserved sequence at its 3' end, said base pairs being highly conserved relative to an alignment of at least AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6;  
 50 (b) optionally subjecting the DNA to further amplification using a second set of primers which specifically amplify a second region which comprises the first region of AAV sequences and sequences which are 5' to the first region, such that AAV 5' extension sequences which anneal to the 5' end of the AAV sequences amplified by the primers for the first region are obtained;  
 55 (c) optionally subjecting the DNA to further amplification using a third set of primers which specifically amplify a third region which comprises the first region of AAV sequences and sequences which are 3' to the first region, such that AAV 3' extension sequences which anneal to the 3' end of the AAV sequences amplified by the primers for the first region are obtained,

each of said second and third regions being predetermined based upon the alignment of the nucleic acid sequences of at least AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6, and each of said regions comprising nucleic acid sequences which are highly conserved over at least 18 base pairs at the 5' end, optionally variable sequences in the middle, and sequences which are highly conserved over at least 18 base pairs at the 3' end of the sequences of the region, relative to the sequences of at least AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6; and  
 each of the sets of primers consisting of a 5' primer and a 3' primer;  
 the presence of amplified sequences indicating the presence of an AAV in the sample, and  
 a comparison of differences between the amplified sequences and the sequences of AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6 indicating the presence of an unknown AAV.

2. A method according to claim 1, wherein the comparison comprises the step of comparing restriction enzyme patterns for the amplified sequences to restriction enzyme patterns of AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6.
3. A method according to claim 1 or claim 2, wherein step (a) amplifies the full-length capsid gene.
4. A method according to any of claims 1 to 3, wherein the amplified sequences comprise the AAV capsid gene and the AAV rep gene.
5. A method according to any of claims 1 to 4, wherein the DNA has been extracted from cells, cell culture, tissue, tissue culture or biological fluids.
6. A method according to any of claims 1 to 5, wherein the first region is highly conserved over at least about 25 base pairs at the 5' end of the region, the 3' end of the region or both.
7. A method according to claim 6, wherein the first region is highly conserved over at least about 30 base pairs at the 5' end of the region, the 3' end of the region or both.
8. A method according to any of claims 1 to 7, wherein the highly conserved sequences of the first region have at least 80% identity among the aligned AAVs at the 5' end of the region, the 3' end of the region or both.
9. A method according to claim 8, wherein the highly conserved sequences of the first region have at least 90% identity among the aligned AAVs at the 5' end of the region, the 3' end of the region or both.
10. A method according to any of claims 1 to 9, wherein the variable sequences in the middle of the first region have less than 70% identity among the aligned AAVs.
11. A method according to any of claims 1 to 10, wherein the first region spans about bp 2800 to about 3200 of AAV 1, SEQ ID NO:6, and corresponding base pairs in other AAVs.
12. A method according to claim 11, wherein the first region is 257 bp spanning bp 2886 to about 3143 of AAV 1, SEQ ID NO:6, and corresponding base pairs in other AAVs.
13. A method according to any of claims 1 to 5, wherein the primers are AV1ns, having the sequence of nucleotides 1398 to 1423 of SEQ ID NO:6, and AV2cas, having the sequence of SEQ ID NO:7.
14. A method according to claim 1 or claim 2, wherein the first set of primers allows isolation of full-length adeno-associated virus capsid sequences from a sample, the first set of primers comprising a 5' primer directed to a region located in the middle of an AAV rep gene, based on a predetermined conserved region, and a 3' primer directed to a region downstream of an AAV cap gene, based on a predetermined conserved region of AAV.
15. A method according to any of claims 1 to 14, wherein the sample comprises AAV integrated into the chromosome.
16. A method according to any of claims 1 to 15, wherein the sample comprises human tissue.
17. A method according to any of claims 1 to 16, wherein the sample contains proviral AAV sequences.
18. A method according to any of claims 1 to 17, wherein the first region is a signature region.

19. A method according to any of claims 1 to 18, wherein the base pairs of the highly conserved sequences are highly conserved relative to an alignment of AAVs 1,2,3,4,5 and 6 and AAVs isolated from geese and ducks.
20. A method according to any of claims 1 to 19, wherein the variable sequence is a hypervariable sequence.
21. A method according to any of claims 1 to 20, wherein the first region comprises up to 10 kilobasepairs in length.
22. A method according to claim 21, wherein the first region comprises a 3-1 kilobase pair fragment comprising the full-length cap sequence.
23. A kit for detecting the presence of an unknown adeno-associated virus (AAV) in a sample from cellular DNA suspected of containing a latent AAV infection, said kit comprising:
  - (a) a first set of primers which specifically amplify a first region comprising 250 bp of AAV capsid nucleic acid sequences, said first region having at least 18 base pairs of highly conserved sequence at its 5' end, a variable sequence, and at least 18 base pairs of highly conserved sequence at its 3' end, said base pairs being highly conserved relative to an alignment of at least AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6;
  - (b) optionally a second set of primers specific for a second region of the AAV nucleic acid sequences which comprises the first region of AAV sequences and sequences which are 5' to the first region, such that AAV 5' extension sequences which anneal to the 5' end of the AAV sequences amplified by the primers for the first region are obtained;
  - (c) optionally a third set of primers which specifically amplify a third region which comprises the first region of AAV sequences and sequences which are 3' to the first region, such that AAV 3' extension sequences which anneal to the 3' end of the AAV sequences amplified by the primers for the first region are obtained;each of said second and third regions being predetermined based upon the alignment of the nucleic acid sequences of at least AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6, and each of said regions comprising nucleic acid sequences which are highly conserved over at least 18 base pairs at the 5' end, optionally variable sequences in the middle, and sequences which are highly conserved over at least 18 base pairs at the 3' end of the sequences of the region, relative to the sequences of at least AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6;  
each of the sets of primers consisting of a 5' primer and a 3' primer, each of said primers comprising at least 15 nucleotides complementary to its respective highly conserved sequence and having exact identity with its respective highly conserved sequence over at least 5 base pairs in its 3' end.
24. A kit according to claim 23, wherein the 5' primer and/or the 3' primer comprises at least 18 nucleotides.
25. A kit according to claim 24, wherein the 5' primer and/or the 3' primer comprises 25 nucleotides.
26. A kit according to any of claims 23 to 25, wherein the 5' primer and/or the 3' primer comprises at least 9 base pairs of exact identity at its 3' end.
27. A kit according to claim 26, wherein the 5' primer and/or the 3' primer comprises at least 18 base pairs of exact identity at its 3' end.
28. A kit according to any of claims 23 to 27, wherein the first set of primers allows isolation of full-length adeno-associated virus capsid sequences from a sample, the first set of primers comprising a 5' primer directed to a region located in the middle of an AAV rep gene, based on a predetermined conserved region of AAV, and a 3' primer directed to a region downstream of an AAV cap gene, based on a predetermined conserved region of AAV.
29. A kit according to claim 23, wherein the 5' primer has a sequence comprising GCTGCGTCAACTGGACCAATGA-GAAC, which corresponds to nt 1398 to 1423 of SEQ ID NO:6.
30. A kit according to claim 23, wherein the 3' primer has a sequence comprising CGCAGAGACCAAAGTTCAACT-GAAACGA, which corresponds to the nucleotides complementary to 4462-4435 of SEQ ID NO:7.
31. A kit according to any of claims 23 to 30, wherein the sample comprises AAV integrated into the chromosome.

## Patentansprüche

1. Verfahren zur Identifizierung unbekannter Sequenzen von adeno-assoziiertem Virus (AAV) in einer Probe, von der man annimmt, daß sie von einer latenten Infektion herrührendes AAV enthält, wobei man in den folgenden Verfahrensschritten

(a) die DNA-haltige Probe einer Amplifikation über eine Polymerasekettenreaktion (PCR) unter Verwendung eines ersten Primersatzes, mit dem spezifisch ein mindestens 250 Bp AAV-Capsid-Nukleinsäuresequenzen umfassender erster AAV-Bereich amplifiziert wird, wobei dieser erste Bereich eine an ihrem 5'-Ende von mindestens 18 Basenpaaren hochkonservierter Sequenz und an ihrem 3'-Ende von mindestens 18 Basenpaaren hochkonservierter Sequenz flankierte variable Sequenz aufweist, wobei die Basenpaare relativ zu einer vergleichenden Anordnung von mindestens AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 hochkonserviert sind, aussetzt,

(b) gegebenenfalls die DNA einer weiteren Amplifikation unter Verwendung eines zweiten Primersatzes, mit dem spezifisch ein zweiter Bereich, der den ersten Bereich von AAV-Sequenzen sowie 5' zum ersten Bereich liegende Sequenzen umfaßt, amplifiziert wird, aussetzt, so daß 5'-AAV-Verlängerungssequenzen, die in einer Annealing-Reaktion an das 5'-Ende der mit den Primern für den ersten Bereich amplifizierten AAV-Sequenzen binden, erhalten werden,

(c) gegebenenfalls die DNA einer weiteren Amplifikation unter Verwendung eines dritten Primersatzes, mit dem spezifisch ein dritter Bereich, der den ersten Bereich von AAV-Sequenzen sowie 3' zum ersten Bereich liegende Sequenzen umfaßt, amplifiziert wird, aussetzt, so daß 3'-AAV-Verlängerungssequenzen, die in einer Annealing-Reaktion an das 3'-Ende der mit den Primern für den ersten Bereich amplifizierten AAV-Sequenzen binden, erhalten werden,

wobei der zweite und der dritte Bereich jeweils auf der Grundlage der vergleichenden Anordnung der Nukleinsäuresequenzen von mindestens AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 vorbestimmt sind und die Bereiche relativ zu den Sequenzen von mindestens AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 jeweils am 5'-Ende der Sequenzen des Bereichs über mindestens 18 Basenpaare hochkonservierte Nukleinsäuresequenzen, in der Mitte gegebenenfalls variable Sequenzen und am 3'-Ende über mindestens 18 Basenpaare hochkonservierte Sequenzen umfassen und

die Primersätze jeweils aus einem 5'-Primer und einem 3'-Primer bestehen, das Vorhandensein amplifizierter Sequenzen das Vorhandensein eines AAV in der Probe anzeigt, und ein Vergleich der Unterschiede zwischen den amplifizierten Sequenzen und den Sequenzen von AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 das Vorhandensein eines unbekannten AAV anzeigt.

2. Verfahren nach Anspruch 1, wobei der Vergleich den Schritt des Vergleichens von Restriktionsenzymmustern für die amplifizierten Sequenzen mit Restriktionsenzymmustern von AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 umfaßt.

3. Verfahren nach Anspruch 1 oder 2, wobei in Schritt (a) das Capsid-Gen in voller Länge amplifiziert wird.

4. Verfahren nach einem der Ansprüche 1 bis 3, wobei die amplifizierten Sequenzen das AAV-Capsid-Gen und das AAV-rep-Gen umfassen.

5. Verfahren nach einem der Ansprüche 1 bis 4, wobei die DNA aus Zellen, Zellkultur, Gewebe, Gewebekultur oder biologischen Flüssigkeiten extrahiert wurde.

6. Verfahren nach einem der Ansprüche 1 bis 5, wobei der erste Bereich über mindestens etwa 25 Basenpaare am 5'-Ende oder/und am 3'-Ende des Bereichs hochkonserviert ist.

7. Verfahren nach Anspruch 6, wobei der erste Bereich über mindestens etwa 30 Basenpaare am 5'-Ende oder/und am 3'-Ende des Bereichs hochkonserviert ist.

8. Verfahren nach einem der Ansprüche 1 bis 7, wobei die hochkonservierten Sequenzen des ersten Bereichs unter den vergleichend angeordneten AAVs eine Identität von mindestens 80% am 5'-Ende oder/und am 3'-Ende des Bereichs aufweisen.

9. Verfahren nach Anspruch 8, wobei die hochkonservierten Sequenzen des ersten Bereichs unter den vergleichend

angeordneten AAVs eine Identität von mindestens 90% am 5'-Ende oder/und am 3'-Ende des Bereichs aufweisen.

10. Verfahren nach einem der Ansprüche 1 bis 9, wobei die variablen Sequenzen in der Mitte des ersten Bereichs unter den vergleichend angeordneten AAVs eine Identität von weniger als 70% aufweisen.

11. Verfahren nach einem der Ansprüche 1 bis 10, wobei der erste Bereich von etwa Bp 2800 bis etwa 3200 von AAV1, SEQ ID NO:6, und den entsprechenden Basenpaaren in anderen AAV reicht.

12. Verfahren nach Anspruch 11, wobei es sich bei dem ersten Bereich um 257 Bp handelt, die von Bp 2886 bis etwa 3143 von AAV1, SEQ ID NO:6, und den entsprechenden Basenpaaren in anderen AAV reichen.

13. Verfahren nach einem der Ansprüche 1 bis 5, wobei es sich bei den Primern um AV1ns mit der Sequenz der Nukleotide 1398 bis 1423 der SEQ ID NO:6 sowie um AV2cas mit der Sequenz der SEQ ID NO:7 handelt.

14. Verfahren nach Anspruch 1 oder Anspruch 2, wobei der erste Primersatz die Isolierung von Capsidsequenzen in voller Länge von adeno-assoziiertem Virus aus einer Probe gestattet, wobei der erste Primersatz einen auf einen in der Mitte eines AAV-rep-Gens liegenden Bereich auf der Grundlage eines vorbestimmten konservierten Bereichs gerichteten 5'-Primer sowie einen auf einen stromabwärts von einem AAV-cap-Gen liegenden Bereich auf der Grundlage eines vorbestimmten konservierten Bereichs von AAV gerichteten 3'-Primer umfaßt.

15. Verfahren nach einem der Ansprüche 1 bis 14, wobei die Probe in das Chromosom integriertes AAV umfaßt.

16. Verfahren nach einem der Ansprüche 1 bis 15, wobei die Probe menschliches Gewebe umfaßt.

17. Verfahren nach einem der Ansprüche 1 bis 16, wobei die Probe provirale AAV-Sequenzen enthält.

18. Verfahren nach einem der Ansprüche 1 bis 17, wobei es sich bei dem ersten Bereich um einen Signaturbereich handelt.

19. Verfahren nach einem der Ansprüche 1 bis 18, wobei die Basenpaare der hochkonservierten Sequenzen relativ zu einer vergleichenden Anordnung von AAV 1, 2, 3, 4, 5 und 6 und aus Gans und Ente isolierten AAV hochkonserviert sind.

20. Verfahren nach einem der Ansprüche 1 bis 19, wobei es sich bei der variablen Sequenz um eine hypervariable Sequenz handelt.

21. Verfahren nach einem der Ansprüche 1 bis 20, wobei der erste Bereich eine Länge von bis zu 10 Kilobasenpaaren umfaßt.

22. Verfahren nach Anspruch 21, wobei der erste Bereich ein die cap-Sequenz in voller Länge umfassendes Fragment von 3,1 Kilobasenpaaren umfaßt.

23. Kit zum Nachweis des Vorhandenseins eines unbekannten adeno-assoziierten Virus (AAV) in einer Probe aus zellulärer DNA, von der man annimmt, daß sie eine latente AAV-Infektion enthält, wobei der Kit umfaßt:

(a) einen ersten Primersatz, mit dem spezifisch ein 250 Bp AAV-Capsid-Nukleinsäuresequenzen umfassender erster AAV-Bereich amplifiziert wird, wobei dieser erste Bereich an seinem 5'-Ende mindestens 18 Basenpaare hochkonservierter Sequenz, eine variable Sequenz und an seinem 3'-Ende mindestens 18 Basenpaare hochkonservierter Sequenz aufweist, wobei die Basenpaare relativ zu einer vergleichenden Anordnung von mindestens AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 hochkonserviert sind,

(b) gegebenenfalls einen für einen zweiten Bereich der AAV-Nukleinsäuresequenzen, der den ersten Bereich von AAV-Sequenzen sowie 5' zum ersten Bereich liegende Sequenzen umfaßt, spezifischen zweiten Primersatz, so daß 5'-AAV-Verlängerungssequenzen, die in einer Annealing-Reaktion an das 5'-Ende der mit den Primern für den ersten Bereich amplifizierten AAV-Sequenzen binden, erhalten werden,

(c) gegebenenfalls einen dritten Primersatz, mit dem spezifisch ein dritter Bereich, der den ersten Bereich von AAV-Sequenzen sowie 3' zum ersten Bereich liegende Sequenzen umfaßt, amplifiziert wird, so daß 3'-AAV-Verlängerungssequenzen, die in einer Annealing-Reaktion an das 3'-Ende der mit den Primern für den ersten

Bereich amplifizierten AAV-Sequenzen binden, erhalten werden,

wobei der zweite und der dritte Bereich jeweils auf der Grundlage der vergleichenden Anordnung der Nukleinsäuresequenzen von mindestens AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 vorbestimmt sind und die Bereiche relativ zu den Sequenzen von mindestens AAV1, AAV2, AAV3, AAV4, AAV5 und AAV6 jeweils am 5'-Ende der Sequenzen des Bereichs über mindestens 18 Basenpaare hochkonservierte Nukleinsäuresequenzen, in der Mitte gegebenenfalls variable Sequenzen und am 3'-Ende über mindestens 18 Basenpaare hochkonservierte Sequenzen umfassen,

die Primersätze jeweils aus einem 5'-Primer und einem 3'-Primer bestehen, wobei jeder Primer mindestens 15 zur hochkonservierten Sequenz des jeweils anderen Primers komplementäre Nukleotide umfaßt und an seinem 3'-Ende über mindestens 5 Basenpaare eine genaue Identität mit der hochkonservierten Sequenz des jeweils anderen Primers aufweist.

24. Kit nach Anspruch 23, wobei der 5'-Primer und/oder der 3'-Primer mindestens 18 Nukleotide umfaßt.

25. Kit nach Anspruch 24, wobei der 5'-Primer und/oder der 3'-Primer mindestens 25 Nukleotide umfaßt.

26. Kit nach einem der Ansprüche 23 bis 25, wobei der 5'-Primer und/oder der 3'-Primer an seinem 3'-Ende mindestens 9 Basenpaare genauer Identität umfaßt.

27. Kit nach Anspruch 26, wobei der 5'-Primer und/oder der 3'-Primer an seinem 3'-Ende mindestens 18 Basenpaare genauer Identität umfaßt.

28. Kit nach einem der Ansprüche 23 bis 27, wobei der erste Primersatz die Isolierung von Capsidsequenzen in voller Länge von adeno-assoziiertem Virus aus einer Probe gestattet, wobei der erste Primersatz einen auf einen in der Mitte eines AAV-rep-Gens liegenden Bereich auf der Grundlage eines vorbestimmten konservierten Bereichs von AAV gerichteten 5'-Primer sowie einen auf einen stromabwärts von einem AAV-cap-Gen liegenden Bereich auf der Grundlage eines vorbestimmten konservierten Bereichs von AAV gerichteten 5'-Primer umfaßt.

29. Kit nach Anspruch 23, wobei der 5'-Primer eine GCTGCGTCAACTGGACCAATGAGAAC umfassende Sequenz aufweist, die Nt 1398 bis 1423 der SEQ ID NO:6 entspricht.

30. Kit nach Anspruch 23, wobei der 3'-Primer eine CGCAGAGACCAAAGTTCAACTGAAACGA umfassende Sequenz aufweist, die den zu 4462-4435 der SEQ ID NO:7 komplementären Nukleotiden entspricht.

31. Kit nach einem der Ansprüche 23 bis 30, wobei die Probe in das Chromosom integriertes AAV umfaßt.

## Revendications

1. Procédé pour identifier des séquences de virus associés à l'adénovirus (VAA) inconnus dans un échantillon dont on suspecte qu'il contient des VAA provenant d'une infection latente, ledit procédé comprenant les étapes :

(a) de soumission de l'échantillon contenant l'ADN à une amplification via une réaction de polymérase en chaîne (PCR) en utilisant une première série d'amorces qui amplifient spécifiquement une première région de VAA comprenant au moins 250 pb des séquences d'acides nucléiques de capsid de VAA, ladite première région présentant une séquence variable adjacente à au moins 18 paires de bases d'une séquence hautement conservée en son extrémité 5' et à au moins 18 paires de bases d'une séquence hautement conservée en son extrémité 3', lesdites paires de bases étant hautement conservées par rapport à un alignement d'au moins VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6;

(b) éventuellement de soumission de l'ADN à une autre amplification en utilisant une deuxième série d'amorces qui amplifient spécifiquement une deuxième région qui comprend la première région de séquences des VAA et des séquences qui sont côté 5' par rapport à la première région, de telle manière qu'on obtient des séquences d'extension 5' de VAA qui hybrident sur l'extrémité 5' des séquences de VAA amplifiées par les amorces pour la première région ;

(c) éventuellement de soumission de l'ADN à une autre amplification utilisant une troisième série d'amorces qui amplifient spécifiquement une troisième région qui comprend la première région de séquences de VAA et



les séquences qui sont situées côté 3' par rapport à la première région, de telle manière qu'on obtient des séquences d'extension 3' de VAA qui hybrident sur l'extrémité 3' des séquences de VAA amplifiées par les amorces pour la première région,

- 5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55
- chacune desdites deuxième et troisième régions étant prédéterminée sur base de l'alignement des séquences d'acides nucléiques d'au moins VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6, et chacune desdites régions comprenant des séquences d'acides nucléiques qui sont hautement conservées sur au moins 18 paires de bases en l'extrémité 5', des séquences éventuellement variables au centre et des séquences qui sont hautement conservées sur au moins 18 paires de bases en l'extrémité 3' des séquences de la région, par rapport aux séquences d'au moins VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6; et
- chacune des séries d'amorces étant constituée par une amorce 5' et une amorce 3';
- la présence de séquences amplifiées indiquant la présence d'un VAA dans l'échantillon et
- une comparaison des différences entre les séquences amplifiées et les séquences des VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6 indiquant la présence d'un VAA inconnu.
2. Procédé selon la revendication 1, dans lequel la comparaison comprend l'étape de comparaison de modèles d'enzymes de restriction pour les séquences amplifiées à des modèles d'enzymes de restriction des VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6.
3. Procédé selon la revendication 1 ou 2, dans lequel l'étape (a) amplifie toute la longueur du gène cap.
4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel les séquences amplifiées comprennent le gène cap du VAA et le gène rep du VAA.
5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel l'ADN a été extrait de cellules, d'une culture cellulaire, de tissu, d'une culture de tissu ou de fluides biologiques.
6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la première région est hautement conservée sur au moins 25 paires de base en l'extrémité 5' de la région, en l'extrémité 3' de la région ou les deux.
7. Procédé selon la revendication 6, dans lequel la première région est hautement conservée sur au moins 30 paires de base en l'extrémité 5' de la région, en l'extrémité 3' de la région ou les deux.
8. Procédé selon l'une quelconque des revendications 1 à 7, dans lequel les séquences hautement conservées de la première région présentent une identité d'au moins 80% avec les VAA alignés en l'extrémité 5' de la région, l'extrémité 3' de la région ou les deux.
9. Procédé selon la revendication 8, dans lequel les séquences hautement conservées de la première région présentent une identité d'au moins 90% avec les VAA alignés en l'extrémité 5' de la région, l'extrémité 3' de la région ou les deux.
10. Procédé selon l'une quelconque des revendications 1 à 9, dans lequel les séquences variables au centre de la première région présentent une identité inférieure à 70% avec les VAA alignés.
11. Procédé selon l'une quelconque des revendications 1 à 10, dans lequel la première région s'étend de la paire de bases 2800 à environ 3200 du VAA 1, SEQ ID NO:6, et les paires de bases correspondantes dans les autres VAA.
12. Procédé selon la revendication 11, dans lequel la première région représente 257 paires de bases, s'étendant de la paire de bases 2886 à environ 3143 du VAA1, SEQ ID NO:6, et les paires de bases correspondantes dans les autres VAA.
13. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel les amorces sont des AV1ns, présentant la séquence des nucléotides 1398 à 1423 de la SEQ ID NO:6, et des AV2cas, présentant la séquence de la SEQ ID NO:7.
14. Procédé selon la revendication 1 ou 2, dans lequel la première série d'amorces permet l'isolement de toute la longueur de séquences de capsid du virus associé à l'adénovirus d'un échantillon, la première série d'amorces comprenant une amorce 5' dirigée sur une région localisée au centre d'un gène rep du VAA, sur base d'une région prédéterminée conservée et une amorce 3', dirigée sur une région en aval d'un gène cap du VAA, basée sur une

région prédéterminée conservée du VAA.

15. Procédé selon l'une quelconque des revendications 1 à 14, dans lequel l'échantillon comprend un VAA intégré dans le chromosome.
16. Procédé selon l'une quelconque des revendications 1 à 15, dans lequel l'échantillon comprend du tissu humain.
17. Procédé selon l'une quelconque des revendications 1 à 16, dans lequel l'échantillon contient des séquences de VAA provirales.
18. Procédé selon l'une quelconque des revendications 1 à 17, dans lequel la première région est une région de signature.
19. Procédé selon l'une quelconque des revendications 1 à 18, dans lequel les paires de bases des séquences hautement conservées sont hautement conservées par rapport à un alignement des VAA 1,2,3,4,5 et 6 et des VAA isolés à partir d'oies et de canards.
20. Procédé selon l'une quelconque des revendications 1 à 19, dans lequel la séquence variable est une séquence hypervariable.
21. Procédé selon l'une quelconque des revendications 1 à 20, dans lequel la première région comprend jusqu'à 10 kilopaires de bases en longueur.
22. Procédé selon la revendication 21, dans lequel la première région comprend un fragment de 3,1 kilopaires de bases comprenant toute la longueur de la séquence du capsid.
23. Kit pour détecter la présence d'un virus associé à l'adénovirus (VAA) inconnu dans un échantillon d'ADN cellulaire dont on suspecte qu'il contient une infection latente par un VAA, ledit kit comprenant:
  - (a) une première série d'amorces qui amplifient spécifiquement une première région comprenant 250 paires de bases de séquences d'acides nucléiques d'un capsid de VAA, ladite première région présentant au moins 18 paires de bases d'une séquence hautement conservée en son extrémité 5', une séquence variable et au moins 18 paires de base d'une séquence hautement conservée en son extrémité 3', lesdites paires de bases étant hautement conservées par rapport à un alignement d'au moins VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6;
  - (b) éventuellement une deuxième série d'amorces spécifiques d'une deuxième région des séquences d'acides nucléiques de VAA qui comprend la première région des séquences de VAA et des séquences qui se situent côté 5' par rapport à la première région, de manière à obtenir des séquences d'extension 5' des VAA qui hybrident sur l'extrémité 5' des séquences de VAA amplifiées par les amorces pour la première région ;
  - (c) éventuellement une troisième série d'amorces qui amplifient spécifiquement une troisième région, qui comprend la première région de séquences de VAA et des séquences qui se situent côté 3' par rapport à la première région, de manière à obtenir des séquences d'extension 3' de VAA qui hybrident sur l'extrémité 3' des séquences de VAA amplifiées par les amorces de la première région;chacune desdites deuxième et troisième région étant prédéterminée sur base de l'alignement des séquences d'acides nucléiques d'au moins les VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6, et chacune desdites régions comprenant des séquences d'acides nucléiques qui sont hautement conservées sur au moins 18 paires de bases en l'extrémité 5', éventuellement des séquences variables au centre et des séquences qui sont hautement conservées sur au moins 18 paires de bases en l'extrémité 3' des séquences de la région, par rapport aux séquences au moins des VAA1, VAA2, VAA3, VAA4, VAA5 et VAA6; chacune des séries d'amorces étant constituée par une amorce 5' et une amorce 3', chacune desdites amorces comprenant au moins 15 nucléotides complémentaires à sa séquence respective hautement conservée et présentant une identité exacte avec sa séquence respective hautement conservée sur au moins 5 paires de bases en son extrémité 3'.
24. Kit selon la revendication 23, dans lequel l'amorce 5' et/ou l'amorce 3' comprend au moins 18 nucléotides.
25. Kit selon la revendication 24, dans lequel l'amorce 5' et/ou l'amorce 3' comprend 25 nucléotides.
26. Kit selon l'une quelconque des revendications 23 à 25, dans lequel l'amorce 5' et/ou l'amorce 3' comprend au moins

9 paires de bases d'identité exacte en son extrémité 3'.

27. Kit selon la revendication 26, dans lequel l'amorce 5' et/ou l'amorce 3' comprend au moins 18 paires de bases d'identité exacte en son extrémité 3'.

5

28. Kit selon l'une quelconque des revendications 23 à 27, dans lequel la première série d'amorces permet l'isolement de toute la longueur des séquences de capsid d'un virus associé à l'adénovirus d'un échantillon, la première série d'amorces comprenant une amorce 5' dirigée sur une région localisée au centre d'un gène rep d'un VAA, basée sur une région prédéterminée conservée d'un VAA et une amorce 3' dirigée sur une région en aval d'un gène cap d'un VAA, basée sur une région prédéterminée conservée d'un VAA.

10

29. Kit selon la revendication 23, dans lequel l'amorce 5' présente une séquence comprenant GCTGCGTCAACTG-GACCAATGAGAAC, ce qui correspond aux nucléotides 1398 à 1423 de la SEQ ID NO:6.

15

30. Kit selon la revendication 23, dans lequel l'amorce 3' présente une séquence comprenant CGCAGAGACCAAAGTT-CAACTGAAACGA, qui correspond aux nucléotides complémentaires à 4462-4435 de la SEQ ID NO:7.

31. Kit selon l'une quelconque des revendications 23 à 30, dans lequel l'échantillon comprend un VAA intégré dans le chromosome.

20

25

30

35

40

45

50

55